Ar 2015

Department of Medicine 2015
TABLE OF CONTENTS
02
03
04
05
06
07
08
11
15
24
34
46
52
2015 By The Numbers...

Comments from the Chair
Leadership Organization
Endocrinology and Diabetes

Gastrointestinal and Liver Diseases
Geriatric, Hospital, Palliative and General
Internal Medicine
Gehr Family Center for Implementation Science
58
66
76
84
94
108
The Hastings Center for Pulmonary Research

USC/UKRO Kidney Research Center
Research Activities
Clinical Activities
Educational Activities
Cardiovascular Medicine
Hematology
Infectious Diseases
Nephrology and Hypertension
Oncology
Pulmonary, Critical Care and Sleep Medicine
Rheumatology
DEPARTMENTAL INDEX
113
116
116
120
121
123
127
128
129
134
146
148
150
Administrative Appointments
Distinguished Societies
Professional Societies
International Societies
Committees Held in Professional Societies
NIH Study Sections/Noteworthy
Government Activities
124
Service on University, School, Hospital and

Departmental Committees
Editorial Boards and Editorships

International Lectures
Invited Lectures
Peer Reviewed Publications
Books, Chapters and Other Publications
Federal Grants
Other Grants
Keck School of Medicine of USC
2015 By The Numbers...

238
10
Divisions
Faculty
Members
472
269
Peer-Reviewed
Publications
Residents and
Fellows
57
$32M
Federal Research
Grants
Federal Grant
Expenditures
Comments from the Chair

We are pleased to present the USC Department of Medicine (DOM) 2015 Annual Report, summarizing our many
accomplishments during this exciting and productive year. We have continued our strong commitment to DOMs
tripartite mission by ensuring the provision of exceptional patient care, by working diligently to advance the science
of medicine and by providing the highest quality of education for our future physicians, medical educators and
clinical leaders. This report is a comprehensive summary of the hard work and dedication of our faculty, trainees
and staff toward this mission.
We continue to recruit clinical and research leaders: 28 exceptional new faculty members were recruited to DOM in
2015, bringing our total full-time faculty workforce to 238. Despite this intensive recruitment success, we
continue to focus on additional recruitments in liver transplant/hepatology, bone marrow transplant, lung and
womens cancers and critical care medicine. Kenneth R. Hallows, MD, PhD, an internationally recognized expert
in kidney research, was recruited as the new Chief of the Division of Nephrology and Hypertension and Director
of the USC/UKRO Kidney Research Center, increasing the visibility of the Division and the Center. We are also
profoundly grateful to the Gehr Family Foundation for the generous $20 million gift to support research in leukemia
and implementation science.
Accomplishments in scientific discovery reflect the robust research
underway in the Department. DOM faculty held research grants with
annual expenditures of $53 million during 2015, of which 83% were
federally (primarily NIH) sponsored. Eight DOM faculty won new
NIH awards during the review period (as PI or Co-PI), and 48 DOM
faculty members are PI or Co-PI on current NIH grants. Five of our
promising junior faculty members have young investigator career
development (K) awards.
Our outstanding physicians treat patients from all around the world.
Patient care services have expanded in Orange County with USC
Oncology/Hematology Newport Beach, Irvine and Hoag Hospital.
With the implementation of a Primary Care Initiative, our private
practices in Beverly Hills, Downtown Los Angeles and the
University Park Campus expanded services during 2015. DOM has
seen continued growth in the provision of ambulatory services over
the last year, with a 24% increase in average daily visits.
DOM has continued to provide quality training in its undergraduate
medical education programs, ranking #1 and #3 by the medical students
for our third and fourth year clerkships, respectively. Additionally, nine
Edward D. Crandall, PhD, MD faculty members won teaching awards, including the USC Mellon
Hastings Professor and Norris Chair
Mentoring Award to Laurie DeLeve, MD, PhD, and the USC KSOM
Department of Medicine
Master Teacher Award to Jeffrey Canceko, MD. We again had a 100%
University of Southern California
match rate for our 55 PG1 categorical internal medicine intern positions.
DOM has increased support to Associate Residency and Residency Program Directors to enhance mentorship and
career advancement programs, resulting in 29 graduating residents moving on to fellowship programs, three
becoming chief residents, 13 joining hospitalist programs (11 of which are academic) and 10 becoming General
Medicine practitioners.
Our commitment to excellence is evidenced by the accomplishments celebrated in this Annual Report. Looking to
the future, we are excited at the prospect of another year filled with opportunity and promise. We are proud to be
associated with our outstanding group of knowledgeable, innovative and dedicated faculty, trainees and students.
Leadership Organization
Ron Ben-Ari, MD
Fred R. Sattler, MD
David A. Goldstein, MD
Kenneth R. Hallows, MD, PhD
Vice Chair, Educational Affairs
Chief, Division of Infectious Diseases
Vice Chair, Clinical Affairs
Chief, Division of Nephrology and

Hypertension
John T. Nicoloff, MD
Darcy V. Spicer, MD
Senior Associate Chair, Scientific Affairs
Chief, Division of Oncology
Laurie D. DeLeve, MD, PhD
Zea Borok, MD
Senior Associate Chair, Scientific Affairs
Chief, Division of Pulmonary, Critical Care

and Sleep Medicine
John L. Brodhead, Jr., MD
Chief of Medicine, Keck Hospital of USC
William Stohl, MD, PhD
Chief, Division of Rheumatology
Ray V. Matthews, MD
Chief, Division of Cardiovascular Medicine
Michael Rice
Vice Chair, Finance and Administration
Thomas A. Buchanan, MD
Chief, Division of Endocrinology and

Diabetes
Eva Blaauw
Executive Administrator
Neil K. Kaplowitz, MD
Chief, Division of Gastrointestinal and

Liver Diseases
Gilberto Martinez
Michael S. Karp, MD
Angie Ibanez
Director, Administrative Operations
Chief, Division of Geriatric, Hospital,

Palliative and General Internal Medicine
Accounting Director
Anh Hwang
Preet M. Chaudhary, MD, PhD
Research and Financial Reporting

Manager
Chief, Division of Hematology
Gehr Family Center for

Implementation Science
Innovating healthcare delivery
The goal of the new Gehr Family Center for Implementation Science is to create innovative collaborations to
develop and promote sustainable, efficient, clinical-quality improvement strategies. The Center will apply
evidence-based programs and practices to improve and innovate health care delivery. Focusing on projects that align
with the triple-aim approach in health care and working with partners such as LAC+USC and the Agency for
Healthcare Research and Quality (AHRQ), the Center will identify and integrate best practices into routine health
care for our patients.
The Center was established by David Goldstein, MD, Associate Professor of Clinical Medicine, Vice Chair for
Clinical Affairs, and is led by Michael Hochman, MD, Assistant Professor of Clinical Medicine, as the newly
inaugurated director. Dr. Hochman graduated Magna Cum Laude from Princeton University, then went on to earn
his MD from Harvard Medical School, with honors. Dr. Hochman has received numerous awards including the
Faculty Teaching Incentive Award from the Keck School of Medicine, and he published a book, 50 Studies
Every Doctor Should Know, which is currently being developed into a series by Oxford University Press.
The Center is funded by a generous gift from Norbert Gehr, a grateful patient of Goldstein, who wished to leave
a legacy promoting scholarly efforts to enhance the delivery of healthcare. The overall mission of the Center is to
partner with health systems in our community to study and apply strategies that we know work in health care to
overcome barriers to improve patient case management and to innovate develop new ways to improve quality
and reduce waste, making the system more efficient. Implementing what we know works and coming up with new
solutions to these challenges.
Among its significant programs, the Center will sponsor two exciting opportunities for grant funding: The Gehr
Family Innovation Awards, which will provide faculty an opportunity to apply for grant funding and The Gehr
Student Innovator Awards, which will provide students an opportunity to apply for summer stipends. The Center
will also host informative sessions addressing key issues in patient-centered outcomes research, The Gehr Speaker
Series will launch this spring.
Gehr Center Triple Aim Principles
Population Experience
Health
of Care
Per Capita Cost
The Hastings Center for

Pulmonary Research
Revolutionizing the future of lung disease research
Chronic respiratory diseases (CRDs) affect tens of
millions of people in the United States. Some of the most
common respiratory conditions are asthma, chronic
obstructive pulmonary disease (COPD), lung cancer,
cystic fibrosis and sleep apnea. Many risk factors play a
role, including tobacco smoke, air pollution,
occupational chemicals and dusts, and frequent lower
respiratory infections during childhood. Lung
transplantation is currently the only viable treatment for
advanced lung disease patients, and organ availability is
rather limited. It is imperative now more than ever to
increase our knowledge and understanding to develop
new therapeutic approaches for these disabling diseases.
between researchers and clinicians must be present.

Zea Borok, MD, Chief of the Division of Pulmonary,
Critical Care and Sleep Medicine, believes it is that
cohesion that will set the Hastings Center for Pulmonary
Research apart from other advanced lung disease centers.
As director of the HCPR, Dr. Borok will apply her basic
expertise related to the role of the alveolar epithelium in
health and disease. Clinicians in the recently established
USC Center for Advanced Lung Disease (CALD) will
collaborate with basic and translational researchers in
HCPR to advance lung science at USC. This will create
unique opportunities for use of patient samples in basic
research and for translation of potential therapeutics
developed in HCPR back to patients.
The Hastings
USC Center of Excellence in Advanced Lung Disease Amy Firth, PhD,
Foundation has
pledged to donate
Assistant Professor
Clinical Center for Advanced
Hastings Center for
$7.5 million over
of Medicine,
Lung Disease (CALD)
Pulmonary Research (HCPR)
five years to
was the first
establish the
faculty member
Hastings Center for
to be recruited to
Advanced Lung Disease
Injury, Repair,
Pulmonary
the new Center.
Regeneration
Potential Therapeutics
COPD
Research (HCPR)
Dr. Firths major
Interstitial Lung Disease
Epithelial Cell Biology
at USC. The
areas of research
Asthma
Epigenetics
Hastings
include:
Cystic Fibrosis
Developmental/Environmental
Pulmonary Hypertension
Lung Diseases
Foundation has had
developing stem
Sleep
a relationship with
cell therapies for
Advanced Procedures Patient Samples Areas of Recruitment
Fibroblast/matrix biology
USC for more than
cystic fibrosis,
Stem cell biology
50 years, and this
understanding
Bioinformatics
Lung Imaging
gift builds upon that
the role of
strong relationship.
multicillin and
The foundation is
associated
very pleased with
pathways in cell
the research it has seen at USC, and looks forward to
development, and utilizing stem cells to develop
having a focal point for faculty research and
effective in vitro models of lung disease. Dr. Firth
recruitment. A major focus of the HCPR is recruitment
believes that the HCPR is perfectly situated to facilitate
of mid to senior level investigators with expertise in
collaboration between physicians, basic biology and
lung stem cell biology and regeneration. This will enable
translational science.
synergistic interactions amongst scientists with a common
interest in advancing our understanding of these chronic
HCPR strives to be a widely recognized leader in lung
lung disease and developing therapies based on research
biology and disease. HCPR scientists will interact
findings in the laboratory, so-called bench-to-bedside.
with clinicians to translate their research findings into
clinical applications. The Center hopes to achieve this
The Division of Pulmonary, Critical Care and Sleep
mission by training and mentoring fellows, graduate
Medicine aims to create an integrated, world-class
students and early career investigators in lung biology.
program of excellence in pulmonary research and
HCPR investigators will be in close proximity with
patient care at USC. In order to become a nationally
shared laboratory space and equipment, facilitating
recognized leader in the field, strong collaborations
collaboration right from the start.
USC/UKRO Kidney
Research Center
Pioneering the advancement of kidney research
Chronic kidney disease (CKD) is a growing epidemic affecting over 26 million Americans, many of whom are
unaware they have it. CKD often involves a progressive loss of kidney function, which can occur at varied rates
depending on the disease and what stage the patient is in. During the early stages patients are usually asymptomatic.
Once symptoms appear, such as exhaustion, body swelling and unexplained high blood pressure, the kidneys could
be seriously impaired. Diabetes and hypertension are the leading underlying causes of chronic kidney disease.
University Kidney Research Organization (UKRO) is a charitable organization that was co-founded by
Dr. Vito Campese, Professor of Medicine, and his patient, Kenneth Kleinberg, a Los Angeles entertainment attorney
who suffered from CKD, on the belief that collaboration among scientists is the key to understanding and
eliminating CKD. A few years ago, UKRO and USC set out to make that belief a reality by establishing the USC/
UKRO Kidney Research Center (KRC).
Keck School of Medicine researchers, along with board members from UKRO, recently celebrated the KRCs
opening on the 5th and 6th floors of the Mudd Memorial Research Building. The Director of the KRC is
Dr. Kenneth Hallows, Professor of Medicine and Chief, Division of Nephrology and Hypertension. An initial $3.5
million pledge was made by UKRO to support the center and its five labs. Dr. Nuria Pastor-Soler, Associate
Professor of Medicine and Assistant Dean for Research Mentoring, is the first clinician/scientist to be recruited for
the Kidney Research Center. Drs. Hallows and Pastor-Soler will focus their research on several areas, including the
mechanisms of hypertension, acute kidney injury, acid regulation and its role in CKD, polycystic kidney disease
and metabolomic biomarkers, and kidney cancer. They plan to partner with other researchers within the larger Keck
School of Medicine community and beyond to work toward new therapies and potential cures for kidney disease.
Dr. Vito Campese serves as Co-Director of the KRC.
Hallows is building a hub for basic and translational kidney research, with clinical initiatives, that should have a
strong positive impact on kidney disease patients. Along with kidney research, UKRO will foster growth for medical
students and other trainees. The center boasts a new multi-photon confocal microscope capable of producing 3D
real-time images of kidneys in vivo, up to 1,000 times larger than they appear to the naked eye. The microscope will
be used primarily to examine kidney structure and function. UKRO is very excited to help build a core group of
researchers and establish new collaborations across Keck Medicine and the world.
The new multi-photon confocal microscope, capable

of producing 3D real-time images
Research Activities
More than 90 Department of Medicine (DOM) faculty are currently engaged in basic and/or clinical (translational)
research activities, 48 of them as Principal Investigators. These medical research programs are supported by
expenditures now exceeding $53 million annually, of which 83% are federally (primarily NIH) sponsored. Among
the DOM faculty who received new NIH grants this reporting period are Zea Borok (P01, NHLBI); Howard Hodis
(R01, NHLBI); Kenneth Hallows and Nuria Pastor-Soler (Co-PIs, R01, NIDDK); Cheng Ji (R21, NIAAA);
Heinz-Josef Lenz (R01, NCCIH); Takeshi Saito (R01, NIDDK); and Anisa Shaker (R03, NCI). In addition, five
DOM faculty members have K awards: Akil Merchant, Kathleen Page, Anisa Shaker, Ling Shao and
Hussein Yassine. These faculty members represent nearly all the DOM divisions and serve to underscore the quality
of medical research currently being conducted by our faculty. It also indicates the ability of our faculty to compete
for the very limited amount of NIH grant resources at a time of intense competition for extramural funding.
Dr. Laurie DeLeve, Professor of Medicine in the Division of Gastrointestinal and Liver Diseases, serves as Senior
Associate Chair for Scientific Affairs for DOM. One of her objectives is to support junior faculty in facilitating
their advancement along the tenure track. Two initiatives have been put into place to support these junior faculty
members. The first is the Career Planning Committee (CPC), a committee that is specifically assigned for each
junior faculty member to advise them on issues relating to their career goals. Committee members include the
primary mentor, the Division Chief (ex officio), the Departments Senior Associate Chair for Scientific Affairs (ex
officio) and two additional members chosen by the junior faculty member after deliberation with his/her mentor. The
committee meets twice annually to monitor the progress of the junior faculty member and to provide advice tailored
to his/her particular needs. To date, this program has been enthusiastically received both by the junior faculty and
CPC members. The second initiative is a program to provide assistance in editing federal grant proposals to increase
the likelihood of award. The program utilizes the services of graduate students in Science Journalism from the
Annenberg School of Communication who are experienced science writers. This program is offered primarily to
junior faculty members on the tenure track, but is also available to other faculty members if desired.
Basic/Translational Science (Prinicipal Investigator)

Research Center for Liver Diseases (Kaplowitz)
Will Rogers Institute Pulmonary Research Center (Crandall, Borok)
Gastrointestinal Oncology Program (Lenz)
Diabetes Center (Buchanan)
Lupus Center (Horwitz, Stohl)
Cardiovascular Devices Program (Saxon)
Large Scale Clinical Trials (Principal Investigator)
Atherosclerosis Research Unit (Hodis)

AIDS Clinical Trials Group and Womens Interagency HIV Study (Sattler)
Keck Diabetes Prevention Initiative and NIH LookAHEAD Study (Peters)
Southern California CTSI Research Program and Clinical Trials Unit (Buchanan)
Basic/Translational Science
The NIH-sponsored Research Center for Liver Diseases and core laboratories (Molecular Biology,
Cell Culture and Organelle), led by Neil K. Kaplowitz, MD, is one of only four such programs in the nation. In
addition to basic and translational research programs in liver disease, this Center provides a major institutional
resource for multidisciplinary and interdepartmental investigations, educational seminars and start-up grant funding
opportunities.
The Will Rogers Institute Pulmonary Research Center, under the direction of
Edward D. Crandall, PhD, MD, and Zea Borok, MD, continues to contribute significant advances in research
related to lung injury and pulmonary edema. Their investigational focus involves studies on transport, growth and
differentiation of lung alveolar epithelial cells from the cellular/molecular to organ levels.
USC Norris Comprehensive Cancer Center projects such as the Colorectal Cancer Center, under the
direction of Heinz-Josef Lenz, MD, are concerned with developing new and innovative chemotherapeutic
approaches to the treatment of cancer.
The Diabetes and Obesity Research Center was established to investigate the origin, prevention
and treatment of diabetes and associated conditions (including obesity, hyperlipidemia, hypertension
and atherosclerosis). Thomas A. Buchanan, MD, shares the leadership role in developing this important
multidisciplinary research program with Michael Goran, PhD, from the Department of Preventive Medicine.
Information gained by Lupus Center investigators from laboratory bench research has served as the basis for
development of prototype treatment strategies for a wide variety of autoimmune diseases.
The Cardiovascular Devices Program, led by Leslie Saxon, MD, is dedicated to the development of
innovative uses of new implantable device technologies. Such new technologies will allow the introduction of major
preventive and/or critical therapeutic measures at the earliest stages of disease development.
Interdisciplinary Research Programs
The Department of Medicines impact on the medical research enterprise of the Keck School of Medicine of USC
has been largely achieved by members of our faculty playing key roles in the development of interdisciplinary
NIH-sponsored research programs. Many of these programs have taken advantage of the unique and diverse patient
populations served by our teaching hospitals and clinics, as well as the leadership talents of our faculty. Prominent
examples of such programmatic efforts include:
Large-Scale Clinical Trial Centers
Under the leadership of Howard N. Hodis, MD, the Atherosclerosis Research Unit focuses on in vivo
assessment of atherosclerosis. Using cutting-edge noninvasive technology to assess changes in intimal thickness in
major arterial vessels, this Unit is conducting studies designed to assess the benefits of a wide variety of therapeutic
interventions for prevention and reversal of atherosclerosis.
Under the direction of Fred R. Sattler, MD, the adult AIDS Clinical Trials Group (ACTG) has become one of
the nations leading centers in carrying out NIH-sponsored AIDS clinical trials in adult populations.
The Keck Diabetes Prevention Initiative, directed by Anne Peters, MD, is a program designed to develop
treatment programs for the epidemic of obesity and type II diabetes occurring in the medically underserved
populations of Los Angeles. As part of this program, the NIH-sponsored LookAHEAD Study focuses on
the benefits of weight loss and exercise in reducing the risk of cardiovascular disease in a select type 2 diabetes
population located in East Los Angeles.
In recognition of the importance of translational research to the improvement of medical care in the community, the
NIH established the Clinical and Translational Science Awards (CTSA) at leading medical research
institutions across the country. Such CTSA funded programs are designed to provide substantially more complex
and sophisticated resources for the conduct of clinical research than were available with the previous General
Clinical Research Center (GCRC) programs that they were designed to supplant. Because of
Dr. Thomas Buchanans outstanding past leadership record in directing our GCRC program, he was selected to take
on the challenge of garnering a CTSA award for the Keck School of Medicine. This goal was achieved with the
award of a $56.8 million grant to support expansion of the USC-based Southern California Clinical and
Translational Science Institute (SC CTSI). Dr. Buchanan also serves as the Keck School of Medicines
Vice Dean for Research. The NIH-sponsored SC CTSI provides a broad range of services and support to promote
the development and conduct of clinical and community trials, develop new methods to enhance the efficiency and
effectiveness of clinical research, provide training in clinical and translational research, and disseminate research
findings to improve clinical care and community health.
10
Clinical Activities
The Department of Medicine is the largest department at one of the most expansive academic medical centers in
the country. The complex is comprised of LAC+USC Medical Center (LAC+USC) and the Keck Medical Center
of USC (KMC). The latter includes USC Norris Cancer Hospital (Norris) and Keck Hospital of USC (KH), as well
as several ambulatory venues Healthcare Centers 1 and 2 (HC1 & HC2) located on the Health Sciences Campus,
Pasadena, La Caada, University Park Campus, Beverly Hills, Downtown Los Angeles and Orange County. The
Department of Medicine leads USC in the provision of clinical care in both the public and private venues of the
Health Sciences Campus and is dedicated to providing quality, state-of-the-art patient care to both insured and
uninsured patient populations. The Department has maintained its goal of providing optimal quality and efficiency
of patient services, in both the private and public settings.
The Department of Medicine delivers a remarkable range and volume of high-quality inpatient and outpatient care
at LAC+USC Medical Center. Its outstanding teaching programs provide direct education to 189 residents, over
80 subspecialty fellows, and approximately 200 medical students at LAC+USC each year. The Department of
Medicine partners with the Medical Centers administrative, physician and nursing leadership to address the needs
of our patients and to continually enhance the safety and quality of our healthcare systems and services.
11
LAC+USC Medical Center
In calendar year 2015, the Department of Medicine accounted for approximately 50% of the average daily census
at LAC+USC. Since opening the new facility in late 2008, the percentage of patients cared for by Department of
Medicine faculty has risen as high as 57%. When formal consultations are included, the Department continues
to be actively involved in the care of more than 75% of all patients at LAC+USC. In addition to our excellent
comprehensive inpatient service, the Department provides the supervision and care for more than 100,000 patients
each year in our outpatient clinics.
The Department of Medicine is tireless in its efforts to deliver the highest quality care for the safety-net population
of Los Angeles County. The following initiatives were recently implemented to enhance the training environment
and patient care delivered by Department of Medicine faculty and physicians in training:
Adult Primary Care Service Enhancements
The Department of Medicine worked with LAC+USC outpatient administration and Director of Primary Care
Services, Dr. Jagruti Shukla, to refine and implement a modified patient-centered medical home model of care
in resident primary care clinics and to initiate a substantial renovation plan for the clinics to create an appealing,
patient-centric outpatient care environment. This type of care provides 24/7 phone access, a team-based approach
and rapid follow-up visits. This effort serves as a model for ambulatory services reorganization by LAC+USC
administration.
Implementation of a New Electronic Medical Record: ORCHID
The Department of Medicine provided substantial support and expertise for the implementation of a comprehensive
electronic medical record at LAC+USC.
Adult Ambulatory Subspecialty Medicine Enhancements
The Department of Medicine worked with LAC+USC outpatient administration and Director of Subspecialty
care services, Dr. Andy Lee, to establish a multidisciplinary patient-centered ambulatory subspecialty hub. A
substantial renovation plan for the subspecialty clinics was planned and initiated to create an appealing, patientcentric outpatient care environment. This new model will enable group visits for enhanced patient education,
12
better coordination of care and serves as a model for specialty ambulatory services reorganization by LAC+USC
administration.
Implementation of eConsult
eConsult is a web-based tool that provides consultations in all medicine subspecialties to its affiliated communitybased and medical center-based primary care practitioners. This eConsult-based dialogue between the primary
care doctor and the specialist helps address clinical questions and co-manage patients in an efficient manner. The
program has reduced the need for face-to-face visits by approximately 33%, improving access to specialty care.
New Admitting Protocol
Internal medicine physicians assume the inpatient care of patients once admitted and when still in the Department
of Emergency Medicine. The early involvement of internal medicine physicians in the course of admitted patients
promotes prompt evaluation and initiation of appropriate diagnostic and treatment strategies.
Blue Service
This program enables the re-assignment of lower acuity inpatients to a service staffed by faculty and nurse
practitioners, thereby maintaining compliance with ACGME census guidelines and duty hour restrictions and
improving the morale of trainees.
Private Practice
The Departments private practice has continued to experience steady growth since its inception in the 1980s,
with overall activity more than doubling and ambulatory visits almost tripling over the past ten years to more than
140,000 annually. The following are some of our most recent achievements:

Initiation of a Primary Care Initiative with recruitment of six of an eventual seven primary care physicians

during the first phase of development

Expansion of Gastroenterology services, including Therapeutic Endoscopy and Inflammatory Bowel
Disease

Implementation of a Center for Advanced Lung Disease

Expansion of cancer services in Orange County with recruitment of two additional oncologists
13
The ambulatory practice has grown in several areas. The Divisions with the highest rate of growth include Oncology
at 141%, Endocrinology and Diabetes at 32%, and Hematology at 25%. Primary Care has expanded at Pasadena by
47%, and the Downtown LA practice has increased by 13% year over year.
Other than Hematology and Oncology, which continue to conduct their private outpatient care at Norris and Orange
Coast Oncology Hematology (OCOH), all divisions practice at HC2. These divisions include Cardiovascular
Medicine; Endocrinology and Diabetes; Gastrointestinal and Liver Diseases; Geriatric, Hospital, Palliative and
General Internal Medicine; Infectious Diseases; Nephrology and Hypertension; Pulmonary, Critical Care and Sleep
Medicine; and Rheumatology.
The Department also provides ambulatory care for patients at the DaVita-USC Kidney Dialysis Center, the Arthritis
Center, the USC Westside Center for Diabetes, Keck Medicine of USC- Beverly Hills, Keck Medicine of USCLa Caada, Keck Medicine of USC- Pasadena, USC Norris OCOH and Keck Medicine of USC- Downtown Los
Angeles (formerly the Executive Health and Imaging Center). In aggregate, the Department of Medicine offers a full
panel of specialists as well as an active group of primary care physicians.
On the inpatient side, the Department of Medicine accounted for 30% of all admissions at Keck Medical Center
of USC. However, because of their consulting relationships with surgical colleagues, Department faculty provided
care to a much larger number of patients. For example, the Departments Pulmonary and Critical Care physicians
provide care to most of the patients in the intensive care units, although the admitting physicians usually are in other
departments or divisions. Similarly, although our Nephrology and Hypertension faculty refer patients to the General
Medicine team for admissions, the Nephrologists are often consulting on as many as 30 inpatients per day. Finally,
at the Norris Cancer Day Hospital, the Departments oncologists and hematologists account for the care of well over
85% of the patients.
The KH Hospital Medicine Program has had a significant impact on quality patient care, and has implemented a
24/7 Rapid Response Team, 24/7 coverage at the Evaluation and Treatment Center, co-management of specified
specialty services, such as Orthopedics, and reduction of catheter-related urinary tract infections. The Department
has added an additional faculty hospitalist and developed a strong co-management service in collaboration with the
Orthopedic Joint Replacement Service. The average length of service for these patients has dipped to below two
days, rivaling best practices across the nation.
The clinical practices website can be found at http://internalmedicine.usc.edu/. This interactive site allows
visitorswhether they are patients, physicians, pharmacists or othersto learn about the practice and its programs
and providers, as well as schedule appointments, request prescription refills and ask general questions.
14
Vice Chair, Educational

Affairs
Program Director
Ron Ben-Ari, MD
Eric Hsieh, MD
Administrator of
Educational Affairs
Nancy G. Shepherd, MS Ed
Chief Medical Residents

2014- 2015
2015- 2016
Associate Program Directors

Nida Hamiduzzaman, MD
Seth Politano, DO
Gina Rossetti, MD
Joshua Sapkin, MD
Patrick Sarte, MD
Elliott Birnstein, MD
Henry Chu, MD
Nima Motamedi, MD
15
Arjun Makam, DO
Alex Shindel, MD
Carrie Ward, MD
Graduate Medical Education
The Department of Medicine continues its intensive investment in advancing educational programs at both the
Graduate and Undergraduate levels. Department of Medicine faculty contribute extensively to medical student
education in both the basic science and clinical clerkship years and directly supervise the training of nearly 270
house officers and fellows each year. The Department reviews, revises and delivers curricula for medical students
and Internal Medicine trainees each year and provides each group with a comprehensive and rich educational milieu.
Administrative Responsibilities
The Office of Educational Affairs coordinates the following activities for the residency and/or fellowship programs
(189 residents and approximately 80 fellows):

Recruitment, interviewing and hiring of intern applicants

Preparation of employment contracts for all postgraduate trainees in the Department of Medicine
Documentation for licensure after the completion of sufficient clinical training
Collection and summarization of resident evaluations by faculty, faculty evaluations by residents and
resident evaluations of clinical rotations and the program as a whole
Annual reporting of resident performance to the American Board of Internal Medicine (ABIM)
Annual in-training examination for all Internal Medicine trainees
Preparation of a master schedule for all residents
Preparation of a master curriculum schedule for residents and scheduling of faculty instructors
Preparation, submission and display of required case report posters by interns
Longitudinal Board Review curriculum at all training levels
General Medicine Continuity Clinic assignments
Semi-annual performance review and meeting with each individual resident
Counseling, preparation of letters of reference and disciplinary issues regarding interns and residents
Designing and reporting quality assurance indicators for trainees
Scheduling faculty participants for all core residency conferences
Verification of training for hospital and clinical privileges for all former USC Internal Medicine graduates
since 1972
Fellowship Training
The Department of Medicine directs 15 fellowship training programs in Internal Medicine subspecialties:
Cardiology, Clinical Cardiac Electrophysiology, Interventional Cardiology, Advanced Heart Failure, Endocrinology,
Gastrointestinal and Liver Diseases, Geriatric Medicine, Hematology, Infectious Diseases, Nephrology, Transplant
Nephrology, Oncology, Pulmonary and Critical Care Medicine, Sleep Medicine and Rheumatology. Each program
provides its trainees with clinical and research education under the supervision of experts in the respective discipline
(see Divisional reports).
Residency Structure
The residency training program is divided into five groups based on Associate Residency Directors with the
following objectives:

To provide house officers with a smaller and consistent peer group of trainees
To enhance Departmental support, structure and morale
To expand and enhance learning opportunities for house officers
To increase house officer participation in new program development and residency program administration
The role of the Associate Director is to supervise and coordinate the educational efforts of the Group as well as be a
resource and liaison for nursing and other support personnel.
Education Officers
Each Division is represented by an Education Officer. These faculty function as informational and scheduling
resources for all educational issues relevant to the Office of Educational Affairs and the Divisions.
16
2015- 2016 Chief Residents (left to right): Drs. Arjun Makam, Alex Shindel and Carrie Ward
House Officer Representatives and Meetings
Peer-selected house officer representatives participate in the development of educational activities, promotion of
resident research and scholarly activity, and coordination of Departmental events. Internal Medicine house officers
have become particularly active on both institutional and Departmental committees. They are lead officers in the
Council for Interns and Residents and have made significant contributions to the programmatic elements of the
residency. The Program Director conducts monthly Education Steering Committee meetings (on which these
peer-selected residents sit) and monthly general house officer meetings open to all trainees.
Daily Schedule
House officers participate in a combination of clinical training experiences and structured didactic sessions each
day. House officers are assigned to a wide range of ambulatory and inpatient clinical experiences in both public and
private settings. Clinical training is provided in General Internal Medicine, all Internal Medicine subspecialties,
Emergency Medicine, Neurology and relevant surgical subspecialties. The General Medicine Ward Service at
LAC+USC Medical Center (LAC+USC) is the Departments largest teaching service and is staffed with 12 faculty
and 36 residents each month. A highly structured calendar of events maximizes the teaching/learning opportunities
for our faculty and house staff, while providing supervised delivery of patient care and consistent educational
experiences for residents. Faculty attendings perform teaching rounds seven days per week. In addition, the
Department requires that patients followed by a subspecialty service, whether primarily or in consultation, be
reviewed daily by the attending faculty and house staff.
Combined Training Program

The combined Internal Medicine/Pediatrics Program is a four-year program, with a total of 24 positions (six per
year). Individuals in the combined Internal Medicine/Pediatrics Program spend each of the four years of training
alternating between Internal Medicine and Pediatric training experiences. Graduates are board eligible in both
Internal Medicine and Pediatrics.
Clinical Experience
Ambulatory Care
All General Internal Medicine continuity clinic activity is located at LAC+USC. A few subspecialty clinics are
located offsite at the Comprehensive Health Centers (CHC) of the LAC+USC Healthcare Network and at the Los
Angeles Veterans Administration. General Medicine Clinics are conducted every afternoon Monday through Friday.
House officers, under direct faculty supervision, provide continuity of care for their own panel of patients. Each
Internal Medicine house officer spends one-half day per week in a General Internal Medicine clinic. Each patient
encounter is carefully reviewed and co-signed by a General Internal Medicine faculty supervisor. House staff also
participate in Internal Medicine subspecialty clinics when on rotation, and spend two months each year taking part
in a variety of surgical and medical subspecialty clinics during an Ambulatory Care Block rotation.
17
Inpatient Care
House officers have extensive opportunities, under the supervision of faculty attendings, to admit and care for a
remarkably diverse patient population. A state-of-the-art $1 billion LAC+USC Medical Center became our primary
inpatient teaching site in November 2008, and more than 90% of inpatient training occurs there. The rest of the
training occurs in private practice settings at Keck Hospital of USC (KH) and USC Norris Cancer Hospital (Norris).
The majority of inpatient wards at LAC+USC are devoted to General Medicine services. Separate ward services are
staffed by the Department to provide MICU, cardiology and hematology care.
Curriculum
The Department delivers a daily Core Residency Conference Series, a Core Ambulatory Curriculum, a longitudinal
Board Review Curriculum and a Mentor Program. In order to optimize the participation of all house staff in the core
educational series, nearly all core clinical and didactic conferences are presented from 12:00 to 1:00 pm, Monday
through Friday. The core curricular sessions are arranged thematically by month, and a relevant board-oriented
multiple-choice examination is administered at the end of each month. Core conference attendance requirements are
determined by level, and all house officers must take and pass eight of the monthly examinations administered each
year. The daily core series is comprised of the Core Curriculum Lecture Series, Medical Grand Rounds, Morbidity
and Mortality Conferences, Master Professor Rounds, Journal Club, Case Report Group, House Officer Meetings
and a Monthly Exam. The Core Ambulatory Curriculum is delivered during the first half-hour of each General
Medicine Continuity Clinic session, and the Board Review and Mentor Program elements are generally delivered to
small groups of residents. Divisions also provide focused didactic and patient-based learning opportunities for those
house staff rotating on their services. The monthly board-oriented examinations are supplemented by an annual
nationally administered in-training examination for each house officer.
Didactic Sessions

Core Curriculum is an ongoing and repeating series on Internal Medicine topics, which are grouped
thematically by month (See table on page 23 for a list of Core Curriculum topics.)
Ambulatory Curriculum is an ongoing and repeating series on topics relevant to the delivery of outpatient
care in Internal Medicine
Medical Grand Rounds are weekly lectures covering the most current developments in Internal Medicine
Journal Club is a monthly conference at which residents and faculty review and critique recent
contributions to the medical literature
Board Review Course is a weekly small group session for senior residents with faculty
Mentor Program consists of small group sessions where medical ethics, professionalism, distributive
justice, searching the medical literature, procedural competency, leadership, teaching and evaluation
techniques, and issues relevant to transitioning from residency to fellowship or the workplace are explored
ECG Interpretation Course is an annual presentation on interpretation of the electrocardiogram
Chest X-ray Interpretation Course is an annual presentation on interpretation of radiographs of the chest
Patient-Based Learning

Morning Report consists of daily sessions at which the most challenging and enigmatic of recently
admitted cases are presented for discussion by residents assigned to the General Medicine Service; the
conference is moderated by the Vice Chair for Clinical Affairs and Chief of the Division of Geriatric,
Hospital, Palliative and General Internal Medicine, with subspecialty faculty present
Intern Report is a weekly session at which challenging, recently admitted cases are presented for discussion
by interns assigned to the General Medicine Service; the conference is moderated by Chief Residents,
Firm Directors or other General Internal Medicine faculty
18
Morbidity and Mortality Conference consists of interdisciplinary sessions in which pathologic specimens
and autopsies are reviewed and Patient Safety initiatives and Continuous Quality Improvement
opportunities are identified
During Daily Bedside Rounds, admissions to inpatient Internal Medicine Services or consultations
requested from Internal Medicine Services are seen, examined and discussed by attending faculty with their
team of house officers. All services combine bedside teaching with focused conferences such as
subspecialty Grand Rounds and Journal Clubs.
Residents as Teachers

Junior residents participate in workshops to receive training in teaching and evaluation techniques and in
team leadership
Senior residents participate in separate sessions focused on teaching at the bedside and teaching in large
group forums
Senior residents prepare case presentations and didactic lectures for Medical Grand Rounds under the
guidance of a faculty mentor
Trainees at all levels give formal presentations at Morbidity and Mortality Conferences, Journal Clubs,
Case Report and Subspecialty Conferences
Senior and junior residents directly supervise first-year residents and medical students in the provision of
patient care
Scholarly Activity

The Research Interest Series provides quarterly noontime presentations to promote resident participation

in research (clinical, translational or bench). The topics include identifying a researchable question,

understanding and obtaining approval from the IRB, research opportunities and resources within the

program, and pursuing an academic career.

Case Report Conference is a monthly conference that provides residents a venue for the delivery of

specific curricular content on identifying unique appropriate clinical cases, documenting and submitting

cases for publication and/or presentation, and poster preparation. Evidence of the impact of this curriculum

is that USC Internal Medicine residents won second place in poster competitions for clinical vignettes at

the regional American College of Physicians Scientific Meeting in 2010 and first place in both 2008 and
2009.
American Board of Internal Medicine Certification

Fifty one recent graduates participated in the 2014 ABIM Certification Examination, and 51 participated in the
2015 exam. The Departments pass rate on the ABIM Certification Examination is 94%. The Department provides
all internal medicine residents with the Medical Knowledge Self Assessment Program (MKSAP), which has
longitudinal and intensive sessions to prepare residents to pass the ABIM Certification Examination.
Accreditation
The core categorical and all subspecialty fellowship training programs maintain full accreditation. The status of full
accreditation of all programs reflects clear recognition from the Residency Review Committee for Internal Medicine
that the residency and fellowship training programs in Internal Medicine at USC achieve substantial success in
meeting ACGME guidelines and in training future internists and subspecialists. In fact, as a result of the most recent
site visits from the ACGME, the core program and all subspecialty programs received maximum cycle lengths.
19
Evaluations
House officers complete evaluations of faculty at the end of each month, rating a variety of characteristics, and
faculty are provided with an annual Department-wide composite summary of their evaluations. In addition, each
faculty is required to evaluate the house officers with whom they have worked and to personally discuss their
impressions with the house officer. Any rated characteristics evaluated as marginal or unsatisfactory prompt a review
of that residents performance by the Program Director and, when appropriate, the Residency Performance Review
Committee of the Department of Medicine. Computerized tracking of evaluations is used to facilitate the ongoing
collection and processing of these data.
National Resident Matching Program Results

The Department of Medicine uses the Electronic Residency Application Service (ERAS) to process over 2,000
applications. Approximately 500 interviews were conducted by the Department of Medicine faculty for the 20142015 academic year. The Department of Medicine offers 55 Categorical PG1 positions and six combined Internal
Medicine-Pediatrics positions annually. We have had a 100% match rate for PG1 categorical positions since 1995.
Recruitment
The Department of Medicine recognizes that the recruitment of high-caliber individuals into the residency program
is essential to achieving the excellent training environment for which it is striving. The Department is working to
increase interest in its program and to fill its postgraduate positions with excellent candidates from medical schools
nationwide. The Department regards USC medical students as particularly strong candidates for its training program
and views the recruitment of USC students to be a high priority. Forty-three USC students from the class of 2015
sought careers in Internal Medicine. The Department revamped its residency program website, and participated
in a USC Residency Fair sponsored by Alpha Omega Alpha Honors Society and a residency fair sponsored by the
American College of Physicians.
Future Goals and Plans

Continue to improve our residents ABIM Certification Examination passage rate through intensive
longitudinal Board Review coursework, by enhancing the didactic and clinical experiences of each clinical
rotation, and by identifying and mentoring those individuals with a record of weak performances on
monthly examinations and the annual in-training examination
Expand use of simulation in training
Expand and track the scholarly output of the Internal Medicine residents
Enhance the mentoring program for residents
20
Establish an annual alumni event

Continue efforts to recruit USC and other high-quality medical students into our program
Study and document the impact of curricular innovations
Maintain ACGME accreditation
Medical Student Educator
Jeffrey Canceko, MD
Sonya Earley, PA-C
Associate Director
Medical Student Program Coordinator
Matthew Johnson, MD
Nikoo Safdari
Administrative Responsibilities

Assignment of senior medical students to four-week blocks of inpatient Internal Medicine Sub-internship

experiences at LAC+USC, KH, Huntington Memorial Hospital (Huntington) and Santa Barbara Cottage

Hospital (Cottage)

Assignment of junior students to six-week blocks of inpatient Internal Medicine experiences at LAC+USC

and Huntington

Assignment of senior medical students to a four-week ambulatory elective rotation with a community-

based faculty preceptor

Preparation and distribution of orientation and curriculum materials to all student participants at all sites

Coordination of faculty instructor assignments with the Education Officers in each of the Departments
divisions

Distribution and retrieval of faculty and resident evaluations of students and student evaluations of faculty,

residents and the program every four to six weeks

Creation of a summary grade and narrative final evaluation for each junior and senior student at all sites

Assignment of all faculty advisors in the Department of Medicine

Career counseling for students seeking careers in Internal Medicine

Preparation and distribution of approximately 80 letters of recommendation for residency training each
year
Internal Medicine Clerkships

Each medical student participates in a required six-week Junior Internal Medicine Clerkship and a four-week Senior
Internal Medicine Sub-internship. Nearly all students complete Medicine I in their third year of medical school
and Medicine II in their fourth year. Approximately 80% of students are assigned to LAC+USC Medical Center
for their junior and senior Internal Medicine experiences. The remaining students are assigned to one of three other
sites: KH, Huntington or Cottage. All students, regardless of training site, are responsible for mastering the learning
objectives and curriculum appropriate for their level.
At LAC+USC, third- and fourth-year medical students are integrated onto a General Medicine team consisting of a
faculty attending, one senior or junior resident, two interns and, typically, one fourth-year medical student and one
third-year medical student. The students participate in all aspects of patient care. While on duty at KH, Huntington
and Cottage, students are assigned clinical duties under the supervision of attending physicians and residents.
21
Undergraduate Medical Education
Program Director
Curriculum
Junior and senior medical students participate in a structured case-based curriculum developed from a nationally
recommended program from the Clerkship Directors of Internal Medicine. In addition, junior students have weekly
Student Morning Report with Dr. Jeffrey Canceko or other faculty, weekly ethics conferences, special exposure
to the cardiac catheterization lab, and one session of Clerkship Director Rounds with Dr. Canceko or Residency
Physician Leadership. Fourth-year medical students also participate in a one-hour problem-solving session per week
with Dr. Canceko and a series of clinical workshops conducted by hospital medicine/generalist faculty. Lastly, all
students meet at least once weekly for a total of two hours of case-based teaching with their faculty attendings on
the General Medicine Service. All medical students are encouraged to attend the core residency conference and
morning report.
Junior and senior medical students are assigned to work directly with attending physicians and residents in the
provision of patient care. In the inpatient setting, patients are assigned to students upon admission (third-year
students receive one to two admissions each call day; fourth-year students receive two to three, typically more
challenging, admissions). They perform histories, physical examinations and common procedures. The students
present their patients on rounds, make daily assessments and write daily progress notes and orders. Supervision is
provided by the attending physician and residents. During ambulatory assignments, students are integrated into all
aspects of patient care delivery and practice management.
The Internal Medicine Clerkship incorporates an Observed Structured Clinical Assessment (OSCA), and both the
Internal Medicine Clerkship and Sub-internship incorporate an Observed Structured Clinical Evaluation (OSCE),
designed to enhance the clinical skills of medical students in evaluating patients with heart or lung disease and
emergent inpatient care issues. Junior medical students meet with Sonya Earley, PA, for a comprehensive review of
their patient/physician communication styles and history and physical examination skills as demonstrated in their
OSCA experience.
Evaluations and Grading

Student performance is assessed by written evaluations from attendings and medical residents, their OSCE
score, required course work and a final standardized National Board of Medical Examiners subject examination.
Additionally, students evaluate the faculty and resident supervisors as well as the program as a whole. USC medical
students may receive grades of Honors, High Pass, Pass, Fail or Incomplete in their required core clerkships.
Approximately 22% of junior students and 38% of senior students received grades of Honors in their respective
clerkships (Internal Medicine or Sub-internship). Approximately 77% and 61% of junior and senior students,
respectively, received grades of High Pass, and the remaining 1% in each clerkship received grades of Pass.
Future Goals and Plans

To increase the use of simulation (especially the Sims Man) in medical student education

To study and document the impact of curricular innovations

To increase Department of Medicine faculty contact with medical students during all four years of medical
school

To continue the promotion of USC student participation in the USC Internal Medicine Interest Group and

the American College of Physicians

To actively recruit USC medical students to choose careers in Internal Medicine and to remain at USC for

their postgraduate training
22
Acute Myocardial Infarction: Diagnosis

and Management
Adult Congenital Heart Disease
Angina: Diagnosis and Treatment
Angioplasty and New Interventional
Devices
Cardiac Arrhythmias and
Anti-Arrhythmic Drugs
Cardiac Catheterization
Cardiac Transplantation
Congestive Heart Failure: Etiology and
Therapy
Coronary Bypass Surgery: Indications
and Outcome
Echocardiography
Endocarditis and Pericarditis
Pacing: Temporary and Permanent
Stress Testing
Valvular Heart Disease: Diagnosis and
Treatment
Dermatology
Bacterial Infections
Changes in Diabetes and Other
Endocrinopathies
Changes in Pneumatic Diseases
and Other Syndromes of Systemic
Importance
Cutaneous Oncology
Drug Reactions
Eczemas and Papulosquamous Diseases
Fungal Infections
Parasite Infections and Infestations
Syphilis
Viral Infections
Diabetes, Hypertension,
Endocrinology and Nutrition
Diabetes and its Complications
Diabetes and Pregnancy
Diabetic Emergencies
Diabetic Nephropathy
Disorders of the Adrenal Gland
Intensive Insulin Therapy
Metabolic Issues and Diseases
Osteoporosis
Pathogenesis of NIDDM
Pituitary Disease and Assessment
Prediction and Prevention of IDDM
(Type I Diabetes)
Thyroid Function Tests Interpretation
Gastrointestinal and Liver

Diseases
Acute and Chronic Pancreatitis

Acute Hepatic Failure
Alcoholic Liver Disease
Cholestatic Liver Disease
Chronic Hepatitis
Colon Polyps, Diverticula and Irritable
Bowel Disease
Complications of Cirrhosis Ascites/
Encephalopathy/Hepatorenal
Syndrome
Diarrhea
Drug-Induced Liver Disease
GI Bleeding
Inflammatory Bowel Disease
Pathogenesis and Treatment of
Gallstones
Peptic Ulcer Disease
Swallowing Disorders and Reflux
Viral Hepatitis Serology Interpretation
General Medicine
Cerebrovascular Disease and Stroke

Common Drug Interactions and
Complications
End-of-Life Care
Headache
Interpretation of Diagnostic Tests
Lipid Disorders
Medical Consultation of the Surgical
Patient
Medical Ethics
Womens Health Issues
Geriatric Medicine
Dementia
Depression in the Elderly
Diabetes in the Elderly
Falls
Incontinence
Long-Term Care
Multidisciplinary Geriatric Assessment
Normal Aging versus Disease
Use of Medications in the Elderly
Hematology
Acute Leukemia
Anemias: Thalassemia and Sickle Cell
Chronic Lymphoid Leukemia and
Lymphoma
Disorders of Platelet Number and
Function (ITP, TTP, etc.)
Hematologic Manifestations of HIV
Hemostasis and Interpretation of
Coagulation Assays
Interpretation of the CBC and Blood
Smear
Multiple Myeloma and Hodgkins
Disease
Myeloproliferative Diseases:
Polycythemia and Chronic
Myelogenous Leukemia
Regulation and Differentiation of the
Bone Marrow
Infectious Diseases
AIDS Fundamentals
Fungal Infections and Their Therapy
Gastrointestinal Infections
Immunizations
Infections in the Compromised Host
Musculoskeletal Infections
New Infectious Diseases
Overview of Antibiotics
(Aminoglycosides and Quinolones)
Overview of Antibiotics (Beta Lactams)
Overview of Antibiotics
(Miscellaneous Agents)
Parasitic Infections
Respiratory Infections
23
STDs other than AIDS

Tuberculosis
Urinary Tract Infections

Acid: Base Problems
Acute Glomerulonephritis
Acute Renal Failure
Chronic Renal Failure
Hematuria
Hypercalcemia and Hypocalcemia
Hypertension
Potassium Disorders
Syndrome of Phosphate Depletion
The Nephrotic Syndrome
Oncology
Biological Therapy Applications

Biological Therapy Principles
Breast Cancer Prevention
Breast Cancer Treatment
Colorectal Cancer: Prevention,
Diagnosis and Treatment
Curative Chemotherapy (Germ Cells)
Ovarian Cancer Biology and Therapy
Principles of Adjuvant Therapy
Principles of Cancer Screening
Prostate Cancer: Diagnosis and
Treatment
Tumor Cell Cycle and Growth
Pulmonary and Critical Care

Medicine
Asthma
Chronic Obstructive Pulmonary
Diseases
Hemodynamics
Interstitial Lung Diseases
Oxygen Transport
Pleural Effusion/Pneumothorax
Pulmonary Embolism
Pulmonary Function Testing and Blood
Gases
Pulmonary Infections in AIDS
Respiratory Failure
Septic Shock
Ventilator Management and Weaning
Rheumatology and
Immunology
Autoimmunity
Common Rheumatic Syndromes
Crystalline-Induced Arthritis
HLA B27-Associated Arthritis
Lupus
Rheumatoid Arthritis
Scleroderma
Understanding the Immune System
Other Services
Gynecology for the General Internist

Managed Care and Health Care Delivery
Systems
Orthopedics for the General Internist
Otorhinolaryngology for the General
Internist
Psychiatry for the General Internist
Graduate Medical Education Core Curriculum
Faculty
Distinguished Professor
Professor Emeritus
Assistant Professor
Shahbudin H. Rahimtoola, MD
L. Julian Haywood, MD
Philip M. Chang, MD
Michael A. Gaglia, MD
Parveen K. Garg, MD
Henry W. Huang, MD
Tomas Konecny, MD, PhD
Tracy D. Lawrence, MD
Anilkumar O. Mehra, MD
Vivian Mo, MD
Jina Sohn, MD
Andrew J. Yoon, MD
George C. Griffith Professor of Cardiology
Professor
Uri Elkayam, MD
Howard N. Hodis, MD
Harry J. Bauer and Dorothy Bauer Rawlins Professor

of Cardiology
Robert A. Kloner, MD, PhD

Ray V. Matthews, MD
Leslie A. Saxon, MD (Clinical Scholar)
Jerold S. Shinbane, MD
Associate Professor
Leonardo C. Clavijo, MD, PhD
Rahul N. Doshi, MD
Michael W. Fong, MD
Luanda P. Grazette, MD
Enrique L. Ostrzega, MD (Educational
Scholar)
David M. Shavelle, MD
Helga Van Herle, MD
Clinical Instructor
James Chao, MD
Antreas Hindoyan, MD
24
Ray V. Matthews, MD, Professor of Clinical Medicine and Chief
Jasmin C. Hernandez, Division Administrator
The Division of Cardiovascular Medicine is at the forefront of the diagnosis and treatment of cardiovascular disease.
The scope of activities in the Division ranges from the early diagnosis and treatment of patients identified as at
risk for cardiovascular disease to cutting-edge medical, device and invasive therapies for patients with established
disease. We are dedicated to preventing, treating and expanding the existing knowledge base of the causes of
cardiovascular disease to ensure the best outcomes for our patients. Our spectrum of activities includes clinical care,
research, and patient and physician education.
An important part of the Divisions clinical activities is its integral role in the Cardiovascular Thoracic Institute
(CVTI). The CVTI is comprised of cardiovascular specialists including cardiothoracic surgeons, vascular surgeons
and cardiologists who are organized to ensure that experts across specialties communicate and partner to deliver
the very best in patient care and produce the highest quality research in cardiovascular disease. The goal is to
provide patients with a collaborative expert opinion regardless of how they access the system. The newest and most
promising therapies are available to USC patients using this unique model of care.
At LAC+USC Medical Center (LAC+USC), the Divisions faculty participate in USCs mission to work with Los
Angeles County to provide high quality healthcare to the underserved. We oversee several outpatient cardiology
clinics, a busy consultation service for inpatients and a coronary care unit service. We also provide services
and laboratories in echocardiography, stress, state-of-the-art cardiac catheterization and electrophysiology.
Outpatient services have been expanded at LAC+USC to include heart failure, adult congenital heart disease and
electrophysiology services.
Research programs in the Division include large-scale clinical trials within the Cardiovascular Research Unit
(CRU). Faculty researchers conduct studies designed to assess the benefits of a wide variety of therapeutic
interventions, including pharmacological agents, intracardiac or vascular sensors, endovascular therapies,
percutaneous valve technologies and more. We are dedicated to the development of innovative technologies that
may enable major preventive and/or critical therapeutic measures at the earliest stages of disease development.
The USC Center for Body Computing (CBC) is a digital health innovation center that continues to partner with
USC schools and institutes on multidisciplinary projects and research with private industry sponsors to further the
field of connected, wireless healthcare. Through innovative research and education, the CBC is working to create
a new service model for health care delivery and patient, provider and caregiver engagement through the use of
smart phone technology, wearable sensors and mobile apps. The CBC has become internationally recognized and
has launched national research studies, garnering attention for the creative boundary-pushing vision of offering
borderless medical care and tailored medical content to patients at USC and beyond.
The Division of Cardiovascular Medicine continues to expand its distinguished faculty with the addition of
electrophysiologist, Dr. Tomas Konecny.
25
Clinical Activities

The Division of Cardiovascular Medicine has an active clinical practice at LAC+USC, which includes a 20bed CCU with telemetry capabilities, consultative services and outpatient cardiology clinic, as well as general
cardiology, interventional, electrophysiology and 24-hour consultation services. The Cardiac Catheterization and
Electrophysiology laboratories are under the supervision of the Division, with programs in interventional cardiology
and interventional electrophysiology. The Division also runs a busy STEMI-Receiving Center at LAC+USC
with consistently top performing door-to-balloon times within the Los Angeles County system. The noninvasive
diagnostic laboratories provide echocardiographic services such as TTE, TEE and stress echocardiography, while an
exercise laboratory provides stress testing and Thallium and Sestamibi rest and stress radionuclide imaging to detect
myocardial ischemia in appropriately symptomatic patients. The ECG service interprets complex ECGs performed,
while a 24-hour Holter monitoring service provides application and interpretation of Holter rhythm monitoring
to assess symptoms and signs of cardiac arrhythmias. The Division oversees outpatient cardiology clinics
including multiple subspecialty clinics in congenital heart disease, interventional cardiology, vascular medicine,
electrophysiology, heart failure disease management and high-risk pregnancy.
Private Practice
Keck Hospital of USC
The Division provides 24-hour consultative services as well as direct patient care to cardiovascular disease
inpatients at Keck Hospital of USC (KH) and USC Norris Cancer Hospital (Norris). Diagnostic and therapeutic
services are offered, such as cardiac catheterization, coronary and peripheral intervention, supported high-risk
coronary intervention, percutaneous therapy of structural heart disease and electrophysiology procedures, including
ablation and device implantation. The Division also offers many novel investigational therapies that are not yet
available in the community.
The core multidisciplinary Advanced Heart Failure Team provides a 24/7 outpatient service. This unique
collaboration in partnership with the KH Cardiovascular Service Line ensures high-level quality care, continuity
of patient care, and optimal use of advanced mechanical, transplant and other high-risk, high-cost therapies. This
beacon program serves as a national model of contemporary care for patients with advanced heart failure.
Cardiovascular Thoracic Institute
The CVTI utilizes a unique model for patient care and for the diagnosis, treatment and research of cardiovascular
diseases through collaboration between cardiovascular specialists. The Institute provides comprehensive
assessment of symptoms, medical history and physical exam findings to initiate an individualized diagnostic
work-up and therapeutic plan that incorporates state-of-the-art studies, including rest and stress echocardiographic
studies, radionuclide myocardial perfusion rest and stress perfusion imaging,
ultrasound peripheral vascular studies, 3Tesla magnetic resonance imaging
and cardiovascular CT imaging. The CVTIs Arrhythmia Center provides
comprehensive arrhythmia assessment, monitoring with Holter and event
monitors, genetic testing and comprehensive pacemaker and implantable
cardiac defibrillator assessment and follow-up, including internet-based remote
monitoring. There is also a comprehensive program for the management of
atrial fibrillation and use of catheter-based procedural therapies performed in the
electrophysiology laboratory or with minimally invasive surgical techniques in the
operating room. The USC Adult Congenital Heart Disease Care Center provides
comprehensive multidisciplinary continuity and transition of care into an adult
setting for adolescent patients reaching adulthood, through collaboration with the
congenital heart experts at Childrens Hospital Los Angeles. The Heart Failure
core program team has expertise in surgical device and medical management, and
runs a weekly Ventricular Assist Device (VAD) clinic.
26
Cardiovascular Medicine Fellows
Class of 2016
Class of 2017
Class of 2018
Michael Aldridge, MD
Lucas Christianson, MD
Khuyen Do, MD
Roy Lin, MD
Meena Narayanan, MD
Anisha Rastogi, MD
Andres Cortes, MD
Mark Goleski, MD
Neel Kapasi, MD
Rani Upadhyay, MD
Erika Jones, MD
Donna Kang, MD
Kenneth Kita, MD
Aaron Wolfson, MD
Electrophysiology
Interventional
Vascular
Heart Failure
Steve Carlson, MD
Sarah Elsayed, MD
Allen Kuo, MD
Ashwat Dhillon, MD
Haroon Yousaf, MD
The Divisions faculty remains committed to the training of the future generation of cardiologists.The mission of
the multifaceted and multidisciplinary USC Cardiovascular Medicine Fellowship Program is to educate fellows
in the comprehensive assessment and management of patients with cardiovascular disease processes.Under the
leadership of Director Dr. David Shavelle and Associate Director Dr. Vivian Mo, the program includes a rich,
comprehensive experience that combines clinical training at LAC+USC, Keck Medical Center of USC and
the Cardiovascular Thoracic Institute; a curriculum that encompasses all aspects of Cardiovascular Medicine,
including clinical cardiology, cardiovascular MR, cardiovascular CT, echocardiography, nuclear cardiology, cardiac
electrophysiology, cardiac intervention, congenital heart disease and congestive heart failure; and opportunities
for clinical and basic research.Additionally, the Division boasts five advanced subspecialty fellowship programs:
clinical cardiac electrophysiology, interventional cardiology, advanced heart failure, vascular medicine and
echocardiography.
The educational experience extends to the education and training of Internal Medicine house staff, USC medical
students and visiting medical students.House staff and students are assigned to the ICCU and the Cardiovascular
27
Medicine ward and participate in all rounds and educational activities.Four interns and nine residents are assigned
to Cardiovascular Medicine on a monthly basis and provide patient care under the supervision of the fellows and
staff on the Cardiovascular Medicine ward, CCU and consult service.Residents also participate in the outpatient
clinic and spend elective time in the inpatient areas or in the imaging, interventional or electrophysiology
laboratories.
Research Activities
The Divisions comprehensive conferences are available to students, house officers, fellows and faculty.Core
curriculum is scheduled weekly, while Visiting Professor Rounds alternate with the Griffith Professor Rounds,
Morbidity & Mortality Conference, Research Conference, EP/EKG Conference, Congenital Heart Disease
Conference, Cath Conference, Noninvasive Conferences and Interventional Conference on a bi-weekly basis.
Journal Club, which provides fellows with practice on critical analysis of research methods and outcomes, is held
monthly by fellows with guidance from a faculty member.The Division also sponsors occasional special lectures
featuring renowned visiting cardiologists. At the start of each academic year, the core curriculum, a series of lectures
on basic and clinical topics in Cardiovascular Medicine, is given by the faculty to the Cardiovascular Medicine
fellows.
The Division is actively conducting various research projects under the oversight of its Cardiovascular Research
Unit (CRU), directed by Dr. Ray Matthews (Medical Director) and Dr. Leonardo Clavijo (Associate Director). Areas
of research include carotid artery disease, coronary artery disease, ischemic heart disease and myocardial infarction,
congenital heart disease, heart failure and electrophysiological heart disorders. The CRU specializes in cuttingedge technology for pacemaker and cardiac devices and oversees all investigator-initiated, federal, foundation and
industry-sponsored studies in the Division of Cardiovascular Medicine, working closely with the USC Clinical
Trials Office (CTO), Department of Contracts and Grants (DCG) and the USC Health Sciences Campus Institutional
Review Board (IRB). The Division also has an active technology development program and has worked closely
with the USC Stevens Institute for Innovation and outside entities to develop new technology and use of modern
communication modalities to diagnose cardiovascular disease and fully engage patients and patients families and
caregivers. Currently, the Division has 48 federal, foundation and industry sponsored protocols and 10 investigatorinitiated protocols.
Faculty Research Areas

Philip M. Chang, MD
Permanent Pacing in Single

Ventricle Patients
Arrhythmias in Adults with
Congenital Heart Disease
Postoperative Arrhythmia
Management
Cardiac Resynchronization Therapy
Heart Disease in Pregnancy

Valvular Heart Disease
Michael W. Fong, MD
Mechanical Circulatory Support in

Cardiogenic Shock
Cardiac Imaging in the Detection of
Transplant Allograft Vasculopathy
Chemotherapy-Induced Cardiotoxicity
Percutaneous Coronary Interventions

Critical Limb Ischemia
Endovascular Treatment of Peripheral
Arterial and Venous Vascular Disease
Vascular Biology: Endothelial
Dysfunction-Inflammation,
Angiogenesis-Arteriogenesis
Michael A. Gaglia, MD
Rahul N. Doshi, MD
Peripheral Artery Disease

Cardiovascular Epidemiology
Inflammatory Biomarkers
Cardiac Devices
Cardiac Resynchronization Therapy
Arrhythmia
Atrial Fibrillation Ablation
Ablation
Uri Elkayam, MD
Congestive Heart Failure

Cardiovascular Pharmacology
Socioeconomic and Racial Disparities

Novel Antiplatelet Therapy
Platelet Function Testing
Peripheral Vascular Disease
Coronary Artery Disease
Parveen K. Garg, MD
Cardiac Recovery and Regeneration

Chemotherapy-Induced Cardiomyopathy
Biomarkers as a Tool in the
Management of Heart Failure
28
Myocardial Ischemia
Pathophysiologic Mechanisms and
Clinical Parameters
Clinical Mechanisms and Management
of Cardiac Arrhythmia
Cardiovascular Manifestations of Sickle
Cell Anemia
Noninvasive Procedures for
Cardiovascular Diagnosis
Clinical Management of High Blood
Pressure
Psychosocial and Socioeconomic
Factors in Cardiac Illness
Percutaneous Cardiac Support Devices

Advanced Cardiac Imaging
Howard N. Hodis, MD
Atherosclerosis
Henry W. Huang, MD
Nuclear Cardiac Imaging

Lipids and Cardiovascular Risk
Hypertension
Myocardial Infarction
Stem Cells for Myocardial Dysfunction
Arrhythmias in Patients with Sleep

Apnea
Arrhythmias in Patients with Chronic
Obstructive Pulmonary Disease
(COPD)
Novel Treatment Strategies for Atrial
Fibrillation and Sudden Cardiac
Death
Right Heart Pressure Using

Echocardiography as a Guide
Women and Heart Disease
Cardiac Issues in Liver Transplant
Ray V. Matthews, MD
Supported High Risk Coronary

Intervention
Peripheral Vascular Disease
Implantable Heart Failure Sensors
Percutaneous Aortic Valve Replacement
Vivian Y. Mo, MD
Jina Sohn, MD
Angiogenesis
Hibernating Myocardium
Patent Foramen Ovale (PFO) Closures
Restenosis: Role of Radiation,
Inflammation and Cytokines
Cardiac Imaging by Echocardiography
Cardiovascular Disease in Women
Right Ventricular Function
Pharmacological Treatment of Valvular
and Coronary Artery Diseases
Valvular and Coronary Artery Surgery
Hibernating Myocardium
Leslie A. Saxon, MD
Heart Failure
Cardiac Devices
Arrhythmias
Med Device Big Data
Mobile Applications for Disease
Management
Wearable and Implantable Sensor
Technology
Elite Athletic & Military Performance &
Resiliency Evaluation
ST Segment Elevation Myocardial

Infarction
Chronic Limb Ischemia
Percutaneous Left Ventricular Support
Devices
Advanced Cardiac Imaging of
Cardiovascular Substrates
Heart Failure and Cardiac Devices
Echocardiography and Application in
Clinical Settings
Helga Van Herle, MD
Preventative Cardiology
Cardiovascular Disease in Women
Cardiac Evaluation of Solid Organ
Transplant Candidates
Application of Information Technology
in Medicine
Andrew J. Yoon, MD

Myocardial Structure and Function
Cardiac MRI Scanning
Research Highlights
Dr. Shavelle is involved in several research studies: he is a Principal Investigator and is on the National Steering
Committee for the post FDA approval CardioMEMS study that is evaluating the use of the CardioMEMS HF device
in patients with class III NYHA heart failure; he is a Co-Investigator for the PARACHUTE IV clinical trial that is
evaluating the use of a novel device placed within the left ventricular apex to improve cardiac function in patients
with class III NYHA heart failure; and he is a Principal Investigator for a stem cell therapy study called ALLSTAR
that is evaluating the use of a novel form of stem cells for patients with a prior anterior wall myocardial infarction.
Ray V. Matthews, MD
Dr. Matthews, Chief of Cardiovascular Medicine is Co-PI along with Dr. Vaughn Starnes, Chief of Cardiac Surgery,
of a clinical trial to investigate the percutaneous implantation of a heart valve called CoreValve for the treatment
of aortic stenosis. This is a large, randomized, landmark trial that addresses the future treatment of valvular heart
disease.
Dr. Matthews is Principal Investigator and a member of the steering committee for the clinical investigation of a
new implantable defibrillator that can detect and then alert a patient when a heart attack occurs, which will save
precious time to treatment.
Rahul N. Doshi, MD
Dr. Doshi, Director of Electrophysiology, is Principal Investigator for the Leadless II NANOSTIM study, which
examines a revolutionary pacemaker that is smaller than conventional pacemakers and doesnt require wire leads.
Leslie A. Saxon, MD
Dr. Saxon founded the USC Center for Body Computing (CBC) in 2007. The Center helps extend the reach and
depth of CVTI research by working with outside entities as diverse as Apple, VSP Global, Qualcomm, Proteus
Digital Health, St. Jude Medical, the United States Army Research Lab and the NFL, to name a few. Collaborating
with the CVTI and the Keck School of Medicine of USC, the CBC is conducting feasibility studies with state-ofthe-art devices that can wirelessly monitor patients remotely, in addition to creating social networks, mobile apps
29
and virtual care providers to help extend the reach of the CVTI cardiovascular specialists to our patient populations
locally, and one day, nationally.
Philip M. Chang, MD
Dr. Chang is the medical director of the Adult Congenital Heart Disease Care Program
and an Electrophysiologist in the division. He has been the site Principal Investigator
for the SAMURAI study, which examines a new MRI safe pacemaker, and the QuadPAS study, evaluating the long-term efficacy of a quadripolar left ventricular pacing
lead. He is also a Co-Investigator for our sites participation in the Nanostim leadless
pacemaker trial and the Principal Investigator for our sites participation in the preand post-market approval studies for the subcutaneous implantable defibrillator. He
is also actively involved in research examining means and outcomes of transitioning
young adult patients with congenital heart disease.
Dr. Clavijo is Principal Investigator of the Same Day Discharge study, which is an
investigator-initiated study sponsored by Abbott. The purpose of this study is to
compare the strategies, outcomes and complication rates of early (same day) versus
delayed (day after the procedure) hospital discharge in patients undergoing single and
multi-vessel stenting of types A, B and C lesions.
Dr. Clavijo is also Principal Investigator and author for ASA/Plavix and STTClips, which are studies that examine clot prevention and high on-treatment platelet
reactivity in patients with critical limb ischemia.
Division HIghlights
Highlighted Publications
The Division published 60 peer-reviewed research papers during the period of January 1 through December 31,
2015, and 11 more are in press. Of these, five are highlighted below:
Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch J, Tomassoni GF, Friedman PA, Estes III M, Ip J, Niazi I,
Plunkitt K, Banker R, Porterfield J, Ip JE, Dukkipati SR: Percutaneous Implantation of an Entirely Intracardiac
Leadless Pacemaker. N Engl J Med 373(12):1125-1135, 2015.
Cardiac pacemakers are limited by device-related complications, notably infection and problems related to
pacemaker leads. This study focused on a miniaturized, fully self-contained pacemaker that is nonsurgically
implanted in the right ventricle with the use of a catheter.
McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich R, Ewald G, Moki K, Alexis JD, Ramani GV, Semigran
MJ, Haythe J, Markham DW, Marek J, Gorcsan J, Wu WC, Lin X, Halder I, Pisarcik J, Cooper LT, Fett J for the
IPAC Investigators: Clinical Outcome for Peripartum Cardiomyopathy in North America; Results of the
Investigation of Pregnancy Associated Cardiomyopathy (IPAC) Study. J Am Coll Cardiol 66:905-14, 2015.
Peripartum cardiomyopathy (PPCM) remains a major cause of maternal morbidity and mortality. This study sought
to prospectively evaluate recovery of the left ventricular ejection fraction (LVEF) and clinical outcomes in the
multicenter IPAC Study.
Herring MJ, Dai W, Hale SL, Kloner RA. Rapid Induction of Hyptothermia by the ThermoSuit System
Profoundly Reduces Infarct Size and an Anatomic Zone of No-Reflow following Ischemia/Reperfusion in Rabbit
and Rat Hearts. J Cardiovasc Pharmacol Ther 20:193-202, 2015.
Therapeutic hypothermia has shown cardioprotective effects but delivering it quickly and safely to patients has been
problematic. This new noninvasive technique uses immersion-convection technology to induce rapid and
effective hypothermia. In 2 separate preclinical models it reduced myocardial infarct size and no reflow
dramatically. The device is currently FDA approved to treat hyperthermia; clinical studies are needed to test it in
patients with STEMI.
30
Saxon LA. Mobile Health Application Solutions. Circulation 9:e002477, 2015.

A comprehensive review of the current landscape of digital health technology creation, regulation and use for
management of the cardiovascular patient. Digital technology has revolutionized how health care consumers access
health information and tools for managing their disease. Many of these solutions are being tested and created at the
USC Center for Body Computing in collaboration with public and private partners and are highlighted.
Shavelle DM, Kirtane AJ, Schreiber TL, Kapasi NK, ONeill WW, Moses JW, Popma J, Matthews RV: Impact of
Surgical Consultation on Outcomes in Hemodynamically Supported High-Risk Percutaneous Coronary Intervention:
Insights from PROTECT II Randomized Study. J Invasive Cardiol [Epub ahead of print], 2015.
In observational studies of patients undergoing percutaneous coronary intervention (PCI), surgical ineligibility is
associated with increased mortality. Whether the use of hemodynamic support during PCI can mitigate the adverse
prognostic importance of surgical ineligibility is unknown. In this high-risk cohort of patients undergoing
hemodynamically supported PCI, clinical outcome was not associated with an antecedent request for surgical
consultation (presumed surgical ineligibility). Whether the use of hemodynamically supported PCI can lessen the
risk conferred by surgical ineligibility requires further study.
Structural Heart Disease Program
The Structural Heart Disease Program at the Keck Medical Center of USC applies a multidisciplinary approach
to the management of patients and includes interventional cardiologists, cardiac surgeons, cardiovascular imaging
experts, cardiac anesthesiologists and advanced care nurse practitioners. Percutaneous aortic valve implantation
forms the core of the program with the Medtronic Core Valve (St. Jude Medical) and the Edwards Sapien XT valve
(Edwards Lifesciences). To date, over 300 percutaneous aortic valve implants have been performed. In addition
to the currently available FDA approved devices, ongoing clinical trials evaluating next generation percutaneous
valves (Portico valve, St. Jude Medical) and treatment options (Medtronic Core Valve for usual operative
risk patients, SURTAVI trial) are also available. Additional structural heart procedures include mitral balloon
valvuloplasty, pulmonary valve implantation (Melody valve, St. Jude Medical), left atrial appendage closure,
alcohol septal ablation for hypertrophic cardiomyopathy and perivalvular defect closure.
Electrophysiology Program
The Electrophysiology Team specializes in all aspects of cardiac rhythm management,

treating arrhythmias with curative procedures called catheter ablations, all aspects
of pacemaker implantation/extraction, preventing sudden death and improving heart
function with implantable cardiac defibrillators. The group offers an established
program to treat the most common arrhythmia atrial fibrillation. USC specializes in
a multidisciplinary approach for atrial fibrillation, including catheter ablation, device
implantation and management of underlying risk factors. The Electrophysiology Team
is also involved in cutting-edge research and offers innovative technology for the
treatment of these disorders.
Vascular Medicine Program
Electrophysiologist, Tomas Konecny, MD
The Vascular Medicine Clinical and Training Program at USC integrates the specialties of vascular surgery,
preventive cardiology and interventional cardiology to bring the best preventive and curative therapies to patients at
risk for or suffering from peripheral vascular disease. The Vascular Medicine Program offers a fellowship training
program with outstandingly rich training in both clinical and didactic vascular medicine and a wide spectrum of
clinical and basic science research opportunities with a strong emphasis on critical limb ischemia (CLI).
Heart Failure Program
The Advanced Heart Failure and Cardiomyopathy Program is a key branch of the USC Center for Advanced Heart
Failure. The dedicated Heart Failure team takes a multidisciplinary approach, working with all subspecialties in
cardiology as well as cardiothoracic surgery, to develop the best treatment plan for heart failure patients. The Heart
Failure team expanded its care to a Ventricular Assist Device (VAD) clinic as well as a bi-weekly Heart Failure
Disease Management clinic for heart failure patients recently discharged from KH. The program has an ACGME
accredited subspecialty fellowship in Advanced Heart Failure and Transplant Cardiology. An implantable pulmonary
artery sensor called the CardioMems was recently FDA approved for use in the noninvasive monitoring at home of
31
heart failure patients, targeted at reducing heart failure admissions. USC has been selected as a regional training site
for other cardiologists to learn about this valuable modality.
Center for Body Computing
The Center for Body Computing was founded in 2007 by Executive Director Dr. Leslie Saxon. The USC Center
for Body Computing (CBC) is an interdisciplinary brain trust that brings together the Keck School of Medicine of
USC, the renowned USC School of Cinematic Arts and the Universitys schools of Business and Engineering to
advance wireless health opportunities in collaboration with industry partners. Digital health can extend the reach
of our most talented physicians, preserve innovation and advance technological development. The CBCs purpose
is to creatively synthesize medicine, engineering, business, communications and entertainment arts into new
paradigms that will innovatively enhance quality of life, especially for the two billion people worldwide who lack
access to healthcare. Considered one of the most comprehensive wireless health institutes in the world, the CBC
has developed award-winning medical applications and pioneered significant research. We are currently working
on several social media prototypes, advancing athletic biosensing, studying the role of Big Data in healthcare and
creating apps for chronic disease management. The CBC also hosts the annual Body Computing Conference, which
is known as the premier event of its kind.
32
Wright Foundation Pilot Grant Award, 2015
Outstanding Fellow of the Year, Department of Medicine, Keck School of Medicine of USC, 2015
Enrique L. Ostrzega, MD
Best Sub-Specialist of the Year Award, Department of Medicine, Keck School of Medicine of USC, 2015
Faculty Teaching Award, Keck School of Medicine of USC, 2015
Golden Apple Award, Division of Cardiovascular Medicine, USC, 2015
Leslie A. Saxon, MD
Voted Most Tech-Friendly Doc in Rock Healths Top 50 in Digital Health, 2015
33
Honors and Awards
Parveen K. Garg, MD
Faculty
Professor
Associate Professor
Assistant Professor
Jorge H. Mestman, MD
Stefan Bughi, MD
John D. Carmichael, MD
Jonathan S. LoPresti, PhD, MD
Charles F. Sharp, Jr., MD
Sylvia J. Shaw, MD
Helen L. Baron, MD
Elizabeth O. Beale, MD
Wei-An Lee, DO
Caroline T. Nguyen, MD
Kathleen A. Page, MD
Hussein N. Yassine, MD
Bernard J. Hanley Chair in Medicine
Anne L. Peters, MD
Peter A. Singer, MD
Carole A. Spencer, PhD
34

Thomas A. Buchanan, MD, Professor of Medicine and Chief
Roxanne Gustovich Odom, Administrator
Division Chief Dr. Thomas Buchanan was ranked in the top 0.7% among more than 35,000 NIH-funded researchers
worldwide, with nearly $6.9M in NIH funds.
Dr. Kathleen Page was awarded a new $2.7 million grant from the National Institutes of Health in December 2015
to study brain, hormone and appetite responses to different types of sugar among obese, lean and obesity prone
individuals. Her study showing differential effects of fructose and glucose on neural and behavioral reward systems
was published in Proceedings of the National Academy of Science in May 2015, and this work received widespread
attention, including featured articles in Scientific American, The New York Times Wellness Section, Forbes and Time
Magazine.
Dr. Caroline Nguyen joined the Division as Assistant Professor of Clinical Medicine. She will focus her clinical
activities in the divisions private practice and continue her research in the role of thyroglobulin and its antibodies as
biomarkers in thyroid cancer.
Dr. Peter Singer directed the USC Thyroid Diagnostic Centers 37th Annual Symposium on Thyroid Disease. The
symposium continues to be the longest running and one of the most successful clinical meetings in the United
States.
Dr. John Carmichael directed the first Annual Southern California Pituitary Symposium at USC. He was awarded
the Teacher of the Year award for the Division of Endocrinology during his first year at USC.
Dr. Hussein Yassine edited the book Lipid Management: Basics to Clinic, which was published by Springer in
March 2015. In addition, Dr. Yassine was awarded a New Investigator Award from the Alzheimers Association
(NIRG-15-361854) to study the delivery of fish oil to the brain by APOE 4 genotype. The study tests the hypothesis
that carriers of the APOE 4 allele have reduced delivery of fish oil to the brain. Confirming this hypothesis will help
us understand a mechanism for the increased risk of Alzheimers Disease with APOE 4 status, and the potential to
prevent cognitive decline by fish oil supplementation.
Dr. Jorge Mestman Co-Directed the 17th Davidson-Mestman Annual Intensive Course on Diabetes, Endocrinology
and Metabolic Disease. The three day Spanish language course was held in Miami, Florida, to educate Spanishspeaking endocrinologists from the United States, Spain and Latin American countries. Dr. Mestman also coauthored two chapters in one of the worlds leading texts on thyroid biology and disease, Werner & Ingbars
The Thyroid a Fundamental and Clinical Text.
Dr. Anne Peters received a $1.2 million grant from the Helmsley Charitable Trust to create and pilot low-literacy
teaching tools for people from lower socioeconomic strata how have type 1 diabetes. She was also awarded a grant
called REPLACE BG from the JAEB Center to study the safety and utility of continuous glucose monitoring as
part of the development of the bionic pancreas.
Dr. Jonathan LoPresti received Teacher of the Year honors in endocrinology from Year II and Year IV medical
students.
35
Clinical Activities

Endocrine Clinics
Outpatient endocrine clinics are held twice weekly at LAC+USC Medical Center (LAC+USC). Since the addition
of John Carmichael, MD, one of these weekly endocrine clinics is now more devoted to pituitary disease, including
diagnosis and management of individuals with functional and nonfunctional pituitary tumors. Full-time faculty
members provide direct supervision (two per clinic). Each fellow evaluates four to six patients per clinic, while
the remaining 25 patients are seen by house staff and medical students assigned to the Endocrine service on a
monthly basis. In addition, fellows have the opportunity to perform thyroid ultrasound examinations and fine needle
aspirations (FNA) in each clinic setting. The primary purpose of these clinics is to provide consultation and develop
treatment plans for patients referred with endocrine problems, with the eventual goal to return the patients to their
primary care physicians for long-term care.
The Endocrine-Pregnancy clinic at LAC+USC provides care to pregnant women affected by endocrine diseases, the
most common of which are diabetes mellitus and thyroid disorders. Dr. Jorge Mestman is the director of the Clinic.
Roybal Diabetes Managed Care Program (DMP)
Based in a purpose-built diabetes center in the Roybal Comprehensive Health Center of the Los Angeles County
Northeast Cluster Healthcare Network, the DMP provides team-based comprehensive diabetes preventative care
(prevention of complications) under the co-leadership of Drs. Michael Roybal and Anne Peters. Drs. Kathleen Page,
Elizabeth Beale, Hussein Yassine and Helen Baron supervise the clinic on a day-to-day basis and oversee patient
care, and Dr. Peters provides administrative leadership. The center includes a clinical laboratory, a phlebotomy room
and an education center. The patient care plan is established by use of written, case-based protocols. This care is
implemented by diabetes nurses, nurse practitioners, social workers and dietitians in a case-based manner under the
supervision of diabetologists. The majority of the patients are Latino and most of the doctors and nursing staff at the
center speak Spanish. This program has served as a model for diabetes disease management throughout Los Angeles
County.
Endocrinology fellows also attend a continuity clinic for the care of patients with type 1 diabetes one half-day per
week. This clinic runs throughout the year and is under the supervision of Drs. Beale and Peters. The clinic provides
a venue for patients with labile diabetes, especially type 1, to receive state-of-the-art care by a specialized team of
providers. The clinic also provides fellows with the opportunity to follow these patients exclusively for the duration
of their fellowships, allowing them to develop and implement long-term management plans and establish a sense of
true doctor-patient relationships.
Thyroid Cancer Clinic
This clinic meets on a weekly basis and is designed to provide care for patients with thyroid cancer. In addition,
patients with other endocrine diseases, including those patients with pituitary disease and disorders of bone and
calcium metabolism, are seen in this clinic. The clinic is under the direct supervision of full-time faculty members
(three per clinic). Finally, the fellow serving as the monthly endocrine consult performs thyroid ultrasounds and
FNAs on those patients referred for the evaluation of a thyroid nodule. Each fellow performs, on average, four
FNAs per week during the month.
Type 1 Diabetes Clinic
A continuity clinic in diabetes has been established at the Roybal Diabetes Center to allow fellows the opportunity
to develop skills in the management of patients with complicated type 1 diabetes.
Diabetes and Metabolism Clinic
This clinic provides endocrine consultations for complex diabetes management and metabolic disorders. Presenting
with heavy medical burden within the LAC+USC Healthcare Network, these patients are referred from their
primary care medical homes for evaluation. The clinic operates five days a week and is directed by Dr. Wei-An Lee,
the supervising physician.
36
Keck Medicine of USC

Division of Endocrinology and Diabetes faculty provide clinical care for private patients at Healthcare Center 2
(HC2) and Keck Hospital of USC (KH) on the USC Health Sciences Campus, Keck Medicine of USC (UPC), at the
USC Westside Center for Diabetes in Beverly Hills and at Keck Medicine of USC in Pasadena.
Health Sciences Campus
The USC Division of Endocrinology and Diabetes provides assessment and management services for patients with a
variety of endocrine disorders, especially in the areas of diabetes, pituitary diseases, adrenal disorders and disorders
of calcium and bone metabolism. Endocrine faculty members have extensive experience in the management of
such disorders and, where necessary, utilize the state-of-the-art USC Endocrine Laboratory to assist in diagnostic
assessment. In addition, the most advanced imaging modalities are available for diagnosis. The latest in medical
management is available where surgery is not indicated; for patients who require surgery, a number of renowned
USC surgeons who specialize in endocrine surgery, especially of the pituitary gland, thyroid and parathyroid glands
and adrenal glands, are available. Clinical care is provided by Drs. Jorge Mestman, Peter Singer, Jonathan LoPresti,
Helen Baron, Wei-An Lee, John Carmichael, Caroline Nguyen and Nurse Practitioner Reiko Sasaki. Of note,
Dr. Nguyen joined the practice after completing her fellowship here at USC in 2015.
The USC Center for Diabetes and Metabolic Diseases,
directed by Dr. Mestman, is an integral part of the
Divisions private clinical practice on the Health
Sciences Campus. The center offers a comprehensive
program that includes state-of-the-art medical care
and a diabetes self-management program that has
achieved American Diabetes Association recognition.
Care is provided by a multidisciplinary team of
endocrinologists, nurse practitioners, certified diabetes
educators (CDE), dietitians and specialty physicians,
such as nephrologists, cardiologists, neurologists,
ophthalmologists and orthopedic surgeons. Services
include intensive diabetes management for individuals with type 1 and type 2 diabetes, early diagnosis and
treatment of type 2 diabetes, prevention of type 2 diabetes, gestational diabetes care, pre-conception care, diabetes
and pregnancy management and insulin pump therapy. In addition to providing patients with the opportunity to
participate in clinical trials, the center also offers two community programs: a monthly support group for patients on
intensive therapy with multiple injections or insulin pump and an annual half-day educational seminar.
USC Westside Center for Diabetes
Directed by Anne Peters, MD, CDE, and staffed by Donna Miller, RNP, CDE, and Meg Moreta, RD, CDE,
this fully functional clinic located in Beverly Hills provides state-of-the-art care to individuals with type 1 and
type 2 diabetes and pre-diabetes. Services include diabetes education and management, and treatment of lipid
disorders, hypertension and gestational diabetes. Areas of particular expertise include use of insulin pumps and
sensors, management of elite athletes, and diabetes in pregnancy. Staff members have accompanied patients to the
Olympics as well as the Indianapolis 500 to help monitor their diabetes during extreme circumstances. The center
is a participating member of the Helmsley Diabetes Registry, which includes 25,000 individuals and is the largest
database ever created for individuals with type 1 diabetes. Dr. Peters, in conjunction with other providers in the
clinic, has published a book entitled Conquering Diabetes. The clinic websites are www.uscdiabetes.com and
www.conqueringdiabetes.com. The Center recently relocated to Archway Medical Plaza in Beverly Hills.
USC Thyroid Diagnostic Center
This program, led by Peter A. Singer, MD has brought together a group of highly experienced, nationally
recognized endocrinologists who specialize in thyroid disease to work in an integrated team approach with experts
in cytopathology, nuclear medicine and the surgical subspecialties in the diagnosis and management of thyroid
37
diseases. This group has available to it one of the finest endocrine laboratories specializing in thyroid testing in the
U.S. The team of physicians in the center has particular expertise in the diagnosis and management of recurrent
thyroid cancers. Working with colleagues in surgery, oncology, radiology and nuclear medicine, the team has
developed protocols to manage even the most difficult cases. The USC Thyroid Diagnostic Center sponsored its
37th Annual Symposium on Thyroid Disease, which continues to be the longest running and most successful clinical
meeting in the United States. The USC Thyroid Diagnostic Center is pleased to welcome Caroline Nguyen, MD, an
endocrine specialist, to the team.
USC Pituitary Center
The USC Pituitary Center is a unique clinical and academic program that is fully dedicated to the treatment and
evaluation of patients with pituitary tumors and other disorders affecting areas of the hypothalamus and pituitary
gland. The center provides a cutting-edge multidisciplinary approach toward patient care under the leadership of
Co-Directors John Carmichael, MD of Endocrinology and Gabriel Zada, MD of Neurosurgery.
The center is staffed by a team of experts
in neurosurgery, neuroendocrinology,
neuroradiology, neuropathology,
neuro-ophthalmology, radiation oncology
and interventional endovascular
neurosurgery. All patients are evaluated
and discussed at weekly multidisciplinary
pituitary conferences to streamline their
care. Physicians provide a comprehensive
focus on both surgical and medical
management of pituitary tumors, including
the treatment of acromegaly, prolactinomas,
Cushings disease and non-functioning
pituitary tumors. There is also a focus on the
optimal treatment of pituitary deficiencies
and hormonal replacement for patients with
hypopituitarism.
First Annual Southern California Pituitary Symposium at USC

From left to right: Drs. Gabriel Zada, John Carmichael, Mark Molitch,
Peter Singer and Martin Weiss
The USC Pituitary Center also provides dynamic endocrine testing for both hormonal excess and pituitary
deficiencies, including growth hormone stimulation testing, testing of adrenal insufficiency, dynamic testing for
Cushings syndrome, and water deprivation testing for diabetes insipidus.
Keck Medicine of USC- Pasadena
Dr. Sharp returned to the faculty of USC in the spring of 2014 after a hiatus of 25 years as Director of the Center
for Metabolic Bone Disease in Pasadena, California, a practice dedicated to the investigation and management of
osteoporosis and diseases involving the skeleton and mineral metabolism. Dr. Sharp has merged his practice into
Keck Medicine of USC- Pasadena, where he continues to offer consultative services in his specialty. Dr. Sharp was
recently awarded the first Emeritus Professorship in Medicine at Huntington Memorial Hospital and continues to
be an active member of the teaching faculty of the Internal Medicine Residency Program at Huntington. Dr. Sharps
research interests include nutrition and bone, hypercalcemic disorders and pharmacologic treatment of osteoporosis.
He has been invited to participate in a multicenter study regarding the long-term effects of bisphosphonates in
patients with osteoporosis. Three abstracts were accepted for presentation at the 97th Annual Meeting of the
Endocrine Society in San Diego, California, in March, 2015.
USC Endocrine Services Laboratory
The USC Endocrine Services Laboratory is a fully licensed, CAP-accredited clinical laboratory that embraces the
mission of offering research-quality endocrine tests at competitive prices to physicians at USC and throughout the
U.S. The laboratory is committed to integrating new research methods and insights into clinical medicine and is
widely recognized as a quality thyroid reference laboratory. The USC Endocrine Laboratory has been featured at
recent American Thyroid Association and Endocrine Society meetings for playing an important role in transferring
TSH and thyroglobulin (Tg) methodologies from the research environment to clinical practice. Under the leadership
38
of Dr. Carole Spencer, the Endocrine Laboratory has become nationally and internationally known for its unique
approach to measuring Tg and Tg antibodies, which are used as tumor-marker tests for managing patients with
differentiated thyroid cancers.
Endocrinology Fellows
Class of 2017
Namrata Bose, MD
Emily Omura, MD
Braden Barnett, MD
Patricia Lorenzo, MD
The overall goal of our training program is to provide broad and comprehensive clinical and didactic training in
endocrinology and metabolism, as defined by the ACGME. Toward that end our four fellows participate in the
following clinical and didactic activities.
Inpatient Consultative Services

This service provides trainees with direct consultation experience (diagnosis and management) in the care
of hospitalized patients with a wide variety of endocrine and metabolic disorders, including diseases of the
hypothalamus, pituitary, thyroid, adrenals, gonads, kidneys and skin; diabetes mellitus, its acute complications and
acute manifestations of chronic complications; hypoglycemia; disorders of bone and mineral metabolism; fluidelectrolyte and acid-based disorders; perioperative management of endocrine patients; and endocrine emergencies.
The service provides trainees with experience in the education of medical students, house staff and peers regarding
the above disease processes.
All fellows achieve the goals and objectives for inpatient and consultative services through participation in inpatient/
consultative rotations for a total of 14 months during the period of training and through participation in outpatient
clinics continually throughout the training period.
The Endocrinology and Diabetes inpatient consultative service provides consultative care for 100-200 patients each
month across a full spectrum of adult endocrine diseases. The service rotation provides trainees with experience in
the management of inpatients with diseases of the hypothalamus, pituitary, thyroid, adrenals, gonads, parathyroids
and bone and mineral metabolism; fluid-electrolyte and acid-based disorders; endocrine emergencies; hormoneproducing neoplasms; treatment of endocrine neoplasia; and endocrine physiology in systemic diseases. Fellows
rotate through the service for 10 months during training and evaluate patients directly or supervise the evaluation of
patients by house staff and students who rotate through the consult service. Fellows also provide didactic teaching
relevant to the endocrinological problems encountered by the service. Cases, including pertinent diagnostic test
results (hormone levels, MRI/CT scans, ultrasounds), are reviewed with full-time faculty members during faculty
rounds, which are held for approximately two hours per day on weekdays.
During this consult service rotation, fellows are responsible for the performance of all thyroid fine-needle biopsies
(two to four per week). Dr. LoPresti and a cytopathologist conduct formal review of the cytological material.
Fellows also perform any special diagnostic tests (e.g., insulin hypoglycemia, TRH stimulation tests) that are
indicated. Fellows are required to keep a log of the biopsies and other special procedures performed during training.
Keck Medical Center of USC
The Division of Endocrinology and Diabetes provides full consultative services to Keck Hospital of USC (KH)
and USC Norris Cancer Hospital (Norris). Each fellow rotates through the KH Endocrine-Metabolism Service
for four months during the training period. Fellows see all consult patients (30-40 per month) and provide
management recommendations and/or manage the patients under the supervision of full-time endocrine-metabolism
39
Class of 2016
faculty members (primarily Drs. Singer, Mestman, Baron, Carmichael and Nguyen). KHs busy neurosurgical
and ophthalmology services provide fellows with considerable experience in the diagnosis and perioperative
management of pituitary, hypothalamic and ophthalmological disorders. Specialized consultations for pituitary
tumor management are supervised by Dr. Carmichael. Consults from Norris are primarily for the management
of diabetes (including patients on enteral and parenteral nutrition), hormone-secreting neoplasia and endocrine
abnormalities in systemic disease.
Outpatient Services
These activities provide trainees with diagnosis and management experience in the care of ambulatory patients
with a variety of endocrine and metabolic disorders, including diseases of the hypothalamus, pituitary, thyroid,
adrenals, gonads, kidneys and skin; diabetes mellitus and its chronic complications; hypoglycemia; disorders of
bone and mineral metabolism; fluid-electrolyte and acid-based disorders; reproductive endocrinology; pediatric
endocrinology; and lipid disorders.
Trainees are required to attend outpatient clinics within the Division of Endocrinology and Diabetes for a minimum
of two half-days each week throughout their training. To ensure continuity of care and experience with the longterm management of endocrine and metabolic disorders, each fellow devotes three half-days per month to his/her
own continuity-of-care clinics in diabetes, general endocrinology and thyroid disorders (one half-day per month in
each clinic). In addition, fellows attend weekly clinics in those three areas on a rotating basis. Finally, fellows spend
two to three months each year attending specialty clinics to obtain training in the following areas: hyperlipidemias,
reproductive endocrinology, pediatric endocrinology and endocrinology of pregnancy (including diabetes). During
their rotations at KH (two to three months per year of training), fellows attend two outpatient clinics.
Conferences
Conferences and lectures complement clinical training by providing trainees with basic education in the normal
physiology of endocrine systems, mechanisms of endocrine disease, laboratory techniques in clinical endocrinology
and research techniques in endocrinology and metabolism. Division of Endocrinology and Diabetes
Grand Rounds is a weekly, topic-oriented one-hour conference that varies in format from case presentations
and discussions by fellows to didactic presentations by USC and visiting faculty members. Full-time and volunteer
faculty, fellows, students and residents attend these conferences. During their training, all first-year fellows are
required to present one grand rounds, and all second-year fellows are required to give two presentations. A visiting
professor program has been established that allows nationally recognized leaders in areas of endocrinology and
diabetes to give grand rounds and meet separately with trainees to discuss their clinical and research activities and
career development.
Fellows participate in the Endocrine-Metabolism Core Curriculum, a weekly didactic lecture series,
which covers basic mechanisms of endocrine function and dysfunction, management of endocrinologic and
metabolic disorders, and clinical laboratory measurements in endocrinology and metabolism.
Journal Club is a monthly one-hour conference. Fellows present a case and a related paper, which is approved by
a faculty member with relevant clinical or research expertise. Fellows discuss with faculty members the structural
aspect of the paper (study design, data presentation and analysis, and discussion) and its relevance to management
of the clinical case.
Research Fellows either choose a topic of interest and develop a study to address a question and hypothesis they
want answered. In addition, the fellow is to present his/her actual research project if applicable.
Diabetes Teaching Rounds is a one-hour conference held monthly.

During the weekly, one-hour Thyroid
Conference, a fellow or resident presents one paper about some aspect
40
of thyroid disease for the first half-hour (paper selected by thyroid faculty). For the remaining time, a patient who
is to be seen in the thyroid clinic that morning is presented by a trainee, and the physical findings, diagnostic tests
(including thyroid and CT scans and MRIs) and management are discussed by the fellows and faculty.
At the semi-annual Performance Reviews, each fellows attendance at Division Grand Rounds and Core
Curriculum lectures is reviewed from conference sign-in sheets. Fellows are counseled if attendance does not meet
the required levels: all of the Thyroid Conferences, at least two-thirds of the Core Curriculum Lectures, and at least
two-thirds of the Endocrine-Diabetes Grand Rounds and Journal Clubs.
Formal Evaluation of Training for each trainees performance focuses on written evaluations, and performance
in clinics and inpatient/consultation services is evaluated. Evaluations are reviewed at semi-annual performance
reviews with Fellowship Program Director Dr. LoPresti, as well as at a final review. Fellows also must complete
an evaluation of the faculty and the experience at the end of each rotation. A final evaluation of each trainee is
completed by Dr. LoPresti at the end of the training period.

Non-Pharmacologic Approaches to
the Management of Type 1 and Type
2 Diabetes
Mechanism of Benefit of Bariatric
Surgery in Diabetes
Role of the Gastrointestinal Tract in
Glucose Homeostasis
Pathogenesis, Genetics and Prevention

of Type 2 Diabetes
Mechanisms for and Approaches to Beta
Cell Preservation
Stefan Bughi, MD
The Endocrinology of Stress Response

Physician Stress and Burnout
Human Factor and Medical Errors
Inpatient Management of Diabetes:
Interventions to Prevent
Hypoglycemia
Gastroparesis: an Invisible Illness
Novel Medications for the Treatment

of Acromegaly, Cushings Disease
and Growth Hormone Deficiency
Interactions between Glucose
Homeostasis and the GH-IGF-I Axis
Treatment Outcomes for Pituitary
Tumors and other Sellar Masses
Wei-An Lee, DO
Healthcare Delivery Models

Endocrine Emergencies in the
Hospitalized Patient
Role of Thyroglobulin in Management
of Thyroid Cancer
Thyroid Disease in Pregnancy

Obstetric, Thyroid and Endocrine
Diseases
Serum Thyroglobulin in Management of

Neoplastic and Other Thyroid Disease
States
and the Bionic Pancreas in Patients

with Type 1 Diabetes
Diabetes Prevention in Communities
Type 1 Diabetes Registries
Vitamin D Supplementation in
Prediabetes

Nutrition and Bone
Hypercalcemic Disorders
Pharmacologic Treatment of
Osteoporosis
Sylvia J. Shaw, MD
Effect of GLP-1 Agonist in Diabetes

with Coronary Artery Disease
Thyroglobulin and Thyroglobulin

Antibodies as Tumor Marker in
Differentiated Thyroid Cancer
Peter A. Singer, MD
Thyroid Physiology and Pathology

Thyroglobulin and Thyroid Cancer
Immunoassay Techniques
Thyroid Hormone Metabolism
Cost-Effective Use of Thyroid Tests
Neuroendocrine Regulation of Eating

Behavior
Effects of Sugar Intake on Brain Reward
and Appetite Pathways
Impact of Gestational Diabetes in utero
on Long-term Health in Offspring
Anne L. Peters, MD
Quality Improvement in Safety Net

Hospitals
Lifestyle Intervention in the Treatment
of Type 2 Diabetes
Use of Continuous Glucose Sensing
41
Thyroid Neoplasms
Lipid Disorders
Mass Spectrometry Techniques
Lipoprotein Metabolism in
Atherosclerosis and Alzheimers
Disease
Research Activities
The Divisions main research activities are currently in clinical and translational research. Current areas of
investigation include pathogenesis and prevention of type 2 diabetes; novel approaches to treatment of obesity;
brain regulation of appetite and food intake; trans-generational effects of maternal diabetes; HDL function and
atherosclerosis; clinical and community approaches to diabetes prevention and treatment; understanding the natural
history of type 1 diabetes; studying the use of new treatments and technologies for the treatment of type 1 diabetes;
and management of thyroid neoplasms.
Faculty Research Activities

Dr. Beales research interest is in the role of the gastrointestinal tract in glucose regulation and energy balance. She
is the Principal Investigator in studies investigating the mechanisms of the benefit of bariatric surgery in obesity
and diabetes, with special areas of interest in bile and incretin effects, and has received grants from the Coulter
Foundation for this work. She is also Co-Investigator on Dr. Buchanans BetaFat Study.
The BetaGene Study (Genetics of Pancreatic -cell Failure in Mexican-Americans; NIH R01-DK-061628) has
created a cohort of more than 2,000 Mexican-American women, either with gestational diabetes or with normal
glucose levels in pregnancy, and their family members. The cohort has been useful in identifying how type 2
diabetes genes contribute to the risk of the disease. Current funding examines biomarkers that may link genetic
variation to phenotypic difference in glucose regulation (R01-DK-100302).
The BetaFat Study (Beta Cell Restoration through Fat Mitigation; U01-DK-094430) is a unique collaboration
among researchers in diabetes, bariatric surgery and imaging at USC and Kaiser Permanente Southern California.
Funding supports a USC-based clinical trial to compare the effects of medical therapy (metformin) to surgical
weight loss (gastric banding) on pancreatic beta cell function in adults with pre- or early type 2 diabetes.
Dr. Beale serves as a Co-Investigator from the Division of Endocrinology and Diabetes. Dr. Namir Katkhouda from
the Department of Surgery is Co-Investigator for gastric banding; Dr. Krishna Nayak from the Viterbi School of
Engineering is co-investigator for MRI studies; and Dr. Anny Xiang of Kaiser Permanente Southern California is
Co-Investigator for data management and analysis. The study extends prior observational and interventional work
implicating excess body fat as the primary cause of beta cell failure that leads to type 2 diabetes. If successful,
it may lead to new and more aggressive approaches to weight loss early in the course of development of type 2
diabetes.
Dr. Carmichael joined the USC Department of Medicine in 2014 to form the USC
Pituitary Center. He holds a joint appointment in the Department of Neurological
Surgery. He is board Certified in internal medicine and endocrinology, diabetes and
metabolism, and has completed fellowship training in translational research. He is
currently the Principal Investigator for several studies focused on pituitary disease.
The LINC Study is a phase 3 multicenter double blind randomized withdrawal study
of LCI699, a steroidogenesis inhibitor, following a 24-week, single-arm, open-label
dose titration and treatment period to evaluate the safety and efficacy of LCI699 for
the treatment of patients with Cushings disease. The REAL1 study is a phase 3,
randomized, parallel-group, placebo-controlled (double blind) and active-controlled
(open) study to evaluate the efficacy and safety of once weekly dosing of NNC01950092 with once weekly dosing of placebo and daily dosing of Norditropin FlexPro
in adults with Growth Hormone Deficiency. The MPOWERED Study is a prospective
trial of the use of oral octreotide in the treatment of acromegaly.
Dr. Carmichael is a Co-Investigator for the USC Pituitary Center research registry and database, currently a
retrospective database that is in the process of transforming into a prospective research registry and tumor bank
to evaluate genetic, histopathological, radiological and clinical aspects of pituitary tumors. This registry forms the
basis for multiple investigations of various pituitary pathologies and already includes data on over 1,400 cases of
pituitary tumors operated on at USC. He remains a Co-Investigator on several ongoing studies at Cedars-Sinai
Medical Center that he devised and conducted during his tenure there.
Dr. Page researches how health conditions such as obesity and diabetes are impacted by the functions of the brain.
Specifically, Dr. Page is interested in understanding how the brain regulates appetite and eating behavior, and in
42
identifying early life determinants of obesity, diabetes and cardiovascular disease. An example of these determinates
is how exposure to diabetes in utero may lead to an increased risk for obesity and type 2 diabetes.
The American Diabetes Association awarded Dr. Page a prestigious Diabetes Research Accelerator Award in
January 2014 as part of the ADAs bold initiative, Pathway to Stop Diabetes. As a result of the award, Dr. Page is
researching the impacts of in utero exposure to diabetes on the likelihood of children developing obesity and type 2
diabetes later in life. Through this research, Dr. Page hopes to better understand how environmental factors impact
development of brain pathways that are important in the control of body weight and sugar levels in the blood.
Ultimately the goal is to develop strategies to prevent or counteract certain developmental exposures early in life.
Dr. Page is also Principal Investigator on two NIH-funded projects (including an R03 awarded in July 2014) that are
aimed at understanding how exposure to maternal gestational diabetes leads to an increased risk for obesity, diabetes
and cardiovascular disease in children. Detailed metabolic studies of adipose tissue biology, insulin resistance and
insulin secretion in conjunction with neuroimaging studies to examine brain appetite pathways in children are now
being conducted. In addition to funding from the NIH, this work is supported by grants from the American Heart
Association and Robert E. and May R. Wright Foundation.
Dr. Pages other research focus is on the role of the brain in the regulation of appetite
and feeding behavior in humans. She has received national recognition for this work,
including Outstanding Investigator Awards from the Western American Federation for
Medical Research, the Endocrine Society and the American Heart Association.
Dr. Page is Principal Investigator on two grants to support this work, including a
recent grant from the American Heart Association and a prestigious Clinical Scientist
Development Award from the Doris Duke Charitable Foundation. A recent project
on brain appetite regulation focused on determining how high-reward foods, such as
sugar, impact the areas of the brain that regulate appetite and food intake. Two types
of sugar, glucose and fructose, were examined in this study, and findings to date show
that the brain reacts differently to each. Functional magnetic imaging (fMRI) was used
to show that lean adults felt more satiated and had decreased activity in the regions of
the brain that regulated activity when they consumed glucose, but not fructose. These
findings suggest that while glucose suppresses brain activity in regions that promote the desire to eat, fructose may
promote overeating through its inability to effectively suppress the desire to seek out food (Page et al, JAMA 2013).
Additionally, Dr. Page and team found that obese young adults reported more hunger and a greater desire to eat
when they viewed pictures of high-calorie foods such as chocolate cake (Luo et al, Obesity 2013). These images
triggered the appetite and reward centers in the brain, and these neural and behavioral responses to high-calorie food
stimuli may promote eating. Dr. Page and team are currently conducting additional studies on peoples reactions
to dual stimulation of food images and sugar intake. These studies have important public health implications in a
society that is inundated with high-sugar foods and tantalizing food stimuli.
Anne L. Peters, MD
Dr. Peters is the USC site Principal Investigator for the NIH Look AHEAD Study, a multicenter study designed to
assess the benefits of weight loss and exercise on cardiovascular disease risk in patients with type 2 diabetes. The
East L.A. cohort offers a unique subset in this national study to show that lifestyle interventions, if done correctly,
can succeed in a variety of populations. She is also the USC site Principal Investigator for the Vitamin D and Type
2 Diabetes (D2d) study, which is a multicenter study designed to assess whether or not Vitamin D prevents the
progression to diabetes in people with pre-diabetes. Dr. Peters just completed her project as a PI in a P50 NIH Grant
with entitled Family and Neighborhood Interventions to Reduce CVD Risk in East LA.
Dr. Peters is the Principal Investigator of the Community Diabetes Initiatives (CDI), formally known as the Keck
Diabetes Prevention Initiative, which is a collaborative project with Childrens Hospital Los Angeles and is designed
to work within communities to create sustainable change that can lower rates of childhood and adult obesity and
diabetes. Two high-risk populations were chosen for the study: East and South Los Angeles. Community coalitions
have been created to help guide efforts to create change. Baseline data was collected and community mapping was
43
performed. Through this project we have helped bring farmers markets to East and South Los Angeles and helped
create mentoring programs based on healthy lifestyles in the local schools. Additional projects as part of the CDI
include implementing and funding a faith-based diabetes and obesity program in South Los Angeles for children and
adults.
Dr. Peters is Principal Investigator of a recently awarded grant for the STEPP-UP Trial, funded by the Helmsley
Charitable Trust. This is a grant designed to help reduce existing health disparities for lower SES individuals
with type 1 diabetes by creating and piloting a program geared for this population. She is a PI in the multi-center
REPLACE BG study, which is assessing the ability of continuous glucose monitoring to replace fingersticks in the
management of people with type 1 diabetes. This is an important step in the development of the bionic pancreas.
Finally, she participated as a PI in the Janssen Phase 2 trial assessing the safety and benefits of canagliflozin in the
treatment of type 1 diabetes. She is the lead Principal Investigator on the submission of the data to the FDA.
The pioneering work of Dr. Spencer and her clinical colleagues maintains USCs position on the cutting edge of
clinical research in thyroid cancer prognosis and management. Dr. Spencers current research on the use of TSH
to detect mild (subclinical) thyroid dysfunction in the non-pregnant and pregnant patient and the clinical utility
of serum thyroglobulin (Tg) and Tg autoantibody (TgAb) measurements in patients with differentiated thyroid
carcinomas (DTC) suggest that the use of a serum Tg assay with 100-fold more sensitivity than current clinical
assays would greatly reduce or obviate the need for expensive recombinant human TSH (rhTSH)-stimulated Tg
testing of DTC patients.
Dr. Yassine has a strong interest in lipid disorders and runs the Lipid Clinic at
LAC+USC. He is the Principal Investigator (and Dr. Buchanan is the primary mentor)
of a five-year NIH K23 grant to determine the effects of saturated fat ingestion on
HDL structure and function in type 2 diabetes. His other research focus is on the role
of the post-translational modifications in the development of diabetes complications
using state-of-the art mass spectrometry applications, and has an American Heart
Association award on The Inflammatory Structure of HDL in Diabetes and
Cardiovascular Disease. He is the editor of Lipid Management: Basic to
Clinic manual in lipidology. In 2015, he published three papers on novel lipoprotein
modifications discovered by mass spectrometry in diabetes, published in PLoS
ONE and Translational Proteomics and a paper on cholesterol efflux capacity of
cerebrospinal fluid in the Journal of the American Heart Association. He was the
inaugural speaker of the Los Angeles Lipid Association in 2015. Dr. Yassine has also
initiated new studies in collaboration with the USC Alzheimers Disease Research Center to study the relationship
between Alzheimers disease and lipid metabolism. Their initial studies examine blood brain barrier handling of
docosahexaenioc acid in relation to Apo 4 genotype.
44
Coulter Award, USC, 2015
Stefan Bughi, MD
First Place Poster Winner, Department of Health Services Patient Safety Conference (Bughi S/Shaw S),
Los Angeles, CA, 2015
Winner, AHRQ Patient Safety Culture Survey as part of the HAS Quality Improvement & Patient Safety Program,
Rancho Los Amigos, 2015
Teacher of the Year, USC Division of Endocrinology and Diabetes, USC, 2015
Faculty Teaching Award, Year II, Keck School of Medicine of USC, 2015
Faculty Teaching Award, Year IV, Keck School of Medicine of USC, 2015
R01, Neural Mechanisms for Appetitive Responses to High Reward Foods, Principal Investigator, National
Institute of Diabetes & Digestive & Kidney Disease, NIH, 2015
Sylvia J. Shaw, MD
First Place Poster Winner, Department of Health Services Patient Safety Conference (Bughi S/Shaw S),
Los Angeles, CA, 2015
New Investigator Award, Alzheimers Association, 2015

Research Award, American Heart Association, 2015
Young Investigator Award, Atherosclerosis and Thrombosis Vascular Biology Council of the American Heart
Association, 2015
45
Honors and Awards
Faculty
Professor
Veronica Garrie-Budnick Chair in Liver Diseases

Thomas H. Brem Chair in Medicine
Edy E. Soffer, MD
Jacques Van Dam, MD, PhD (Clinical
Scholar)
Associate Professor
James L. Buxbaum, MD
Tse-Ling Fong, MD
Cheng Ji, PhD
Jeffrey A. Kahn, MD
Michael M. Kline, MD
Murad Ookhtens, PhD
Andrew A. Stolz, MD
Thomas M. Zarchy, MD
Assistant Professor
John A. Donovan, MD
Helen Han, MD
Caroline Hwang, MD
Gregory E. Idos, MD
Saro Khemichian, MD
Brian Kim, MD
Zhang-Xu Liu, MD, PhD
46
Ara Sahakian, MD
Takeshi Saito, MD, PhD
Anisa Shaker, MD
Ling Shao, MD, PhD
Sarah Sheibani, MD
Tin Aung Than, MBBS, PhD
Sanda Win, MD, PhD
Liyun Yuan, MD
Instructor of Clinical
Medicine
Lily Dara, MD
Linda Hou, MD

Neil K. Kaplowitz, MD, Professor of Medicine and Chief
Maria Vidrio, Administrator
This past year was a successful period of continuing growth on all fronts for the Division of Gastrointestinal and
Liver Diseases. Our research programs and practice activities continue to flourish. The members of the Division are
to be applauded for their dedication and accomplishments. We are proud of our position as one of the nations most
outstanding programs in all spheres of Gastrointestinal and Liver Diseases.
The Division continues to grow with the recruitment of new faculty members. These new members expand our
expertise in transplant hepatology- Helen Han, MD, and Liyun Yuan, MD, PhD. The organization of the Division
includes clinical, teaching and translational research components at Keck Medical Center of USC, including the
Liver Transplant and Hepatology program (Drs. Kahn, Fong, Khemichian, Kim, Han, and Yuan) and the Digestive
Health Center, which includes endoscopy, inflammatory bowel disease, pancreaticobiliary and motility
(Drs. Van Dam, Buxbaum, Sahakian, Zarchy, Kline, Sheibani, Hwang, Idos, Soffer). We anticipate the arrival of
Dr. Andrew Ippoliti in 2016. He is a senior clinician-educator and will assume the role of Chief of GI Operations for
the Division. The liver group working exclusively at LAC+USC Medical Center (LAC+USC) includes
Drs. Kaplowitz, Stolz, Dara, Donovan and Saito; GI is cross covered. At LAC+USC, Dr. Stolz is GI Section Chief
and Dr. Buxbaum is Director of the Endoscopy Unit. The Division now has eight physician-scientists
(Drs. Kaplowitz, Stolz, Saito, DeLeve, Idos, Shaker, Shao and Dara); six are NIH-funded. Underpinning the
outstanding research of our NIDDK-sponsored Research Center for Liver Diseases are the following PhD scientists:
Ookhtens, Ji, Than, Win and Liu.
Our Gastroenterology fellowship training has been a major focus. The fellowship training program, directed by
Dr. Donovan and Dr. Sheibani, continues to attract and recruit an increasing number of outstanding applicants.
Private Practice
Divisional activities at Keck Hospital of USC (KH) and USC Norris Cancer Hospital (Norris) encompass inpatient
and outpatient services in gastroenterology and hepatology. Independent consultative services provide subspecialty
care for patients with all varieties of gastrointestinal and liver diseases. Elective outpatient upper gastrointestinal
endoscopy and colonoscopy, small bowel enteroscopy, capsule endoscopy, ERCP and EUS, and liver biopsy
47
Clinical Activities
The Division is actively engaged in patient care, education of fellows, residents and medical students, and clinical
research at LAC+USC. Separate Gastroenterology and Hepatology Consult Services provide inpatient consultations,
outpatient consultations and follow-up care at the LAC+USC GI and Liver clinics, relocated to join the Hepatitis
Clinic in the LAC+USC Outpatient Building. To enhance consultative services, eConsults was initiated in 2013
to facilitate the evaluation of patients and to educate primary care providers, as well as to schedule patients for
outpatient clinics. A full range of endoscopic procedures are provided in the Endoscopy Suite in the Diagnostic
and Treatment Building at LAC+USC. In addition to standard GI procedures, the Division performs a variety of
advanced procedures, including endoscopic retrograde cholangio-pancreatography (ERCP), choledochoscopy with
laser lithotripsy, endoscopic ultrasound (EUS), radiofrequency ablation of Barretts esophagus and double balloon
small bowel enteroscopy. Areas of research interest for the faculty and fellows include GI bleeding, esophageal
motility, Barretts esophagus, pancreatitis and inflammatory bowel disease (IBD).
procedures are performed in a new and expanded outpatient endoscopy center. The program is a referral center
for Norris/KH but has also received cases from the San Gabriel Valley as well as the central coast, Nevada and
Washington. Special EUS services include fine needle aspiration as well as celiac plexus blocks and pseudocyst
drainage.
In an effort to expand the versatility of the university practice, additional clinicians have recently been recruited:
Brian Kim (hepatology) and Linda Hou (general GI). We plan to initiate clinics specializing in the treatment
of patients with IBD, chronic abdominal pain and altered gastrointestinal motility. The KH program also seeks
to expand its inpatient and outpatient facilities. A new advanced endoscopy suite comprising state-of-the-art
fluoroscopy and ultrasound technologies will provide the new and existing faculty with a modern venue for its
expanding care.
The USC Liver Transplantation Program at KH provides pre- and post-transplant care to patients with end-stage
liver disease and the complications of portal hypertension. Liver replacement options include cadaveric and live
donor liver transplantation. During the January through December 2015 period, the Liver Transplant Program
performed a total of 125 adult transplants 113 cadaveric and 12 from live donors. There have been a total of 16
pediatric transplants 11 cadaveric and five from living donors. The adjunct Healthcare Consultation Center (HCC)
Program provides multidisciplinary evaluation and collaborative care provided by hepatology, surgery and medical
oncology faculty for patients with liver cell cancer.
GI and Liver Diseases Fellows

The Division of Gastrointestinal and Liver Diseases strives to provide fellows with a robust clinical experience
and a stimulating training environment that strongly support clinical and academic career development. The USC
GI and Liver Diseases Fellowship Program is committed to providing excellent clinical training in consultative
gastroenterology and hepatology and diagnostic and therapeutic endoscopy. Fellows are initially matched to a 3-year
general gastroenterology and hepatology training program that expects an active participation in the management of
a variety of GI and liver diseases.
The integrated fellowship program offers expert training in capsule endoscopy, deep enteroscopy, EMR,
radiofrequency ablation, Bravo pH, impedance/pH, manometry/pH, EUS and advanced biliary endoscopy. The
training program emphasizes the pursuit of new scientific advancements in the fields of gastroenterology and
hepatology that supports outstanding opportunities for learning and educational endeavor.
Class of 2016
Class of 2017
Class of 2018
Saddea Abassi, MD
Laura McEnerney, MD
Nitzan Roth, MD
Anna Skay, MD
Anand Dutta, MD
Hannah Do, MD
David Homozdi, MD
Sharon Kim, MD
Daniel Shue, MD
Nirumpama Bonthala, MD
Beverly Chen, MD
Jenny Chiu, MD
Clinical Training
Division of Gastrointestinal and Liver Diseases fellows participate in inpatient GI and liver disease consultation
services at LAC+USC and KH. Outpatient training is provided through weekly GI or liver diseases clinics. Fellows
also participate in specialized hepatitis clinics at LAC+USC. Through these activities fellows gain experience in the
outpatient management of a wide variety of gastrointestinal and liver diseases.
48
Fellowship Research
Fellows in Gastroenterology and Hepatology have the opportunity to participate in the divisions clinical and basic
science research activities. These may include ongoing research projects or newly initiated projects based upon the
fellows personal research interests. Fellows work closely with faculty mentors who provide support, guidance and
instruction in study design, clinical and basic science research techniques, laboratory methods and biostatistics.
Fellows have the opportunity to present the results of investigation at divisional research seminars and at national
meetings (American Gastroenterological Association and American Association for the Study of Liver Diseases).
Liver Transplant Program

The USC Liver Transplant Program was started in December 1995 and is based at KH. Fellows rotating at KH
participate in the perioperative care of patients, with emphasis on decision-making regarding the evaluation of
patients with cirrhosis and the complications of portal hypertension.
Research Training and Career Development

The USC Division of Gastrointestinal and Liver Diseases is involved in a wide
range of basic science and clinical research activities. Laboratories are located
on the Health Sciences Campus of USC and at LAC+USC. Three years of
fellowship training are supported by the program. Fellows choosing to pursue
an academic research career may spend up to 18 months performing clinical
or basic science research during the three-year program. Fourth-year training
(Instructor) positions are available for selected fellows interested in clinical
research and advanced gastroenterology training, clinical hepatology and basic
science laboratory research. Beyond the three-year program, individual training
grants may be obtained from NIH (NRSA) for an additional 2-3 years of
research career development.
Digestive Disease Core Center Grant

This NIH-funded program at the USC Research Center for Liver Diseases
started in 1995 and received notice that it successfully competed for a fifth
five-year cycle of funding for the period 2016-2021. It offers core facilities for support, training and research
applications in cell culture, cell and tissue imaging and analytical-metabolic approaches, and maintains an extensive
base of shared instrumentation. The Center funds pilot and feasibility projects. An enrichment and educational
and research seminars program with the participation of more than 60 scientists from clinical and basic science
departments is available.
Medical Students
Significant activities in student teaching include instruction during Year II GI/Liver diseases courses, Year I and
II hepatology lectures and a gastroenterology board review course. The Didactic Lecture series provides formal
education in gastroenterology and hepatology for medical students on Internal Medicine and the gastroenterology
consult services.
49
Research Activities
Faculty members of the Division were actively engaged in clinical and basic research
in all locations. In the laboratory, the areas of gut and liver injury, animal models, cell
and molecular biology were actively investigated (Kaplowitz, DeLeve, Dara, Idos,
Saito, Shaker, Shao). In addition, strong clinical research was conducted by Division
members in esophageal diseases (Drs. Soffer, Shaker and
Kline), liver transplantation (Drs. Fong, Kahn,
Khemichian, Kim, Han, Yuan), colonic disease, polyps,
colon cancer and inflammatory bowel disease
(Drs. Hwang, Idos, Shao, Sheibani and Zarchy),
pancreatitis/exploratory endoscopy (Drs. Van Dam,
Sahakian and Buxbaum), and alcohol and drug-induced
liver disease (Drs. Stolz, Donovan and Kaplowitz).
Laurie DeLeve, MD, PhD
Takeshi Saito, MD
The Division of Gastrointestinal and Liver Diseases

published 52 peer-reviewed research papers during the period of January 1 through
December 31, 2015, and nine more are in press. This body of work represents a broad
range of clinical and basic research activities from nearly all of the division.

Clinical and Endoscopic Management of

Pancreatitis
Gastrointestinal Malignancy
Complex Biliary Disease
Development of Biomarkers for
Pancreatic and Gastric Cancer
Lily Dara, MD
Signaling Pathways Involved in Liver

Cell Death
Drug-Induced Liver Injury
Acetaminophen Toxicity and Acute
Liver Failure
Role of Liver Sinusoidal Endothelial

Cell in Liver Injury Recovery and
Liver Fibrosis
John A. Donovan, MD
Liver Transplantation
Hepatocellular Carcinoma
Complications of Portal Hypertension
Tse-Ling Fong, MD
Complications of End-Stage Liver

Diseases and Liver Transplantation
Treatment of Chronic Viral Hepatitis
IBD
Colon Cancer Surveillance in IBD
Gregory E. Idos, MD
Gastrointestinal Cancer Screening and

Prevention
Diagnosis and Management of
Hereditary/Familial Cancer
Syndromes
Cancer Epidemiology and
Genetics, Endoscopic Screening,
Chemoprevention
Cheng Ji, PhD
Endoplasmic Reticulum (ER) Stress and

Liver Disease
Hyperhomocysteinemia
Hepatotoxicity of HIV Drugs and
Alcohol
Tackling Alcohol Intoxication with
Nanotechnology
Jeffrey A. Kahn, MD
Hepatocellular Carcinoma
Acute Liver Failure
Portal Hypertension
Viral Hepatitis
Complications of End Stage Liver
Disease
Drug Toxicity
Signal Transduction
Oxidative Stress
Glutathione Metabolism
Pathogenesis of Alcoholic Liver Disease
Endoplasmic Reticulum (ER) Stress
Mitochondrial Biogenesis
Caroline Hwang, MD
Saro Khemichian, MD
Helen Han, MD
Novel Therapeutics and Diagnostics in

Inflammatory Bowel Disease (IBD)
Nutritional Monitoring and Interventions
in IBD, Microscopic Colitis and
Celiac Disease
Issues of Adherence and Disparities in
Treatment of Hepatitis C Virus

Acute Liver Failure
Complications of Portal Hypertension
Foregut Disorders
Treatment of Barretts Esophagus with
EMR and Barrx Radiofrequency
Esophageal Chest Pain
Motor Disorders
Deep Enteroscopy Using the Spirus
Technique
Function of Liver NK and NKT Cells
Liver Immunology and Diseases
Innate Immunity in Drug-Induced
Hepatotoxicity
Murad Ookhtens, PhD
Methylation and Trans-Sulfuration

Pathways
Tracer-Kinetics and Mathematical
Modeling-Simulation
Ara Sahakian, MD
Diagnosis and Endoscopic Management

of Complex Biliary and Pancreatic
Disorders
Endoscopic Ultrasound for Evaluation
of Pancreatic Cysts and Malignancies
Endoscopic Mucosal Resection and
Large Colonic Polyps
Takeshi Saito, MD
Hepatitis C Treatment
Cirrhotic Cardiomyopathy
Molecular Virology of Hepatitis C Virus

Intrahepatic Innate Immunity against
Hepatitis Virus
Interferon Biology
Synergism between Metabolic Liver
Disease and Viral Hepatitis
Brian Kim, MD
Anisa Shaker, MD
50
Epithelial-Stromal Interactions in GI
Tract Injury, Repair and Carcinogenesis
Sarah Sheibani, MD
Health Maintenance in Inflammatory

Bowel Disease
Pregnancy in Inflammatory Bowel
Disease
Management of Variceal and Tumor
Bleeding
Ling Shao, MD, PhD
Mechanisms of Cell Death in the

Intestine
Enterocyte Signal Transduction
Pathogenesis of Inflammatory Bowel
Disease
Mucosal Immunology
Intestinal Epithelial Cells
Colorectal Cancer
Edy E. Soffer, MD
Motility Disorders of the GI Tract
Andrew A. Stolz, MD
Gene Regulation by Oxidant Stress

Dysregulation of Androgen Metabolism
in Prostate Cancer
Drug-Induced Liver Injury/Alcoholic
Hepatitis and NAFLD
Tin Aung Than, MBBS, PhD

Mitochondrial Biogenesis in Liver
Diseases
Signal Transduction across
Mitochondrial Membrane
Jacques Van Dam, MD, PhD
Diagnosis and Treatment of Pancreatic,

Esophageal, Gastric and Colorectal
Cancers
Advanced Endoscopic Management of
Pancreatic Cysts, Large Common Bile
Duct Stones, Complex Biliary
Strictures and Large Colonic Polyps
Sanda Win, MD, PhD
Signal Transduction in Drug-Induced

Hepatotoxicity, Non-Alcoholic
Steatohepatitis and Alcoholic
Hepatitis
Identification of Therapeutic Target to
Prevent Drug-Induced Hepatotoxicity
Mitochondrial Biogenesis
Oxidative Stress
Liyun Yuan, MD, PhD
Complications of Cirrhosis
Autoimmune Hepatitis
Non-Alcoholic Steatohepatitis
Alcoholic Liver Diseases
Risk Profile for Colon Cancer on

Sigmoidoscopy and Colonoscopy
Demographics and Inflammatory Bowel
Disease
USC/Mellon Mentoring Award for Faculty Mentoring Faculty, 2015
Ling Shao, MD, PhD
USC GI Fellows Teaching Award, USC Division of Gastroenterology, 2015
Distinguished Service Award, American Society for Gastrointestinal Endoscopy, 2015
51
Honors and Awards
Faculty
Associate Professor
Ron Ben-Ari, MD (Educational Scholar)
Julia Cassetta, MD
Pamelyn Close, MD
Diana C. Homeier, MD
Kurt M. Hong, MD, PhD
Jennifer Marks, MD
Michael D. Wang, MD
Assistant Professor
Jesse F. Abelson, MD
Haig H. Aharonian, MD
Josh Banerjee, MD
Kevin A. Bechler, MD
Linda Calvillo-King, MD
Jeffrey B. Canceko, MD
Bharat B. Chaudry, MD
D. Steven Fox, MD
Jose L. Gonzalez, MD
Cynthia H. Ho, MD
Michael Hochman, MD
Eric P. Hsieh, MD
Edward K. Hu, MD
Douglass Hutcheon, MD
James Ji, MD
Arek Jibilian, MD
Section Head, General Internal Medicine
Matthew S. Johnson, MD
Matthew Jung, MD
Ronald Kall, MD
Michael S. Karp, MD
Mahmood M. Khaledy, MD
Shazia S. Khan, MD
Dohwa Kim, MD
Edward Lee, MD
Justin J. Lee, MD
Daniel Martinez, MD
Carlo Medina, MD
Allen Milani, MD
Sharon E. Orrange, MD
James E. Pacino, MD
52
Seth A. Politano, DO
Sunita Puri, MD
Glenn Rogers, MD
Gina C. Rossetti, MD
Joshua D. Sapkin, MD
Patrick E. Sarte, MD
Aneesah Smith, MD
Aaron Storms, MD
Gregory L. Taylor, MD
Arnold Tsai, MD
Carin van Zyl, MD
Section Head, Palliative Care
Mabel Vasquez, MD
Vickie Wu, MD
Andrew Young, DO
Section Head, Hospital Medicine
Stephanie Zia, MD
Clinical Instructor
Shadi Dowlatshahi, MD
Sonya L. Earley, PA
Geriatric, Hospital, Palliative and

General Internal Medicine
Michael S. Karp, MD, Assistant Professor of Clinical Medicine and Chief
Jennifer K. Severa, MPA, Senior Administrator
The Division of Geriatric, Hospital, Palliative and General Internal Medicine (GHPGIM) has demonstrated
significant growth in the areas of clinical practice and teaching. The private practice has steadily grown over the last
year as we expand our services and branch out within the USC community. The GHPGIM Division is one of the
Department of Medicines leaders in terms of private practice revenue and number of patient visits. The Healthcare
Center 2 (HC2) has continued to serve as the hub of the Divisions ambulatory private practice, in which Division
faculty saw an average of 140 patient visits per day during 2015. The evolution of the Divisions Hospital Medicine
Program at LAC+USC Medical Center (LAC+USC) has achieved the Departments goal of providing all of the
teaching and supervision on the General Medicine Service by General Medicine faculty.

In conjunction with Jagruti Shukla, MD, MPH, Director of Primary Care for the LAC+USC Healthcare Network,
members of the Division, including Drs. Bharat Chaudry and Arek Jibilian have worked to establish team-based care
in the resident continuity clinics, where our faculty provide direct patient care and supervise residents in providing
care to over 35,000 patient visits a year. This effort will significantly improve patient experience as well as physician
and staff satisfaction. Our faculty also provided comprehensive care to the elderly population in our Geriatric Clinic,
where approximately 4,000 visits are performed per year.
The faculty have been key partners with Dr. Shukla in building a resident continuity clinic modeled as a Patient
Centered Medical Home (PCMH). This type of clinic redesign allows for improved access, continuity, care
coordination, chronic disease management, preventive care and population management. Lessons learned from our
Galaxy model of care are being built into the PCMH model. Other enhancements include patient empanelment for
over 170 resident physician patients and improved telephone access for all our empaneled patients in adult primary
care clinics.
Our faculty continue to work with pharmacy, nursing, information systems and hospital information management
to develop a multidisciplinary approach to the management of chronic pain. This includes the successful
implementation of a treatment agreement within our primary care clinics. A workgroup continues to meet regularly
to refine our approach to managing this difficult subset of patients.
Inpatient Care
The Hospital Medicine Program consists of the General Medicine Service, the Medicine Consult Service and the
Medicine Blue Service. The General Medicine Service includes patients supervised by faculty on 12 teaching teams
and two non-teaching teams comprising the Blue Service.
The Hospital Medicine faculty continue to work with facility leadership and other departments to develop
initiatives aimed at decreasing length of stay, improving operational efficiency, improving inter-departmental
communication and reducing denied days. Of note, on May 29, 2015, LAC+USC Medical Center went live with
a fully integrated electronic health record system (ORCHID). The Hospital Medicine faculty, in cooperation with
the care coordinators, were instrumental in making the go-live successful. This same group of faculty provides
an educational workshop for senior medical students at the Keck School of Medicine of USC, which is one of the
53
Clinical Activities
Outpatient Care
most highly regarded by the medical students. The Medicine Consult Service provides ongoing medical care to
those inpatients on surgical services, evaluates patients for transfer to LAC+USC and facilitates the flow of patients
within the hospital. This service continues to actively work with Patient Flow on improving transitions of care in the
hospital, including overhauling the admission process as well as the transfer of patients from the Medical Intensive
Care Unit and the Medicine Ward.
The Blue Service has an average daily census as high as 70 patients. Care is provided by teams of nurse practitioners
and faculty physicians. The Blue Service continues to help improve compliance with resident duty hours, as well as
working with administration to case manage complex placement issues on this service.
Adult and Pediatric Palliative Care
The Adult and Pediatric Palliative Care consult service at LAC+USC has undergone some change over the last
year. Our previous Section Head, Dr. Pamelyn Close retired and we welcomed her replacement, Dr. Carin van Zyl.
The Palliative Care patients are seen in all inpatient units of the hospital, from the Emergency Department and
all active medicine-surgery wards and ICUs to the NICU, Pediatric ICU and Specialty ICUs. The Palliative Care
team continues to benefit from our other faculty including Dr. Aaron Storms and another new hire, Dr. Sunita Puri.
The team continues to include a dedicated nurse, a chaplain, a nurse practitioner and a social worker to support the
inpatient consult team and the Outpatient Palliative Care in the Oncology and Gynecology-Oncology Clinics.
Carin van Zyl, MD
Sunita Puri, MD
Private Practice
GHPGIM faculty conducted 45,336 private practice patient visits during 2015. The Division continues to have
robust annual revenues, passing the $4 million mark, emanating from the practice. In addition to our core facility,
located in HC2 on the Health Sciences Campus, patients are seen in our satellite locations including Downtown Los
Angeles, La Caada, Beverly Hills, Pasadena and our location on the USC University Park Campus. Our geriatric
physicians see patients at several long-term care facilities. All inpatients are admitted to Keck Hospital of USC
(KH), where the Divisions average daily census has grown to 33 patients. Dr. Michael Wang, a geriatrician who
heads up our KH hospitalist program, addresses the special issues of hospitalized older individuals.
The Division has begun the process of seeking certification as a Patient Centered Medical Home. The concept is
based on patient-centered care focusing on safety, quality, prevention, education and communication. We have
engaged our faculty in the process with the goal of not only achieving recognition, but transforming the practice of
medicine at USC altogether.
The Section of Adult and Pediatric Palliative Care continues to grow. Our group continues to see inpatient consults
at both the Keck Hospital and the Norris Cancer Center. We have begun to see outpatient consults as well in
partnership with our Oncology faculty. The Palliative Medicine and Supportive Care Team was initially led by
Dr. Alex Madonis who has since left USC and is now led by Dr. Sunita Puri. The team includes an NP, a social
worker, a care coordinator and a data assistant. The Palliative Care Section provides extensive core training and
54
educational support in pain and symptom management and communications skills for Keck medical students,
residents and fellows across multiple academic departments within the USC health care system.
Hospital Medicine Program
The Hospital Medicine Program (HMP) at KH, headed by Dr. Michael Wang, allows for 24/7 onsite faculty
inpatient coverage and resident supervision, staffing at the Evaluation and Treatment Center (ETC) and rapid
response coverage for the hospital campus (Rapid Response Team). The HMP faculty also play vital roles in quality
initiatives, utilization management and clinical care. We have expanded our services to include the co-management
of complex orthopedic patients. During the last fiscal year, Medicine was the leading provider of patient services
in the ETC, with the GHPGIM Division providing the bulk of the care. Admissions and census numbers grew and
consultation and co-management services evolved. The Program has also supplemented the Employee Health Work
Injury Program (which helps employees receive care onsite), developed a preoperative clinic to support the inpatient
services and collaborated to provide for inpatient geriatrics services. Regarding residency and student education,
twice weekly resident conferences were continued, Medicine inpatient orientation was refined, and ongoing
resident feedback was elicited to optimize the educational experience. Lastly, members of the program have been
actively involved in a variety of quality improvement activities, such as Throughput, Rapid Response, Code Spine,
Transfusion Free Medicine, and Hospital Acquired Infection prevention.
Electronic Health Record System
USC has implemented Cerner to update and transform the electronic health record (EHR) system at Keck Medical
Center of USC. The hope is to improve medical care and communication, reduce errors and provide for a unified
system that maintains or enhances functionality. Under Dr. Michael Karps leadership, monthly departmental
meetings were organized in an attempt to coordinate our efforts. Representatives from the Division are active
participants in the monthly interdepartmental Physician Technology Advisory Group and in the implementation of
the EHR in both the inpatient and ambulatory sectors.
Internal Medicine Residents
Dr. Seth Politano, Associate Residency Director (right), teaching residents
55
Faculty members in the Division of GHPGIM are responsible for the supervision of Internal Medicine Residents as
they care for patients at LAC+USC on the Inpatient Medicine Wards service, a robust Medicine Consultation service
and daily Primary Care Clinics. Faculty also supervise residents on the KH Inpatient Ward service. Each month, 40
house officers comprising 13 teams rotate through both hospitals Inpatient Ward Services. Each team is supervised
by one GHPGIM faculty member using an academic hospital medicine model. Each day, supervising faculty
conduct 2-hour attending rounds in order to meet and discuss newly admitted patients, review the clinical course
of the established inpatients, and educate the residents on inpatient medicine concepts. In addition, faculty conduct
daily afternoon discharge and management rounds. These clinical/bedside teaching rounds complement other
structured curricular sessions for house officers and medical students. GHPGIM faculty also supervise the training
of house officers in ambulatory general internal medicine at the continuity clinics. The continuity clinics are situated
onsite at LAC+USC and provide approximately 25,000 visits annually. These efforts are ably led by
Drs. Ron Ben-Ari (Vice Chair for Educational Affairs), Eric Hsieh (Residency Director) and Jeff Canceko
(Clerkship Director).
Research Activities
The Division of GHPGIM has taken an active role in enhancing its educational mission and program for students at
the Health Sciences Campus and for medical house staff. It is imperative that our young physicians and allied health
personnel are prepared to meet the challenges presented by the ever-changing nature of medicine as well as the
aging of the American population. The clinical and didactic instruction provided by GHPGIM faculty goes a long
way toward preparing our resident physicians with information and expertise to make them better able to understand
and cope with the emerging problems of our citizens.
D. Steven Fox, MD
Dr. Fox has taken a lead in regards to clinical research being performed by faculty in
our division. His research program is focused on using available evidence to improve
both healthcare decision-making and patient outcomes.Recently published work
looked at who benefits most from immediate treatment with the new direct acting oral
agents for Hepatitis C infection.That work took advantage of our ongoing relationship
with the Veterans Health Administration, which gave access to patient records for over
30,000 patients who received the new regimens.Other ongoing research includes the
analysis of health economic value of treatments for type I diabetes in a clinical trial
comparing closed loop glucose sensor/insulin pump systems versus standard therapy.
Dr. Fox is also developing a long-term project that leverages machine learning and
other predictive analytics techniques to help identify in real time those patients at
greatest health risk.
Gehr Family Center for Implementation Science
The Division was provided a very generous donation from a grateful patient, Mr. Norbert Gehr. Mr. Gehrs gift of
$10,000,000 will be used to create the Gehr Family Center for Implementation Science. Implementation science
explores scholarly endeavors to improve the delivery of health care. In the Centers charge to study innovative
approaches to healthcare delivery it will also have an immediate impact on the scholarly pursuits of the Divisions
faculty. The Centers first Director is Dr. Michael Hochman. Dr. Hochman obtained his medical degree from
Harvard University, his residency training from Cambridge Hospital and his fellowship in General Medicine at the
Robert Wood Johnson Program at UCLA/Rand. Most recently he has served as the Director of Innovative Medicine
at AltaMed.
Dr. Homeier is the Medical Director of the Geriatrics Clinic and Adult Protection Team at LAC+USC and serves
as a consultant to Los Angeles County Adult Protective Services. She also spearheaded the development of the
Los Angeles County Elder Abuse Forensic Center. She has received funding from the UniHealth Foundation, the
Archstone Foundation and the National Institute on Justice to support her work with the Forensic Center and toward
a better understanding of elder mistreatment in community settings.
Eric P. Hsieh, MD
Dr. Hsieh received funding from Western Group on Educational Affairs (WGEA) to
study the effects of physician stigma on medical decisions. The study explores
resident-physicians explicit and implicit stigma toward patients with depression, and
how these attitudes influence patient encounters, clinical decisions, and treatment
plans. Methods and instruments may be of value for studying other areas where
physician biases may exist such as drug addiction, obesity, HIV status, gender,
ethnicity, homelessness and others.
56
Senior Resident of the Year, Internal Medicine Residency Program, University of Southern California, 2015
Jennifer R. Marks, MD
Attending of the Year Award, Internal Medicine Residency Program, LAC+USC Medical Center, 2015
Inaugural Recipient, Etz Chaim Tree of Life Award of Compassionate Care, 2015
Medicine Clerkship Teaching Award, Department of Medicine, Keck School of Medicine of USC, 2015
Stephanie K. Zia, MD
Attending of the Year Award, Internal Medicine Residency Program, LAC+USC Medical Center, 2015
Award of Recognition, Burmese American Medical Association, 2015
First Place Poster, American Academy of Pediatrics National Conference, Section on Quality Improvement,
Facilitating Transition: A Care Notebook for Young Adults with Chronic Disease, 2015
Maurice Hitchcock Award for Outstanding Posters, Innovations in Medical Education Conference, 2015
57
Honors and Awards
Faculty
Professor
Associate Professor
Assistant Professor
Mojtaba Akhtari, MD
Kevin Kelly, MD, PhD
Ann F. Mohrbacher, MD
Casey L. OConnell, MD
Vasu Punj, PhD
Anil Tulpule, MD
Ilene C. Weitz, MD
Hittu Matta, PhD

Akil A. Merchant, MD
Venkatesh Natarajan, PhD
Caroline I. Piatek, MD
Giridharan Ramsingh, MD
Ronald H. Bloom Family Chair in Lymphoma

Research
Parkash S. Gill, MD
Renette and Marshall Ezralow Family Chair in

Cancer Therapeutics
Howard A. Liebman, MD
Professor Emeritus
Clinical Instructor
Noah M. Merin, MD, PhD
Donald I. Feinstein, MD
Cage S. Johnson, MD
58
Hematology
Preet M. Chaudhary, MD, PhD, Professor of Medicine and Chief
Janette Espaa, Division Administrator
In the past year, the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases continued
its growth in the areas of clinical practice, teaching and research.
Caroline Piatek, MD, joined the Division in July as Assistant Professor of Clinical
Medicine. Dr. Piatek graduated from Creighton University School of Medicine in
2009. She completed residency training in Internal Medicine at University of Southern
California and then stayed to finish a clinical fellowship in Hematology and Medical
Oncology. Dr. Piatek has been serving as the Chief Fellow in Hematology in our
division since 2014. She is board certified in Internal Medicine and board eligible in
Hematology and Medical Oncology. Aside from her clinical work, Dr. Piatek has also
been involved in clinical and laboratory research work. She has published several
abstracts and manuscripts in the areas of hematology and oncology. Dr. Piatek is the
recipient of numerous honors and awards, including 2014 Conquer Cancer Foundation
of American Society of Clinical Oncology Merit Award and Medical Oncology Fellow
Research Award for the 2012-2013 Academic Year.
Noah Merin, MD, PhD, joined the Division in July as Clinical Instructor of Medicine.
Dr. Merin obtained his MD and PhD degrees from University of California, Davis in
2008. He completed residency training in Internal Medicine at Harbor-UCLA and then
finished his Fellowship training in Hematology and Medical Oncology at University
of Southern California. Dr. Merin has been serving as the Chief Fellow in Hematology
in our division since July, 2014. He is board certified in Internal Medicine and board
eligible in Hematology and Medical Oncology. Aside from his clinical work, Dr. Merin
has also been involved in clinical and laboratory research work. He has published
several abstracts and manuscripts in the areas of hematology and oncology. Dr. Merin
is the recipient of numerous honors and awards, including the Plummer-Linzy Trust
Scholarship and CIRM Clinical Fellowship Grant.
Venkatesh Natarajan, PhD, joined the Division in August as Assistant Professor of Research Medicine. Dr. Natarajan
received his Masters of Science in Biotechnology from Indian Institute of Technology, Bombay, India in 1994, and
PhD in Biochemistry from Indian Institute of Science, Bangalore, India in 2000. He presently is an affiliate member
at the Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo NY. Dr. Natarajan has authored
or co-authored 20 peer-reviewed articles, including three articles in PNAS (one as first author) and an article in
Science. He has also been granted 10 patents. Dr. Natarajan is interested in functional genomic approaches to gain
global understanding of signal transduction pathways related to cancer, innate immunity, inflammation and cellular
senescence. His areas of research expertise include, among others, the development of cell based platforms for highthroughput screening, small molecule library screens to target signaling pathways, lentiviral shRNA library screens
to identify new therapeutic targets, phage-display library screens to identify peptide drugs, and development of
lentiviral peptide libraries. Dr. Natarajan will be using his expertise in cellular and molecular biology and functional
genomics to develop genetic and pharmacological interventions to improve the outcome of chimeric antigen
receptor based cellular therapies.
Members of the Division are conducting research in several areas of benign and malignant hematology. In particular,
Division faculty members have special strengths in basic, translational and clinical research in the area of viral
59
associated malignancies, including those seen in patients with HIV/AIDS. Members of the Division are also
involved in a number of innovative investigator-initiated and National Cooperative Group (e.g., SWOG, AMC)
sponsored clinical studies. These trials reflect the broad research interests of our faculty and cover diverse areas,
such as conventional chemotherapeutics, small molecules and monoclonal antibodies.
Regarding its clinical activities, the Division is responsible for multiple clinical services at LAC+USC Medical
Center (LAC+USC), USC Norris Cancer Hospital (Norris) and Keck Hospital of USC (KH). At Norris, the Division
is responsible for a busy inpatient service and the Bone Marrow/Stem Cell Transplantation (BMT) service, which
successfully performs transplantation on patients with acute leukemia and other hematologic malignancies. The
BMT Program, run by the Division, successfully received full certification by the Federation for Accreditation
of Cellular Therapies (FACT). The Division is experiencing increases in new outpatient visits, admissions and
clinical efficiency (reduced length of stay) at Norris and LAC+USC. At the same time, a substantial number of
cases are placed into peer-reviewed clinical trials with accompanying translational research protocols, thus bringing
innovative treatment strategies and therapeutic reagents to patients.
Regarding its teaching activities, the Division continues to refine and implement a new curriculum in Hematology
and Clinical Immunology for Year III medical students. The eight-week course emphasizes case-based learning and
received outstanding evaluations from students.
Clinical Activities

At LAC+USC, members of the Division conduct inpatient services for severely ill patients with hematologic
malignancies and patients receiving chemotherapy on Ward 7B. Additionally, the Division maintains a consultation
service and seven outpatient half-day clinics.

USC Norris Cancer Hospital
Members of the Division see private patients with various types of hematologic malignancies at Norris. Our
faculty see patients on a daily basis in the clinic and Day Hospital, where they supervise the administration of
chemotherapy, stem cell collection and other procedures. The Division is also responsible for an active Stem Cell
Transplantation (SCT) program managed through Norris. We have expanded the program to include allogeneic
transplantation in addition to autologous. Candidates for stem cell transplantation are screened at Norris. The
Division also performs peripheral blood stem cell collections, which totaled 84 over this past academic year.
The Division of Hematology is responsible for seeing patients with various hematologic problems on a consultative
basis at KH. One fellow and one faculty are assigned to this rotation on a monthly basis.
60
Clinical Studies
Recruitment into clinical trials from all hospitals affiliated with Norris Comprehensive Cancer Center (Cancer
Center) was strong over the past year.
The faculty are responsible for the education of approximately 84 interns and 120 residents each year.
Hematology and Blood Diseases Fellows

Grace Chang, MD
Anishka DSouza, MD
Umair Ghani, MD
Ming Li, MD
Xin Li, MD
Irene Kang, MD
Charlene Lee, MD
Derrick Su, MD
Steven Yu, MD
Post-Doctoral Fellows and Graduate Students

Kwasi Connor, PhD

Devi Thiagarajan, PhD
Ram Gopalakrishnan, PhD

Tim Triche, PhD
Parvesh Chaudhry, PhD
Conferences
Fellow Specific Seminars in Hematology are advanced seminars where pertinent literature on the
speaker topic of the week is discussed, with mentoring and education provided at the fellow level by all faculty
throughout the year.
Hematology Grand Rounds Conference is held weekly. A specific topic is discussed in depth by invited
expert discussants from USC and from throughout the country and world.
Each year the Hematology section hosts an internationally recognized hematologist for the Donald I. Feinstein
Lectureship, an endowed lectureship named in honor of the former Chief of the Division of Hematology at USC.
The weekly Hematology Patient Care Conference is attended by clinical hematologists,
hematopathologists, radiologists and radiotherapists, as well as house officers, fellows and medical students.
Members of the Hematology section provide a brief clinical review of the patients problem, which is followed
by a display of the patients morphologic material, scans and radiographs. Further diagnostic and therapeutic
recommendations are then discussed by the multidisciplinary team.
Cancer Center Grand Rounds is a weekly multidisciplinary conference that includes all of the departments
and divisions involved in the care of patients with various types of cancer at the Keck School of Medicine of USC.
This conference is mandatory for all combined Hematology/Oncology fellows.
Didactic Hematology Seminars are two one-hour didactic seminars held each week. During the first six
months of the year, the topics are regularly assigned to faculty. During the second six months of the year, the fellow
is expected to select four different topics for presentation at these seminars.
Fellow Weekly Mentor Sessions/Journal Clubs begin in October of each year. Faculty meet with
fellows on a weekly basis to discuss various topics in benign and malignant hematology. Literature on the topic is
carefully reviewed, in a format designed specifically for the level of our fellows.
61
Fellows
Medical Students
Research Activities
Our course in Hematology and Clinical Immunology involves approximately six weeks per year as part of a
newly developed curriculum. In addition, the Senior Clinical Hematology Elective takes two to four students for
a four- to six-week elective on the Hematology Consultation Service. This elective is over-subscribed, and, as a
consequence, approximately four to six additional students are taken each year on a special elective on Ward 7B.
The Division is actively involved in basic, translational and clinical research in benign and malignant blood
disorders. Active areas of basic and translational research in the Division include molecular pathogenesis and animal
models of AIDS-associated malignancies, multiple myeloma and lymphoma, development of targeted therapies
for hematologic malignancies, cancer drug resistance, and clotting and bleeding disorders. In the area of clinical
research, the Division is conducting clinical trials involving conventional agents, novel drugs and immunotherapy
for the treatment of benign and malignant blood disorders.

Mojtaba Akhtari, MD
Bone Marrow Transplant
Acute Leukemia

Adoptive Cellular Therapies
Chimeric Antigen Receptors
NF-B Signaling
AIDS-Associated Malignancies
Animal Models of Lymphoma and
Myeloma
Molecularly Targeted Therapies
Parkash S. Gill, MD
Role of Angiogenesis in Malignant

Disease
Development of Novel Anti-Angiogenic
Compounds
Therapeutic Aspects of Kaposis
Sarcoma
Cage S. Johnson, MD
Hemoglobinopathies
Red Blood Cell Enzyme Defects
Iron Deficiency
Malignant and Benign Hematologic

Disorders
Preclinical Drug Development
Myeloma
Lymphoma
Acute Myeloid Leukemia
Heparin-Induced Thrombocytopenia in
Vascular Surgery
Role of ADAMTS 13 in Vascular
Disease
Thromboembolism Secondary to
Chemotherapy and Cancer
Thrombopoeitic Agents in
the Management of Immune
Thrombocytopenic Purpura
Multiple Myeloma
Immunotherapy of B-Cell Cancers
Phase I/II Trials of New Agents for
Hematologic Malignancies
Blood Clotting Disorders
Cancer-Related Thrombosis
Vasu Punj, PhD

Bioinformatics
Acute Leukemias
Drug Resistance
Leukemia Stem Cells
Hittu Matta, PhD
Anil Tulpule, MD
KSHV-Associated Malignancies
Drug Development
AIDS-Related Lymphoma
Kaposis Sarcoma in HIV Patients
Multi-Drug Resistance in Lymphoma
Ilene C. Weitz, MD
Sonic-Hedgehog Signaling
62
Hemostasis Abnormalities in Cancer

Patients
Hightlighted Publications
Aldoss I, Douer D, Behrendt CI, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V: Toxicity Profile of Repeated
Doses of PEG-Asparaginase Incorporated into a Pediatric-Type Regimen for Adult Acute Lymphoblastic Leukemia.
Eur J Haematol [Epub ahead of print], 2015.
Despite having been long regarded as too toxic for adult patients, pediatric-like regimens containing L-asparaginase
have resulted in improved outcomes for adults with acute lymphoblastic leukemia (ALL). To characterize the
spectrum of toxicity of repeated doses of polyethylene glycolated-asparaginase (PEG-asp) in adults, we reviewed all
doses (2000 IU/m2 ) administered as part of a pediatric-inspired regimen in adult ALL at our center. Subjects aged
18-60 yr with ALL (n = 152, 69.1% male) contributed 522 dose cycles to the study. Hepatotoxicity was the most
common adverse event: grades 3-4 transaminitis and hyperbilirubinemia occurred in 53.9% and 23.7% of subjects,
respectively. Hepatotoxicity was reversible; no cases of fulminate hepatic failure were observed. Other toxicities
affecting at least 5% of subjects were grades 3-4 triglyceridemia in 50.9%, hypofibrinogenemia (<100 mg/dL) in
47.9%, clinical pancreatitis in 12.6%, venous thromboembolism in 11.2%, allergic reaction in 7.2%, and any grade
bleeding in 5.3%. PEG-asp was always discontinued after grades 3-4 pancreatitis or allergic reaction. Otherwise,
toxicities did not preclude administration of additional cycles of the drug. Our results suggest that repeated PEG-asp
dosing is safe in adults aged 18-60 yr, even after occurrence of a drug-related toxicity.
Gopalakrishnan R, Matta H, Tolani V, Triche T Jr, Chaudhary PM: Immunomodulatory Drugs Target IKZF1IRF4-MYC Axis in Primary Effusion Lymphoma in a Cereblon-Dependent Manner and Display Synergistic
Cytotoxicity with BRD4 Inhibitors. Oncogene, in press, 2015.
Primary effusion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized predominantly in
body cavities. Kaposis sarcoma-associated herpes virus (KSHV) is the causative agent of PEL. PEL is an incurable
malignancy and has extremely poor prognosis when treated with conventional chemotherapy. Immunomodulatory
drugs (IMiDs) lenalidomide and pomalidomide are Food and Drug Administration-approved drugs for the treatment
of various ailments. IMiDs display pronounced antiproliferative effect against majority of PEL cell lines within their
clinically achievable concentrations, by arresting cells at G0/G1 phase of cell cycle and without any induction of
KSHV lytic cycle reactivation. Although microarray examination of PEL cells treated with lenalidomide revealed
activation of interferon (IFN) signaling, blocking the IFN pathway did not block the anti-PEL activity of IMiDs. The
anti-PEL effects of IMiDs involved cereblon-dependent suppression of IRF4 and rapid degradation of IKZF1, but
not IKZF3. Small hairpin RNA-mediated knockdown of MYC enhanced the cytotoxicity of IMiDs. Bromodomain
(BRD) and extra-terminal domain (BET) proteins are epigenetic readers, which perform a vital role in chromatin
remodeling and transcriptional regulation. BRD4, a widely expressed transcriptional coactivator, belongs to the
BET family of proteins, which has been shown to co-occupy the super enhancers associated with MYC. Specific
BRD4 inhibitors were developed, which suppress MYC transcriptionally. Lenalidomide displayed synergistic
cytotoxicity with several structurally distinct BRD4 inhibitors (JQ-1, IBET151 and PFI-1). Furthermore, combined
administration of lenalidomide and BRD4 inhibitor JQ-1 significantly increased the survival of PEL bearing NODSCID mice in an orthotopic xenograft model as compared with either agent alone. These results provide compelling
evidence for clinical testing of IMiDs alone and in combination with BRD4 inhibitors for PEL.
Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST: Junctional Adhesion
Molecule-A is Overexpressed in Advanced Multiple Myeloma and Determines Response to Oncolytic Reovirus.
Oncotarget 6(38):41275-89, 2015.
Despite the development of several new agents for multiple myeloma (MM) therapy over the last decade, drug
resistance continues to be a significant problem. Patients with relapsed/refractory disease have high mortality rates
and desperately need new precision approaches that directly target specific molecular features that are prevalent in
the refractory setting. Reolysin is a proprietary formulation of reovirus for cancer therapy that has demonstrated
efficacy in multiple clinical trials. Its selective effects against solid tumors have been largely attributed to RASmediated control of reovirus replication. However, the mechanisms regulating its preferential anti-neoplastic effects
in MM and other hematological malignancies have not been rigorously studied. Here we report that the reovirus
receptor, junctional adhesion molecule-A (JAM-A) is highly expressed in primary cells from patients with MM
and the majority of MM cell lines compared to normal controls. A series of experiments demonstrated that JAM-A
63
Division Hightlights
Division of Hematology faculty published 54 peer-reviewed research papers during the January 1 through
December 31, 2015 period, and another seven are in press. The following stand out as noteworthy accomplishments:
expression, rather than RAS, was required for Reolysin-induced cell death in MM models. Notably, analysis of
paired primary MM specimens revealed that JAM-A expression was significantly increased at relapse compared to
diagnosis. Two different models of acquired resistance to bortezomib also displayed both higher JAM-A expression
and elevated sensitivity to Reolysin compared to parental cells, suggesting that Reolysin may be an effective agent
for patients with relapsed/refractory disease due to their high JAM-A levels. Taken together, these findings support
further investigation of Reolysin for the treatment of patients with relapsed/refractory MM and of JAM-A as a
predictive biomarker for sensitivity to Reolysin-induced cell death.
OConnell C: How I Treat Incidental Pulmonary Embolism. Blood 125(12):1877-82, 2015.
The identification of pulmonary embolism (PE) on computed tomography scans performed for indications other
than identification of thromboembolism is a growing clinical problem that has not been adequately addressed
by prospective treatment trials. The prevalence of incidentally detected PE ranges from 1% to 4% in unselected
populations, with higher rates among hospital inpatients and patients with cancer. Current guidelines recommend
using the same approach to type and duration of anticoagulation as is used for patients with suspected PE. Available
data regarding the significance of symptomatic subsegmental PE (SSPE) are conflicting, making it difficult to
draw conclusions about the appropriate treatment of incidentally detected SSPE, for which the data are sparse.
Among cancer patients, the bulk of available data suggest that incidental SSPE is associated with recurrent venous
thromboembolism and, when symptomatic, may adversely impact survival. Here, the topic is reviewed utilizing 3
clinical cases, each of which is followed by a discussion of salient features and then by treatment recommendations.
OConnell C: Incidentally Found Pulmonary Embolism: Whats the Clinician to Do? Hematology Am Soc Hematol
Educ Program (1):197-201, 2015.
Incidental pulmonary embolism (IPE) is a management challenge for the unsuspecting clinician. Patients with IPE
frequently have signs or symptoms that are unrecognized as PE related, and their clots occur predominantly in
the proximal pulmonary vasculature. There is uniformity in recommending anticoagulation for patients with IPE
proximal to the subsegmental pulmonary vasculature, but prospective data are not currently available to guide the
duration of therapy in this population. Several studies suggest that outcomes, including recurrence, mortality, and
bleeding, are similar for patients with IPE and suspected PE, especially among those who also have cancer. Patients
with isolated incidental subsegmental pulmonary embolism (ISSPE) are particularly challenging because some
studies suggest that they can be managed without anticoagulation. Therefore, an algorithm is proposed to guide the
evaluation and treatment of patients with ISSPE.
Piatek C, El-Hemaidi I, Feinstein D, Liebman HA, Akhtari M: Management of Immunie-Medicated Cytopenias
in Pregnancy. Autoimmun Rev (9):806-11, 2015.
Immune-mediated cytopenias are a well-described complication of pregnancy. Appropriate recognition and
treatment are important in order to limit maternal and fetal morbidity and mortality. First line treatment options are
fairly well-established for these entities. Refractory disease may be difficult to manage because treatment choices
are limited by known or unestablished risk to the fetus. While the use of new agents, such as romiplostim and
rituximab, has been reported, their safety in pregnancy is not known. This article summarizes immune cytopenias
seen in pregnant patients, and it also discusses management of these cytopenias, and provides practical strategies for
the treatment of these challenging conditions.
64
BCRP/BC102678, Co-Targeting HER2 and EphB4 Pathways, Department of Army/Department of Defense, 2015
Pilot Award, Clinical Development of Soluble EphB4HSA, Whittier Initiative, 2015
Research Innovation Award, USC, 2015
SPORE in Prostate Cancer, Northwestern University, Principal Investigator, 2015
Translational Award, Targeting the Ephrin Pathway: Phase I Therapeutic Trial with Circulating Tumor Cell
Molecular Correlates, V Foundation for Cancer Research, Co-Principal Investigator, 2015
Whittier Foundation Award, Reovirus Therapy for Multiple Myeloma: A Phase 1b Clinical Trial, 2015
Immune Profiling Patients Treated with sEphB4-HSA, Ming Hsieh Institute for Research of Engineering Medicine
for Cancer, Principal Investigator, 2015
Stop Cancer Gift Fund, 2015
Recipient of a $10,000,000 gift from the Norbert Gehr Family Foundation toward translational research targeting
myeloid malignancies over the next 10 years, 2015
Illumina Grant, BaseSpace Applications for Next Generation Sequencing Analysis, 2015
Leukemia and Lymphoma Society, Characterizing Hematopoietic Senescence with Aging in Humans, Principal
Investigator, 2015
Tower Cancer Research Foundation, Hematopoietic Stem and Progenitor Cell Senescence and Therapy Related
AML, Principal Investigator, 2015
65
Honors and Awards
Parkash S. Gill, MD
Faculty
Professor
Professor Emeritus
Assistant Professor
Michael P. Dub, MD (Clinical Scholar)

Paul D. Holtom, MD
Fred R. Sattler, MD
Brad Spellberg, MD
Robert A. Larsen, MD
Emily Blodget, MD
Joseph J. Cadden, MD
Darren W. Wong, MD
Associate Professor
P. Jan Geiseler, MD
Brenda E. Jones, MD
66
Infectious Diseases
Fred R. Sattler, MD, Professor of Medicine and Chief
Erika Anaya, Division Administrator
The overarching mission of the Division of Infectious Diseases is threefold: to advance the development of therapies
to improve health through clinical and translational research in infectious diseases; to promote excellence in the
education of medical students, house officers and clinical fellows; and to deliver compassionate, evidence-based,
state-of-the-art care to the large, diverse, multicultural community of Southern California served by LAC+USC
Medical Center (LAC+USC), Rand Schrader Health and Research Center, Keck Hospital of USC, USC Norris
Cancer Hospital (Norris Hospital), and the USC Healthcare Center 2 (HC2).
A primary research mission of the Division of Infectious Diseases for more than three decades has been to
investigate strategies to prevent and treat HIV and its complications. The NIH-supported AIDS Clinical Trials
Group (ACTG) is a major focus of research in the Division. Dr. Fred Sattler serves as Principal Investigator. The
ACTG Clinical Research Site (CRS) at USC is in its 28th year and recently successfully re-competed to be funded
for another seven-year cycle. The USC ACTG CRS has continuously performed at a very high level and has been
second in enrollment of total research subjects amongst 72 domestic and international sites. It is also the leading
site in the continental U.S. for enrolling minorities and women. Moreover, USC faculty (Drs. Sattler and Dub,)
continue to hold important scientific and administrative leadership positions during the current funding cycle. These
key positions enabled faculty from our Division to contribute to and facilitate the scientific agenda and productivity
of this world-leading HIV collaborative research group. Tuberculosis, hepatitis C and cryptococcal meningitis, along
with complications of chronic inflammation and immune activation including cardiovascular and lipid disorders
and neurocognitive impairment, and aging-related disabilities including frailty have been areas of leadership by ID
faculty. Drs. Dub and Sattler are members of the Inflammation and End-Organ Transformative Science Group and
have developed a number of concept proposals that are either under review or are being implemented for studies.
Dr. Sattler is Chair of the Exercise Focus Group and Dr. Dub is a member of the Data Monitoring Committee.
The Division of Infectious Diseases also remains a lead member of the California Collaborative Treatment
Group (CCTG), which is funded by the State of California University Wide AIDS Program. The CCTG is the
largest collaborative HIV clinical research group in California and has been continuously funded for more than
two and a half decades. Dr. Dub is the Principal Investigator of the USC component of the CCTG. Under his
leadership, the CCTG was recently awarded $1.6 million to lead a large four-year CCTG project at USC and
the other collaborative research sites to improve patient retention in HIV care and to provide HIV pre-exposure
prophylaxis (PrEP) to individuals at high risk of acquiring HIV.
The Rand Schrader Health and Research Center has been under the medical leadership of the Division
(Drs. Sattler, Cadden and Dub) since 1986 and has been a national flagship for the outpatient care of persons with
HIV. The Clinic was conceived around a model whereby all care would be facilitated at a single site, the medical
care home. Up to 40 USC faculty from virtually all specialties provide primary care and consultation during 11
weekly clinics session (Monday through Friday AM and PM as well as Tuesday evenings for patients who work
during the daytime). A primary care provider, a registered nurse and a social service case manager constitute the
Medical Care Coordination team for each patient; they facilitate all aspects of patient care in and away from the
Clinic (including in the patients home).
Specialty clinics have included Pulmonary, Hematology-Oncology, Neurology, Psychiatry, Ophthalmology,
Colorectal and Nutrition-Metabolism. Two new clinics have been created to meet the changing face of chronic HIV
infection. The Dermatology service staffs a weekly Lipodystrophy Clinic, whereby patients receive autologous fat
67
transfer for facial wasting, or liposuction to relieve pain and suffering associated with buffalo humps or other fatty
depositions. The other new clinic is the Hepatitis Treatment Evaluation Clinic for patients co-infected with HIV and
HCV or HBV. The goal of this clinic is to treat all patients co-infected with HBV and HCV at increased risk for
liver related complications, especially now as multiple oral agents are available.
The Rand Schrader Health and Research Clinic also sponsors a broad range of education programs in HIV for
the faculty, staff, ID fellows and other house officers rotating through the adult and pediatric ID services. As
just one example, a Resistance Workshop is held monthly where patients with complex HIV resistance profiles
and multiclass drug-resistance profiles are presented. Attendees use cART treatment histories along with HIV
phenotypes and genotypes and work with an expert facilitator to arrive at treatment recommendations. The Clinic
also serves as the primary site for OPD continuity care for ID fellows who learn all aspects of ambulatory care of
HIV.
The Infectious Diseases Solid Organ Transplant Consultation Service was created in the spring of 2010 to
provide complex ID consultation for a large number of solid organ transplants (heart-lung, liver, pancreas and
kidney) at Keck Hospital. Dr. Emily Blodget serves as the lead consultant with assistance from Drs. Cadden,
Geiseler and Sattler in creating the first dedicated infectious diseases transplant service at Keck Hospital. This
addition provides a unique and focused training experience for infectious diseases fellows, house officers and
students rotating through the ID consultation service.
The unique tripartite training in Infectious Diseases at USC offers an unparalleled clinical experience in three
very different settings. First, the new training experience in transplantation infectious diseases is complemented by
existing training provided by highly experienced faculty on the inpatient general ID consultation services at two
private university hospitals (Keck Hospital and Norris Hospital), serving privately insured patients. The second
involves the very busy ID consultation service at LAC+USC, which provides care to the underserved population
of the greater Los Angeles Basin, many of whom are recent immigrants and travelers who bring from their home
countries infections not routinely seen in the United States. The third component involves unparalleled opportunities
for training in HIV medicine at the 33,000-square-foot, fully dedicated Rand Schrader Health and Research Clinic,
which provides primary and specialty HIV care for approximately 2,500 HIV infected individuals. LAC+USC and
the Rand Schrader Clinic provide care for a largely underserved minority population (60-70% Latinos and 12-15%
African-Americans). The clinical and racial/ethnic diversity make ID fellowship training at USC one of the truly
unique programs in the U.S.
Dr. Brad Spellberg, previously a faculty member at Harbor UCLA, was recruited to USC last year to serve as
Chief Medical Officer for LAC+USC Medical Center. He is also an active member of the Division of Infectious
Diseases, attends regularly on the ID consult services and participates in all other teaching functions in the Division
(including weekly cases conferences, ID grand rounds and CPCs, journal club, and research seminarssee below).
Dr. Paul Holtom now serves as Director of Infection Control and and Prevention at LAC+USC Medical Center
and is the founder and leader of the Orthopedic ID service at the facility; Dr. Holtom like Dr. Spellberg attends and
participates in all of the teaching activities of the ID Division.
Dr. Darren Wong joined the Division of Infectious Disease in July after completing
his ID fellowship training at Montefiore Medical Center and Albert Einstein College
of Medicine. Dr. Wong has assumed leadership and lead roles in the antimicrobial
stewardship programs at LAC+USC Medical Center and Keck Hospital, monitoring all
daily blood cultures as done by the ID fellows, and for the large weekly communicable
diseases clinic at Rand Schrader Clinic. He also serves in a support capacity to
Dr. Paul Holtom, Infection Prevention Officer, at the LAC+USC Medical Center.
Dr. Wong serves on the ID consultation services at Keck Hospital and LAC+USC
Medical Center. For his research, he works with Dr. Brad Spellberg on studies of
antimicrobial resistance and therapeutic strategies for these infections (including
monoclonal antibody and vaccine development).
The Division of Infectious Diseases provides care and consultation in all the clinical venues served by the
Department of Medicine at the University of Southern California.
68
LAC+USC Medical Center/Outpatient Clinics
Rand Schrader Health and Research Clinic
The ID Division maintains overall responsibility for the medical operations of the Rand Schrader Clinic. Dr. Cadden
serves as Medical Director and Dr. Dub as Associate Medical Director. This modern facility is fully dedicated to
the comprehensive care of persons infected with HIV. Faculty from the Division and all other major specialties
provide primary and specialty care and serve as attending physicians for house officers and students. Patients
receive primary care at the Clinic mornings and afternoons Monday through Friday and Tuesday evenings.
Hospital Infection Control and Antibiotic Stewardship
Dr. Paul Holtom serves as the Hospital Epidemiologist, Infection Control Officer and heads Infection Prevention at
LAC+USC. He also oversees the Antibiotic Stewardship Program (ASP), as well as chairing the Infection Control
Committee, the Pharmacy and Therapeutics Committee and the Antibiotic Subcommittee at LAC+USC Medical
Center. Drs. Sattler and Dub also serve on the Antibiotic Subcommittee. Drs. Wong and Dub are members of the
ASP and make daily teaching and stewardship rounds with pharmacists at LAC+USC, with special focus on critical
care and hematology units and services.

Drs. Geiseler, Cadden, Blodget, Wong and Sattler provide consultative inpatient services (both teaching and private)
and outpatient services at Keck Hospital and HC2, respectively there are more than 2,000 new patient consultations
annually at this facility. Dr. Blodget also serves as the Interim Hospital Epidemiologist. Dr. Sattler oversees the
Antibiotic Stewardship Program at this facility and makes daily antimicrobial stewardship rounds with a hospital
pharmacist and Drs. Blodget, Cadden and Geiseler to evaluate patients receiving restricted antibiotics and to help
the primary care teams in the management of their patients. Dr. Dub serves as compliance officer for the USC
Clinical Trials Unit at Norris Hospital.
USC Healthcare Centers

Drs. Cadden, Geiseler, Blodget and Wong have regularly scheduled weekly outpatient clinic sessions for ID patients
at these facilities. The clinics generate approximately 1000 outpatient visits annually. These faculty also provide
consultations for outgoing international travelers needing prophylaxis and immunizations and for returning travelers
with new signs and symptoms of infections acquired overseas. They also oversee outpatient IV antimicrobial
therapy for patients recently discharged for Keck and Norris hospitals.
69
Clinical Activities
The Division provides a very active consultation service (approximately 3,000 new infectious diseases consultations
each year) at LAC+USC. The Division also operates a weekly general ID outpatient clinic (~1,000 visits annually),
staffed by ID faculty (Drs. Dub, Sattah, Jones and Wong), fellows, residents and students who provide outpatient
consultation and continuity care for patients with and without HIV who have complicated infections or those
needing outpatient IV antimicrobial therapy.
Infectious Disease Fellows

Class of 2016
Class of 2017
Supriya Bhat, MD
Daniel Chelliah, MD
Melissa Barger, MD
Rohit Kaliah, MD
Elham Rahmati, MD
The Infectious Disease Fellowship program has grown from four to five trainees and will have a sixth fellow trainee
in July 2016. The addition of trainees provides greater diversity in electives (e.g. stewardship, clinical microbiology,
infection control/prevention, ortho ID) with greater flexibility for research projects.
Conferences
The Infectious Diseases Core Lectures (Monday mornings 8:00-9:00) are a vital component of the
didactic portion of the ID curriculum and provide a comprehensive overview of virtually all important infectious
diseases topics over a two-year cycle. Lectures are usually given by ID faculty, but each fellow is expected to give
one to two lectures annually.
The Infectious Diseases Case Conference (Wednesday mornings 8:30-9:30) features two case
presentations, usually one from the LAC+USC Consult Service and one from the Keck or Norris Hospitals; one
case per month is selected from the Pediatric ID Service. Fellows unfamiliar with the cases discuss diagnostic
and therapeutic issues. Faculty then provide additional insights into the case, followed by a five minute didactic
presentation by one of the fellows that highlights important or unique aspects of the cases presented. This lively
conference is usually attended by 30-40 participants, including faculty, trainees, Rand Schrader Clinic providers and
community ID practitioners.
Infectious Diseases Grand Rounds (second Friday of each month) features guest speakers selected and
hosted by the USC ID faculty, including visiting faculty of local and national stature in their respective areas of
expertise.
70
The Clinicopathologic Conference (fourth Friday of each month) is a multidisciplinary conference that
includes faculty from other specialties who discuss diagnostic elements and review pathologic slides, microbiologic
specimens, radiographic imaging, retinal photographs and/or their specialtys contribution to the patient care of the
case presented.
For Infectious Diseases Journal Club (monthly), two articles are selected by an ID faculty facilitator.
One fellow is assigned as the primary presenter/discussant for each article, presenting a critical analysis of
study hypotheses, study design, statistical methods, results and appropriateness of the authors conclusions, and
applicability of the results to patient care.
The Combined Pulmonary-Infectious Diseases Teaching Conference (third Tuesday morning
8:30-9:30) consists of case presentations of two unknowns, one selected by ID and the other by Pulmonary. Faculty,
fellows, residents and students from both divisions attend the conference and participate in the discussion of
instructive cases. A short review of the relevant literature follows each presentation.
Intercity Infectious Diseases Rounds is a long-standing two-hour monthly meeting of academic ID
specialists, trainees and allied health professionals that rotates among the participant hospitals (USC, Harbor UCLA,
Harbor City Kaiser, St. Marys Medical Center, Long Beach VA and Torrance Memorial Hospital). Four to five cases
are presented as unknowns and discussed by faculty selected at the conference by the facilitator from the hosting
institution. At the end of each case presentation, a fellow from the sponsoring facility gives a didactic slide overview
of salient features of the case.
Combined Adult-Pediatric Infectious Diseases Research Conference is a monthly clinical
research conference (coordinated by Dr. Dub) on topics of current clinical and translational research of adult and
pediatric ID faculty, other USC faculty (e.g. from the School of Pharmacy, Department of Molecular Microbiology
and Immunology), and clinical fellows of USC and, CHLA; occasionally guest experts from affiliated institutions
(e.g., City of Hope) give seminars. The conference is interactive and participants discuss study design, statistical
approaches and analytical methods.

Emily Blodget, MD
Dr. Blodget has initiated research on the incidence and outcomes of vancomycinresistant enterococcus (VRE) infection in patients with cirrhosis who are awaiting
liver transplantation. She is conducting a large ongoing retrospective study in these
patients to determine the risk factors as well as morbidity and mortality of VRE
infection. She is planning on expanding these studies to include other multi-drug
resistant organisms such as pseudomonas and ESBL E. coli. She is continuing to
develop research plans to evaluate the effectiveness of screening liver transplant
candidates with interferon gamma release assay versus standard PPD testing and
outcomes after transplant.
71
Research Activities
The Division maintains consistent funding for ongoing investigations relating to HIV and other areas of infectious
diseases. The Division has had an important and productive role in large, multicenter collaborative research groups
that emphasize development of treatment and prevention modalities for HIV infection and complications associated
with antiretroviral therapy and the underlying disease as well as other bacterial, fungal, and viral infections in HIVpatient populations.
Dr. Cadden is conducting several important studies. He serves as Co-PI with Amy Wohl, PhD (Chief Epidemiologist
in the HIV Epidemiology Program, Los Angeles County Department of Health Services), on an NIH-funded
investigation to evaluate and develop better social support services for persons with HIV. He is also a member of
the protocol team for ACTG 5293, which evaluates the effect of HDL-raising therapies on endothelial function,
lipoproteins and inflammation in HIV-infected subjects with low HDL cholesterol.
Michael P. Dub, MD
Dr. Dubs research interests focus on the complications of HIV infection as well as on HIV prevention. He has
been the USC PI of the California Collaborative Treatment Group (CCTG) for HIV research since 2009; the CCTG
is the largest collaborative HIV clinical research group in California and is funded by the California HIV Research
Program. Currently, Dr. Dub is wrapping up a major 4-year CCTG project at USC to improve patient retention
in HIV care and to optimize HIV pre-exposure prophylaxis (PrEP) to individuals at high risk of acquiring HIV.
As part of this project, Dr. Dub is leading a study of vitamin D supplementation to preserve bone health in this
population. He was just awarded a new 4-year CCTG grant that will focus on PrEP in transgender persons. He is
also an active member of the AIDS Clinical Trials Group and is protocol co-chair for the ongoing ACTG 5346 study
A Randomized, Blinded Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for
Reducing Inflammation and Immune Activation in HIV Infected Men and Women.
P. Jan Geiseler, MD
Dr. Geiseler continued his role as Co-Investigator in ACTG and CCTG studies that
evaluate antiretroviral therapy utilizing new treatment and prevention strategies for
patients infected with HIV. Dr. Geiseler was the USC PI for two important ACTG
trials, A5175 and A5202, which evaluated the efficacy of once daily protease inhibitor
and once daily non-nucleoside reverse transcriptase inhibitor-containing therapy in
combination with nucleoside analogues. These studies resulted in impact bearing
publications. More recently he has been working with ID fellows and colleagues
in other departments to investigate how to better manage patients with transplant
infections.
Brenda E. Jones, MD
Dr. Jones is the USC Principal Investigator of the tuberculosis (TB) diagnostic study, Evaluation of the 4th
Generation Quantiferon TB Test (CST001) for the Detection of Tuberculosis Infection (Cellestis, Qiagen NV,
the Netherlands). The 4th Generation Quantiferon TB test aims to further increase the sensitivity of the assay
in immunocompromised patients as well as to possibly aid in differentiating latent TB infection from active TB
disease. Dr. Jones will also investigate Mycobacterium Tuberculosis CD8 cell response as a surrogate marker for TB
treatment response. Dr. Jones is a co-investigator of the NIH R01 proposal entitled, Integrated Cost-Effective Point
of Care Nucleic Acid Testing for TB Diagnosis (PI: Niemz, Keck Graduate Institute, Claremont), which received
an impact score of 29. Future collaborative studies on TB diagnostics are planned.
Dr. Jones was co-investigator with Dr. Michael Neely (PI), Department of Pediatrics at Childrens Hospital Los
Angeles, for the NIH funded Prospective Study to Optimize Vancomycin Dosing in Children and Adults using
Multiple-Model Bayesian Adaptive Control. The finding that vancomycin troughs were not adequate for optimal
dosing in 90 patients enrolled at LAC+USC was submitted for presentation. Dr. Jones also participated in the
International Food Information Council (IFIC) Foundation Physicians Roundtable on Antibiotic Resistance.
Paul D. Holtom, MD
Dr. Holtom is Director of the Jeanette Wilkins Memorial Microbiology Laboratory. He collaborates with faculty in
the Department of Orthopaedic Surgery on clinical studies of new treatment strategies for bone and joint infections.
These studies include evaluation of new antimicrobials for skin and soft-tissue infections and in vitro and in vivo
studies on local antibiotic therapy and the elution of antibiotics from PMMA beads and spacers. Dr. Holtom also
conducts studies with ID fellows on the epidemiology of nosocomial bacterial infections and invasive candidal
disease.
72
Fred R. Sattler, MD
In addition to serving as PI of the USC ACTG grant, Dr. Sattler recently served on a NIAID Task Force that
was ordered by the President to design the first therapeutic trials to study new treatments of H1N1 and seasonal
influenza. In the ACTG, Dr. Sattler is voting member of the Inflammation and End Organ Transformative Sciences
Group. He is also a member and facilitator for the Immune Activation Focus Group and Co-Chair of the Exercise
Focus Group. In addition, Dr. Sattler (PI) along with collaborators at University of California, San Diego showed
that neurocognitive dysfunction in patients with HIV is aggravated by abdominal obesity and mediated by systemic
inflammation and is associated with CNS activation of microglial cells. The latter studies results in his obtaining
an R01 grant to evaluate the growth hormone releasing factor (Tesamorelin) to assess its efficacy in increasing the
powerful IGF-1 brain neurotroph and reducing visceral adipose tissue in abdominally obese HIV infected patients
with neurocognitive impairment. Dr. Sattler also has two foundation grants to study the effects of sitagliptin for
suppressing macrophage activation in abdominal adipose tissue and its effects on proatherogenic mediators. Finally,
Dr. Sattler was recently honored by a request from the editorial board of Elsevier to write a peer-reviewed overview
on growth hormone in the aging male for Best Practices & Research: Clinical Endocrinology & Metabolism.
Brad Spellberg, MD
Dr. Spellbergs NIH-funded research interests are diverse, ranging from basic immunology and vaccinology, to
pure clinical and outcomes research, to process improvement work related to delivery of care, focusing on safety
net hospitals. Dr. Spellberg is currently working on the immunology, vaccinology, and host defense against highly
resistant Gram negative bacilli, including Acinetobacter and carbapenem-resistant Enterobacteriaceae infections.
He has an active discovery and development program that has been NIH-funded for monoclonal antibodies targeting
A. baumannii. He also is working on the pathogenesis of these infections, including
the interface between diabetes, inflammation, and iron. He has an NIH-funded
translational program evaluating transferrin as a potential therapeutic agent to treat
infections and reduce the frequency of emergence of antibiotic resistance. His lab also
has an NIH grant to evaluate a multi-valent antigen approach to vaccination for
S. aureus infections. He has several clinical research projects in development, funded
by NIH, including a randomized trial of fosfomycin therapy for complicated urinary
tract infections which is in protocol development, and an adaptive, platform trial to
enable superiority trials to be conducted for highly resistant Gram negative bacilli,
which is in the design phase. The over-arching theme of the work in his lab is to
understand the pathogenesis of infections caused by highly resistant bacteria, as well
as fungi, with an intent to develop immune-modulatory therapeutic interventions to
improve morbidity and mortality of these infections.
Darren W. Wong, MD
Darren Wong is a new junior faculty member in the Division of Infectious Diseases. He is actively involved in
infection control and antimicrobial stewardship, and integrating both programs to optimize clinical care.
Dr. Wong has initiated research examining empiric gram negative therapy for sepsis with the goal of improving
risk stratification to identify patients with potential drug resistant pathogens, optimizing empiric antimicrobial
therapy, and integrating these findings into the existing antimicrobial stewardship program. He is also the Principal
Investigator in the consortium on resistance against carbapenems in Klebsiella pneumoniae (CRACKLE) an NIH
and Antibiotic Resistance Leadership Group funded multi-center national study analyzing the epidemiology and
regional resistance patterns of these extensively-drug resistant bacterium. He is, under the mentorship of
Dr. Brad Spellberg, participating in the FOCUS trial, examining the efficacy the potential role of fosfomycin for
new treatment indications. Future plans include serving as an investigator for phase 3 clinical trials of experimental
antimicrobial therapeutic agents and resuming Clostridium difficile clinical research, an area of his research prior to
joining the USC faculty.
73
Highlighted Publications
The Division of Infectious Diseases published 22 papers in peer-reviewed journals during the period of January 1
through December 31, 2015, and seven are in press. Five publications are highlighted below:
Dub MP, Komarow L, Fichtenbaum CJ, Cadden JJ, Overton ET, Hodis HN, Currier JS, Stein JH: Extended
Release Niacin vs. Fenofibrate in HIV-Infected Participants with Low HDL Cholesterol: Effects on Endothelial
Function, Lipoproteins, and Inflammation. Clin Infect Dis 61:840-9, 2015.
Low levels of high-density lipoprotein cholesterol (HDL-C) are common in individuals with human
immunodeficiency virus (HIV) infection, persist during antiretroviral therapy (ART), and are associated with
increased cardiovascular disease (CVD) risk. Virologically controlled participants without CVD on stable ART
with low HDL-C (men <40 mg/dL, women <50 mg/dL) and triglycerides >150 mg/dL were randomized to receive
open-label extended-release niacin 1500 mg/day with aspirin 325 mg/day or fenofibrate 200 mg/day for 24 weeks.
The primary endpoint was the week 24 within-arm change in brachial artery flow-mediated dilation (FMD) in
participants with complete follow-up scans. Of 99 participants, 74 had complete data (35 niacin, 39 fenofibrate).
Median age was 45 years, 77% were male, median CD4(+) count was 561 cells/L, and brachial FMD was 4.2%.
Median HDL-C was 32 mg/dL for men and 38 mg/dL for women, low-density lipoprotein cholesterol was 103 mg/
dL, and triglycerides were 232 mg/dL. In men, HDL-C increased a median of 3 mg/dL with niacin and 6.5 mg/
dL with fenofibrate (P < .001 for both). In women, HDL-C increased a median of 16 mg/dL with niacin and 8 mg/
dL with fenofibrate (P = .08 for both). After 24 weeks, there was no significant change in FMD in either arm; the
median (interquartile range) change was +0.6% (-1.6 to 2.3) with niacin (P = .28) and +0.5% (-1.0 to 3.0) with
fenofibrate (P = .19). Neither treatment significantly affected C-reactive protein, interleukin 6, or D-dimer levels.
Despite improvements in lipids, niacin or fenofibrate treatment for 24 weeks did not improve endothelial function or
inflammatory markers in participants with well-controlled HIV infection and low HDL-C.
Berbari EF, Souha SK, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot EF, Holtom PD,
Huddleston III PM, Petermann GW, Osmon DR: 2015 Infectious Diseases Society of America (IDSA) Clinical
Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Inf Dis
61:e26-46, 2015.
These guidelines are intended for use by infectious disease specialists, orthopedic surgeons, neurosurgeons,
radiologists, and other healthcare professionals who care for patients with native vertebral osteomyelitis (NVO).
They include evidence and opinion-based recommendations for the diagnosis and management of patients with
NVO treated with antimicrobial therapy, with or without surgical intervention.
Villarino ME, Scott N, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro R, Shang N,
Sterling TR, the International Maternal Pediatric and Adolescents AIDS Clinical Trials Group (IMPAACT), and the
Tuberculosis Trials Consortium (TBTC): New Treatment for Preventing Tuberculosis in Children: A Three Month
(12 Dose) Regimen of Rifapentine and Isoniazid. JAMA Pediatrics 169(3):247-55, 2015.
Three months of a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberculosis
infection is safe and effective for persons 12 years or older. Published data for children are limited. To compare
treatment safety and assess noninferiority treatment effectiveness of combination therapy with rifapentine and
isoniazid vs 9 months of isoniazid treatment for latent tuberculosis infection in children. A pediatric cohort nested
within a randomized, open-label clinical trial conducted from June 11, 2001, through December 17, 2010, with
follow-up through September 5, 2013, in 29 study sites in the United States, Canada, Brazil, Hong Kong (China),
and Spain. Participants were children (aged 2-17 years) who were eligible for treatment of latent tuberculosis
infection. Twelve once-weekly doses of the combination drugs, given with supervision by a health care professional,
for 3 months vs 270 daily doses of isoniazid, without supervision by a health care professional, for 9 months.
We compared rates of treatment discontinuation because of adverse events (AEs), toxicity grades 1 to 4, and
deaths from any cause. The equivalence margin for the comparison of AE-related discontinuation rates was 5%.
Tuberculosis disease diagnosed within 33 months of enrollment was the main end point for testing effectiveness.
The noninferiority margin was 0.75%. Of 1058 children enrolled, 905 were eligible for evaluation of effectiveness.
Of 471 in the combination-therapy group, 415 (88.1%) completed treatment vs 351 of 434 (80.9%) in the isoniazidonly group (P =.003). The 95% CI for the difference in rates of discontinuation attributed to an AE was -2.6 to
0.1, which was within the equivalence range. In the safety population, 3 of 539 participants (0.6%) who took
the combination drugs had a grade 3 AE vs 1 of 493 (0.2%) who received isoniazid only. Neither arm had any
74
hepatotoxicity, grade 4 AEs, or treatment-attributed death. None of the 471 in the combination-therapy group
developed tuberculosis vs 3 of 434 (cumulative rate, 0.74%) in the isoniazid-only group, for a difference of -0.74%
and an upper bound of the 95% CI of the difference of +0.32%, which met the noninferiority criterion. Treatment
with the combination of rifapentine and isoniazid was as effective as isoniazid-only treatment for the prevention of
tuberculosis in children aged 2 to 17 years. The combination-therapy group had a higher treatment completion rate
than did the isoniazid-only group and was safe.
Sattler F, He J, Letendre S, Wilson C, Sanders C, Heaton R, Ellis R, Franklin D, Aldrovandi G, Marra CM, Clifford
D, Morgello S, Grant I, McCutchan JA: Abdominal Obesity Contributes to Neurocognitive Impairment in HIV
Infected Patients with Increased Inflammation and Immune Activation. JAIDS 68(3):281-8, 2015.
We tested our hypothesis that abdominal obesity when associated with increased levels of systemic and central
nervous system immunoinflammatory mediators contributes to neurocognitive impairment (NCI). One hundred
fifty-two patients with plasma HIV RNA <1000 copies per milliliter had clinical evaluations and cognitive function
quantified by global deficit scores (GDS). GDS, waist circumference (WC) and plasma IL-6, sCD163, and sCD14
and CSF sCD40L, sTNFrII, MCP-1, sICAM, and MMP-9. WC and plasma IL-6 levels positively correlated with
GDS; the WC correlation was strongest in the high tertile of IL-6 ( = 0.39, P = 0.005). IL-6 correlated with GDS
only if WC was 99 cm. In the high tertile of CSF sCD40L, a biomarker of macrophage and microglial activation,
the correlation of IL-6 to GDS was strongest ( = 0.60, P < 0.0001). Across 3-5 visits within 1 year of the index
visit, GDS remained worse in patients with IL-6 levels in the high versus low tertile (P = 0.02). Path analysis to
explore potential mediators of NCI produced a strong integrated model for patients in the high CSF sCD40L tertile.
In this model, WC affected GDS both directly and through a second path that was mediated by IL-6. Inclusion of
plasma sCD14 levels strengthened the model. NCI was more common in men and for individuals with components
of the metabolic syndrome. Neurocognitive function was significantly linked to abdominal obesity, systemic
inflammation (high IL-6), and immune activation in plasma (high sCD14) and CSF (high sCD40L). Abdominal
obesity, inflammation, and central nervous system immune activation are potential therapeutic targets for NCI in
HIV-positive patients.
Spellberg B, Bartlett JG, Wunderink R, Gilbert DN: Novel Approaches Are Needed to Develop Tomorrows
Antibacterial Therapies. Am J Resp Crit Care Medicine 191:135-40, 2015.
Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up.
Antibiotics are a public trust; every individuals use of antibiotics affects their efficacy for everyone else. As such,
responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a
combination of scientific challenges to discovering and developing new antibiotics, unfavorable economics, and
a hostile regulatory environment. Scientific solutions include changing the way we screen for new antibiotics.
More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that
modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance
emergence. Economic transformation will require new business models to support antibiotic development. Finally,
regulatory reform is needed so that clinical development programs are feasible, rigorous, and clinically relevant.
Pulmonary and critical care specialists can have tremendous impact on the continued availability of effective
antibiotics. Encouraging use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic
therapy, using short rather than unnecessarily long course therapy, reducing inappropriate antibiotic use for probable
viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.
75
Faculty
Professor
Associate Professor
Assistant Professor
Vito M. Campese, MD
Elaine M. Kaptein, MD
Mitra K. Nadim, MD
Saeid M. Nosrati, MD
Nuria Pastor-Soler, MD, PhD
Yasir A. Qazi, MD
Miroslaw J. Smogorzewski, MD, PhD
Joseph Abdelmalek, MD
Gbemisola A. Adenuga, MD
Rahul Dhawan, DO
Arshia Ghaffari, DO
Hui Li, MD
Chong Y. Parke, MD
Hui-Yi Shan, MD
Shilpa Sharma, MD
Professor Emeritus
Shaul G. Massry, MD
76

Kenneth R. Hallows, MD, PhD, Professor of Medicine and Chief
Jennifer K. Severa, MPA, Senior Administrator
The Division of Nephrology and Hypertension is committed to providing comprehensive up-to-date medical care
to patients with a variety of kidney diseases, hypertension, renal failure, fluid and electrolyte disturbances and
transplantation of the kidney, kidney-pancreas and kidney-liver. The Division operates both in the public sector
at LAC+USC Medical Center (LAC+USC) and in the private sector at Keck Hospital of USC (KH), USC Norris
Cancer Hospital (Norris) and DaVita-USC Kidney Dialysis Center (DaVita-USC).
At LAC+USC, the Division of Nephrology has two consult services and manages approximately 160 consultations
per month. The Division provides more than 7,000 acute hemodialysis treatments annually, as well as continuous
renal replacement therapy (CRRT) for fluids, electrolytes and metabolic support of acutely ill patients in the
intensive care units. We also provide charcoal hemoperfusion for treatment of selected patients with drug overdose
in coordination with the Poison Center in the Emergency Medicine Department.
At KH and Norris, Nephrology and Hypertension faculty members admit private patients and provide consultations
to patients with kidney diseases, fluid and electrolyte disturbances, acid-base disorders and hypertension. In
addition, our faculty work very closely with the kidney, pancreas, heart, lung and liver transplant surgeons to
provide care to patients with end-stage renal disease who require living-related, living-unrelated or cadaveric kidney
transplants. The Division of Nephrology and Hypertension and the Division of Vascular Surgery are dedicated to
providing care to patients with renovascular hypertension, ischemic kidney disease and others forms of secondary
hypertension. The Division of Interventional Radiology provides excellent access for our hemodialysis patients,
including establishing dialysis access with tunneled dialysis catheters and percutaneous inserting PD catheters, in
addition to procedures aimed at maintenance of dialysis fistulas and grafts.
In addition, Nephrology and Hypertension faculty follow over 350 patients with end-stage renal disease on
maintenance hemodialysis or peritoneal dialysis at DaVita-USC. This unit is recognized as an example for the
community due to its efficiency, quality of care and dedication of staff. It is rated in the top 10% of dialysis units in
the county.
The Division of Nephrology and Hypertension is committed to providing excellent teaching to medical students,
house staff and nephrologists in the community. To this end, nephrology faculty conduct the Year II Renal System
Course, which includes lectures, laboratory work and small group discussions. The faculty teach house staff and
medical students during their rotations on the renal service, both at the bedside and through didactic lectures. The
faculty also participate in the postgraduate educational activities of the Department of Medicine. Nephrology has
been awarded best teaching award by the 2nd year medical students.
The Divisions new USC/UKRO Kidney Research Center (KRC) is supported by private funding (principally the
University Kidney Research Organization (UKRO), federal grants from the National Institutes of Health and US
Department of Defense, and University grants and supporting funds. The KRC has expanded significantly over the
last year with the arrival of Drs. Kenneth Hallows and Nria Pastor-Soler and their team of seven faculty and staff.
The lab space on the 5th and 6th floors of the Mudd Memorial Research Building has undergone renovations, and
there is space for recruitment of additional kidney researchers. Recruitment efforts are underway and the KRC is
rapidly evolving to become one of the best kidney research centers in the country.
77
The Division of Nephrology and Hypertension maintains a wide range of clinical activities in all areas of
Nephrology, including hemodialysis and peritoneal dialysis. Members of the Division provide care for renal patients
at LAC+USC and KH, and consultative services at LAC+USC, KH and Norris. Nephrology faculty also take care of
patients at Los Angeles Countys Renal clinics, and in the Diabetic Nephrology Clinic.
Clinical Activities

The Division has two faculty attending on the consult service throughout the year at LAC+USC. These faculty see
all of the renal consults and provide follow-up visits with the house staff, fellows and students. The former Division
Chief, Dr. Vito Campese, conducts weekly rounds on the renal service, and Nephrology faculty attend in the renal
clinics throughout the year. In addition, the Division performs approximately 200 acute dialyses per month and sees
30 to 50 patients per session in the general renal outpatient clinics at LAC+USC.
Chronic Kidney Disease Clinics
The Division of Nephrology and Hypertension provides highly specialized care for many indigent patients in
Los Angeles County who have all aspects of kidney disease, hypertension, kidney stones and kidney transplant.
These patients are seen at the LAC+USC Outpatient Center. The Division runs the Diabetic Nephropathy Clinic at
LAC+USC, which is fully staffed by highly qualified faculty.
The mission of the Chronic Kidney Disease Clinics is to educate patients about their kidney diseases; to prevent
the progression to end-stage renal disease and prevent and treat its complications; to diagnose and treat secondary
and complicated forms of hypertension; to diagnose and treat different metabolic stone diseases; and to prepare
those with advanced kidney disease for the appropriate renal replacement therapy. In addition, the clinics provide
treatment for anemia of chronic kidney disease, secondary hyperparathyroidism and metabolic bone disease due to
renal osteodystrophy. The faculty also provide ambulatory training and education for medical students, medicine
interns, residents and nephrology fellows on the service. In addition, the clinics provide care for many long-term
kidney transplant patients on multiple immunosuppressive medications.
The Division has developed a Diabetic Nephropathy Clinic to provide care to patients with diabetes and kidney
disease and to develop research protocols for this disease. Plans for additional specialty clinics within nephrology
are underway.
Private Practice
Nephrology faculty provide renal replacement therapy and consultation services at KH and Norris. At present, the
Division has approximately 250 hemodialysis and 100 continuous ambulatory peritoneal dialysis patients at
DaVita-USC. In addition, Nephrology faculty see ambulatory patients at Healthcare Center 2.
USC Hypertension Center
The USC Hypertension Center is a comprehensive clinical program for the diagnosis and management of patients
with secondary and resistant forms of hypertension. The Hypertension Center is staffed by full-time teaching
faculty who are certified in hypertension. Besides physician specialists, resources include clinical nurse specialists,
nutritionists and pharmacologists. The Center specializes in the diagnosis and management of renovascular
hypertension, pheochomocythoma and primary aldosteronism, and in the management of resistant hypertension
and orthostatic hypotension. This Center has been ranked number one in the country for quality care and clinical
outcome.
USC Kidney Transplant Center
The Kidney Transplant Program at USC is the fastest growing program of its kind in Los Angeles. The transplant
waiting list and number of transplants performed has grown steadily over the last several years. Out of more than
300 programs in the country, the USC program ranked number 45 in the nation by volume in the year 2014. In 2015,
158 kidney transplants were performed, the highest annual volume since the inception of the program131 of these
were kidney transplant alone; 21 were a combination of kidney/liver and; the remaining six were a combination
78
of kidney/pancreas. Not only has the program grown in numbers, but the outcomes at the center have placed it
as a premier kidney transplant institute. It has recently been ranked number seven in the nation for outcomes by
Carechex, an independent organization. It is the only program in Los Angeles with a statistically superior deceaseddonor transplant rate and a statistically superior one-year graft survival rate.
The program was certified by the American Society of Transplantation for a transplant fellowship in 2014.
Dr. Rahul Dhawan was recruited as the first transplant renal fellow in the program for 2014-2015, and
Dr. Cesar Martinez is the current transplant fellow. The transplant program is one of the only programs in the
country to perform kidney-pancreas transplants in type 2 diabetics and transfusion-free living-donor kidney
transplants. Faculty in the program have published and presented at national transplant meetings. Dr. Yasir Qazi is
Medical Director of the program; other participating transplant nephrologists in the Division during 2015 were
Drs. Miroslaw Smogorzewski and Chong Y. Parke.
Nephrology Fellows
Class of 2017
Transplant Fellowship
Matthew Kaptein, MD
Ravi Lakdawala, MD
Joseph Meouchy, MD
Christopher C.D. Wong, DO
Lama Matni, MD
Roshan Rojani, MD
Syed Affan Hashmi, MD
Cesar A. Martinez, MD
The Nephrology Fellowship Program is designed to provide training in all fields of Nephrology, including
abnormalities of fluids and electrolytes, glomerulonephritis, tubulo-interstitial nephritis, renal vascular diseases,
dialysis and transplantation. The clinical phase of the training includes rotations at LAC+USC, KH, Norris, two
Comprehensive Health Care Center clinics per week, USC Transplant Clinic and DaVita-USC. During these
rotations, fellows are exposed to all aspects of clinical nephrology, including dialysis and transplantation. Fellows
are also involved in a variety of clinical and basic research in the fields of hypertension, treatment of acute and
chronic kidney disease, progression of renal disease and management of dialysis.
Nephrology faculty provide continuous teaching to the house staff and students during their rotations on the renal
service and while attending on General Medicine. In addition to bedside teaching, they provide didactic lectures.
Division faculty conduct the Year II Renal System Course, which includes lectures, laboratory work and small
group discussions. Division faculty also participate in the postgraduate educational activities of the Department of
Medicine. At LAC+USC, renal fellows and house staff receive training in ultrasonography use at the bedside, which
enhances clinical assessment of patients with acute and chronic renal failure.
79
Class of 2016
Research Activities
The Division of Nephrology and Hypertension is committed to basic as well as clinical research. Current areas of
basic and translational investigation include the mechanisms of hypertension, acute kidney injury, acid regulation
and its role in CKD, polycystic kidney disease and metabolomic biomarkers, kidney cancer, and the noradrenergic
control of blood pressure in kidney disease. Clinical research areas include the testing of novel therapeutics in
polycystic kidney disease, mechanisms and management of vascular calcifications in dialysis patients, detection
and management of cardiovascular disease in dialysis patients, prevention of progressive renal disease in AfricanAmericans, and new experimental therapeutics in kidney transplantation. The Division has also developed an
urgent-start peritoneal dialysis program, which is the largest of its kind in the country. In addition, research is
ongoing to enhance assessment of intravascular volume and response to ultrafiltration in critically ill patients.
Division of Nephrology and Hypertension faculty are actively involved in both basic
and clinical research. Within the KRC facilities, Dr. Hallows is studying the metabolic
control of kidney epithelial salt and water transport mechanisms with relevance to
hypertension, acute kidney injury and chronic kidney disease. He is also studying
the role of metabolic changes in autosomal dominant polycystic kidney disease at
various levels: (1) the molecular and cellular level using in vitro model systems
and electrophysiological, molecular genetic, biochemical, and imaging techniques;
(2) animal disease models using in vivo imaging and functional studies (e.g., of
metabolism, metabolomics and proteomics); and (3) patient samples (analysis of urine
to identify and evaluate novel biomarkers that inform on disease severity, prognosis
and response to new therapies). Dr. Pastor-Soler is
studying the molecular and cellular mechanisms by
which metabolic pathways in the kidney are affected
by acidosis, a known predictor of CKD progression. She is also studying renal cell
carcinomas with the aim to confirm a novel biomarker that could be used clinically
to assess the presence and severity of this disease. Dr. Campese has been studying
the role of the sympathetic nervous system in hypertension associated with kidney
disease as well as essential hypertension. He is also involved in studying the role of
renal denervation or baroreceptor stimulation in patients with resistant hypertension.
Other faculty have a variety of clinical protocols dealing with diabetic nephropathy,
bone disease, progression of kidney disease, kidney transplantation, vitamin deficiency
in chronic kidney disease, end-stage renal disease, transplantation and nutrition in
patients with acute kidney injury.

Albuminuria and CKD

Renin and Cardiovascular Outcomes
Cardiovascular Disease and End Stage
Renal Disease
Cardiovascular Outcomes in CKD

Epidemiology of CKD
Management of Lupus Nephritis
Impact of Health Literacy on CKD and
ESRD Outcomes
Vito M. Campese, MD
Interactions between the Kidney and the

Central Noradrenergic Control of
Blood Pressure
Microalbuminuria in Essential
Hypertension
Role of Aldosterone in the Progression
of CKD
Role of Dyslipidemia in the Progression

of CKD
Renal Denervation in the Management
of Resistant Hypertension
Arshia Ghaffari, DO
Home Dialysis Modalities: Benefits and

Cost
Management of Glomerular Diseases
Optimizing Clinical Outcomes in
Hemodialysis and Peritoneal Dialysis
Urgent Start Peritoneal Dialysis
Effect of Hemodialysis on Obstructive
Sleep Apnea
Optimal Practices in Managing Kidney
Stones
Regulation of the Epithelial Ion

Channels (CFTR and ENaC) and
other Ion Transport Proteins by AMPActivated Protein Kinase (AMPK)
80
Regulation of AMPK Function by CFTR

in Polarized Epithelial Cells
Regulation of the Ubiquitin Ligase
Nedd4-2 by Kinases
AMPK Activation by Metformin as
a Novel Therapeutic Strategy for
Autosomal Dominant Polycystic
Kidney Disease (ADPKD)
Role of AMPK in Acute Kidney Injury
(AKI) and Chronic Kidney Disease
(CKD)
Inferior Vena Cava Ultrasound to Assess

Intravascular Volume and Response to
Ultrafiltration
Vitamin D Deficiency and Effects of
Treatment in CKD
Diagnosing Adrenocortical Insufficiency
in Critically Ill Patients
Thyroid Hormone and Iodine
Metabolism in Health and Disease
and in Renal Failure Patients
Mitra K. Nadim, MD
Acute Renal Failure in Patients with

Liver Failure
Continuous Renal Replacement Therapy
Renovascular Disease

Renal Osteodystrophy
Anemia
Proteinuria
Hypercoagulopathy Related to Nephritic
Syndrome
Chong Y. Parke, MD
BK Nephropathy in Post-Kidney
Transplant
Delayed Graft Function
Kidney Transplant
Nuria M. Pastor-Soler, MD, PhD

Regulation of the Vacuolar H+-ATPase
(V-ATPase) in the Male Reproductive
Tract
Regulation of Na+ Transport in the
Collecting Duct by BicarbonateRegulated sAC
Regulation of the V-ATPase in the

Kidney Collecting Duct and Proximal
Tubule by PKA and AMPK
Regulation of the V-ATPase by Aurora
Kinase A (AURKA) in Kidney and
Breast Malignancies
Regulation of Aquaporin-2 (AQP2) by
AMPK in the Kidney Collecting Duct
Regulation of Epithelial Transport
Proteins in Sepsis-Induced AKI
Regulation of Muc-1 in Kidney
Epithelial Cells
Regulation of Kidney Epithelial Apical
Endocytosis by Flow
Renal Salt Transport Regulation by
WNK Kinases
Yasir A. Qazi, MD
Estimation of Glomerular Filtration Rate

in the Transplanted Kidney
BK Virus Nephropathy
Safety and Reliability of Virtual
Crossmatch
Shilpa Sharma, MD
Acute Kidney Injury

Continuous Renal Replacement
Therapies
Renal Nutrition

Effect of Elevated Cytosolic Calcium on
Cell Function
Mechanisms of Heart Hypertrophy in
Mechanisms Underlying the Uremic
Syndrome
Pancreatic Islets Transplantation for
Treatment of Diabetic Nephropathy
Role of Excess PTH in the Genesis of
Uremia
Hypertensive Nephrosclerosis in
African-Americans (AASK Study)
History of Nephrology
BK Nephropathy in Post-Transplant
Kidney
Living Donor Transplant Outcome
Hui-Yi Shan, MD
Management of Acute
Glomerulonephritides
Campese VM, Lakdawala R: The Challenges of Blood Pressure Control in Dialysis Patients. Recent Pat Cardiovasc
Drug Discov 10:34-59, 2015.
Hypertension is very prevalent among patients with chronic kidney disease (CKD) and end-stage kidney disease
(ESRD). However, there are still several unsolved issues pertaining to the definition, variability, diagnosis and
management of hypertension in these patients. This manuscript critically reviews the current challenges in clinical
practice in defining, diagnosing and treating hypertension in CKD and ESRD patients. Moreover, the manuscript
reviews the pharmacokinetics, pharmacodynamics and safety of most anti-hypertensive drugs used in the
management of these patients.
Roy A, Al-Qusairi L, Donnelly BF, Ronzaud C, Marciszyn AL, Gong F, Chang YP, Butterworth MB,
Pastor-Soler NM, Hallows KR, Staub O, Subramanya AR: Alternatively Spliced Proline-Rich Cassettes Link
WNK1 to Aldosterone Action. J Clin Invest 125:3433-3348, 2015.
The thiazide-sensitive NaCl cotransporter (NCC) is important for renal salt handling and blood-pressure
homeostasis. The canonical NCC-activating pathway consists of With-No-Lysine (WNK) kinases and their
downstream effector kinases SPAK and OSR1, which phosphorylate NCC directly. The upstream mechanisms that
connect physiological stimuli to this system remain obscure. Here, we have shown that aldosterone activates SPAK/
OSR1 via WNK1. We identified 2 alternatively spliced exons embedded within a proline-rich region of WNK1
that contain PY motifs, which bind the E3 ubiquitin ligase NEDD4-2. PY motif-containing WNK1 isoforms were
expressed in human kidney, and these isoforms were efficiently degraded by the ubiquitin proteasome system, an
effect reversed by the aldosterone-induced kinase SGK1. In gene-edited cells, WNK1 deficiency negated regulatory
effects of NEDD4-2 and SGK1 on NCC, suggesting that WNK1 mediates aldosterone-dependent activity of the
WNK/SPAK/OSR1 pathway. Aldosterone infusion increased proline-rich WNK1 isoform abundance in WT mice
but did not alter WNK1 abundance in hypertensive Nedd4-2 KO mice, which exhibit high baseline WNK1 and
SPAK/OSR1 activity toward NCC. Conversely, hypotensive Sgk1 KO mice exhibited low WNK1 expression and
activity. Together, our findings indicate that the proline-rich exons are modular cassettes that convert WNK1 into a
81
The Division of Nephrology and Hypertension published 18 papers in peer-reviewed journals during the period
of January 1 through December 31, 2015, and another five were in press by the end of 2015. Five publications are
highlighted below:
NEDD4-2 substrate, thereby linking aldosterone and other NEDD4-2-suppressing antinatriuretic hormones to NCC
phosphorylation status.
Fong M, Shavelle D, Weaver FA, Nadim MK: Renal Denervation in Heart Failure. Curr Hyptertens Rep 17:17,
2015.
Heart failure has emerged as one of the most important diseases of the past century. The understanding and
treatment of heart failure has evolved significantly over the years. As we move further into the era of device therapy,
attention has turned to the idea of sympathetic nervous system modulation through renal denervation to treat heart
failure. In this review, we summarize the background research, denervation technique, and current studies on renal
denervation for the treatment of heart failure. We also compare and contrast the work on carotid barostimulation.
Shah N, Meouchy J, Qazi Y: Bortezomib in Kidney Transplantation. Curr Opin Organ Transplant 20:652-656,
2015.
The purpose of this review is to evaluate the effectiveness of bortezomib in the recent literature for the prevention
and treatment of kidney transplant rejection. Several studies have analyzed bortezomib alone and in comparison
to more traditional immunosuppressive agents during the last 2 years. If administered prior to transplant or soon
thereafter, bortezomib appears to lower donor-specific antibody levels and improves graft survival. Its role as a
treatment option for antibody-mediated rejection after transplant remains unclear, with limited evidence supporting
its long-term success. Bortezomib appears to be a promising early desensitizing agent in the world of kidney
transplantation and high short-term success rates have been observed. However, additional randomized trials would
be useful to more conclusively demonstrate its effectiveness and optimal administration time in relation to transplant
surgery.
Matsuoka L, Alicuben E, Woo K, Cao S, Groshen S, Qazi Y, Smogorzewski M, Selby R, Alexopoulos S: Kidney
Transplantation in the Hispanic Population. Clin Transplant, in press, 2015.
Hispanic race and low socioeconomic status are established predictors of disparity in access to kidney
transplantation. This single-center retrospective review was undertaken to determine whether Hispanic race
predicted kidney transplant outcomes. A total of 720 patients underwent kidney transplantation from January 1,
2004 to December 31, 2013, including 398 Hispanic patients and 322 non-Hispanic patients. Hispanic patients were
significantly younger (p < 0.0001), on hemodialysis for longer (p = 0.0018), had a greater percentage with public
insurance (p < 0.0001), more commonly had diabetes as the cause of end-stage renal disease (p = 0.0167), and
had a lower percentage of living donors (p = 0.0013) compared to non-Hispanic patients. There was no difference
in one-, five-, and 10-yr graft (97%, 81%, and 61% vs. 95%, 76%, and 42% p = 0.18) or patient survival (98%,
90%, and 84% vs. 97%, 87%, and 69% p = 0.11) between the Hispanic and non-Hispanic recipients. Multivariate
analysis identified increased recipient age and kidney donor profile index to be predictive of lower graft survival
and increasing recipient age to be predictive of lower patient survival. In the largest single-center study on kidney
transplantation outcomes in Hispanic patients, there is no difference in graft and recipient survival between Hispanic
and non-Hispanic kidney transplant patients, and in multivariate analysis, Hispanic race is not a risk factor for graft
or patient survival.
82
American Transplant Congress Poster of Distinction Award, 2015
Baltimore PKD Core Center Pilot Grant Award, 2015

U.S. Department of Defense Investigator-Initiated Research Award, 2015
U.S. Department of Defense Clinical Trial Award, 2015
R01, DK075048 Grant Award, NIH, 2015
Mitra K. Nadim, MD
Faculty Teaching Award, Year II, Keck School of Medicine of USC, 2015

Wright Foundation Pilot Grant Award, 2015
83
Honors and Awards
Rahul Dhawan, DO
Faculty
Professor
David B. Agus, MD
Stephen B. Gruber, MD, PhD
Heinz-Josef Lenz, MD
J. Terrence Lanni Chair in Cancer Research and

Kathryn M. Balakrishnan Chair in Cancer Research
Louis A. VanderMolen, MD
Michael K.Wong, MD, PhD
H. Leslie Hoffman and Elaine S. Hoffman Chair in

Cancer Research
Associate Professor
Greg R. Angstreich, MD
John R. Daniels, MD
Anthony B. El-Khoueiry, MD
Agustin A. Garcia, MD
Barbara J. Gitlitz, MD
Amir Goldkorn, MD
Mitchell E. Gross, MD, PhD
Syma Iqbal, MD
Mark V. McNamara, MD
Minh D. Nguyen, MD
Jorge J. Nieva, MD
Jacek K. Pinski, MD, PhD
David I. Quinn, MD, PhD (Clinical
Scholar)
Christy A. Russell, MD
George Semeniuk, MD
Darcy V. Spicer, MD
Assistant Professor
Afsaneh Barzi, MD, PhD
Nyam-Osor Chimge, PhD
Tanya B. Dorff, MD
Diana L. Hanna, MD
Dilruba N. Haque, MD
84
James S. Hu, MD
Kian Kani, PhD
Jonathan Katz, PhD
Paul Macklin, PhD
Parag Mallick, PhD
Cynthia L. Martel, MD, PhD
Shannon M. Mumenthaler, PhD
An Nguyen, MD
Daniel L. Ruderman, PhD
Sarmad Sadeghi, MD, PhD
Shigang Xiong, MD, PhD
Instructor of Clinical
Medicine
Kevin McDonnell, MD, PhD
Charite N. Ricker, MS
Oncology
Darcy V. Spicer, MD, Associate Professor of Clinical Medicine and Chief
Dianne Moody, Senior Clinical Administrator
The Division of Oncology has four sections: Gastrointestinal Malignancies, Genitourinary Malignancies,
Solid Tumors and Womens Malignancies. The Division has been productive and successful, with strengths in
postgraduate training, patient care and clinical practice, peer-reviewed research, administration, and hospital,
university and community service.
The Division provides medical oncology clinical services at LAC+USC Medical Center (LAC+USC), USC Norris
Cancer Hospital (Norris) and Keck Hospital of USC (KH). At LAC+USC, the Division is responsible for two
busy inpatient consultative services for seriously ill patients with solid tumors and those receiving inpatient-based
chemotherapy. Ambulatory patients are seen in five half-day clinics. Outpatient-based chemotherapy and blood
product administration occur daily in the LAC+USC Infusion Center.
The Division operates a busy inpatient service at Norris, and provides consultative services at KH. Ambulatory
patients at Norris are seen in multiple daily outpatient clinics, and chemotherapy is administered in the Day
Hospital.
The Division of Oncology is experiencing increases in new outpatient visits, admissions and clinical efficiency at
Norris and LAC+USC. At the same time, a substantial number of patients are entered into peer-reviewed clinical
trials with accompanying translational research protocols, thus bringing innovative treatment strategies and
therapeutic agents to patients.
Our research programs received substantial funding from the NIH and other peer-reviewed grant support, as well as
industry-funded studies, and our faculty and fellows published extensively in peer-reviewed literature. In addition,
members of the Division have participated in intramural undergraduate and postgraduate teaching activities, as well
as lecturing in numerous international forums in Europe and Asia.
The USC Westside Cancer Center in Beverly Hills offers the latest in treatments from a range of specialties, all
focused on the oncologic care of patients with prostate cancer. The Center strives to bring new therapies to patients
and is advancing the clinical care of prostate cancer through novel clinical trials. The Center is closely tied with
the Health Sciences Campus-based USC Center for Applied Molecular Medicine and the USC National Cancer
Institute Physical Sciences-Oncology Center. Both centers focus on using current molecular technologies, bringing
together physicists, mathematicians, engineers, biologists and physicians to increase the understanding and control
of cancer. Virtual Cancer Models based on measurements from individual cancer patients will be created and used
to simulate cancer growth and predict drug responses for each patient.
The Keck Medicine of USC- Pasadena office offers treatments in all aspects of both hematologic and oncologic care
for residents of the San Gabriel Valley. Patients are offered participation in the many clinical trials being conducted
by the Division.
Keck Medicine of USC has acquired the prestigious Orange Coast Oncology Hematology (OCOH) group to create
USC Norris Oncology/Hematology in Orange County. This is an important step for USC and part of a larger strategy
to grow Keck Medicine of USCs oncology services throughout Southern California. This acquisition allows us
to offer our cancer research options to patients in Orange County. We are helping to expand these opportunities in
collaboration with Hoag Hospital.
85
Clinical Activities

The Division is responsible for outpatient clinics, two consultative services for patients with solid tumors, and a
daily Infusion Center/Day Hospital. The GI, GU, Solid Tumor and Womens sections of the Division rotate and
provide daily attending rounds on two services for consult patients on the Medicine Wards of the new Inpatient
Tower. During the year 2015, there were 199 admissions to Ward 7B for chemotherapy, 322 inpatient consults for
Team 1, and 357 inpatient Team 2 consults.
Faculty members staff five clinics per week, with allocation of patients being predicated on tumor type. During
2015, Division staff provided care for 12,537 patients in clinic and 10,020 patients at the Infusion Center. Because
of the specific nature of modern oncological practice and the absence of accepted standards of care for many
advanced malignancies (traditionally with poor prognosis), the application of novel treatment strategies has been
crucial to the successful management of patients with metastatic cancer, thus achieving total integration of clinical
and clinical research practice.
Private Practice
USC Norris Cancer Hospital- Outpatient Clinic/Day Hospital
The Oncology Divisions faculty provide care at the Norris Outpatient Clinics. The Solid Tumor Service saw 23,248
outpatient visits between January 1 and December 31, 2015. The breakdown for the outpatient services by section
are as follows:
Section
Outpatient New &

Follow-up Visits
Day Hospital Visits
GI Program
GU Program
Breast Program
Solid Tumor Program
Total Number of Visits
6,535
5,127
2,618
1,604
15,884
3,047
1,028
1,420
1,869
7,364
Division faculty at the Keck Medicine of USC- Pasadena office saw 4,395 patients in clinic (820 new patients and
3,575 follow-ups). The USC Westside Cancer Center saw 1,144 clinic visits.
Keck Hospital/Norris Hospital- Inpatient Service
From January through December 2015, Oncology faculty were responsible for 1,008 admits, an increase of 36%
over the previous year, and 6,225 inpatient days. The average length of stay was 5.1 days. One fellow and one
faculty are assigned to an inpatient rotation on a monthly basis. During the year 2015, faculty billed 6,225 inpatient
visits.
Keck Hospital
At KH, one fellow and one faculty are assigned to see inpatient consultations on a monthly basis for all tumor types.
Our teams consulted on 155 patients at Keck Hospital.
Clinical Cancer Genetics
The Cancer Genetics Unit at USC Norris Comprehensive Cancer Center (Cancer Center) includes genetic
counselors and a team of cancer specialists who provide genetic counseling for hereditary cancer. Genetic testing
is offered to individuals from high-risk families for breast, ovarian and colorectal cancers. Genetic counseling and
cancer risk assessment is also offered to individuals who have been diagnosed with cancer at a young age or at
multiple sites and others who may be at high risk because of their ethnic backgrounds. Drs. Stephen Gruber and
Kevin McDonnell provide expert consultations in the Cancer Genetics Unit for affected or high-risk individuals.
86
Clinical Trials
Recruitment into clinical trials from all hospitals affiliated with Cancer Center was strong, with more than 2,993
cases recruited from January through December 2015. Patient recruitment was represented by study type as follows:
78% institutional, 10.6% industry, 3.4% national cooperative group, 8% other peer review (includes consortium).
Enrollment by ethnicity was 42% Hispanic or Latino, 58% non-Hispanic or non-Latino. Accrual by gender showed
63% females and 37% males.
An interactive research and treatment program for the development of new anticancer agents, funded by the
National Cancer Institute and conducted by a consortium consisting of USC, City of Hope National Medical Center
and the University of California, Davis, has made novel compounds available to patients treated in the hospitals of
the USC Health Sciences Campus. This program has included components of Phase I testing (assessment of correct
dose and definition of toxicity profiles of new compounds) and Phase II trials (assessing the anticancer effectiveness
of these agents). Specific attempts have been made to expand the utilization of the Southern California Clinical and
Translational Science Institute (SC CTSI) for Phase I and pharmacologic studies of novel anticancer agents.
Drs. Russell, Garcia, Spicer, and Daniels undertake breast cancer treatment and research, with an expansion of
clinical trials for breast cancer. Drs. Lenz, Iqbal, El-Khoueiry and Barzi are developing strategies of clinical research
for gastrointestinal cancers, with an emphasis on molecular correlates of tumor responsiveness and of the familial
clustering of gastrointestinal cancer. An active program of research and treatment of genitourinary cancers was
initiated by Drs. Quinn, Goldkorn, Dorff, Hu, Pinski and Sadeghi, with specific programs of new drug development
and multidisciplinary management. Multidisciplinary management has also been a governing theme in the clinical
trials programs that have been developed for lung cancer and head and neck malignancies by Drs. Gitlitz, Wong and
Nieva.
Each of these teams has been developed to allow maximum synergy with staff members from other clinical units,
including surgical oncology, radiation oncology and urology, as well as an expanded translational interface with the
scientists of the Cancer Center and the School of Pharmacy.
87
Oncology Fellows
Class of 2016
Class of 2017
Class of 2018
Victoria Forte, MD
Gino In, MD, Chief Fellow
Byron Jennings, MD
Swati Sikaria, MD
Christina To, MD
Kelly Yap, MD
Grace Chang, MD
Irene Kang, MD
Charlene Lee, MD
James Shen, MD
Derrick Su, MD
Steven Yu, MD
Jacob Thomas, MD
Kristopher Wentzel, MD
Division of Oncology faculty are responsible for the education of approximately 52 interns and 120 residents on
rotation each year. These individuals have been assigned to either the Consultation Service at LAC+USC or Norris
Hospital. During daily consultative rounds, patients with solid tumors are seen on the wards of the hospital, and
their morphologic material x-rays and scans are reviewed. This provides an important setting for clinical teaching
by the faculty at the bedside.
Fellowship training activities include involvement in the design and conduct of early-phase clinical trials, bedside
teaching and a series of tumor boards and conferences designed to illustrate principles of the biology of cancer and
its management. Participants in a bi-weekly protocol meeting review cases entered into research activities of the
Division. Multidisciplinary conferences allow residents and fellows to participate in the decision process with input
from several different clinical disciplines.
A series of didactic lectures, including the Cancer Center Grand Rounds, Didactic Fellows Conference Series,
Journal Club for fellows and Friday Case Presentation provide instruction regarding the basic principles and biology
of cancer. Weekly lectures and conferences include Multidisciplinary Breast Conference on Mondays; Cancer
Center Grand Rounds and Multidisciplinary Hepatocellular Cancer Conference on Tuesdays; Didactic Lectures,
Multidisciplinary Gastrointestinal Oncology Conference, Oncology Pathology Conference, Sarcoma Tumor Board
88
and Multidisciplinary Genitourinary Oncology Conference on Wednesdays; Urology Grand Rounds on Thursdays;
and Didactic Lecture on Wednesdays and Fridays. Bi-weekly conferences include ENT Tumor Board on Thursdays,
and Head & Neck Tumor Board, Neuro-Oncology, and Protocol/Research Meeting on Fridays. The Journal Club
meets monthly on Wednesdays.
Medical students from the USC Campus and from other national and international institutions spend three to four
weeks in an Oncology selective throughout the year. We typically have one to two students per month.
The Division has increased its interaction with scientists at the Cancer Center, which has led to several
interdisciplinary projects that have allowed overlap of some of the scientific programs of the Center, including
Genitourinary, Gastrointestinal, Breast Cancer, Developmental Therapeutics and several core programs. The
divisions list of publications attests to the level of interdisciplinary collaboration that has been achieved, including
detailed reports of preclinical assessment of new anticancer compounds, pharmacology of anticancer agents,
molecular mechanisms of resistance to fluoropyrimidine and other cytotoxic agents, and genes associated with
breast, genitourinary and colon cancer. Members of the Division hold leadership roles in a key NIH-funded
multicenter trial assessing molecular correlates and utility of adjuvant chemotherapy for invasive bladder cancer.
Oncology faculty have leadership roles in the scientific agenda of the Southwest Oncology Group (SWOG) and
have provided core laboratory resources for translational trials conducted by the Group. In addition, important
clinical and scientific leadership has been provided to the Phase I-II Consortium (funded by the National Cancer
Institute and shared between City of Hope National Medical Center, University of California, Davis and USC).
Members of the Division have led the USC program of immunotherapeutic research in cancer. Of particular
importance has been the study of vaccines for patients with malignant melanoma and cervical cancer, as well as the
utility of bispecific antibodies directed against determinants on prostate cancer.
Division of Oncology faculty published 106 peer-reviewed research papers during the January 1 through
December 31, 2015 period, and another 15 are in press.

David B. Agus, MD
Treatment of Prostate Cancer

Development of Proteomic Technologies
Cancer Biomarker Development
Clinical Trials with Molecular Targeted
Therapeutics
Applications of Nanotechnology in
Cancer
GU Oncology/Lymphoma
Afsaneh Barzi, MD, PhD
Treatment of GI Oncology
Drug Development in Gastrointestinal
Maligancies
Healthcare Outcome and Quality
Measure Development
Cost-Effectiveness in Clinical Practice
John R. Daniels, MD
Chemoembolization of Liver Tumors

Breast Cancer Prevention
Drug Development in GI Oncology

Design and Conduct of Clinical Trial in
GI Oncology
Tanya B. Dorff, MD
Treatment of Genitourinary
Malignancies
Molecular/Genetic Markers of Response
to Chemotherapy and Hormone
Therapy in Prostate Cancer
Testosterone Therapy in Prostate Cancer
Perioperative Chemotherapy in Bladder
Cancer
Early Prostate Cancer: HGPIN
Predictors of Progression, Imaging
and Active Surveillance
Treatment of GI Malignancies
Development of Phase I Program for
89
Treatment of Breast and Gynecological

Tumors
Treatment of Lung Cancer and Head and

Neck Malignancies
Clinical Trials in Head and Neck Cancer
In vivo Generated Dendritic Cell
Based Immunotherapy
Amir Goldkorn, MD
Treatment of Genitourinary
Malignancies
Investigation of Novel Therapies
Targeting Telomerase and Cancer
Research Activities
The Division of Oncology increased its emphasis on translational research based on fundamental concepts of
molecular biology. This approach has been predicated on the emerging knowledge of the molecular correlates of
anticancer drug resistance, increased understanding of the genes associated with familial and sporadic patterns of
malignancy (colorectal and breast cancer, in particular), the immunological basis of tumor response and resistance,
and a more precise assessment of the pharmacology of novel anticancer compounds.
Stem Cells

Clinical and Laboratory Aspects of
Cancer Research
Developmental and Experimental
Therapeutics Focused on Prostate
Cancer
Molecular Profiling to Identify New
Cancer Biomarkers
Androgen Receptor Signaling and
Signaling Transduction in Cancer
Genetic Epidemiology of Cancer, with

an Emphasis on Colorectal Cancer
Molecular Pathogenesis of Cancer,
Integrated with Genetic Epidemiology
Methods in Genetic and Molecular
Epidemiology, Focused on Founder
Populations
Clinical Cancer Genetics and
Translational Research in Cancer
Prevention
Treatment of Sarcoma/Myeloma
James S. Hu, MD
of Clinical Outcome and Toxicity

Development of Novel Agents and
Identification of Novel Targets
Clinical Trials in Hormone Refractory

Prostate Cancer
Paul Macklin, PhD
Integrative Computational Oncology

Patient-Calibrated Models of Breast
Cancer
Mechanistic Agent-Based Cell Models
Tissue Biomechanics and Transport
Open Source Software and Open Model/
Date Standards
Treatment of GU Malignancies
Clinical and Molecular Predictors of
Cancer Outcome
Molecular Cancer Profiling for New
Therapeutic Targets
Development of New Anticancer
Therapies Phase I/II Trials and
Molecular Correlates
Parag Mallick, PhD
Proteomics
Systems Biology
Cellular Networks
Oncogene Addiction
Bioinformatics and Computational
Biology
Molecular Profiling to Identify New
Cancer Biomarkers
Applications of Nanotechnology in
Cancer
Treatment of Breast and GU Cancers
Sarcoma
Neuro-Oncology
Testicular Cancer
Colon Cancer
Cancer Genetics
Functional Genomics
Personalized Cancer Medicine
Syma Iqbal, MD
Esophageal Cancer
Gastric Carcinoma
Metastatic Gallbladder and Colon
Cancers
Jonathan Katz, PhD
Mass Spectrometry
Proteomics
Elucidation of Novel Clinical Prognostic
Markers
Molecular Tumor Profiling to Predict
Outcome
Regulation of Gene Expression Involved
in Drug Resistance (TS, TP, ERCC1,
GST-P1, XPD)
Germline Polymorphisms as Predictors
Treatment of General Oncology

Malignancies
Treatment of Gastrointestinal, Breast
and Lung Cancers, and Lymphoma
An Nguyen, MD
GI Malignancies
Lung Cancer
David I. Quinn, MD, PhD
Clinical Biomarker Discovery:

Shotgun Proteomics, Tumor/Host
Modeling
Statistical Analysis of High-Dimensional
Biological Data, Experimental Design
Prevention and Systemic Treatment of

Breast Cancer

Treatment of GU Oncology
Cancer Outcomes
Health Economics
Healthcare Policy
George Semeniuk, MD
Treatment of Head, Neck and Lung

Cancers and Melanoma
Darcy V. Spicer, MD
Breast Cancer Treatment and Prevention

Human Subjects Research
Treatment of Breast Cancer and
Leukemia
Michael K. Wong, MD, PhD
Minh D. Nguyen, MD
Treatment of CNS/GI Oncology
Jorge J. Nieva, MD
Treatment of Lung, Head and Neck

Malignancies
Modality Metastases
Biomarker Development
Treatment of Melanoma and Sarcoma

Solid Tumor Biology
Immunotherapy
Angiogenesis
Drug Development
Tumor-Host Interactions
Prostate Cancer Endocrinology and

Control
Special Basic Research Activities

Amir Goldkorn, MD
Dr. Goldkorns research program focuses on developing the therapeutic and prognostic potential of circulating
tumor cells, cancer stem cells, and telomerase three areas that offer unique opportunities to better understand and
surmount cancer heterogeneity. 1) Circulating Tumor Cells (CTCs) are cancer cells shed by solid tumors into the
bloodstream, where they can be captured and analyzed. Dr. Goldkorns team is leading CTC studies in a phase III
multi-center prostate cancer trial as well as a multicenter bladder cancer trial. CTC capture and NextGen sequencing
is also being conducted in several other clinical trial settings and in mouse models to identify drivers of tumor
90
resistance and disease progression. Dr. Goldkorn also founded and directs a CTC Research Core at USC Norris.
2) In the area of Cancer Stem Cell (CSC) research, Dr. Goldkorns laboratory discovered that cancer cells could
cyclically lose and regain CSC properties, a phenotypic plasticity that is mediated in part by PI3K/AKT (upstream)
and -catenin/CBP (downstream). Most recently, gene expression profiling of 300 radical prostatectomy specimens
showed that AXIN2, a transcriptional target and feedback regulator of -catenin, is predictive of cancer recurrence
after prostatectomy and directly regulates invasion and tumor formation. 3) Telomerase is a reverse transcriptase
ribonucleoprotein that protects and lengthens telomeres at the ends of chromosomes. Telomerase activation is
an essential step in the formation and progression of >90% of all malignancies and therefore may constitute an
effective therapeutic target across heterogeneous malignancies. Dr. Goldkorns team is currently working to develop
a novel therapeutic strategy that interferes with telomerase to preferentially kill cancer cells.
Dr. Pinski is a tenured Associate Professor of Medicine practicing at the Norris Comprehensive Cancer Center,
where he combines clinical care with basic research on the biology of prostate cancer and other hormonal cancers.
He completed medical school and earned his PhD in Frankfurt, Germany before coming to the U.S. in 1990, to work
at the Tulane University in New Orleans, with Nobel laureate Andrew Schally, MD, one of the pioneers of hormonal
therapy in oncology. From 1998 until his move to California in 2001, Dr. Pinski received continued clinical training
in Medical Oncology at the Baltimore Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, where he
collaborated with John Issacs, PhD, another respected figure in prostate cancer research. His publications comprise
more than 100 articles in the field of cancer research and he has been the recipient of multiple awards and grants
from the NCI, DOD and ACS. Dr. Pinskis area of focus has been in studying the role of the hypothalamic/pituitary
hormones in cancer and in the value of novel prognostic and predictive molecular markers related to hormonal
synthesis for clinical outcomes in cancer patients.
Special Clinical Research Activities

Tanya B. Dorff, MD
Dr. Dorff is the Principal Investigator for several clinical trials investigating
mechanisms of resistance to therapeutics, such as the use of Src inhibition to delay
resistance to abiraterone in men with metastatic, castration-resistant prostate cancer
and inhibition of CD105 to avoid escape of VEGF suppression during bevacizumab
treatment for patients with metastatic renal cell cancer. In addition, she has a strong
interest in integrative medicine, which has led to translation of basic scientist Valter
Longos work into two clinical trials of fasting or a fasting-mimic diet for patients
receiving chemotherapy, aimed at reducing toxicity and enhancing treatment effect.
Breast/Womens Cancers Program
Over the last year, the clinical trials portfolio has grown in number and accrual, with
an ongoing focus on investigator-initiated and other trials to translate early findings emanating from USC-generated
research and through internal and external collaborators. Progress has also been made in securing grants as well as
other funding for clinical trials efforts and outreach. The Program has continued to generate pivotal publications that
change research directions and clinical practice.
Dr. Agustin Garcia is conducting investigator-initiated clinical trials evaluating a novel alternate potentially less
toxic schedule of chemotherapy administration (metronomic cyclophosphamide and capecitabine combined
with trastuzumab and lapatinib as first-line therapy for advanced HER2+ breast cancer), as well as evaluating
novel regimens to prevent chemotherapy-induced nausea with correlative predictive host biomarkers studies. In
collaboration with Dr. Dorff he is evaluating the effects that dietary interventions have in the efficacy and toxicity of
chemotherapy in breast cancer. In collaboration with Dr. Lin from the Division of Gynecologic Oncology, Dr. Garcia
is leading a national phase I trial, conducted under the auspices of the NCI and the Gynecologic Oncology Group,
evaluating the combination of novel immunotherapies (ipilimumab) in combination with standard chemotherapy and
radiation in cervical cancer. He is also studying the efficacy of eribulin in advanced cervical cancer and evaluating
the role of the endoplasmic reticulum stress mediator GRP78 in determining resistance to chemotherapy.
91
Accrual has been completed to a study assessing soy effects on breast cancer risk biomarkers (breast density), and
results from an earlier green tea prevention study have been published by Dr. Spicer. Drs. Garcia, Russell and Spicer
had their work published in prestigious journals such as Lancet Oncology, Journal of Clinical Oncology, Clinical
Cancer Research, Breast Cancer Research and Treatment, The Oncologist, Breast and Frontiers in Oncology.
Genitourinary Cancer Section
The Genitourinary Cancer Section of the Division of Medical Oncology has continued to make meritorious progress
in the past year. Members have excelled in obtaining peer reviewed funding, running innovative clinical trials and
publishing in high-impact journals.
Dr. David Agus received an R01 grant to explore the potential for modeled therapeutics across different cancers
as an extension of work done in the Physical Sciences-Oncology Consortium grant. In addition, his book A Short
Guide to a Long Life graced the New York Times bestseller list for a second year in a row. Dr. Amir Goldkorn
excelled in his work on circulating tumor cells with publications on CTC numbers
and CTC telomerase expression and a new R01 grant with Dr. Jacek Pinski for
correlatives for the SWOG trial S1216, which adds the hydrolyze inhibitor orterenol
to initial androgen deprivation therapy in metastatic prostate cancer. In an NCI grantfunded phase I/II clinical trial, Dr. Pinski also continued his focus on the LH receptor
pathology in prostate and other cancers with development of doxorubicin linked to
a LH avid molecule that binds the drug to cancer cells;
the work will be published in Clinical Cancer Research.
Dr. Mitchell Gross worked on the development of
resistance to androgen pathway blockade in prostate
cancer with high-technology interrogation of CTCs that
demonstrated the phenomena of c-myc amplification
and androgen receptor aberration as resistance develops;
the work was presented at AACR. Dr. James Hu is the
USC principal investigator on several internationally important germ cell cancer trials,
working through SWOG as well as with the Australian New Zealand Urology and
Prostate Cancer Group and Memorial Sloan Kettering Cancer Center. In addition, he
continues his physician leadership role with the Adolescent Young Adult program.
Dr. David Quinn continues work with eribulin in urothelial cancer, with translational
James Hu, MD
and correlative studies in prostate cancer, genomic-therapeutic combinations and
fasting in chemo protection and sensitization. Dr. Sarmad Sadeghi joined the GU team from Cleveland Clinic and
received an NCI CTEP Career Development Award for his clinical trial work looking at gemcitabine and eribulin in
non-cisplatin eligible patients with advanced urothelial cancer. He will also pursue an interest in outcomes research
and modeling of cost contingencies in GU cancer care.
Section members have published in high-impact journals including the New England Journal of Medicine, Lancet
Oncology, Journal of Clinical Oncology, Cell Stem Cells, Journal of Nuclear Medicine and Journal of the National
Cancer Institute. Future clinical trials will focus on emergent checkpoint inhibitors, mutation targeted agents and
EphB4. Key collaborations are ongoing with colleagues in the Departments of Urology, Radiation Oncology,
Pathology, Pharmacy, Gerontology, Preventative Medicine, Radiology and Nuclear Medicine as well as with other
Cancer Center members.
92
Best of Journal of Clinical Oncology: Genitourinary Cancer, 2015

Outstanding Investigator Award, American Federation for Medical Research, 2015
Elected to Board of Directors, Association of American Cancer Institutes, 2015
R01, Assessing Patient Experience in Cancer Care: An Observational Communication Study, Principal
Investigator, National Center for Complementary and Integrative Health, NIH, 2015
93
Honors and Awards
Amir Goldkorn, MD
Faculty
Professor
Associate Professor
Richard G. Barbers, MD
Ahmet Baydur, MD
Zea Borok, MD
Ulf Per Flodby, PhD

David M. Kelley, MD
Richard L. Lubman, MD
Edward D. Crandall, PhD, MD
Assistant Professor
Ralph Edgington Chair in Medicine

Hastings Professor of Medicine
Kenneth T. Norris Chair of Medicine
Kwang-Jin Kim, PhD

Janice M. Liebler, MD
Ami Oren, MD
Renli Qiao, MD, PhD
Alex A. Balekian, MD
Ching-Fei Chang, MD
Raj R. Dasgupta, MD
Sivagini Ganesh, MD
94
Terese C. Hammond, MD
Santhi Iyer- Kumar, MD
Ricardo H. Juarez, MD
Ramyar Mahdavi, MD
A. Purush Rao, MD
Arnold Sipos, MD, PhD
Bassam Yaghmour, MD
Beiyun Zhou, PhD
Pulmonary, Critical Care and

Sleep Medicine
Zea Borok, MD, Professor of Medicine and Chief
Ian Quiza, Senior Clinical Administrator
The Division of Pulmonary, Critical Care and Sleep Medicine (PCCSM) provides a vigorous, creative basic and
clinical science core, with an active clinical service and a high-quality fellowship training program. The Division
provides services at all three Health Sciences Campus teaching hospitals: LAC+USC Medical Center (LAC+USC),
Keck Hospital of USC (KH) and USC Norris Cancer Hospital (Norris). Our nationally and internationally
recognized full-time faculty members share the combined research, clinical and teaching mission.
The Division provides services in seven Intensive Care Units, three at LAC+USC, four at KH, and one at Norris.
Consultative services to inpatients are provided at LAC+USC, KH and Norris. Annually, more than 4,500 patients
are seen in the weekly Continuity Chest Clinic, Pulmonary-HIV Clinic and Pulmonary-Rehab Clinic, with
consultations provided on over 600 patients annually at LAC+USC. More than 1,060 private outpatient visits
were conducted at Healthcare Center 2 (HC2) in 2015, and more than 700 bronchoscopic examinations and other
diagnostic procedures were performed by the Division, providing a wealth of opportunities for trainees to rapidly
achieve procedural competence. The Division prides itself on the quality, depth and breadth of its clinical services.
Patient satisfaction and state-of-the-art pulmonary, critical care and sleep medicine services in a cordial,
professional manner remain our primary clinical objectives.
Basic and applied research are the cornerstones of the Division, long known for cutting edge mechanistic studies
in regulation of function and biology of the pulmonary alveolar epithelium. Applied research areas include gene
regulation in lung injury and repair, immunology in lung transplantation and asthma, nanoparticle trafficking across
alveolar epithelium, therapeutic interventions in interstitial pulmonary fibrosis and sarcoidosis, stem cell biology
in lung injury/fibrosis, and outcomes in critical care, lung cancer, cystic fibrosis and venous thromboembolism.
Division faculty and fellows published 24 peer-reviewed research papers and received more than $5.3 million in
research funds in the period from January 1 through December 31, 2015.
The Division of PCCSM remains strongly committed to providing the best possible educational environment and
learning opportunities for USC medical students, residents, fellowship trainees and practicing physicians. Daily
formal attending rounds are conducted on all division services for medical students, residents and fellows. These
rounds take place at the bedside and culminate in multidisciplinary discussions involving pulmonary physiology,
radiology and pathology. An extensive daily conference schedule emphasizes case discussions and grand rounds
conducted in cooperation with other specialties, including infectious diseases, pathology, radiology and surgery,
as well as quality improvement projects. In-depth lectures in clinical and basic research as well as journal clubs
are held regularly. Our well-rounded teaching program provides outstanding educational experiences for fellows,
residents and medical students throughout the Health Sciences Campus.
Overall, the Division continues to build on a tradition of excellence in its tripartite mission. We strive to be the
best in teaching, research and clinical care delivery. We look forward to continued growth in partnership with our
colleagues in the Department of Medicine and the entire Health Sciences Campus community.
95
Clinical Activities

The Division of PCCSM operates the Medical Intensive Care Unit services at LAC+USC. In addition, the Division
provides consultative services to inpatients and to intensive care units of other divisions and departments, including
internal medicine, surgery (including trauma), neurology, neurosurgery, burns, emergency medicine and cardiology.
The Division conducts a weekly Chest Continuity Clinic, at which residents and fellows evaluate new patients and
provide continued care for established patients. The Procedural Service at LAC+USC performs more than 700
bronchoscopic examinations annually, as well as advanced procedures such as percutaneous tracheostomy, bronchial
thermoplasty, endobronchial ultrasound (EBUS) and electromagnetic navigational bronchoscopy. The Pulmonary
Physiology Laboratory and Sleep Center under the medical direction of the Division performs an average of 6,500
lung function tests and 1,184 sleep studies every year.

The Division participates in the care of patients at four Intensive Care Units at KH, including the newly established
Medical Intensive Care Unit, involving the care of inpatients with a wide spectrum of lung disease and critical
illnesses. The PCCSM fellow performs all diagnostic and therapeutic procedures, including bronchoscopies, under
the supervision of an attending physician. Specialized, multidisciplinary programs that provide patient-centered
care include the Lung Transplant Program, Adult Cystic Fibrosis Center, Center for Advanced Lung Disease,
Multidisciplinary Center for Lung Cancer Management, Asthma and Allergy Program, Sleep Center and Pulmonary
Hypertension Program. The Center for Advanced Lung Disease sees patients with interstitial lung disease and
airway diseases, including chronic obstructive pulmonary disease (COPD) and asthma, and recently established a
bronchial thermoplasty program for treatment of patients with refractory asthma.
USC Norris Cancer Hospital

Norris provides an unparalleled opportunity to deliver care to a large number of patients with malignancy,
immunosuppression and bone marrow transplantation. The Division of PCCSM runs the Intensive Care Unit at
Norris Hospital and provides consultative services to floor patients. The PCCSM fellow carries out all consultations
and performs diagnostic, invasive and noninvasive, and therapeutic procedures under the supervision of the
attending staff. Lung cancer patients are seen at the Multidisciplinary Clinic and reviewed at the weekly thoracic
tumor board.
96
Special Clinical Services

The Division of PCCSM has established several clinical programs of excellence, each of which offers specialized
treatment of various pulmonary disorders, as well as an educational setting for fellowship training:
The USC Asthma and Allergy Center is a comprehensive clinical program for the diagnosis and
management of patients with asthmatic and/or atopic disorders (such as allergic rhinitis and sinusitis), which
affect more than 20 million people in this country. The Asthma and Allergy Center is staffed by full-time teaching
faculty who are certified in pulmonary, allergic and immunologic diseases. Besides physician specialists, resources
include clinical allergy nurse specialists, respiratory therapists, nutritionists and pharmacologists. A state-of-the-art
pulmonary function laboratory has capabilities for airflow measurements, including methacholine challenge studies
to detect hyperirritable airway disorders. State-of-the-art skin testing for common pollen allergens, animal dander,
dust mites, common molds and common foods is available. Testing by the RAST method for hypersensitivity
pulmonary disease, including allergic bronchopulmonary aspergillus, is also offered. Skin testing for hymenoptera
hypersensitivity (bee venom) and penicillin allergy is also available. If warranted, immunotherapy (desensitization)
can be initiated for selected patients. Other novel therapeutic interventions offered include biological therapy for
selected asthma phenotypes such as omalizumab (Xolair) and mepolizumab (Nucala).
The Center participates in several U.S. multi-center clinical trials that include patients with asthma. An ongoing trial
sponsored by the pharmaceutical industry is the use of librikizumab for patients with severe asthma.
Our Division was the first academic center in Southern California to successfully perform a bronchial thermoplasty
(BT) procedure in 2013. The USC Bronchial Thermoplasty Program was subsequently launched, and
we are one of the only national sites with a unique multi-disciplinary format. Our bronchial thermoplasty team is
comprised of both allergists and pulmonologists, as well as trained respiratory therapists and a nurse coordinator.
Each month, the group meets to formally discuss patients and obtain consensus opinion on whether or not they can
undergo BT safely. Dr. Richard Barbers, Dr. Ching-Fei Chang and Dr. Ramyar Mahdavi comprise the interventional
arm of this program, while Dr. Edward Hu performs the initial screening and manages the clinical aspects of care.
Between the KH and LAC+USC sites, we have performed over 67 of these complicated procedures to date, with
excellent results. In addition to being officially designated a Center of Excellence for Bronchial Thermoplasty,
USC is also a major BT training site for Boston Scientific. Thus far, we have hosted six successful physician
preceptorships at our campus, including both out-of-state colleagues as well as international visitors from Brazil.
In the past year, the Division has also greatly expanded its interventional pulmonary
capabilities. Previously, Dr. Ching-Fei Chang spearheaded the availability of advanced
flexible bronchoscopy procedures (e.g. EBUS-TBNA, Electromagnetic Navigational
Bronchoscopy, and Bronchial Thermoplasty) at both the KH and LAC+USC sites,
and to date, over 500 EBUS, 150 EMN, and 67 BT procedures have been successfully
performed. Not only are these cutting-edge outpatient procedures less invasive
and more comfortable than traditional surgical options, but they offer comparable
diagnostic yields at a fraction of the cost. Now, with the recruitment of
Dr. Ramyar Mahdavi, a board certified, fellowship trained interventional
pulmonologist from the University of Wisconsin, our division is able to offer
interventions requiring rigid bronchoscopysuch as argon plasma ablation, laser
debulking, balloon dilation and stenting--for the palliative treatment of endobronchial
tumors as well as stent placement for benign pathologies like tracheobronchomalacia,
lung transplant complications or management of tracheal and airway stenosis resulting
from complications of prolonged intubation or other etiologies.
Ramyar Mahdavi, MD
Other procedures that we offer include: percutaneous tracheostomy, medical thoracoscopy, and pleur-X catheter
placement. Together, Dr. Chang and Dr. Mahdavi comprise the new USC Interventional Pulmonary Team,
and they provide a full spectrum of services for the minimally-invasive diagnosis, staging, and management of lung
cancer, as well as advanced cutting-edge interventions in the airways, parenchyma, and pleural space.
97
Under the direction of Dr. Ching-Fei Chang, our division was the first to organize, lead, and execute a two-day
Regional Fellowship Critical Care Ultrasonography Training Workshop in the Southern
California area. With the assistance of UCLA colleague, Dr. Igor Barjaktarevic, and nationally-renowned ultrasound
expert, Dr. Pierre Kory, Dr. Chang and colleagues trained over 35 first year fellows from USC and neighboring
institutions, including UCLA, Harbor-UCLA, Cedar-Sinai, and UC Irvine. The overwhelming success of this
collaborative inter-fellowship program has led to the commitment of all involved to continue this introductory
course on an annual basis at rotating sites.
The USC Sleep Disorders Center continued its double-digit growth rate in 2015. As a vital component of
our Center for Advanced Lung Disease, sleep medicine continued its expansion, with outpatient visit volume up
approximately 20% and outpatient sleep study volume up 9% in 2015. We also initiated a new program for out of
center home sleep testing. Our two sleep specialists, Terese C. Hammond, MD, and Raj Dasgupta, MD, saw 1,184
new and follow up sleep patients last year, both individually and in conjunction with our two sleep fellows,
David Kent, MD, and Katherine Green, MD. Both of our 2014-2015 graduating sleep fellows, Kaveh Rezvan, DO,
and Emily Gillett, MD, PhD, successfully attained board certification in sleep medicine and we participated in the
NRMP matching program to fill our two ACGME-accredited sleep fellowship slots for 2016-2017.
Fostering research collaborations remained a principle focus of
the Sleep Disorders Center in 2015. Through our continued close
collaboration with Eric Kezirian, MD, of the USC Caruso Department
of Otolaryngology, we became the first center in Southern California
to implant the Inspire hypoglossal nerve stimulation device, which
received FDA approval in 2015 for the treatment of obstructive
sleep apnea in patients resistant to CPAP therapy. We also concluded
our enrollment for the multi-center Respircardia trial of its Remede
transvenous phrenic nerve pacing device for treatment of central
sleep apnea. We initiated a cross-discipline research collaboration
with Michael Khoo and Krishna Nayak of the Viterbi School
of Engineering to use advanced MRI techniques to phenotype
the airways of adult patients with obstructive sleep apnea. This
complements previous work done by Sally Ward, MD, and other
CHLA investigators who incorporated us into their ongoing work
using dynamic MRI to characterize the airways of obese children with
OSA. Additional research initiatives in 2015 included collaboration
with Jason Kutch, PhD, to examine relationships between sleep
architecture and pelvic floor muscle activation in patients with chronic
pelvic pain and ongoing work with Tomas Konecny, MD, of the
Division of Cardiovascular Medicine, to more closely examine the
generation of atrial arrhythmias in patients with implantable recording
devices and sleep disordered breathing.
Raj Dasgupta, MD (left), and Terese Hammond, MD
Both Drs. Hammond and Dasgupta continued their community outreach work. Dr. Dasgupta had a number of guest
appearances as the resident sleep expert on the syndicated television show The Doctors and was a featured guest
on Larry King Live and ESPN. He was also appointed the National Director of Media Outreach and Education
for the American Academy of Sleep Medicine (AASM). Dr. Hammond gave multiple community grand rounds
presentations and was invited to serve as a keynote speaker for the Trojan 50 2016 Back to College Day, where
she presented her vision of the future of sleep medicine and collaborative sleep research.
The USC Pulmonary Exercise Program provides outpatient exercise evaluations. Exercise studies are
performed with state-of-the-art equipment by experienced exercise technologists. Individuals with suspected
functional impairment during any type or grade of exercise would benefit from an exercise evaluation to identify
the physiologic cause for impairment. Information obtained from the study can be used to tailor specific exercise
regimens and therapeutic strategies. The program offers Standard Pulmonary Stress Tests, Oxygen Desaturation
Studies, Exercise-Induced Bronchospasm Studies and Metabolic Studies. The Medical Director of Respiratory
Services is Dr. David Kelley.
98
The High-Altitude Simulation Test (HAST) is a specialized type of oxygenation study available in our
Pulmonary Function Laboratory at KH. This study is performed on individuals who have marginal oxygenation and
are considering excursions into high altitudes, including flying in an airplane. The study objective is to determine
the quantity of supplemental oxygen that is required for a safe trip at various altitudes, and it is performed at rest and
with gradients of activity. The Medical Director is Dr. David Kelley.
The USC Pulmonary Rehabilitation Program based at LAC+USC offers a wide range of services to
patients with chronic pulmonary disease, from single sessions focused upon a specific need (such as training in the
use of metered dose inhalers) to a comprehensive program consisting of two afternoons per week for a total of six
to eight weeks. The comprehensive program includes exercise training, patient education, psychosocial support
services, physical therapy, vocational therapy, symptom control techniques and the use of low-flow oxygen. Patients
typically referred to the program include those with emphysema and pulmonary fibrosis. The program also offers
on-site educational opportunities for pulmonary fellows with emphasis on respiratory physiology, quality-of-life
assessment and key aspects of evaluating physical impairment and disability. The Medical Director is
Dr. Ahmet Baydur.
Our Division was instrumental in the launching of the USC Multidisciplinary Lung Cancer Program
in 2012. The program includes several faculty members from PCCSM (Drs. Alex Balekian, Ching-Fei Chang and
Ramyar Mahdavi) who actively participate in the evaluation, diagnosis and management of patients with thoracic
cancers. In
collaboration
with two thoracic
surgeons,
Dr. Hagen and
Dr. Oh, this
program is
nationally
recognized
by the Lung
Cancer Alliance
as a Center of
Excellence for
Lung Cancer
Screening. Thus
far, we have
From left to right: Alex Balekian, MD; Nancy Berman, RN; Daniel Oh, MD; Barbara Gitlitz, MD;
screened 232
Jeffrey Hagen, MD; Jorge Nieva, MD; Ching-Fei Chang, MD; Christopher Lee, MD and P. Michael McFadden, MD
patients for lung
cancer with the discovery of three malignancies. Our multidisciplinary team format is especially unique; not only
does our tumor board meet every Wednesday - complete with a dedicated thoracic radiologist, three pulmonologists,
two medical oncologists, two radiation oncologists, two thoracic surgeons, and a nurse navigator - but every
Friday, we hold a multidisciplinary lung cancer clinic staffed by pulmonologists and representatives from medical
oncology, radiation oncology and thoracic surgery, at the Multidisciplinary Lung Cancer Clinic at Norris. This clinic
is designed to streamline the coordinated assessment of patients with or suspected of having lung cancer. Each
faculty member also has a separate private clinic in which they assist with evaluation and management of dyspnea
and other respiratory complications, which may arise during the course of oncologic treatment. The pulmonary
faculty members also provide teaching and guidance in the management of lung cancer patients at the LAC+USC
Pulmonary Clinic every Wednesday afternoon. We are also on the path to creating a new air way program which
is a collaborative multi-specialty program including interventional pulmonary, otolaryngology and thoracic surgery.
The USC Center for Advanced Lung Disease is a newly established program that deals with the diagnosis
and treatment of all types of complex lung diseases. In addition to cystic fibrosis and sleep breathing disorders, the
Center for Advanced Lung Disease houses clinics specializing in COPD, sarcoidosis and interstitial lung diseases,
including idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, collagen vascular disease, eosinophilic
granuloma, pulmonary eosinophilia and other rare lung diseases. The USC Center for Advanced Lung Disease
99
has been designated as an Alpha-1 Foundation Clinical Resource Center and a LAM Foundation Core Clinic. The
Medical Director of the Center is Dr. A. Purush Rao.
The USC Sarcoidosis and Interstitial Lung Disease Center is now housed under the USC Center for
Advanced Lung Disease. The Center continues to deal with the diagnosis and treatment of all types of interstitial
lung diseases including sarcoidosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, collagen vascular
disease, eosinophilic granuloma and pulmonary eosinophilia. Over the last 40 years, and previously led by the late
world-renowned expert Dr. Om Sharma, these services have been provided to patients from all over the world.
Dr. Alex Balekian now sees patients with interstitial lung disease.
The USC Comprehensive Adult Cystic Fibrosis Center provides direct care and consultation for adult
cystic fibrosis patients. The cystic fibrosis care team is headed by pulmonologists supported by a full range of
consultants, including endocrinologists, gastroenterologists, otolaryngologists, infectious diseases experts, general
surgeons and cardiothoracic surgeons. Allied health services are provided by pulmonary clinical nurse specialists,
dieticians, clinical social workers, physical therapists, occupational therapists and respiratory therapists. State-ofthe-art therapies are offered, and there are gateways to research protocols and lung transplantation.
Dr. A. Purush Rao serves as Medical Director.
Lung transplantation is a treatment option for many patients with end-stage pulmonary disease. The USC Lung
Transplant Program at Keck Medical Center of USC is comprised of experts in cardiothoracic surgery,
pulmonary medicine, cardiology, immunology, infectious disease, critical care medicine, cystic fibrosis, perfusion
medicine, immunosuppression pharmacology, occupational and physical rehabilitation, and social/psychological
services. Patients eligible for lung transplantation include those severely debilitated by cardiopulmonary disease
and not hampered by other organ system dysfunction. Candidates frequently have the diagnosis of obstructive lung
disease (e.g., emphysema, cystic fibrosis, bronchiectasis), pulmonary hypertension (both primary and secondary) or
pulmonary fibrosis (e.g; IPF, hypersensitivity pneumonitis, sarcoidosis, LAM).
Patient education and communication are essential to improve the awareness to lung transplant referral and long
term outcome. We have created Lung Transplant support groups to help our patients cope with their illnesses and
learn more about their diagnoses. The Lung Transplant program is under the direction of Sivagini Ganesh, MD.
The Pulmonary Hypertension Program offers a comprehensive and multidisciplinary approach to patients
with this rare and very serious disorder of the blood vessels of the lung. Patients with pulmonary hypertension are
frequently not recognized until they have advanced disease because early symptoms can lead to misdiagnosis. A
higher awareness, earlier diagnosis and development of a comprehensive treatment plan can dramatically improve
quality of life and prognosis for patients with this life-threatening condition. Many
therapeutic modalities are highly complex and require intensive patient education and
ongoing follow-up with subspecialty physicians and nurse specialists. Medical services
such as continuous prostaglandin therapy, oral vasodilator therapy, anticoagulation
therapy and home oxygen therapy are provided and coordinated by a multidisciplinary
team. When appropriate, referrals are made for lung transplant, heart lung transplant as
well as ECMO as a bridge to transplant.
Pulmonary hypertension research is rapidly growing, and patient education and
communication are essential to support that growth. We have created pulmonary
hypertension support groups to help our patients cope with their illness and learn
more about their diagnoses. Patients with pulmonary hypertension are evaluated and
managed by Sivagini Ganesh, MD (Medical Director), and Bassam Yaghmour, MD.
100
Bassam Yaghmour, MD
Fellows are also exposed to a wide spectrum and volume of procedural skills training as part of their patient
care duties, and have both fresh tissue and simulation skills sessions throughout their fellowship. All fellows are
scheduled to attend bi-annual half-day skills workshops in which they practice such key procedures as central lines,
chest tube insertion, intubation, percutaneous tracheostomy, intraosseus access, thoracentesis and management of
difficult airways.
The Division has also been committed to providing essential teaching for the education of second-year medical
students. Both current and former faculty members participate in lectures and small group discussions on various
topics in respiratory medicine.
PCCSM Fellows
Class of 2016
Class of 2017
Class of 2018
Class of 2019
Brian Belluci, MD
Khadir Kakal, MD
Kriti Lonial, MD
Kavitha Bagavathy, MD
Walter Chou, MD
Jordan Lee, MD
Andrew Morado, MD
Raju Reddy, MD
Kelly Walsma, MD
Udit Chaddha, MD
Rahul Chillapa, MD
Niusha Dimaghi, MD
Sean Dooley, MD
Jamie Kagahara, MD
Darren Mahera, MD
Mircea Pucas, DO
Samridhi Amba, MD
Abigail Beggs, MD
Rami El-Yousef, MD
Kelly Fan, MD
Aaron Glucksman, MD
John Kern, DO
Reza Ronaghi, MD
Van Derick Mangulabnan, MD
Jaymica Patel, MD
Linh Truong, MD
Ravi Paul Singh Virdi, MD
Yashaswini Yeragunta, MD
Sleep, Class of 2016
Sleep, Class of 2017
Katherine Green, MD
David Kent, MD
Osezemeghonghon Ekateh, MD
Jihane Zaza, MD
Conferences
Our strong commitment to teaching is evident in an extensive daily conference schedule, starting at 8:30 am
and consisting of didactic lectures, multidisciplinary case conferences, grand rounds, morbidity and mortality
conferences, and research seminars on various aspects of pulmonary, critical care and sleep medicine and related
sciences. Combined thoracic surgery and thoracic oncology conferences (Tumor Board) are held every Wednesday
from 5:00-6:00pm.
Monthly Journal Clubs stress the importance of evaluating, analyzing and presenting medical research literature.
Guest lectures and both clinical and basic research seminars featuring nationally and internationally known
physician-scientists are held bi-monthly. Daily rounds conducted in all the USC hospitals form the cornerstone of
our clinical teaching program. These in-depth sessions ensure the highest quality patient care. Full-time faculty
conduct bedside rounds as well as clinical discussions. House staff, medical students, fellows and attending
physicians participate in these daily rounds.
101
The PCCSM Fellowship Program is designed to provide each trainee with a range of exposure to the diagnosis
and management of pulmonary diseases, the experience and skills required of an intensivist and the opportunity
to develop research interests. Seven new fellows are currently admitted to the program every year. Clinical and
teaching responsibilities encompass most of the first and second years, with a significant part of the third year
devoted to research activities. During the clinical phase of training, fellows devote their time to evaluation,
diagnosis and treatment of patients admitted to LAC+USC, KH and Norris. Fellows assess problems, make
appropriate diagnostic and therapeutic recommendations and perform specialized procedures, including fiberoptic
and advanced bronchoscopy, percutaneous needle biopsy of the lung and pleura, thoracentesis and pleurodesis.
Trainees receive instruction in pulmonary function testing, thoracic and critical care ultrasonography and x-ray
interpretation, including high-resolution computerized tomography (HRCT), the principles and techniques of
mechanical ventilation and inhalation therapy, and all aspects of tertiary pulmonary, critical care and sleep medicine.
Research Activities
Basic and clinical research remains a major focus of the Divisions interests and activities. A number of investigators
are studying pulmonary structure and function at the organ, tissue, cellular and molecular levels. Current areas
of investigation include study of mechanisms and regulation of water, solute, macromolecule and nanoparticle
transport across the pulmonary alveolar epithelium; development of cell-type specific markers for alveolar type I
and type II cells using monoclonal antibodies and genetic markers; transcriptional regulation of lung cell growth,
differentiation and gene expression in vitro and in vivo; the role of alveolar epithelial cell plasticity in pulmonary
fibrosis; stem cells in lung injury and repair; and epigenetic regulation of alveolar epithelial cell differentiation.
In addition, clinical research studies are underway in the fields of sarcoidosis and other granulomatous disorders,
asthma, septic shock, barotrauma, pulmonary edema, acute respiratory distress syndrome (ARDS), tuberculosis,
cystic fibrosis, lung transplantation, pulmonary hypertension and health care outcomes.
Dr. Zea Borok is Associate Director of the Will Rogers Institute Pulmonary Research
Center, the major research operation of the Division. The primary focus of the
laboratory has been on understanding the function of the cells lining the lung, known
as alveolar epithelial cells (AEC), in order to understand how the lung repairs itself
following injury and why it sometimes fails to do so. Under the leadership of
Dr. Borok, important new insights have been gained into a possible role of AEC in
driving fibrosis. Dr. Boroks group demonstrated that AEC can be induced to express
genes/proteins normally expressed by scar-forming cells, or fibroblasts, in a process
called epithelial-mesenchymal transition (EMT) in response to factors such as
transforming growth factor- (TGF-), a molecule that has been shown previously to
promote scarring through its effects on fibroblasts. In fact, when they examined lungs
from patients with idiopathic pulmonary fibrosis, they could identify cells that shared
characteristics of both epithelial cells and fibroblasts, supporting this possibility.
Zea Borok, MD
Together with studies showing that blockade of TGF- signaling specifically in AEC
ameliorated lung fibrosis in a mouse model of lung injury, these studies suggest a central role for epithelial cells in
mediating pulmonary fibrosis. Cells that have undergone EMT may also modulate behavior of resident fibroblasts
through release of pro-fibrogenic and pro-inflammatory mediators. Investigations are ongoing to explore differential
roles of Wnt signaling in promoting normal AEC differentiation/repair versus EMT. Dr. Borok has also recently
received funding for collaborative studies with Dr. Ite Laird of the USC Epigenome Center to explore genome-wide
epigenetic mechanisms that regulate normal AEC differentiation and to integrate these results with transcriptomic
analyses.

Quality of Care in Lung Cancer

Racial and Gender Disparities in Lung
Cancer
Mechanisms of Remodeling in
Near-Fatal Asthma
Potential Therapies for Remodeling in
Pulmonary Fibrosis
Novel Therapeutic Interventions
(Bronchial Thermoplasty in Severe
Asthma)
Ahmet Baydur, MD
Respiratory Mechanics
Control of Ventilation
Neuromuscular Disorders
Chronic Obstructive Pulmonary Disease
Pulmonary Rehabilitation
Zea Borok, MD
Transcriptional and Epigenetic

Regulation of Alveolar Epithelial Cell
Differentiation/Plasticity
Modulation of Alveolar Epithelial Cell
Phenotype and Recovery Following
Lung Injury
Role of Alveolar Epithelium in
Pulmonary Fibrosis
Biology of Lung Stem Cells
Alveolar Epithelial Tight Junction
Regulation
Ching-Fei Chang, MD
Endobronchial Ultrasound
Electromagnetic Navigation
Bronchial Thermoplasty
Critical Care Ultrasonography
Lung Cancer
Simulation Training
Medical Education

Acute and Chronic Lung Injury/
Recovery
Barrier Properties of Pulmonary
Alveolar Epithelium
102
Nanoparticle Interactions with Alveolar

Epithelium
Regulation of Alveolar Epithelial Cell
Differentiation
Fate Mapping/Lineage Tracing of
Alveolar Epithelial Cells
Raj R. Dasgupta, MD
Sleep Medicine
Medical Education
Ulf Per Flodby, PhD
Development of Transgenic Mouse and

Rat Models for Lung Research
Lung Injury and Repair of Alveolar
Epithelium
Lung Stem/Progenitor Cells
Lung Ion Transport
Alveolar Epithelial Tight Junction
Regulation
Sivagini Ganesh, MD
Lung Transplantation
Sleep Medicine
Insomnia and Psychiatric Disorders
Obstructive Sleep Apnea
Pulmonary Arterial Hypertension and
Activity Monitoring
Santhi Iyer-Kumar, MD
Critical Care
Quality Improvement
Patient Safety
Team Science
Mechanical Ventilation in Respiratory

Failure
Endotracheal Intubation in the ICU
Kwang-Jin Kim, PhD
Pulmonary Drug Delivery

Active and Passive Transport Properties
of Airway and Alveolar Epithelium
Regulation of Tight Junctional
Properties of Alveolar Epithelium
Nanoparticle Interactions with Alveolar

Epithelium
Renli Qiao, MD, PhD

Sleep Medicine
Cell-Based Therapy for Lung Diseases

Lung Epithelial Cell Biology
Lung Injury and Repair
Critical Care Medicine
A. Purush Rao, MD
Bassam Yaghmour, MD
Rare Lung Diseases
Ramyar Mahdavi, MD
Central Airway Obstruction
Interventional Pulmonary
Lung Cancer
Ami Oren, MD
Exercise Physiology in Health and

Disease
Control of Ventilation
Obesity Effects on Respiratory Function
Cystic Fibrosis
Bronchiectasis
Quality Improvement Measures and
Outcomes in Cystic Fibrosis
Advanced Lung Disease
Interstitial Lung Disease
Beiyun Zhou, PhD
Transcriptional Regulation of Alveolar

Epithelial Cell Differentiation
Mechanisms Underlying EpithelialMesenchymal Transition in AEC
Epigenetic Regulation of EpithelialSpecific Gene Expression
Endoplasmic Reticulum Stress in Lung
Fibrosis
Special Basic/Translational Research Activities

Zea Borok, MD, Director, Hastings Center for Pulmonary Research and Associate
Director, Will Rogers Institute Pulmonary Research Center
Regulation of Alveolar Epithelial Cell Differentiation and Phenotypic Plasticity in Lung Injury, Fibrosis and Repair
The alveolar epithelium lining the gas exchange surface of the adult lung consists of two highly specialized
cell types, type I and type II cells. These cell types are distinguished from each other by their characteristic
morphologic appearances and by expression of unique cell-specific phenotypic markers. Dr. Boroks research
program is broadly focused on cell and molecular biology of the alveolar epithelium with a view to developing
new therapeutic strategies to enhance regeneration following lung injury. Aquaporin-5 (AQP5) is a member of
a family of water channel proteins that is expressed in type I but not type II cells of the alveolar epithelium. Dr.
Borok is studying the mechanisms underlying cell-specific expression of AQP5 in order to understand how gene
expression is regulated in type I cells. She and her associates are using the regulatory (promoter) region of AQP5 as
a tool with which to generate animal models in which genes are deleted specifically in type I cells to investigate the
functional contribution of type I cells to alveolar homeostasis and for lineage tracing studies in vivo. Dr. Borok has
also demonstrated that alveolar epithelial cells (AEC) exhibit considerable plasticity, and that following treatment
with certain growth factors they can be induced to acquire mesenchymal characteristics, thereby contributing to
development of lung fibrosis. Acquisition of mesenchymal characteristics can be prevented by inhibition of the Wnt
signaling pathway accompanied by improved preservation of epithelial integrity. These studies, which are funded
by NIH/NHLB, will provide important insights into mechanisms that regulate repair of the alveolar epithelium
following injury and could lead to the development of novel therapeutic approaches for lung fibrosis by preserving
the epithelium. Dr. Borok is also investigating the role of epigenetic changes in regulation of phenotypic transitions
of AEC as well as the role of epithelial tight junction proteins in regulation of alveolar homeostasis.
Edward D. Crandall, PhD, MD, Director, Will Rogers Institute Pulmonary Research Center
Lung Alveolar Epithelial Cell Biology
Dr. Crandalls research group focuses on the lungs primary barrier between the external environment and the
internal milieu, the alveolar epithelium (lining cells of the terminal air sacs). Dr. Crandall and his group are
comprehensively studying many aspects of alveolar epithelial cell biology (e.g., during lung injury/recovery and
alveolar epithelial interactions with engineered nanomaterials). Current projects include studies on interactions
of inhaled nanoparticles with the alveolar epithelial barrier, regulation of alveolar fluid clearance from distal lung
airspaces, and mechanisms underlying alveolar epithelial cell differentiation/regeneration. The ultimate goal of
these studies is to develop new therapeutic approaches to lung diseases that cause respiratory failure due to excess
alveolar fluid (i.e., pulmonary edema).
103
Ulf Per Flodby, PhD, Investigator, Will Rogers Institute Pulmonary Research Center
Development of Transgenic Mouse and Rat Models for Modulation of Gene Expression in Alveolar Epithelial Cells
Dr. Flodby is using in vivo approaches to modulate gene expression in alveolar epithelial cells. Capitalizing on
the efficient Cre/loxP DNA recombination system, he is using state-of-the-art approaches to develop mouse and
rat models in which genes can be deleted specifically in type I or type II cells, or in both cell types. The Cre/loxP
system is also being used to direct cell-specific expression of fluorescent reporter genes to enable cell fate mapping
in response to lung injury. Development of these animal models will facilitate investigation of the contribution of
type I and/or type II cells to alveolar homeostasis and the role of specific genes in alveolar epithelial cell function
and biology. Genes of specific interest are involved in active ion transport, formation and function of tight junction
complexes, in lung fibrosis or in progenitor cell proliferation. Analysis of animals expressing reporter transgenes
will facilitate studies of lung stem/progenitor cells and their roles in regeneration after lung injury. Dr. Flodby
has gained considerable experience from in vivo analyses to evaluate effects of gene deletions (knockouts) on
pulmonary function in these animal models. These experiments will result in important insights into mechanisms
that regulate alveolar homeostasis in health and disease.
Beiyun Zhou, PhD, Investigator, Will Rogers Institute Pulmonary Research Center
Transcriptional Regulation of Alveolar Epithelial Cell (AEC) Differentiation and Role of ER Stress in Pulmonary
Fibrosis
Dr. Zhous research focuses on alveolar epithelial cell biology in general and delineation of mechanisms regulating
AEC function and differentiation in the context of lung injury and repair. A major focus has been to elucidate
pathways (e.g., Wnt/-catenin, Forkhead box (Fox) and GATA6) that regulate normal differentiation of the alveolar
epithelium (including pulmonary stem/progenitor cell proliferation/differentiation) in order to understand how they
are altered in disease and injury. She is also engaged in studies to investigate the role of endoplasmic reticulum
(ER) stress and the ER master regulator GRP78 in AEC in chronic lung diseases such as idiopathic pulmonary
fibrosis (IPF) and bronchopulmonary dysplasia (BPD). Her goal is to identify signaling pathways and epithelialmesenchymal interactions underlying ER stress-mediated fibrosis and identify new approaches to alleviate ER
stress and inhibit fibrosis. She has demonstrated that the alveolar epithelium has considerable phenotypic plasticity,
and reported that the alveolar epithelium itself can undergo EMT and express mesenchymal markers in response
to TGF- signaling or injuries (e.g., endoplasmic reticulum [ER] stress), suggesting a direct contribution of the
epithelium to the pathogenesis of pulmonary fibrosis. These studies have capitalized on in vitro models developed
using isolated rat, mouse or human type II cells which, when
placed in culture, undergo differentiation to a type I cell-like
phenotype. Studies have been expanded to explore epigenetic
mechanisms that regulate AEC plasticity and understand their
roles in EMT/fibrosis using integrated transcriptomic and
epigenomic analysis in collaboration with the Epigenome Center
at USC. Elucidating transcriptional/epigenetic mechanisms
that regulate gene expression within the alveolar epithelium
and identification of new type I cell-specific markers should
provide novel insights into mechanisms of alveolar homeostasis
under both normal and pathologic conditions and also offer
the potential for future translational application to lung disease
through modulation of signaling pathways and epigenetic
changes with various small-molecule inhibitors.
Special Clinical Research Activities

Chronic Inflammation and Remodeling in Asthmatics

Remodeling may occur in mild, moderate and severe asthmatics and may be a reason for persistent and refractory
asthma episodes. However, not all asthma patients manifest remodeling. There may be differences in the genetic,
inflammatory and immune responses. In order to define these processes in the airways, severe asthmatic subjects
undergo bronchoscopy, bronchoalveolar lavage (BAL) and proximal airway biopsies. The cellular and protein
104
material retrieved by BAL as well as airway biopsies are studied in the laboratory. Our research attempts to
show that abnormal repair processes (which include inflammatory and immune mechanisms) and growth factors
eventually lead to airway fibrosis (remodeling). Collaborative efforts with basic and translational scientists will yield
results that can lead to successful interventions to alter the remodeling process in the airways.
A. Purush Rao, MD
Cystic Fibrosis
The Adult Cystic Fibrosis (CF) program was established in 1994 and has expanded in volume to 200 patients. The
program has been accredited by the Cystic Fibrosis Foundation (CFF) and actively participates in CFF-sponsored
research and quality improvement programs. The expansion of this program has provided an opportunity for
multiple faculty members to be involved in research studies of CF patients. The program has increased the number
of investigator-initiated studies to include studies of drug distribution, delivery and metabolism in CF patients, and
therapeutic factors important in maintaining lung function.
Li C, Bellusci S, Borok Z, Minoo P: Non-Canonical WNT Signaling in the Lung. J Biochem 158(5):355-65, 2015.
The role of WNT signaling in metazoan organogenesis has been a topic of widespread interest. In the lung,
while the role of canonical WNT signaling has been examined in some detail by multiple studies, non-canonical
WNT signaling has received limited attention. Reliable evidence shows that this important signaling mechanism
constitutes a major regulatory pathway in lung development. In addition, accumulating evidence has also shown
that the non-canonical WNT pathway is critical for maintaining lung homeostasis and that aberrant activation of
this pathway may underlie several debilitating lung diseases. Functional analyses have further revealed that the noncanonical WNT pathway regulates multiple cellular activities in the lung that are dependent on the specific cellular
context. In most cell types, non-canonical WNT signaling regulates canonical WNT activity, which is also critical
for many aspects of lung biology. This review summarizes what is currently known about the role of non-canonical
WNT signaling in lung development, homeostasis and pathogenesis of disease.
Catalan MA, Kondo Y, Pena-Munzenmayer G, Jaramillo Y, Liu F, Crandall ED, Borok Z, Flodby P, Shull GE,
Melvin JE: A Novel Fluid Secretion Pathway Unmasked by Acinar-Specific Tmem16A Gene Ablation in the Adult
Mouse Salivary Gland. Proc Natl Acad Sci 112(7):2263-2268, 2015.
Activation of an apical Ca(2+)-activated Cl(-) channel (CaCC) triggers the secretion of saliva. It was previously
demonstrated that CaCC-mediated Cl(-) current and Cl(-) efflux are absent in the acinar cells of systemic Tmem16A
(Tmem16A Cl(-) channel) null mice, but salivation was not assessed in fully developed glands because Tmem16A
null mice die within a few days after birth. To test the role of Tmem16A in adult salivary glands, conditional
knockout mice lacking Tmem16A in acinar cells (Tmem16A(-/-)) were generated. Ca(2+)-dependent salivation was
abolished in Tmem16A(-/-) mice, demonstrating that Tmem16A is obligatory for Ca(2+)-mediated fluid secretion.
However, the amount of saliva secreted by Tmem16A(-/-) mice in response to the -adrenergic receptor agonist
isoproterenol (IPR) was comparable to that seen in controls, indicating that Tmem16A does not significantly
contribute to cAMP-induced secretion. Furthermore, IPR-stimulated secretion was unaffected in mice lacking Cftr
(Cftr(F508/F508)) or ClC-2 (Clcn2(-/-)) Cl(-) channels. The time course for activation of IPR-stimulated fluid
secretion closely correlated with that of the IPR-induced cell volume increase, suggesting that acinar swelling may
activate a volume-sensitive Cl(-) channel. Indeed, Cl(-) channel blockers abolished fluid secretion, indicating that
Cl(-) channel activity is critical for IPR-stimulated secretion. These data suggest that -adrenergic-induced, cAMPdependent fluid secretion involves a volume-regulated anion channel. In summary, our results using acinar-specific
Tmem16A(-/-) mice identify Tmem16A as the Cl(-) channel essential for muscarinic, Ca(2+)-dependent fluid
secretion in adult mouse salivary glands.
Liebler JM, Marconett CN, Juul N, Wang H, Liu Y, Flodby P, Laird-Offringa IA, Minoo P, Zhou B: Combinations
of Differentiation Markers Distinguish Subpopulations of Alveolar Epithelial Cells in Adult Lung. Am J Physiol
Lung Cell Mol Physiol [Epub ahead of print], 2015.
105
The Division published 10 peer-reviewed research papers during the period of January 1 through December 31,
2015, and four more are in press. Of these, three studies are especially noteworthy accomplishments:
Distal lung epithelium is maintained by proliferation of alveolar type II (AT2) cells and, for some daughter AT2
cells, transdifferentiation into alveolar type I (AT1) cells. We investigated if subpopulations of alveolar epithelial
cells (AEC) exist that represent various stages in transdifferentiation from AT2 to AT1 cell phenotypes in normal
adult lung and if they can be identified using combinations of cell-specific markers. Immunofluorescence
microscopy showed that, in distal rat and mouse lungs, 20-30% of NKX2.1(+) (or thyroid transcription factor 1(+))
cells did not colocalize with pro-surfactant protein C (pro-SP-C), a highly specific AT2 cell marker. In distal rat
lung, NKX2.1(+) cells coexpressed either pro-SP-C or the AT1 cell marker homeodomain only protein x (HOPX).
Not all HOPX(+) cells colocalize with the AT1 cell marker aquaporin 5 (AQP5), and some AQP5(+) cells were
NKX2.1(+). HOPX was expressed earlier than AQP5 during transdifferentiation in rat AEC primary culture, with
robust expression of both by day 7. We speculate that NKX2.1 and pro-SP-C colocalize in AT2 cells, NKX2.1
and HOPX or AQP5 colocalize in intermediate or transitional cells, and HOPX and AQP5 are expressed without
NKX2.1 in AT1 cells. These findings suggest marked heterogeneity among cells previously identified as exclusively
AT1 or AT2 cells, implying the presence of subpopulations of intermediate or transitional AEC in normal adult lung.
Major Lectures
Zea Borok, MD
Role of Alveolar Epithelium in Pulmonary Fibrosis: Innocent Bystander or Active Participant? University of
California, Los Angeles, CA, January 2015.
Alveolar Epithelial Cell Plasticity in Pulmonary Fibrosis, University of Pennsylvania, Philadelphia, PA, February,
2015.
Alveolar Epithelial Cell Plasticity in Pulmonary Fibrosis, University of Texas Southwestern, Robert L. Johnson
Memorial Lectureship, Dallas, TX, March 2015.
Role of Alveolar Epithelium in Pulmonary Fibrosis. New York University, William N. Rom Symposium, New York,
NY, April 2015.
Ching-Fei Chang, MD
Electromagnetic Navigational Bronchoscopy in the Workup of Lung Cancer. Lung Cancer in 2015: A
Multidisciplinary Update Regional CME Conference, Westin Hotel, Pasadena CA, April 2015.
Basics of Ultrasound Physics and Knobology. Southern California Regional PCCM Fellowship Bedside
Ultrasonography Course, LAC+USC Medical Center, Los Angeles, CA, November 2015.
Diagnosis/Management of Pulmonary Arterial Hypertension. CME Invited Lecture, Citrus Valley Medical Center
Conference Center, Covina, CA, April 2015.
Insomnia: Implications and Treatment. CME Invited Lecture, Citrus Valley Medical Center, Covina CA, April 2015.
Chronic Thromboembolic Pulmonary Hypertension: What you Need to Know? CME Invited Lecture, Providence
Tarzana Medical Center, Tarzana, CA, April 2015.
Update: Non-Infectious Interstitial Lung Disease. CME Invited Lecture, Citrus Valley Medical Center Conference
Center, Covina, CA, June 2015.
Prevention of PE/DVT. CME Invited Lecture, Providence Tarzana Medical Center, Tarzana CA, July 2015.
Interstitial Lung Disease. CME Invited Lecture, Northridge Hospital Education Auditorium, Northridge, CA, August
2015.
Interstitial Lung Disease. CME Invited Lecture, West Hills Medical Center, West Hills, CA, August 2015.
Renli Qiao, MD, PhD
Mechanical Ventilation. Anzhen Respiratory and Critical Care Forum, Beijing, China, April 2015.
Pulmonary Embolism in 2015. Anzhen Respiratory and Critical Care Forum, Beijing, China, April 2015.
Pulmonary Hypertension in COPD. Anzhen PCCM Symposium, Anzhen, China, April 2015.
The Science Behind PCCM Fellowship Training. Second General Assembly, Chest and CTS Joint Steering
Committee on PCCM Fellowship, Prime Hotel, Beijing, China, April 2015.
Why China Needs PCCM Subspecialty Training. Northwest Jiaotong University Medical College, XiAn, China,
April 2015.
The Evolving Concept of Cor Pulmonale. Best of Chest Joint Symposium ACCP-CTS, Beijing, China, July 2015.
106
A Days Life of a PCCM fellow. Invited Speech, The 16th Annual Congress, Chinese Thoracic Society, Guiyang,
Guizhou, September 2015.
Quantification of Critical Medicine. 16th Annual Conference, Chinese Thoracic Society, Guiyang, Guizhou,
September 2015.
Bassam Yaghmour, MD
Lung Ultrasound in Respiratory Failure. University of Tennessee Health Science Center, Division of Pulmonary,
Critical Care and Sleep Medicine, Memphis, TN, 2015.
Beiyun Zhou, PhD
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis. Vermont Lung Center, University of
Vermont, Burlington, VT, April 2015.
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis: Integrative Respiratory Physiology and
Pathophysiology Program, University of Wisconsin, Madison, WI, May 2015.
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis. The Ohio State University, Columbus,
OH, May 2015.
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis. Center for Comparative Respiratory
Biology and Medicine, University of California, Davis, CA, June 2015.
Chair, American Thoracic Society International Conference Committee, 2015

Inaugural Director, Hastings Center for Pulmonary Research, 2015
Raj R. Dasgupta, MD
Teaching Faculty of the Year, Keck School of Medicine of USC, 2015
Beiyun Zhou, PhD
Award for Best Scientific Abstract, American Thoracic Society International Conference, Denver, Co, May 2015
107
Honors and Awards
Zea Borok, MD
Faculty
Professor
Associate Professor
Assistant Professor
Daniel G. Arkfeld, MD
David A. Horwitz, MD
Chaim O. Jacob, MD, PhD
Richard S. Panush, MD
Francisco P. Quismorio, Jr., MD
Glenn R. Ehresmann, MD
Stratos Christianakis, MD
Michelle Koolaee, DO
Elizabeth C. Ortiz, MD
Shuntaro Shinada, MD
108
Rheumatology
William Stohl, MD, PhD, Professor of Medicine and Chief
Gabriela Gutierrez, Administrator
The mission of the Rheumatology Division is a tripartite one, focused on patient care, education and research. On
the research front, the Division has historically been especially strong in the area of systemic lupus erythematosus
(SLE) and continues that tradition. In terms of basic science investigation, Division Chief William Stohl, MD, PhD,
continues to focus on factors that affect the survival and function of B cells, a type of cell that is critical to normal
function of the immune system but which functions abnormally in SLE and drives disease. In parallel,
Dr. Chaim Jacob continues his groundbreaking work in discovering and characterizing new genes important to the
development of SLE. More recently Dr. Stohl, in collaboration with Dr. Sarah Hamm-Alvarez in the Department of
Ophthalmology, has embarked on a program in Sjgrens syndrome to identify tear-based biomarkers to help in the
diagnosis and management of this disease.
In terms of clinical investigation, Dr. Stohl continues to direct several clinical trials to study the effectiveness of
various novel B cell-targeting biologic agents in patients with SLE.
On the patient care front, the Division provides broad clinical services at LAC+USC Medical Center (LAC+USC)
and Keck Hospital of USC (KH). Dr. Richard Panush directs the Rheumatology Fellowship Training Program and
Drs. Daniel Arkfeld and Glenn Ehresmann serve as co-chiefs of the LAC+USC Arthritis Outpatient Clinic. They,
along with Drs. Stratos Christianakis, Michelle Koolaee, Elizabeth Ortiz, Richard Panush, and Shuntaro Shinada,
are using new state-of-the-art agents to treat patients at KH afflicted with a variety of rheumatic diseases and are
working with their orthopedic colleagues to provide comprehensive care for all their patients. The Rheumatology
faculty continue to provide oversight to the unique rehabilitation and chronic care services offered at the Rancho
Los Amigos National Rehabilitation Center (Rancho).
On the education front, the Division leverages the diverse clinical resources of LAC+USC, Rancho and KH to
provide outstanding training for medical students, postdoctoral medical residents, and fellows. The Rheumatology
Fellowship emphasizes patient care for a broad range of rheumatic diseases and understanding the role of the
immune system in the pathogenesis of autoimmune diseases. New and expanded programs in musculoskeletal
ultrasonography, led by Drs. Michelle Koolaee and Shuntaro Shinada, and in bone densitometry, led by
Dr. Michelle Koolaee, highlight the Divisions commitment to being at the educational forefront of Rheumatology.
The Divisions many accomplishments during the past year reflect the skills and creativity of dedicated faculty.
109
Clinical Activities
The clinical service consists of active inpatient and outpatient consultation services, including two general
Rheumatology outpatient clinics per week supervised by our general faculty at LAC+USC, as well as a third clinic
specifically for patients requiring ultrasonographic evaluation, supervised by Drs. Shinada and Koolaee. Two
additional clinics per week are staffed by Dr. Christianakis, and another two clinics per week are staffed by
Dr. Ortiz. Thus, our physicians handle approximately 10,000 outpatient visits annually. In addition, we consult
on 500+ inpatients at LAC+USC each year, and we continue to have an active working relationship with the
Department of Orthopedics at Ranchos Arthritis Service in the management of patients needing joint replacement
and rehabilitation.
Private Practice
Drs. Arkfeld, Ehresmann, Christianakis, Koolaee, Ortiz, Panush, and Shinada treat more than 100 different types of
arthritis and rheumatic conditions at the USC Healthcare Center and satellite offices. More than 5,000 patients are
seen each year, and the numbers have been increasing. Our physicians develop and present an annual community
education symposium on rheumatic diseases.
Rheumatology Fellows
Class of 2016
Class of 2017
Jennifer Johnson, DO
Dawn Piarulli, MD
Stavros Savvas, MD
Christina Chen, DO
Andrew Kelly, DO
Beatrice Kenol, MD
The Division of Rheumatology is strongly committed to the education of medical students, house staff, and
postgraduate fellows. The curriculum for house staff and fellows is continually updated to reflect new insights into
pathogenesis and treatment of rheumatic diseases. To offer our trainees a broad and diverse experience, our training
programs utilize LAC+USC, KH, and Rancho. Childrens Hospital of Los Angeles (CHLA), a USC-affiliated
institution, serves as an additional resource for exposure to pediatric rheumatology.
The Division conducts three weekly conferences: Rheumatology Clinical Conference, Journal Club/Research
Conference and Clinical Core Lecture. At the Rheumatology Clinical Conference, one patient seen by the trainee
is presented and discussed. At the Journal Club/Research Conference, faculty and fellows present one carefully
selected journal article or discuss ongoing cutting-edge research activities. At the Clinical Core Lecture, a
fundamental topic in Rheumatology is presented in a didactic manner. Our fellows also attend a monthly radiology
conference for musculoskeletal imaging at LAC+USC.
Research Activities
The research component of the fellowship combines the expertise of a team of basic science-oriented faculty and
clinical faculty with the exceptional resources in rheumatic diseases available at our teaching hospitals. The research
laboratories occupy ~1,500 square feet of space and are located in the Hoffman Medical Research Building, in close
physical proximity to LAC+USC and KH.
The Division of Rheumatology historically is best known for its basic and clinical
research on systemic lupus erythematosus (SLE). SLE is a disorder of generalized
autoimmunity when immune regulation fails. Drs. Stohl and Jacob have taken
advantage of the extraordinary clinical and research resources at the USC Health
Sciences Campus to study immune regulation in human SLE. Dr. Stohls efforts are
primarily focused on B cells, and Dr. Jacobs focus is primarily on genetics.
The Divisions research activities are not limited to SLE. Drs. Arkfeld, Christianakis,
Ehresmann, Ortiz, Panush and Shinada have been investigating new strategies to treat
patients with rheumatoid arthritis and other inflammatory arthritides. In addition,
Dr. Stohl has been conducting clinical trials in patients with SLE with novel biologic
agents, and he has initiated a collaboration with investigators in the Department of
Ophthalmology to examine the early events in Sjgrens syndrome.
110

Osteoarthritis
Novel Immune Therapies for Immune
Disorders
Sjgrens Syndrome
Fibromyalgia
B Cell Directed Autoimmune Therapies
Osteoporosis
Scleroderma
Spondyloarthropies
Myositis
Rheumatic Diseases
Regulatory T Cell Subsets in SLE
Regulatory Cells to Treat Autoimmune
Diseases and Prevent Graft Rejection

SLE Genetics
Pathogenesis of SLE
Ultrasonographic Evaluation of Arthritis
Systemic Lupus Erythematosus
Cytokine-Mediated Down-Regulation of
B Cell Hyperactivity in SLE
Immunoregulatory Mechanisms in the
Autoimmunity/Immunopathology of
Rheumatic and Systemic Connective
Tissue Diseases
Antiphospholipid Antibodies
Autoantibodies in Rheumatic Diseases

Effects of Rituximab in Early
Rheumatoid Arthritis and Systemic
Sclerosis
Bone Mineral Density in the Hispanic
Population
B Cell Survival Factors (especially the

BAFF axis)
B Cell Depletion Therapy in Rheumatic
Diseases
Sjgrens Syndrome
Escalante P, Kooda KJ, Khan R, Aye SS, Christianakis S, Arkfeld DG, Ehresmann GR, Kort JJ, Jones BE:
Diagnosis of Latent Tuberculosis Infection with T-SPOT().TB in a Predominantly Immigrant Population with
Rheumatologic Disorders. Lung 193(1):3-11, 2015.
The objective of this study is to compare how likely positive tuberculin skin test (TST) and T-SPOT(). TB
(TSPOT) results predict risk factors for tuberculosis in a predominantly immigrant patient population at risk
of latent TB infection (LTBI) and with rheumatologic conditions requiring immunomodulatory therapy (IMT).
Prospective study conducted at a referral rheumatology clinic. Inclusion criteria included patients on various
IMT, including immunosuppressive drugs that could predispose to TB progression. We studied risk factors
associated with LTBI, test results, and tests agreement.
McHugh MD, Park J, Uhrich R, Gao W, Horwitz DA, Fahmy TM: Paracrine Co-Delivery of TGF- and IL-2
using CD4-Targeted Nanoparticles for Induction and Maintenance of Regulatory T Cells. Biomaterials 59:17281, 2015.
The cytokine milieu is critical for orchestration of lineage development towards effector T cell (Teff) or
regulatory T cell (Treg) subsets implicated in the progression of cancer and autoimmune disease. Importantly,
the fitness and survival of the Treg subset is dependent on the cytokines Interleukin-2 (IL-2) and transforming
growth factor beta (TGF-). The production of these cytokines is impaired in autoimmunity increasing the
probability of Treg conversion to aggressive effector cells in a proinflammatory microenvironment.
Jacob CO, Yu N, Sindhava V, Cancro MP, Pawar RD, Putterman C, Stohl W: Differential Development of
Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors. Arthritis
Rheumatol 67(9):2523-35, 2015.
To determine the development of systemic lupus erythematosus (SLE) in NZM 2328 (NZM) mice deficient in 2
BAFF receptors. Renal immunopathology and clinical disease were attenuated in NZM.BR-3(-/-) .BCMA(-/-)
111
The Division of Rheumatology published 20 peer-reviewed research papers during the period of January 1
through December 31, 2015, and three more are in press. Of these, five publications are especially
noteworthy:
and NZM.BR-3(-/-) .TACI(-/-) mice but were accelerated in NZM.BCMA(-/-) .TACI(-/-) mice. Accelerated disease
was associated with increases in B cells, IgG-secreting cells, serum autoantibody levels, and T cells (especially
CD4+ activated memory cells), whereas attenuated disease was associated with reductions in many of these
parameters.
Torralba KD, Villasenor-Ovies P, Evelyn CM, Koolaee RM, Kalish RA: Teaching of Clinical Anatomy in
Rheumatology: A Review of Methodologies. Clinical Rheumatology 34(7):1157-63, 2015.
Clinical anatomy may be defined as anatomy that is applied to the care of the patient. It is the foundation of a
well-informed physical examination that is so important in rheumatologic practice. Unfortunately, there is both
documented and observed evidence of a significant deficiency in the teaching and performance of a competent
musculoskeletal examination at multiple levels of medical education including in rheumatology trainees.
Honors and Awards
Johnson JA, Yu SS, Elist M, Arkfeld D, Panush RS: Rheumatologic Manisfestations of the MonoMAC
Syndrome: A Systematic Review. Clin Rheumatol 34(9):1643-5, 2015.
MonoMAC syndrome is characterized by monocytopenia with susceptibility to nontuberculous mycobacterial
infections. First recognized in 2011, it is caused by GATA2 mutations and can manifest as disseminated
mycobacterial, fungal, and viral infections. While mortality rates for this disorder have been high, it has recently
been successfully treated with haploidentical allogeneic stem cell transplant. Since approximately one third of
patients may have rheumatologic symptoms, such as erythema nodosum, panniculitis, or arthralgias,
rheumatologists may expect to encounter this newly described entity with increasing frequency.
Faculty Teaching Incentive Award, Keck School of Medicine of USC, 2015
112
Administrative Appointments
Philip M. Chang, MD
Medical Director, Adult Congenital Heart Disease Care

Program, LAC+USC Medical Center
Director, Cardiovascular Research Unit, Keck School of

Medicine of USC
Director, Interventional Cardiology Fellowship Program,
Director, Vascular Medicine Fellowship Program, Keck
School of Medicine of USC
Ischemic Attack Program, Neurology Department, Keck

Director, Womens Cardiovascular Center, Cardiovascular
Thoracic Institute, Keck School of Medicine of USC
Chair, Cardiovascular Organ System (Year II), Keck School

of Medicine of USC
Director, Cardiology Clinics, LAC+USC Medical Center
Director, Inpatient Cardiology, LAC+USC Medical Center
Chair, George C. Griffith Center, USC
Rahul N. Doshi, MD
Leslie A. Saxon, MD
Director, Electrophysiology Fellowship Program, Keck

Director, Electrophysiology, Keck Medical Center of USC
Director, Electrophysiology Lab, Keck Medical Center of
USC
Director, Electrophysiology Lab, LAC+USC Medical Center
Director, Cardiovascular Clinical Research Unit, Keck

Executive Director, USC Center for Body Computing, Keck
Executive Director, USC Virtual Care Clinic, Keck School of
Medicine of USC
Uri Elkayam, MD
Director, Cardiology High-Risk Pregnancy Service, Keck

Michael W. Fong, MD
Clinical Preceptor, Physician Assistant Students, Keck

Medical Center of USC
Co-Director, Advanced Heart Failure and Cardiomyopathy,
Co-Director, Advanced Heart Failure and Cardiomyopathy,

Director, Advanced Heart Failure and Transplant Fellowship,
Howard N. Hodis, MD
Co-Director, Atherosclerosis Research Unit (ARU) Lipid

Laboratory, Keck School of Medicine of USC
Co-Director, Vascular Screening Program, Keck School of
Medicine of USC
Director, ARU, Keck School of Medicine of USC
Director, Clinical Research Core Facilities, ARU, Keck
Director, Core Imaging and Reading Center, ARU, Keck
Director, Lipid and Atherosclerosis Treatment Center, Keck
Henry W. Huang, MD
Director, Nuclear Cardiology, Keck School of Medicine of

USC
Director of Research, Board of Directors, The Heart

Institute, Hospital of the Good Samaritan
Director, Echocardiography Services, Cardiovascular

Thoracic Institute, Keck School of Medicine of USC
Director, Echocardiography Services, LAC+USC Medical
Center
Interim Director, Noninvasive Cardiovascular Stress and
ECG Lab, LAC+USC Medical Center
Ray V. Matthews, MD
Chief, Division of Cardiovascular Medicine, Department of

Medicine
Director, Interventional Cardiology, Cardiovascular Thoracic
Institute, Keck School of Medicine of USC
Director, Coronary Care Unit, LAC+USC Medical Center
Vivian Y. Mo, MD
Associate Director, Cardiovascular Medicine Fellowship

Training Program, Keck School of Medicine of USC
Cardiology Director, Roxanna Todd Hodges Transient
Co-Director, Peer to Peer Lower Extremity Interventional

Training Course, Keck School of Medicine of USC
Director, Cardiac Catherization Laboratories, LAC+USC
Medical Center
Director, General Cardiovascular Fellowship, Keck School
of Medicine of USC
Director, Interventional Cardiology, Cardiovascular Thoracic
Institute, Keck School of Medicine of USC
Director, Peer to Peer CardioMems Training Course, Keck
Medical Director, STEMI Receiving Center, LAC+USC
Medical Center
Director, Cardiovascular CT, Keck School of Medicine of

USC
Director, USC Arrhythmia Center, Keck School of Medicine
of USC

Helen L. Baron, MD
Director, Bone Mineral Density Unit, Keck School of

Medicine of USC
Chief, Division of Endocrinology and Diabetes, Department

of Medicine
Co-Director, USC Diabetes and Obesity Research Institute
Director, Southern California Clinical and Translational
Science Institute, Keck School of Medicine of USC
Vice Dean for Research, Keck School of Medicine of USC
Co-Director, USC Center for Pituitary Disorders, Keck

Wei-An Lee, MD
Director, Diabetes and Metabolism Clinic, LAC+USC

Medical Center
Director, Subspecialty Integration, LAC+USC Medical
Center
Director, Endocrinology Fellowship Training Program, Keck

Director, Thyroid Clinic, LAC+USC Medical Center
Director, Intensive Course in Diabetes, Endocrinology and

Metabolic Diseases, Keck School of Medicine of USC
Director, USC Center for Diabetes and Metabolic Diseases,
Director, Endocrine Services Laboratory, Keck School of
113
Medicine of USC
Senior Associate Chair of Research, Department of Medicine
Anne L. Peters, MD
Director, Clinical Diabetes Program, Keck School of

Medicine of USC
Sylvia J. Shaw, MD
Associate Chief Medical Officer, Rancho Los Amigos

National Rehabilitation Center
Chief of Staff, Rancho Los Amigos National Rehabilitation
Center
Peter A. Singer, MD
Chief, Clinical Endocrinology, Division of Endocrinology,

Course Director, Annual Thyroid Symposium, Keck School
of Medicine of USC
Director, Thyroid Diagnostic Center, Keck School of
Medicine of USC
Technical Director, Endocrine Services Laboratory, Keck

Gastrointestinal and Liver

Diseases
Director of Endoscopy, LAC+USC Medical Center
Director, Pilot/Feasibility Projects Program, USC Research

Center for Liver Diseases
Senior Associate Chair for Scientific Affairs, Department of
Medicine
John A. Donovan, MD
Director, Gastrointestinal and Liver Diseases Fellowship

Cheng Ji, PhD
PhD Advisor, Programs in the Biomedical and Biological

Sciences, USC
Jeffrey A. Kahn, MD
Medical Director, Liver Transplantation, Keck Medical

Center of USC
Chief, Division of Gastrointestinal and Liver Diseases,

Director, USC Research Center for Liver Diseases (NIDDK
Digestive Disease Core Center Grant)
Murad Ookhtens, PhD
Assistant Director, USC Research Center for Liver Diseases

Director, Analytical, Metabolic, Instrumentation Core, USC
Research Center for Liver Diseases
Director, Mathematical Analysis-Modeling and Image
Processing Services, USC Research Center for Liver
Diseases
Sarah Sheibani, MD
Associate Program Director, Gastrointestinal and Liver

Diseases Fellowship Training Program, Keck School of
Medicine of USC
Edy E. Soffer, MD
Director, GI Motility and Esophageal Center, Keck Medical

Center of USC
Andrew A. Stolz, MD
Chief, GI Service, LAC+USC Medical Center

Director, Liver Consult Services, LAC+USC Medical Center
Director, Roybal Outpatient Liver Clinic, Los Angeles
County Health Services

Director, Digestive Health Center, Keck Medical Center of

USC
Arek Jibilian, MD
Section Head, General Internal Medicine, Department of

Medicine
Geriatric, Hospital, Palliative

and General Internal Medicine
Ron Ben-Ari, MD
Michael S. Karp, MD
Assistant Dean, Curriculum, Keck School of Medicine of

USC
Associate Dean, Continuing Medical Education and
Professional Development, Keck School of Medicine of
USC
Service Chief, Internal Medicine Services, LAC+USC
Medical Center
Vice Chair for Educational Affairs, Department of Medicine
Associate Chief Medical Officer, Keck School of Medicine

of USC
Associate Medical Director for Clinical Services, Keck
Medical Center of USC
Chief of Medicine, Keck Hospital of USC
Director, Athletic Medicine, Department of Athletics, USC
Medical Director, Executive Health Assessment Program,
Medical Director, Keck Hospital of USC
Director, Internal Medicine Clerkship Program, Keck School

of Medicine of USC
Associate Medical Director, LAC+USC Medical Center

Director, Outpatient Services, LAC+USC Medical Center
Co-Director, Pacific Center for Health Policy and Ethics,

Coordinator, HEAL Curriculum (Humanities, Economics
and the Law), Keck School of Medicine of USC
Director of Primary Care, Keck Medicine of USC
Vice Chair, Clinical Affairs, Department of Medicine
Director, Geriatric Medicine Fellowship Training Program,

Director, Los Angeles County Elder Abuse Forensic Center,
Violence Intervention Program, LAC+USC Medical
Center
Medical Director, Adult Protection Team, LAC+USC
Medical Center
Medical Director, Geriatrics Clinic, LAC+USC Medical
Center
Executive Director, Center for Clinical Nutrition and Applied

Health Research, Keck School of Medicine of USC
Medical Director, Metabolism and Bariatric Unit, Digestive
Health Center, Keck Medical Center of USC
Eric P. Hsieh, MD
Director, Keck School of Medicine Intersessions,

Director, USC Internal Medicine Outpatient Clerkship
Rotation, Department of Medicine
Director, USC Internal Medicine Residency Program,
Faculty Advisor, Internal Medicine Student Interest Group,
Internal Medicine Student Advisor, Keck School of Medicine
of USC
Edward K. Hu, MD
Medical Director, Center for Asthma, Allergy and

Immunology, Keck Medical Center of USC
Douglass B. Hutcheon, MD
Director, Internal Medicine Residency Evidence-Based

Medicine Journal Club Curriculum, Keck School of
Medicine of USC
Associate Clerkship Director, Internal Medicine Clerkship,

Chief, Division of Geriatric, Hospital, Palliative and General
Internal Medicine, Department of Medicine
Medical Director, USC Executive Health Program, Keck
Medical Director, USC PCMH Faculty Model, Keck School
of Medicine of USC
Joshua Lee, MD
Chief Information Officer, Keck Medicine of USC
Carlo Medina, MD
Director, Co-Management Services, Keck Hospital Medicine

Program, Keck Hospital of USC
Admissions Interviewer, Keck School of Medicine of USC

Associate Director, Internal Medicine Residency Training
Program, Department of Medicine


Firm Director, Internal Medicine Residency Training

Medical Director, Keck Medicine of USC, Downtown Los

Angeles
Carin van Zyl, MD
Director/Section Head, Adult and Pediatric Palliative Care,

Michael D. Wang, MD
Director, Hospital Medicine Program, Keck Hospital of USC
Vickie Wu, MD
Director, Hospital Medicine Program, Keck Hospital of USC

Director, Inpatient Hospital Medicine, Keck Hospital of USC
Medicine Rotation Site Coordinator, Keck Hospital of USC
Andrew S. Young, DO
Director, Inpatient Medicine Consult Services, LAC+USC

Medical Center
Section Head, Hospital Medicine, Department of Medicine
Assistant Director, Combined Internal Medicine/Pediatrics

Residency Program, Keck School of Medicine of USC
Co-Course Director, Professionalism and Practice of
Medicine, Keck School of Medicine of USC
Combined Internal Medicine/Pediatrics Medical Student
Advisor, Keck School of Medicine of USC
Hematology
Norris Comprehensive Cancer Center
Cage S. Johnson, MD
Director, Comprehensive Sickle Cell Center, LAC+USC

Medical Center
Assistant Medical Director, Clinical Investigations Support

Office, USC Norris Comprehensive Cancer Center
Director, Hematology Fellowship Training Program, Keck

Medical Director, Special Hemostasis Laboratory, USC
Norris Cancer Hospital
Chair, Year II Hematology/Immunology Course, Keck

Medical Director, Anticoagulation Services, LAC+USC
Medical Center
Anil Tulpule, MD
Director, Inpatient Hematology Services, LAC+USC

Medical Center
Infectious Diseases
Director, Infectious Diseases Fellowship Training Program,

Director, Rand Schrader Clinic, LAC+USC Medical Center
P. Jan Geiseler, MD
Chief, Infectious Diseases Services, Keck Hospital of USC
Paul D. Holtom, MD
Associate Medical Director, Regulatory Affairs, LAC+USC

Medical Center
Chief of Staff, Attending Staff Association, LAC+USC
Medical Center
Director, Antibiotic Stewardship Program, LAC+USC
Medical Center
Program Director, Infectious Diseases Fellowship Training
Program, Keck School of Medicine of USC
Associate Program Director, Infectious Diseases Fellowship

Fred R. Sattler, MD
Associate Program Director, USC General Clinic Research

Center
Chief, Division of Infectious Diseases, Department of
Medicine
Brad Spellberg, MD
Associate Dean for Clinical Affairs, Keck School of

Medicine of USC
Chief Medical Officer, LAC+USC Medical Center

Director, Nephrology Fellowship Training Program, Keck

Vito M. Campese, MD
Director, Hypertension Center, Keck School of Medicine

of USC
Arshia Ghaffari, DO
Chief, Division of Hematology and Center for the Study of

Blood Diseases, Department of Medicine
Clinical Program Director, Blood and Marrow Transplant
Program, USC Norris Cancer Hospital
Co-Leader, Molecular Genetics Program, USC Norris
Comprehensive Cancer Center
Medical Director, DaVita/USC Kidney Dialysis Center
Chief, Division of Nephrology and Hypertension,

Director, USC/UKRO Kidney Research Center, Keck School
of Medicine of USC
Parkash S. Gill, MD
Program Leader, Translational and Clinical Sciences, USC
114
Director, Inpatient Nephrology Consult Services, LAC+USC

Medical Center
Mitra K. Nadim, MD
Chair, Year II Renal System, Keck School of Medicine of

USC
Director, USC Hypertension Center, Keck School of
Medicine of USC
Medical Director, Home Dialysis and Peritoneal Dialysis

Program, DaVita-USC Kidney Dialysis Center
Medical Director, Nephrology, Hypertension, CKD and
Renal Transplant Clinic, Hudson Comprehensive Health
Center, Los Angeles Department of Health Services
Assistant Dean, Research Mentoring, Keck School of

Medicine of USC
Yasir A. Qazi, MD
Medical Director, Kidney-Pancreas Transplant Program,

Associate Director, Nephrology Fellowship Training

Director, Clinical Nephrology Teaching Program, Keck
Oncology
David B. Agus, MD
Director, USC Center for Applied Molecular Medicine

Director, USC Norris Westside Cancer Center
Senior Fellow, Schaeffer Health Policy Center, USC Sol
Price School of Public Policy
Director, Center for Human Studies and Clinical Trials Unit,

Clinical and Translational Science Institute, Keck School
of Medicine of USC
Medical Director, Clinical Investigations Support Office,
USC Norris Comprehensive Cancer Center
Director of Clinical Research, Womens Cancer Program,

Amir Goldkorn, MD
Founding Director, Circulating Tumor Cell Research Core,

Research Director, Center for Applied Molecular Medicine,

Director, USC Norris Comprehensive Cancer Center
James S. Hu, MD
Co-Director, Adolescent and Young Adult Program, USC

Norris Comprehensive Cancer Center
Director, Oncology Fellowship Training Program, Keck
Medical Director, Sarcoma Program, USC Norris
Syma Iqbal, MD
Director, Oncology Fellowship Training Program, Keck

Educational Officer, Division of Oncology, Department of
Medicine
Associate Director, Adult Oncology, USC Norris

Co-Director, Colorectal Center, USC Norris Comprehensive
Cancer Center
Co-Director, USC Center for Molecular Pathways and Drug
Discovery, Keck School of Medicine of USC
Program Co-Leader, GI Cancers Program, USC Norris
Scientific Director, Cancer Genetics Unit, USC Norris

Section Head, GI Oncology, Division of Oncology
Paul Macklin, PhD
Co-Director, Consortium for Integrative Computational

Oncology, USC
Director of Education, Physical Sciences in Oncology
Center, USC
Laboratory Director, Center for Applied Molecular

Medicine, USC
Co-Director, Prostate Cancer Research Program, USC Norris

Medical Director, USC Norris Comprehensive Cancer Center

Section Head, Genitourinary Oncology Section, Division of
Oncology, Department of Medicine
Co-Director, Norris Breast Center, USC Norris

Medical Director, Utilization Review, Norris Breast Center,
Darcy V. Spicer, MD
Assistant Dean for Clinical Studies, Keck School of

Medicine of USC
Chief, Division of Oncology, Department of Medicine
Section Head, Solid Tumors, Division of Oncology,

Pulmonary, Critical Care and

Sleep Medicine
Assistant Director, Chest Clinic, LAC+USC Medical Center
Associate Director, Lung Transplantation Program, Keck

Hospital of USC
Associate Medical Director, Adult Asthma and Allergy
Center, Keck School of Medicine of USC
Ahmet N. Baydur, MD
Chair, Year II Respiratory System, Keck School of Medicine

of USC
Medical Director, Pulmonary Rehabilitation Clinic,
Medical Director, Respiratory Therapy Department,
Medicine of USC
Medical Director, Pulmonary Hypertension Program, Keck
Director, Pulmonary and Critical Care Fellowship Training

Director, Sleep Medicine Fellowship Training Program,
Medical Director, USC Sleep Disorders Center, Keck
Hospital of USC
Associate Director, Medical Intensive Care Unit, LAC+USC

Medical Center
Medical Director, Medical-Surgical Intensive Care Unit,

David M. Kelley, MD
Medical Director, Respiratory Services, USC Pulmonary

Exercise Program, Keck School of Medicine of USC
Kwang-Jin Kim, PhD
Radiation and Laboratory Safety Officer, Will Rogers

Institute Pulmonary Research Center, Keck School of
Medicine of USC
Medical Director, Medical Intensive Care Unit, LAC+USC

Medical Center
Medical Director, Sleep Laboratory, LAC+USC Medical
Center
Ami Oren, MD
Director, Chest Clinic and Pulmonary-HIV Clinic,

Director, Respiratory Physiology, LAC+USC Medical Center
A. Purush Rao, MD
Co-Director, Cardiothoracic Transplant Intensive Care Unit,

Director, Adult Cystic Fibrosis Program, Keck School of
Medicine of USC
Director, Center for Advanced Lung Disease, Keck Medical
Center of USC
Rheumatology
Co-Chief, Rheumatology Clinic, LAC+USC Medical Center

Director, Rheumatology Education, Keck Hospital of USC
Chief of Staff, Keck Hospital of USC
Zea Borok, MD
Associate Director, Will Rogers Institute Pulmonary

Research Center, Keck School of Medicine of USC
Chief, Division of Pulmonary, Critical Care and Sleep
Medicine, Department of Medicine
Director, Hastings Center for Pulmonary Research, Keck
Director, Flow Cytometry Facility, Keck School of Medicine

of USC
Ching-Fei Chang, MD
Associate Director, Pulmonary and Critical Care Fellowship

Director, Bronchoscopy Services, LAC+USC Medical
Center
Chair, Department of Medicine, USC

Director, Will Rogers Institute Pulmonary Research Center,
President, USC Care Medical Group, USC
Rajkumar R. Dasgupta, MD
Assistant Director, Internal Medicine Residency Training

Sivagini Ganesh, MD
Medical Director, Lung Transplant Program, Keck School of
115
Director, Federation of Clinical Immunology Societies

Center of Excellence, USC
Director, Lupus Clinic, LAC+USC Medical Center
Director, Rheumatology Fellowship Training Program, Keck

Vice Chief, Division of Rheumatology, Department of

Medicine
Chief, Division of Rheumatology, Department of Medicine
Distinguished Societies
Alpha Omega Alpha
Ron Ben-Ari, MD
Sonya L. Earley, PA
Cynthia H. Ho, MD
Paul D. Holtom, MD
Eric P. Hsieh, MD
Cage S. Johnson, MD
Jeffrey A. Kahn, MD
James E. Pacino, MD
Glenn T. Rogers, MD
Sarah Sheibani, MD
Carin van Zyl, MD
Ilene C. Weitz, MD
American Society for Clinical

Investigation
Shaul G. Massry, MD
Association of American Physicians

Zea Borok, MD
Howard N. Hodis, MD
Shaul G. Massry, MD
Phi Beta Kappa
Fred R. Sattler, MD
Hui Y. Shan, MD
Sarah Sheibani, MD
Royal College of Physicians

Sigma Phi Omega Honor Society

Rahul Dhawan, DO
Sigma Xi
Gold Humanism Honor Society

Paul D. Holtom, MD
Eric P. Hsieh, MD
Sarah Sheibani, MD
Golden Key Honor Society

Parag Mallick, PhD
Sarah Sheibani, MD

Southern Society for Clinical

Investigation
Tau Beta Pi

Helga M. Van Herle, MD
Western Association of Physicians

Shaul G. Massry, MD
Western Society for Clinical

Investigation
Zea Borok, MD
Vito M. Campese, MD
Uri Elkayam, MD
Tse-Ling Fong, MD
Amir Goldkorn, MD
J. Julian Haywood, MD
Howard N. Hodis, MD
Cage S. Johnson, MD
Shaul G. Massry, MD
Fred R. Sattler, MD, Counselor
Andrew A. Stolz, MD
Professional Societies
Academic and Community Cancer
Research United
Tanya B. Dorff, MD
Academy of Certified Diabetes

Educators
Sonya L. Earley, PA
American Academy of Pediatrics

Cynthia H. Ho, MD
Edward K. Hu, MD
Stephanie K. Zia, MD (Fellow)
American Academy of Sleep

Medicine
Philip M. Chang, MD
Rajkumar R. Dasgupta, MD (Fellow)

AIDS Malignancies Consortium
American Aging Association
Murad Ookhtens, PhD
Alliance for Academic Internal

Medicine
American Association for the

Advancement of Science
Adult Congenital Heart Association
American Academy of Allergy and

Immunology
Edward K. Hu, MD
Richard S. Panush, MD (Fellow)
American Academy of Family

Physicians
Diana C. Homeier, MD (Fellow)
American Academy of HIV

Medicine
Arek Jibilian, MD
Michael S. Karp, MD
American Academy of HIV

Specialists
American Academy of Hospice and

Palliative Medicine
Sunita Puri, MD
Aaron D. Storms, MD
David B. Agus, MD
Mojtaba Akhtari, MD
L. Julian Haywood, MD (Fellow)
Cheng Ji, PhD
Kwang-Jin Kim, PhD
Parag Mallick, PhD
Murad Ookhtens, PhD
Andrew A. Stolz, MD
American Association of
Bronchology and Interventional
Pulmonology
Amir Goldkorn, MD
Gregory E. Idos, MD
Hittu Matta, PhD
Andrew A. Stolz, MD
American Association of Clinical

Chemists
American Association of Clinical

Endocrinologists
Helen L. Baron, MD
Stefan Bughi, MD
Wei-An Lee, MD
Sylvia J. Shaw, MD
Peter A. Singer, MD
Ching-Fei Chang, MD
Ramyar Mahdavi, MD
Bassam Yaghmour, MD
American Association of Critical

Care Nurses
American Association of Cancer

Research
American Association of Diabetes

Educators
David B. Agus, MD
Mojtaba Akhtari, MD
John R. Daniels, MD
Aneesah Smith, MD
Sonya L. Earley, PA
American Association of Hospice

and Palliative Medicine
Dohwa Kim, MD
Carin van Zyl, MD
116
Immunologists
Pathologists
American Association of Physicians

of Indian Origin
American Association for the Study

of Liver Diseases
Lily Dara, MD
John A. Donovan, MD
Tse-Ling Fong, MD (Fellow)
Helen Han, MD
Jeffrey A. Kahn, MD
Neil K. Kaplowitz, MD (Fellow)
Saro Khemichian, MD
Brian Kim, MD
Murad Ookhtens, PhD
Sarah Sheibani, MD
Andrew A. Stolz, MD
Sanda Win, MD, PhD
Liyun Yuan, MD, PhD
American Association of University

Professors
American Cancer Society


American Chemical Society
Parag Mallick, PhD
American College of Angiology

Cage S. Johnson, MD (Fellow)
American College of Allergy,

Asthma and Immunology
Edward K. Hu, MD
American College of Cardiology

James Y. Chao, MD
Rahul N. Doshi, MD (Fellow)
Uri Elkayam, MD (Fellow)
Michael W. Fong, MD
Henry W. Huang, MD
Robert A. Kloner, MD, PhD (Fellow)
Ray V. Matthews, MD (Fellow)
Vivian Y. Mo, MD (Fellow)
Enrique L. Ostrzega, MD (Fellow)
Leslie A. Saxon, MD (Fellow)
Jerold S. Shinbane, MD (Fellow)
Jina Sohn, MD
Andrew J. Yoon, MD (Fellow)
American College of Chest

Physicians
Ahmet N. Baydur, MD
Zea Borok, MD (Fellow)
Ching-Fei Chang, MD
Edward D. Crandall, PhD, MD (Fellow)
Rajkumar R. Dasgupta, MD (Fellow)
Sivagini Ganesh, MD
Janice M. Liebler, MD (Fellow)
Richard L. Lubman, MD (Fellow)
Ramyar Mahdavi, MD
Ray V. Matthews, MD
Ami Oren, MD (Fellow)
Renli Qiao, MD, PhD
A. Purush Rao, MD
Bassam Yaghmour, MD
American College of Emergency

Physicians
Carin van Zyl, MD
American College of Endocrinology

Peter A. Singer, MD
American College of
Gastroenterology
Helen Han, MD
Gregory E. Idos, MD
Saro Khemichian, MD
Brian Kim, MD
Ara B. Sahakian, MD
Edy E. Soffer, MD (Fellow)
Jacques Van Dam, MD, PhD (Fellow)
American College of Physicians

Jesse F. Abelson, MD
David B. Agus, MD
Mojtaba Akhtari, MD (Fellow)
Helen L. Baron, MD
Ahmet N. Baydur, MD
Ron Ben-Ari, MD
Zea Borok, MD (Fellow)
Edward D. Crandall, PhD, MD (Fellow)
Rahul Dhawan, DO
Ashwat S. Dhillon, MD
Michael P. Dub, MD
Tse-Ling Fong, MD (Fellow)
P. Jan Geiseler, MD (Fellow)
Arshia Ghaffari, DO
Jose L. Gonzalez, MD
Cynthia H. Ho, MD
Howard N. Hodis, MD
Paul D. Holtom, MD
Eric P. Hsieh, MD
James S. Hu, MD
Gregory E. Idos, MD
Syma Iqbal, MD
James Ji, MD
Arek Jibilian, MD
Ronald J. Kall, MD
Michael S. Karp, MD
Shazia S. Khan, MD
Howard A. Liebman, MD (Fellow)
Ramyar Mahdavi, MD
Shaul G. Massry, MD (Fellow)
Ray V. Matthews, MD
Carlo Medina, MD
K. Allen Milani, MD
Sharon E. Orrange, MD (Fellow)
Richard S. Panush, MD (Master)
Anne L. Peters, MD
Renli Qiao, MD, PhD
Glenn T. Rogers, MD
Fred R. Sattler, MD
George B. Semeniuk, MD
Aneesah Smith, MD
Darcy V. Spicer, MD
Robert S. Swinney, MD
Arnold Tsai, MD
Mabel Vasquez, MD
Michael D. Wang, MD (Fellow)
Vickie Wu, MD
Bassam Yaghmour, MD
Andrew S. Young, DO
Thomas M. Zarchy, MD (Fellow)
Stephanie K. Zia, MD (Fellow)
American College of Physician

Executives
K. Allen Milani, MD
Michael D. Wang, MD
American College of Rheumatology
American Heart Association
Daniel G. Arkfeld, MD (Fellow)

Richard S. Panush, MD (Master)
American College of Sports

Medicine
Fred R. Sattler, MD
American Diabetes Association

Helen L. Baron, MD
Stefan Bughi, MD
Wei-An Lee, MD
Anne L. Peters, MD
Sylvia J. Shaw, MD
American Endosonography Club

American Federation for Clinical

Research
Zea Borok, MD
P. Jan Geiseler, MD
Howard N. Hodis, MD
Cage S. Johnson, MD
Shaul G. Massry, MD
Fred R. Sattler, MD
Andrew A. Stolz, MD
American Gastroenterology
Association
Lily Dara, MD
John A. Donovan, MD
Helen Han, MD
Caroline Hwang, MD
Gregory E. Idos, MD
Cheng Ji, PhD
Brian Kim, MD
Ara B. Sahakian, MD
Anisha Shaker, MD
Ling Shao, MD, PhD
Sarah Sheibani, MD
Edy E. Soffer, MD
Andrew A. Stolz, MD
Liyun Yuan, MD, PhD
Thomas M. Zarchy, MD (Fellow)
American Geriatrics Society

Dohwa Kim, MD
117
Ulf Per Flodby, PhD
Howard N. Hodis, MD (Fellow)
Henry W. Huang, MD
Vivian Y. Mo, MD
American Institute of Chemical

Engineers
American Institute of Stress

Stefan Bughi, MD (Fellow)
American Institute of Ultrasound in

Medicine
American Israeli Medical Society

American Medical Association

Mojtaba Akhtari, MD
Helen L. Baron, MD
Arshia Ghaffari, DO
James S. Hu, MD
Caroline Hwang, MD
James Ji, MD
Ronald J. Kall, MD
Shazia S. Khan, MD
Ray V. Matthews, MD
K. Allen Milani, MD
James E. Pacino, MD
A. Purush Rao, MD
Arnold Tsai, MD
Carin van Zyl, MD
American Medical Informatics

Association
American Medical Society for Sports

Medicine
Julia A. Cassetta, MD
American Medical Womens

Association
Ilene C. Weitz, MD
American Motility Society

Edy E. Soffer, MD

American Mycologic Society
American Osteopathic Association

Arshia Ghaffari, DO
Andrew S. Young, DO
American Pancreas Association

American Physiological Society

Vito M. Campese, MD
Ulf Per Flodby, PhD
Kwang-Jin Kim, PhD
Shaul G. Massry, MD
Fred R. Sattler, MD
Beiyun Zhou, PhD
American Sleep Disorders

Association
American Society for Biochemistry

and Molecular Biology
American Society of Bioethics and

Humanities
Mojtaba Akhtari, MD
American Society for Blood and

Marrow Transplantation
Mojtaba Akhtari, MD
American Society for Bone and

Mineral Research
Nyam-Osor Chimge, PhD
American Society of Breast Disease

American Society of Breast

Surgeons
American Society of Cardiovascular

Interventionalists
Ray V. Matthews, MD (Fellow)
American Society for Cell Biology

Zea Borok, MD
American Society of Clinical

Oncology
David B. Agus, MD
Mojtaba Akhtari, MD
John R. Daniels, MD
Tanya B. Dorff, MD
Parkash S. Gill, MD
Amir Goldkorn, MD
Diana L. Hanna, MD
James S. Hu, MD
Syma Iqbal, MD
Jorge J. Nieva, MD
An D. Nguyen, MD
Minh D. Nguyen, MD
Darcy V. Spicer, MD
Anil Tulpule, MD
Ilene C. Weitz, MD
American Society for Clinical

Pathology
American Society of
Echocardiography
James Y. Chao, MD
Henry W. Huang, MD
Vivian Y. Mo, MD (Fellow)
Jina Sohn, MD
American Society for

Gastrointestinal Endoscopy
Helen Han, MD
Caroline Hwang, MD
Ara B. Sahakian, MD
American Society of Hematology

David B. Agus, MD
Mojtaba Akhtari, MD
Diana L. Hanna, MD
Parkash S. Gill, MD
Cage S. Johnson, MD
Hittu Matta, PhD
An D. Nguyen, MD
Anil Tulpule, MD
Ilene C. Weitz, MD
American Society of Human

Genetics
American Society of Hypertension

Vito M. Campese, MD
American Society of Internal

Medicine
Vito M. Campese, MD
Michael S. Karp, MD
Richard L. Lubman, MD (Fellow)
American Society for Laser

Medicine and Surgery
American Society for Mass

Spectrometry
American Thyroid Association
Helen L. Baron, MD
Peter A. Singer, MD
American Society of Microbiology
Argentine American Medical Society
Jonathan Katz, PhD

Parag Mallick, PhD
American Society for Matrix Biology

Michael P. Dub, MD
P. Jan Geiseler, MD
Paul D. Holtom, MD
Fred R. Sattler, MD
Darren W. Wong, MD
American Society of Nephrology
Vito M. Campese, MD
Arshia Ghaffari, DO
Kenneth R. Hallows, MD, PhD (Fellow)
Hui Li, MD
Shaul G. Massry, MD
Chong Y. Parke, MD
Hui Y. Shan, MD
American Society of Nuclear

Cardiology
James Y. Chao, MD
Henry W. Huang, MD
Armenian American Medical Society

Ara B. Sahakian, MD
Arthritis Foundation
Association for the Advancement of

Medical Instrumentation
Association of Black Cardiologists

Association of Chiefs of General

Internal Medicine
Association for Computing

Machinery
Parag Mallick, PhD
Association of Hematology-Oncology
American Society for Pharmacology

and Experimental Therapeutics
Association of Philippine Physicians

in America
American Society of Renal

Biochemistry and Metabolism
Association of Professors of
Medicine
Shaul G. Massry, MD
American Society of Sleep Medicine

American Society of Transplant

Physicians
Tse-Ling Fong, MD
Saro Khemichian, MD
American Society of Transplantation
Association of Program Directors in

Internal Medicine
Ron Ben-Ari, MD
Eric P. Hsieh, MD
Association of Program Directors in

Pulmonary Critical Care Medicine
Mitra K. Nadim, MD
Chong Y. Parke, MD
Yasir A. Qazi, MD
Liyun Yuan, MD, PhD
American Society of Tropical

Medicine and Hygiene
Association of Subspecialty
Professors
American Thoracic Society
Association of University
Cardiologists
Paul D. Holtom, MD
Ahmet N. Baydur, MD
Zea Borok, MD
Ulf Per Flodby, PhD
Sivagini Ganesh, MD
Brenda E. Jones, MD
Ramyar Mahdavi, MD
Ami Oren, MD
Bassam Yaghmour, MD
Beiyun Zhou, PhD
118
Association of Specialty Professors

Asthma and Allergy Foundation of

America
Biophysical Society
California Academy of Family

Physicians
California Biomedical Research

Association

California Cancer Consortium
Amir Goldkorn, MD
California Geriatrics Society

California Lung Association

Ami Oren, MD
California Medical Association

Shazia S. Khan, MD
Cross Town Endocrine Society

Developmental Biology Society

E.E. Just Society
Cage S. Johnson, MD
Chong Y. Parke, MD
The Endocrine Society
Latin American and Caribbean

Society of Medical Oncology
Epidemiology Intelligence Service

Alumni Association
Aaron D. Storms, MD
Candonians of Southern California
Florida Society of Rheumatology
Cardiac Electrophysiology Society
Gerontological Society of America
Edward K. Hu, MD
California Society of Internal

Medicine
California Thoracic Society

Ahmet N. Baydur, MD
Brenda E. Jones, MD
Center for Womens Health

Research
Leslie A. Saxon, MD
Charles Drew Medical Society

Clerkship Directors of Internal

Medicine
Ron Ben-Ari, MD
Eric P. Hsieh, MD
Gynecologic Oncology Group

Heart Failure Society of America

Uri Elkayam, MD
Leslie A. Saxon, MD
Heart Rhythm Society
Philip M. Chang, MD
Rahul N. Doshi, MD (Fellow)
Ray V. Matthews, MD
Leslie A. Saxon, MD (Fellow)
Clinical Ligand Assay Society
Henry Kunkel Society
Clinical Immunology Society
Collaborative Group of the

Americas on Inherited Colorectal
Cancer
Gregory E. Idos, MD
Connective Tissue Oncology Society
Kidney Cancer Association

Korean American Graduate Medical
Association
Cambridge Philosophical Society
California Society of Allergy,

Asthma and Immunology
Tanya B. Dorff, MD
Cheng Ji, PhD
California Tuberculosis Elimination

Advisory Group
Iranian American Medical

Association
Digestive Disease Week
Stefan Bughi, MD
Vito M. Campese, MD
Wei-An Lee, MD
Shaul G. Massry, MD
Anne L. Peters, MD
Fred R. Sattler, MD
Sylvia J. Shaw, MD
Peter A. Singer, MD
Andrew A. Stolz, MD
California Rheumatologic Alliance
Leslie A. Saxon, MD
Human Proteome Organization

Jonathan Katz, PhD
Parag Mallick, PhD
Infectious Diseases Society of

America
Latin American Medical Student

Association
Jose L. Gonzalez
Lipidologists of Los Angeles

Henry W. Huang, MD
Los Angeles Academy of Medicine

Los Angeles Cardiology Society

Los Angeles County Medication

Association
Shazia S. Khan, MD
Los Angeles County Medical Society

Los Angeles County Medical

Womens Association
Ilene C. Weitz, MD
Los Angeles Society of Allergy,

Asthma and Clinical Immunology
Edward K. Hu, MD
Los Angeles Society of

Echocardiography
Los Angeles Transplant Society

Shaul G. Massry, MD
Mars Society
Parag Mallick, PhD
Massachusetts Medical Society

Michael Hochman, MD
Med/Peds Program Directors

Association
National Kidney Foundation
Rahul Dhawan, DO
Arshia Ghaffari, DO
National Lipid Association

Henry W. Huang, MD
National Med-Peds Residency

Association
Cynthia H. Ho, MD
National Medical Association

National Society of Clinical

Rheumatologists
National Society of Genetic

Counselors
National Space Society

Parag Mallick, PhD
National Surgical Adjuvant Breast

and Bowel Project
New England Endoscopy Society

New York Academy of Sciences

Cage S. Johnson, MD (Fellow)
Norfolk District Medical Society

North American Menopause Society

Howard N. Hodis, MD
North American Neuroendocrine

Tumor Society
Diana L. Hanna, MD
Syma Iqbal, MD
North American Society of Pacing

Electrophysiology
Ray V. Matthews, MD
North American Taiwanese Medical

Association
Henry W. Huang, MD
The Obesity Society
Orange County Medical Association

Medical Oncology Association of

Southern California
Pediatric and Adult Congenital

Electrophysiology Society
Vito M. Campese, MD
Michael P. Dub, MD
P. Jan Geiseler, MD (Fellow)
Paul D. Holtom, MD (Fellow)
Fred R. Sattler, MD (Fellow)
Brad Spellberg, MD
Darren W. Wong, MD
Molecular Medicine Society
Pennsylvania Society of Oncology

and Hematology
Crohns and Colitis Foundation of

America
Inflammatory Bowel Disease

Working Group
Morehouse College National Alumni

Association
Institute of Electrical and

Electronics Engineers
Musculoskeletal Infection Society
James S. Hu, MD
Council for High Blood Pressure

Research
Caroline Hwang, MD
Ling Shao, MD, PhD
Ling Shao, MD, PhD
Parag Mallick, PhD
Minh D. Nguyen, MD
Chaim O. Jacob, MD, PhD (Fellow)
Paul D. Holtom, MD
119
Philip M. Chang, MD
Philippine Medical Society of

Southern California
Pituitary Society

Protein Society
Parag Mallick, PhD
Association
Sivagini Ganesh, MD
Radiation Therapy Oncology Group

Red Cell Club
Renal Physician Association

Research Society for Alcoholism

Cheng Ji, PhD
Salerni Collegium
Ron Ben-Ari, MD
The Salt and Water Club
Society of Cardiovascular Computed

Tomography
Parveen K. Garg, MD
Society for Preventive Cardiology
Ahmet N. Baydur, MD
Zea Borok, MD
Ami Oren, MD
A. Purush Rao, MD
Bassam Yaghmour, MD
Society of Vascular Medicine

Parveen K. Garg, MD
Society for Vascular Medicine and

Biology
Leonardo C. Clavijo, MD, PhD (Fellow)
Sleep Research Society

Society for Cardiac Computed

Tomography
Society of Cardiac Magnetic

Resonance
Michael W. Fong, MD
Society for Cardiovascular

Angiography and Interventions
Southern California Islet Cell

Consortium
Society for Experimental Biology

and Medicine
Yasir A. Qazi, MD
Shaul G. Massry, MD
Southern California Liver Research

Forum
Society of General Internal Medicine
Society of General Physiologists
Skull and Dagger Honor Society
Howard N. Hodis, MD
Society of Critical Care Medicine
Science Advisory Board

Cynthia H. Ho, MD
Schwartz Center for Compassionate

Health Care
James S. Hu, MD
Minh D. Nguyen, MD
Society of Obstetric Medicine
Society of Cardiovascular Magnetic

Resonance
Ron Ben-Ari, MD
Eric P. Hsieh, MD
Vickie Wu, MD

Kwang-Jin Kim, PhD
Society of Neuro-Oncology
Neil K. Kaplowitz, MD (Founder)
Southern California Pancreas Study

Group
Student National Medical

Association
Aneesah Smith, MD
Thomas J. Blocker Society

Trudeau Society
Southern California Rheumatology

Society
Ultrasound School of North

American Rheumatologists
Society for Healthcare Epidemiology

of America
Southern California Society of

Gastroenterology
Stefan Bughi, MD
Cynthia H. Ho, MD
Shazia S. Khan, MD
Carlo Medina, MD
K. Allen Milani, MD
Michael D. Wang, MD
Vickie Wu, MD
Andrew S. Young, DO
Stefan Bughi, MD
Southern California Rheumatism

Association

Clinical Hypnosis
Society of Hospital Medicine
Stress and Anxiety Research Society
Ron Ben-Ari, MD
Paul D. Holtom, MD (Fellow)

Tanya B. Dorff, MD
Parkash S. Gill, MD
Amir Goldkorn, MD
Diana L. Hanna, MD
James S. Hu, MD
Syma Iqbal, MD
Ilene C. Weitz, MD
Society of Graduate Internists
Southwest Oncology Group
John A. Donovan, MD
Brian Kim, MD
Andrew A. Stolz, MD

United States Coast Guard Auxiliary

John L. Brodhead, Jr., MD (Division
Captain)
United States Naval Academy

Alumni Association
John L. Brodhead, Jr., MD (Lifetime

Member)
University of the Philippines

Medical Alumni Society in America
Wisconsin Medical Society

K. Allen Milani, MD
Women in Nephrology
International Societies
Association of Food Science and
Technologists of India
Hittu Matta, PhD
Association of Microbiologists of
India
Hittu Matta, PhD
Australian Medical Association

Sivagini Ganesh, MD
Australian Society for Clinical and

Experimental Pharmacology and
Toxicology
British Cardiac Society
Czech Cardiological Society
Canadian Association of Medical

Oncologists
Dominican Society of
Gastroenterology
Canadian Association for the Study

of the Liver
Epithelial-Mesenchymal Transition
International Association
Chinese American Professors and

Professionals Network
European Association of Palliative

Medicine
Chinese Association of Physiological

Sciences
European Association for the Study

of Diabetes
Tse-Ling, Fong, MD
Cheng Ji, PhD
Bockus International Society of

Gastroenterology
Renli Qiao, MD, PhD
Breast Cancer International

Research Group
Clinical Oncology Society of

Australia
Beiyun Zhou, PhD
Carin van Zyl, MD
Anne L. Peters, MD
European Association for the Study

of the Liver
Gregory E. Idos, MD
European Dialysis and

Transplantation Association
Shaul G. Massry, MD
European Hematology Association

European Renal Association
European Respiratory Society

Sivagini Ganesh, MD
Ami Oren, MD
European Society of Cardiology

120

European Society of Intensive Care
Medicine
Ami Oren, MD
European Society of Medical

Oncology
International Society of Hematology
Ami Oren, MD
International Society of
Atherosclerosis
International Society for Biological
Therapy of Cancer
Hematology Association of Ireland
International Society of Biorheology
Cage S. Johnson, MD
Indian Science Congress Association
International Society for Clinical

Densitometry
Vito M. Campese, MD
Hittu Matta, PhD
International AIDS Society

International Association of
Cardiologists
International Association of the

History of Nephrology
Shaul G. Massry, MD
International Association for the

Study of Liver Disease
International Biliary Association

International Diabetes Federation

International Mammalian Genome

Society
International Society for Aerosols in

Medicine
Japan Society of Hepatology

Hypertension in Blacks
Japanese Gastroenterological
Endoscopy Society
Immunopharmacology
Japanese Society of
Gastroenterology
Helen L. Baron, MD
International Society for Interferon

and Cytokine Research
International Society for

Computational Biology
International Society of Nephrology
Vito M. Campese, MD
Shaul G. Massry, MD
Parag Mallick, PhD
Experimental Hematology
Mojtaba Akhtari, MD
International Society of Pleural

Diseases
Gastrointestinal Oncology
Bassam Yaghmour, MD
Diana L. Hanna, MD
International Society for Renal

Nutrition and Metabolism
International Society of Gynecologic

Oncology
Shaul G. Massry, MD
International Society on Thrombosis

and Haemostasis
International Society of Heart and

Michael W. Fong, MD
Sivagini Ganesh, MD
International Society of Heart

Research
International Union Against

Tuberculosis and Lung Disease
Brenda E. Jones, MD
Hypertension
Diana L. Hanna, MD
Japanese Society of Internal

Medicine
Medical Oncology Group of

Australia
Medical Society of the Hospital de

Clinicas Caracas
National Asian Taiwanese Medical

Association
Wei-An Lee, MD
Polish Society of Nephrology
Royal College of Physicians and

Surgeons of Canada
International Stress Management

Association
World Association of Medical

Editors
Stefan Bughi, MD

Committees Held in National, Regional & Professional Societies

David B. Agus, MD
Applied Proteomics, Inc.: Founder and Board of Directors

Council on Foreign Relations: Non-Communicable Disease
Independent Task Force
Peres Center for Peace: Board of Directors
TEDMED: Board of Advisors
World Economic Forum: Vice-Chair, Biotechnology Council
and Chair, Genetics Council, Network of the Global
Agenda Councils on Genetics and the Summit on the
Global Agenda; and Technology Pioneers Committee
PAC-12 Conference: Student Health and Well-Being Board

Member
American Heart Association: Council on High Blood

Pressure
European Association for the Study of Diabetes: Diabetes in
Pregnancy Study Group
Southern California Society of Clinical Hypnosis: Board of
Directors
Ron Ben-Ari, MD
American College of Physicians: Southern California Region

I Governors Advisory Council
Association of American Medical Colleges (AAMC):
Western Region Representative, Continuing Education
and Improvement (CEI), Western Group on Educational
Affairs (GEA) Steering Committee
Collaborative of the AAMC GEA CEI Section Steering
Committee and the Society for Academic Continuing
Medical Education: Joint Working Group
Zea Borok, MD
American Thoracic Society: Chair-Elect, International

Conference Committee
American Association of Clinical Endocrinologists: Pituitary

Scientific Committee
Pituitary Society: Digital Communications Committee
Julia A. Cassetta, MD
Internal Medicine Group: Compensation Committee
American Heart Association: Cardiopulmonary Council
Stefan Bughi, MD
Southwest Oncology Group: Genitourinary Committee

American College of Chest Physicians: Annual Meeting
Abstract Reviewer
American College of Gastroenterology: Clinical Vignettes

Abstract Review Committee
American Society for Gastrointestinal Endoscopy:
Educational Products Committee; and Gastrointestinal
Endoscopy Self-Assessment Program (GESEP) Task
Force
HIV/AIDS Legal Services Alliance: Board Member
Society of General Internal Medicine: Workshop Reviewer;

and Vignette Reviewer, Southern Regional Meeting
Vito M. Campese, MD
Italian American Scientists and Scholars Society Foundation:

Chair
Kidney Foundation of Southern California: Advisory Council
John R. Daniels, MD
Balance Pharmaceuticals: Chair and Director

Endocare: Director
American Association for the Study of Liver Diseases:

Abstract Review Committee, Fibrosis and NonParenchymal Cell Special Interest Group; and Chair,
Federal Agency Liaison Committee
International Society for Hepatic Sinusoidal Research:
Councilor
John A. Donovan, MD
Southern California Society of Gastroenterology: Board

of Councilors; and Co-Director, Annual Post AASLD
Meeting
Tanya B. Dorff, MD
Academic and Community Cancer Research United: CoLeader, GI Disease Group
Rahul N. Doshi, MD
Heart Rhythm Society: Co-Chair, Communications
121

Committee
Remote Healthcare Society: Board of Trustees
Michael P. Dub, MD
AIDS and Cancer Specimen Resource: Reviewer, Research

Evaluation and Decision Panel
AIDS Clinical Trials Group: Safety Monitoring Committee,
Inflammation TSG
International AIDS Society-USA: Working Group on
Guidelines for the Management of Metabolic Disorders
in HIV
International Workshop on Adverse Drug Reactions and
Lipodystrophy in HIV: Scientific Program Committee
Uri Elkayam, MD
American Heart Association: Council on Arteriosclerosis,

Thrombosis and Vascular Biology; and Council on
Clinical Cardiology
Southwest Oncology Group: Co-Chair, Hepatobiliary

Cancers Subcommittee
American College of Physicians: Governors Advisory

Council, Southern California Region
Southern California Lymphoma Group, Inc: Board of
Directors
Amgen: Data Monitoring Committee

Gynecologic Oncology Group: Developmental Therapeutics
Committee
Southwest Oncology Group: Breast Committee; and
Gynecology Oncology Committee
Amir Goldkorn, MD
American Academy of Cancer Research: Membership

Development Task Force
Southwest Oncology Group: Genitourinary Committee
American Heart Association: Council on Basic

Cardiovascular Sciences
Institute for Clinical and Economic Review: California
Technology Assessment Forum
American Association of Cancer Research: Frontiers in

Prevention Program Committee
American Society of Clinical Oncology: Cancer Genetics
Education Committee; and Chair, Cancer Prevention
Committee
American Society of Nephrology: Biosciences Research

Advisory Group
Faculty of 1000: Evaluation Board Member
American Heart Association: Council on Epidemiology

and Prevention; Electrocardiography Task Force; and
Executive Committee
International Society on Hypertension in Blacks: Heart
Failure Council
Howard N. Hodis, MD
American Heart Association: Council on Arteriosclerosis

Hormone Health Network: Educational Council Member
North American Menopause Society: Board Member; and
Panel Member
Paul D. Holtom, MD
United States Pharmacopeia: Keck School of Medicine of

USC Representative
The Obesity Society: Education Committee; and Integrative

Health Task Force
Southern California Clinical and Translational Science
Institute: Reviewer
Henry W. Huang, MD
American College of Cardiology: FDA Network of Experts
American Heart Association: Council on Clinical

Cardiology; and Exercise and Cardio Rehabilitation
Committee
Pacific Lipid Association: Special Populations Committee
Caroline Hwang, MD
Crohns and Colitis Foundation of America: Medical

Advisory Board
Syma Iqbal, MD
American Society of Clinical Oncology: Medical Oncology

Program Committee; and Non-Colorectal Gastrointestinal
Program Committee
Southwest Oncology Group: Esophago-Gastric Task Force;
and Co-Chair, Gastric-Esophageal Subcommittee
Cage S. Johnson, MD
American Society of Hematology: Co-Chair, Ad-hoc

Committee on Minority Recruitment
National Medical Fellowships: Southern California Advisory
Committee
Sickle Cell Disease Association of America: Medical
Research Advisory Committee
Team HEAL: Board of Directors and Vice President
Brenda E. Jones, MD
Barlow Respiratory Research Center: Board of Directors
Chair, Subcommittee on Haemostasis and Thrombosis in

Malignancy
Janssen Pharmaceuticals: Steering Committee
Platelet Disorder Support Association: Medical Advisory
Board
American Heart Association: Cardiopulmonary Council

American Lung Association of California: Research
Fellowship Training Review Committee
Medical Board of California: Expert Reviewer
Vivian Y. Mo, MD
Southern California Clinical and Translational Science

Institute: Reviewer, Committee for Cardiovascular,
Metabolism, and Neuroscience Funding Program
Southern California Rheumatology Society: Program Chair
American Heart Association: Council on Clinical Cardiology
American Diabetes Association: Scientific Sessions

Pregnancy Subcommittee
American Association for the Study of Liver Diseases:

Program Selection Committee
American Gastroenterological Association: Program
Selection Committee
National Kidney Foundation of Southern California:

Scientific Advisory Council
Southwest Oncology Group: Early Therapeutics, Leukemia,

and Lymphoma Committee
Kwang-Jin Kim, PhD
American Physiological Society: Councillor, Epithelial

Transport Group Steering Committee
American Heart Association: Basic Science Council; Fellow,

Council on Clinical Cardiology; and Council on Geriatric
Cardiology
Amlodipine Cardiovascular Community Trial: Steering
Committee
Academic and Community Cancer Research United: GI

Disease Group Committee
American Association for Cancer Research: Grants
Committee, and Scientific Committee
American Cancer Society: Scientific Review Committee
American Society of Clinical Oncology: Program
Subcommittee Colorectal Cancer
Association of Community Cancer Centers: Advisory Board
Committee
Cholangiocarcinoma Foundation: Medical Advisory
Committee
Faculty of 1000: Section Head, Gastrointestinal Cancers,
Gastroenterology & Hematology
Irish Cancer Societys Collaborative Cancer Research
Centers: Oversight Committee
National Cancer Institute: GI Steering Committee; and
Investigational Drug Steering Committee
Southwest Oncology Group: Co-Chair, Correlative Science
Subcommittee; Co-Chair GI Committee; Gastrointestinal
Steering Committee; and Intergroup Chairman
Correlative Science Subcommittee
Western Society for Clinical Investigation Committee
American College of Rheumatology: Manpower and

Workforce Subcommittee for New Accreditation System
National Society of Clinical Rheumatologists: President
American Heart Association: Vice Chair, Council for the

Kidney in Cardiovascular Disease; Great Rivers Research
Committee; and Leadership Committee
American Physiological Society: Joint Program Committee;
Renal Section Awards Committee; and Steering
Committee, Epithelial Transport Group
American Society of Nephrology: Grant Review Committee
Women in Nephrology: President Elect; and Professional
Development Organization Committee
Anne L. Peters, MD
American Diabetes Association/European Association for

the Study of Diabetes: Technology Working Group; and
Writing Group
Endocrine Society: Chair, Diabetes Technology Guideline
Working Group
Vasu Punj, PhD
Portuguese Foundation for Science and Technology: Peer

Grant Review Committee
Renli Qiao, MD, PhD
American College of Chest Physicians: Executive

Committee, Second Chest World Congress; and Global
Advisor, International Reagents Committee
American College of Chest Physicians/Chinese Thoracic
Society: Chair, Joint Steering Committee for Subspecialty
Training in PCCM
Chinese Association of Medical Doctors: Committee on
Medical Subspecialty Training
California Cancer Consortium with Pittsburgh: Co-Leader,

Genitourinary Cancer Committee
Southwest Oncology Group: Professional Review/Standards
Committee; and Advanced Prostate Cancer Organ Site
Chair, Genitourinary Cancer Committee
American Heart Association: Council on Circulation;

Council on Clinical Cardiology; and Griffith
Commission, Greater Los Angeles Affiliate
American Thoracic Society: Program Committee, Assembly

on Critical Care
American Society of Hematology: Education Committee

International Society of Haemostasis and Thrombosis: Co-
122
American Cancer Society: Advisory Committee, San Gabriel

Valley Division; Health Promotions Advisory Group;
Honorary Life Board Member, California Division; Los
Angeles Regional Council; and Chair, Reach to Recovery
Advisory Group
American Cancer Society Cancer Action Network: Chair,
Board of Directors

Southwest Oncology Group: Breast Committee
Anisa Shaker, MD
American Gastroenterological Association: Institute Abstract

Review Committee
St. Jude Medical: CardioMems Post Approval Study Steering

Committee
Peter A. Singer, MD
American Association of Clinical Endocrinologists: Board

of Directors
American Thyroid Association: Clinical Excellence Task
Force; and Trainee and Career Advancement Committee
Viet-American Cervical Cancer Prevention Project: Advisory
Board
Brad Spellberg, MD
Infectious Disease Society of America: Antimicrobial

Resistance Committee
American Thyroid Association: Executive Council;
Laboratory Services Committee; Nominations
Committee; and Public Health Committee
Andrew A. Stolz, MD
American Association for the Advancement of Liver

Diseases: Hepatotoxicity Special Interest Group
Committee
American Federation for Clinical Research: Medical School
Representative
Heidelberger and Wang Scholarships: Review Committee
Prostate Cancer Charity (United Kingdom): Grant Proposal
Reviewer
National Kidney Foundation of Southern California: Board

Member
Southern California Society of Gastroenterology: Councilor,

Governing Board
American Womens Medical Association: Mentor
Vickie Wu, MD
American College of Physicians: Poster Subcommittee

Chair, Southern California Region
Beiyun Zhou, PhD
American Thoracic Society: Program Committee,

Respiratory Cell and Molecular Biology Assembly
American Academy of Pediatrics: Critical Care Section;

Hospital Medicine Section; and Med-Peds Section
National Med-Peds Residents Association: Recruitment
Committee
NIH Study Sections/Noteworthy Government Activities

David B. Agus, MD
National Cancer Institute: Alliance for Nanotechnology in

Cancer; and Physical Sciences in Oncology Steering
Committee
National Institute of Diabetes and Digestive and Kidney
Diseases: External Advisory Committee, Chronic Kidney
Disease Biomarker
NIH: Ad-hoc Member, Cancer Drug Development and
Therapeutics Study Section
Los Angeles County Department of Health Services:

Thought Leaders Group for Diabetes, Clinical Resource
Management

Diagnostic Services Subcommittee; and Multi-Center
Gastroenterology Working Group
Los Angeles County Department of Health Services: Chair,

HIV Best Practices Committee
Los Angeles County Commission on HIV: Commissioner
NIH: AIDS Associated Opportunistic Infections and Cancer

Study Section
National Research Council: Committee to Develop a

Research Strategy for Environmental, Health and Safety
Aspects of Engineered Nanomaterials
Amir Goldkorn, MD
Kwang-Jin Kim, PhD
Neuroblastoma Pediatric Phase I Clinical Trials Consortium:

Data Safety Monitoring Board
Cancer Prevention Research Institute of Texas: Peer Review
Panel
National Heart Failure Biomarker Workgroup
California State Department of Health Services: Ex-Officio

Member, Executive Committee, IMPACT Program
Department of Veterans Affairs: Data Safety Monitoring
Board, Cooperative Studies Program
National Cancer Institute: Online Review Panel, Loan
Repayment Program
National Cancer Institute: Chair, Colorectal Family

Registries Advisory Panel; Chair, Data Safety Monitoring
Board, ID00-109; Rare Tumors Task Force, Head and
Neck Cancer Steering Committee
National Comprehensive Cancer Network: Colon/Rectal
Screening Panel; Genetic/Familial High-Risk Assessment:
Breast and Ovarian; and Genetic Testing Panel
Jorge J. Nieva, MD
National Cancer Institute: Reviewer, IMAT Innovative and

Applied Emerging Technologies in Biospecimen Science;
and Reviewer, Omnibus Special Emphasis Review Panel
Veterans Affairs: Reviewer, Special Emphasis Panel,
Oncology Merit Award
Veterans Affairs: Ad-hoc Reviewer, Nephrology Study

Section
Anne L. Peters, MD
Michael W. Fong, MD
Gregory E. Idos, MD
California Colorectal Cancer Coalition: Board Member
Cheng Ji, PhD
Los Angeles Department of Health Services: Specialty Care

Initiative- Expected Practices for Clinical Care
German-Israeli Foundation for Scientific Research and

Development: Reviewer
NIH: Ad-hoc Member, Research Grant Review Committee
NIH: R01 Grant Ad-hoc Reviewer, Neurotoxicology and
Alcohol Study Section
Qatar Foundation: Reviewing Member
Cage S. Johnson, MD
Arshia Ghaffari, DO
Coalition of National Cancer Cooperative Groups: GI

Scientific Leadership Council
National Cancer Institute: GI National Leadership Group;
GI Steering Committee; and PDQ Voluntary Protocol
Review Board
Veterans Affairs: Merit Review, Oncology Study Section
Howard N. Hodis, MD
National Cancer Institute: Hepatobiliary Cancers Task Force

Oncology Expert Panel
National Cancer Institute: Gynecologic Cancer Scientific
Steering Committee, Cervical Cancer Task Force
California State Department of Health Services: Consultant,

Hypertension Control Program
D. Steven Fox, MD
NIH: Consultant and Reviewers Reserve
American Board of Internal Medicine: Endocrinology

Subspecialty Board
Diabetes Content Team, Clinical Resource Management
NIH: National Heart, Lung and Blood Institute, Data and

Safety Monitoring Board for Evaluating Calitriol and
Heart Outcomes in CKD Patients
American Board of Internal Medicine: Relevance Reviewer

for Cardiovascular Disease Exam
Heart Failure Clinical Content Team, Clinical Resource
Management
California Cancer Consortium: Data Safety Monitoring

Committee
California Department of Health Services: Chair, Advisory

Committee, Genetically Handicapped Persons Program
Los Angeles County Department of Health Services: Patient
Focus Task Force for Laboratory Services
NIH: Ad-hoc Review Panels and National Reviewers
Reserve

Nephrology Specialty Primary Care Workgroup Member
123
American Cancer Society: Clinical Cancer Research and

Epidemiology Study Section
Veterans Affairs: Rehabilitation Research and Development
Section
National Heart, Lung and Blood Institute: Site Visitor

Veterans Administration: Cardiac Surgery Consultants
Committee; Executive Committee, Cooperative Study on
Valvular Heart Disease; and Site Visitor
NIH: Special Emphasis Panel Study Section
Fred R. Sattler, MD
AIDS Clinical Trials Group: Co-Chair, Exercise Sciences

Focus Group; and Inflammation and End Organ Disease
Transformative Sciences Group
Department of Defense and Veterans Association Study
Section: Ad-hoc Member
NIH National Center for Research Resources: Ad-hoc
Member
NIH General Clinical Research Centers Program: Site Visitor
United States Food and Drug Administration: Consultant

Leslie A. Saxon, MD
Left Atrial Pressure Monitoring to Optimize Heart Failure

Therapy (LAPTOP-HF) Clinical Study: Steering
Committee
eHealthcare Steering Committee
NIH: Reviewer, Cardiovascular Sciences Small Business
Study Section
Brad Spellberg, MD
Data Use Executive Committee; eHealthcare Steering

Committee; and ICD-10 Implementation Physician
Champion
NIH: Antibiotic Resistance Leadership Group; and Chair,
Gram Negative Bacteria Review Committee
Andrew A. Stolz, MD
Los Angeles County Department of Health Services: GI

eConsult Steering Committee; and Hepatology eConsult
Steering Committee
NIH General Clinical Research Center: Executive Advisory
Board; and Local Advisory Board
NIH U0-1 Drug-Induced Liver Injury Network: Causality

Assessment Committee; Genetics Committee; HSD
Committee; Co-Chair, Publication/Ancillary Study
Committee
Tuberculosis Trials Consortium: Hepatotoxicity Working
Group
Andrew S. Young, DO
Los Angeles County Department of Health Services: Data

Steward; and Sepsis Waiver Steering Committee
Service on University, School, Hospital & Departmental Committees

Mojtaba Akhtari, MD
Department of Medicine, Division of Hematology: BMT

Steering Committee; and Fellowship Committee
Hoag Memorial Presbyterian Hospital: Healthcare Ethics

Committee; and Interdisciplinary Practice Committee
Keck Hospital of USC: Ad-hoc Infection Control

Committee; and Performance Improvement Committee
Keck School of Medicine of USC: Co-Chair, Quality
Improvement Committee
Keck Hospital of USC: Ad-hoc Subcommittee on Space

Allocation for Outpatient Surgical Procedures; Critical
Care Committee; Endoscopy Committee; Chair, Lung
Transplant Selection Committee; Multi-Organ Transplant
Committee; and Pharmacy & Therapeutics Committee
USC Norris/Cancer Hospital: Pharmacy & Therapeutics
Committee
USC Transplant Institute: Ad-hoc Committee on Space
Allocation
Helen L. Baron, MD
Doctors of USC: Electronic Health Record Planning

Committee and Practice Operations & Development
Committee
Keck Hospital of USC: Chair, Diabetes Instructional Group
for ICU Nurses; Co-Chair, Insulin Error Reduction Team;
Heart & Lung Transplant Team; Medical Error Reduction
Team; Quality Operations & Standards Subcommittee;
and Chair, South ICU Glycemic Control Performance
Group
Keck School of Medicine of USC: Interviewer, Medical
School Admissions
Ahmet N. Baydur, MD
Keck School of Medicine of USC: Respiratory Organ

System Chair, Years I/II Curriculum Revision Committee;
Years I/II Student Performance Evaluation Committee;
and Years I/II Undergraduate Education Committee
USC Southern California Clinical and Translational Science

Institute: Peer Reviewer, Clinical Trials Unit
Ron Ben-Ari, MD
Department of Medicine: Education Committee; Chair,

Resident Patient Safety and Quality Improvement
Committee; and Resident Performance Review
Committee
Keck School of Medicine of USC: Clinical Services Student
Performance Committee; Faculty Advisor, Dinner and
Differential Club; Co-Developer, Four Year Ethics
Curriculum; Graduate Medical Education Steering
Committee; Medical Educators Collegium Executive
Committee; and Year III/IV Clinical Curriculum
Committee
LAC+USC Medical Center: Credentialing Committee,
Attending Staff Association
USC Society of Internal Medicine: Board Member
Emily Blodget, MD
Keck Hospital of USC: Electronic Health Record

Committee; Chair, Infection Control Committee;
Medical Executive Committee; Multi-organ Transplant

Committee; and Subcommittee of Infection Control
Zea Borok, MD
Department of Medicine: Chair, Research Committee,

Division of Pulmonary, Critical Care and Sleep Medicine;
and Interviewer, Internal Medicine Residency Program
Keck School of Medicine of USC: Faculty Research
Council; MD/PhD Executive Committee; Interviewer,
Biomedical and Biological Sciences Programs and MD/
PhD Program and Medical School Admissions
Department of Medicine: Practice Operations and

Development Committee
Keck Hospital of USC: Committee of Champions; Executive
Peer Review Committee; Medical Executive Committee;
Patient Safety and Risk Management Committee; Quality
Subcommittee; and Chair, Utilization Management
Committee
USC: University Committee on Appointments, Promotions

and Tenure
Stefan Bughi, MD
Keck School of Medicine of USC: Medical Educators

Collegium
Rancho Los Amigos National Rehabilitation Center: CME
Committee and Subcommittee; Chair, Department
of Medicine Education Committee; Chair, Graduate
Medical Education Ad-hoc Committee; Medical Records
Committee; and Chair, Physician Well-Being Committee
Department of Medicine: Internal Medicine Residency

Selection Committee
Keck Medical Center of USC: Endoscopy Committee
Keck School of Medicine of USC: Gastroenterology
Fellowship Core Competency Committee; and Medical
School Selection Committee
Department of Medicine: Chair, Practice Operations and

Vito M. Campese, MD
Department of Medicine: Appointments and Promotions

Committee
Keck School of Medicine of USC: Medical Student Research
Committee
USC: Appointments and Promotions Committee; and

Electronic Health Record Planning Committee
USC Norris Cancer Hospital: Chair, Grand Rounds

Committee
USC/Norris Comprehensive Cancer Center: Co-Chair,
Clinical Council; Clinical Investigations Committee;
Executive Committee; Leadership Council;
Redevelopment Council; and Chair, Whittier Initiative
and Tenure, Clinical Science Panel
124
Department of Medicine: Quality Improvement Committee

LAC+USC Medical Center: Medication Reconciliation
Task Force; and Redesign Team Advocate, Primary Care
Continuity Clinics
Keck Medical Center of USC: Rheumatology

Representative, Electronic Health Record Committee
Keck Medicine of USC, Pasadena: Steering Committee
LAC+USC Medical Center: ORCHID Subject Matter
Expert, Electronic Medical Record Committee; and
Rheumatology Representative, Infusion Steering
Committee
Keck Medical Center of USC: Electronic Health Record

Committee
Keck School of Medicine of USC: Internal Medicine
Operations Committee; and Physician Technology
Advisory Group
Keck Medical Center of USC: Board of Directors

USC Care: Executive Committee
Keck School of Medicine of USC: Deans Recognition

Committee
and Tenure
Rahul Dhawan, DO
Department of Medicine: Educational Steering Committee

University of Southern California: Alumni Association
John A. Donovan, MD
Keck Hospital of USC: GI Committee

USC Care: Integrated Credentialing Committee
Tanya B. Dorff, MD
Keck School of Medicine of USC: Medical Student Required

Scholarly Project Committee
USC Norris Cancer Hospital: Chair, Genitourinary Cancer
Clinical Research Operations; and Chair, Quality
Assurance Committee
USC/Norris Comprehensive Cancer Center: Cancer
Investigations Committee
Rahul N. Doshi, MD
Keck School of Medicine of USC: Core Curriculum

Committee, Cardiovascular Medicine
Sonya L. Earley, PA
Keck School of Medicine of USC: Medical School Applicant

Selection Subcommittee
USC/Norris Comprehensive Cancer Center: Data Safety &

Monitoring Committee; Phase I Program Director; and
Quality Assurance Committee
Department of Medicine: Appointments & Promotions

Committee; and Medical Executive Committee
Keck Hospital of USC: Executive Peer Review Committee;
Nominating Committee; Performance Improvement

Committee; Tissue and Transfusion Committee; and
Utilization Management Committee
USC/Norris Comprehensive Cancer Center: Chair, Bylaws
Committee; Clinical Activities Committee; Clinical
Advisory Committee; Executive Committee, Clinical
Cancer Education Program; Medical Executive
Committee; Chair, Subcommittee on Postgraduate
Education University Pathology Associates: Board
Michael W. Fong, MD
Keck Medical Center of USC: Clinical Metrics Workgroup;

Working Group Subcommittee, Electronic Health
Record Planning Committee; Electronic Health Record
Subcommittee, Medical Records Committee; and Quality
Operations and Standards Subcommittee
Keck School of Medicine of USC: Value Analysis
Committee
D. Steven Fox, MD
USC: Pharmacoeconomics Research Design, PhD Screening

Exam Committee
Sivagini Ganesh, MD
Department of Medicine: Clinical Competency Committee

Keck Medical Center of USC: Advanced Lung Disease
Research Program; Heart Transplant & Ventricular
Assist Device Candidate Selection Committee; and Lung
Transplant Recipient Candidate Selection Committee
USC Transplant Institute: Operations Council; and Strategic
Council
Los Angeles University of Best Practices of the California

Right Care Initiative: Faculty Member/Resident
Cardiologist
USC: Institutional Review Board
Institute: External Grant Review Committee
Keck School of Medicine of USC: Associate Director, MD/

PhD Combined Program
USC/Norris Comprehensive Cancer Center: Clinical
Investigation Committee
Amir Goldkorn, MD
Department of Medicine: Interviewer, Internal Medicine

Residency Program
Keck School of Medicine of USC: Interviewer, Hematology/
Oncology Fellowship Program; and Resident Research
Proposal Review Committee
USC: Heidelberger Award Review Committee; and Wright
Foundation Award Review Committee
USC/Norris Comprehensive Cancer Center: American
Cancer Society Institutional Research Grant Review
Committee; Clinical Investigations Committee; and
Leadership Council
Keck Hospital of USC: ETC Steering Committee; and

P-TAG Committee
Keck Medical Center of USC: Co-Chair, Bioethics
Committee
Keck School of Medicine of USC: Ambassadors Program;
Committee for Faculty Tenure and Privileges Appeals;
and Executive Research Compliance Committee
LAC+USC Medical Center: Chair, Credentialing Committee
Keck Medical Center: Quality Leadership Committee; and

Quality Operations and Standards Subcommittee
Cage S. Johnson, MD
Department of Medicine: Clinical Competency Committee,

Division of Pulmonary, Critical Care and Sleep Medicine
Association of Physicians of Los Angeles County Hospital:

Board of Directors
USC Salerni Collegium: Board of Directors
Cynthia H. Ho, MD
Howard N. Hodis, MD
Keck School of Medicine of USC: Head and Neck

Cancer Case Conference; and Director, Thoracic Case
Conference
USC/Norris Comprehensive Cancer Center: Scientific
Review Committee, Clinical Investigation Support
Office; and Translational and Clinical Sciences Program,
Disease-Specific Affinity Team Leader- Lung Cancers
USC PIBBS Graduate Program

Institute: External Review Member
Arshia Ghaffari, DO
Cheng Ji, PhD
Keck Hospital of USC: Board of Directors

USC: Provost Search Committee
USC/Norris Comprehensive Cancer Center: Board of
Directors
Keck School of Medicine of USC: Evaluation and

Recruitment Subcommittee; and Interdisciplinary Practice
Committee
LAC+USC Medical Center: Pharmacy and Therapeutics
Committee
USC/Norris Comprehensive Cancer Center: Cancer
Committee; and Clinical Investigations Committee
Institute: Pilot Funding Review Committee
Keck Medical Center of USC: Electronic Medical Record
Committee; and Practice Operations and Development
Committee
Keck Medical Center of USC: Division Representative,

Electronic Health Records Committee
LAC+USC Medical Center: Critical Care Committee
Keck School of Medicine of USC: Library and Learning

Resource Committee, Medical Faculty Association; Year
I Student Performance Committee; and Year II Student
Performance Committee
LAC+USC Medical Center: Blood Utilization Committee;
Clinical Laboratory Advisory Committee; and Operations
Committee, Internal Medicine Working Group
Alpha Omega Alpha: 4th Year Medical Student Selection

Committee
LAC+USC Medical Center: Clinical Competency
Committee, Pediatric Residency Program and Combined
Internal Medicine/Pediatrics Residency Program;
Faculty Merit Scores Committee; Fetal Infant Child
Ethics Committee, Department of Pediatrics; Program
Evaluation Committee, Pediatric Residency Program and
Combined Internal Medicine and Pediatrics Residency
Program; Residency Selection Committee, Pediatric
Residency Program and Combined Internal Medicine
and Pediatrics Residency Program; Quality Improvement
Committee, Department of Medicine/Pediatrics.
Department of Medicine: Research Advisory Committee

Keck School of Medicine of USC: Ad-hoc Committee for
Faculty Appointments and Promotions; Clinical Research
Committee; Deans Research Cabinet; and Graduate
Student Guidance and Dissertation Committee
LAC+USC Medical Center: Interviewer, Intern and Resident
Applicants
Paul D. Holtom, MD
LAC+USC Medical Center: Chair, Comprehensive

Antimicrobial Utilization Subcommittee; Chair, Infection
Control Committee; Medical Executive Committee; and
Chair, Pharmacy and Therapeutics Committee
Keck Hospital of USC: Bariatric Steering Committee
Eric P. Hsieh, MD
Alpha Omega Alpha: Director, USC Chapter

Department of Medicine: Chair, Education Steering
Committee; and Chair, Internal Medicine Hospitalist
Education Committee
Keck School of Medicine of USC: Admissions Committee;
and Graduate Medical Education Committee
Henry W. Huang, MD
Keck School of Medicine of USC: Radiation Safety

Committee
Douglass B. Hutcheon, MD
Keck School of Medicine of USC: Facilitator, Internal

Medicine Residency Quality Improvement Curriculum
Syma Iqbal, MD
Keck School of Medicine of USC: Graduate Medical

Education Committee; and Quality Assurance Committee
Clinical Investigations Committee; and Associate
Member, Gastrointestinal Cancer Research Program
125
Keck School of Medicine of USC: Chair, Year III/IV

Committee on Performance, Professionalism and
Promotion; and Year III/IV Curriculum Committee
Brenda E. Jones, MD
Department of Medicine: Internal Medicine Education

Committee
Keck School of Medicine of USC: Infectious Disease
Education Officer, Curriculum Revision Committee
Department of Medicine: Fellowship Clinical Competency

Committee, Division of Pulmonary, Critical Care and
Sleep Medicine
Keck Hospital of USC: Code Blue Committee; Chair,
Critical Care Committee; Performance Improvement
Committee; Chair, Pharmacy and Therapeutics
Committee; and Medical Executive Committee

USC Free Radical Institute: Steering Committee
Keck School of Medicine of USC: Ad-hoc Committee for

Evaluations of Promotions
LAC+USC Medical Center: Intern Recruitment Interviewer;
Radiation Safety Committee; and Utilization Review
Case Management Committee
Michael S. Karp, MD
Department of Medicine: Chair, Electronic Health Records

Committee; and Practice Management Committee
Keck Medical Center: Chair, Clinical Practices Committee;
and Physician Technology Advisory Group
Keck School of Medicine of USC: Community Primary Care
and Managed Care Patient Acquisition Committee; Keck
Perioperative Service Redesign Committee; KeckCare
Health Maintenance Redesign Committee; and Patient
Keeper Implementation Committee
USC Center for Implementation Science: Steering
Committee
David M. Kelley, MD
Keck Hospital of USC: Co-Chair, Critical Competency

Committee; and Resuscitation Committee
University of Southern California: Clinical Investigations

Committee; and Chair, Scientific Progress and Accrual
Monitoring Subcommittee
Saro Khemichian, MD
Keck School of Medicine of USC: Practice Operations and

Keck School of Medicine of USC: Practice Operations and

Hospital of the Good Samaritan: Institutional Animal

Care and Use Committee; Chair, Research Advisory
Committee; and Steering Committee, Heart Institute

LAC+USC Medical Center: Vice Chair, Institutional Review

Board
Edward Lee, MD
Keck Medical Center of USC: Core Measures Committee;

Electronic Health Record Subcommittee; and ITIC
Committee
Joshua Lee, MD
Keck Medical Center of USC: Pharmacy and Therapeutics

Committee
USC Academic Senate: Ex Officio, Committee on
Information Services
USC Southern California Clinical Translational Science
Institute: Director, Informatics Core
Keck School of Medicine of USC: Developmental

Therapeutic Search Committee; Deans Ad-hoc Faculty
Appointments & Promotion Committee; Review
Committee for American Cancer Society
University Cancer Center, Dresden, Germany: Scientific
Advisory Board
USC/Norris Comprehensive Cancer Center: Scientific
Director, Cancer Genetics; Clinical Investigations
Committee; and Scientific Review Committee
Keck Hospital of USC: Critical Care Committee; and

Performance Improvement Committee
Keck Medical Center of USC: Lung Transplant Recipient
Candidate Selection Committee
LAC+USC Medical Center: Critical Care Committee, and
Clinical Council Committee

Committee
Planning Committee; Integrated Ambulatory Quality

Committee; and Practice Operations and Development
Committee
LAC+USC Medical Center: Internal Medicine Ambulatory
Clinical Council
Department of Medicine: Post-Graduate Education

Committee
Keck School of Medicine of USC: Hematology Division
Education Officer
Clinical Investigations Committee
USC: Dissertation Committee, PIBBS Cancer Biology

Program; Co-Chair, Women Advancing Together
Workshop; Co-Chair, Women in Health Sciences
Professional Development Luncheon
Mitra K. Nadim, MD
Keck School of Medicine of USC: Year I & II Curriculum

Committee
Minh D. Nguyen, MD
Hoag Memorial Presbyterian Hospital: Pharmacy and

Therapeutics Committee
Keck School of Medicine of USC: Deans Research Cabinet
Jorge J. Nieva, MD

Investigations Committee
LAC+USC Medical Center: House Staff Committee; and

Peer Review Committee
USC Kidney Disease Research Association: Scientific
Advisory Board
Childrens Hospital Los Angeles: Data Safety Monitoring

Committee
Keck Medical Center of USC: Chair, Medical Records
Committee
USC/Norris Comprehensive Cancer Center: Chair,
Informatics Committee; Chair, Leadership Committee;
and Member at Large, Practice Operations and
Department of Medicine: Promotion Review Committee

Keck Hospital of USC: Planning Committee
Keck School of Medicine of USC: Ambulatory Clinic
Advisory Committee
A. Purush Rao, MD
Department of Medicine: Clinical Competency Committee,

Division of Pulmonary, Critical Care and Sleep Medicine;
and Practice Operations and Development Committee
Keck Hospital of USC: Electronic Health Record
Subcommittee; and Lung Transplant Selection Committee
LAC+USC Medical Center: Genetic Counseling

Representative, Commission on Cancer Committee; and
Voting Member, Institutional Review Board
USC: Voting Member, Institutional Review Board
LAC+USC Medical Center: Chapter President, Committee

of Interns and Residents
Keck School of Medicine of USC: Medical Faculty Womens

Association; and USC Ambassador
Department of Medicine: Education Committee

LAC+USC Medical Center: Quality Assurance Committee;
and Standards of Care Committee
Murad Ookhtens, PhD
USC Research Center for Liver Diseases: Executive

Committee
LAC+USC Medical Center: Physician Champion, Cerner

Oncology Module, ORCHID Project; and Physician
Champion, Infusion Center Committee
USC: Vice Chair, Institutional Review Board
USC/Norris Comprehensive Cancer Center: Physician
Champion, Cerner Oncology Module
Ami Oren, MD
Ara B. Sahakian, MD
Keck School of Medicine of USC: Chair, CQI Committee
Keck Hospital of USC: Chair, Endoscopy Committee
Department of Medicine: Interviewer, Internship Program

Keck School of Medicine of USC: Medical Student Research
Committee
Continuing Medical Education: Steering Committee
Daniel P. Martinez, MD
Keck School of Medicine of USC: Representative/Delegate,

Committee of Interns and Residents
Ray V. Matthews, MD
Cardiovascular Thoracic Institute, Keck School of Medicine

of USC: Chair, Clinical Operations Committee; and
Executive Committee
Carlo Medina, MD
Keck Hospital of USC: Antimicrobial Subcommittee

Keck School of Medicine of USC: MD Evaluation and
Recruitment Subcommittee
Keck Hospital of USC: Critical Care Committee

Keck School of Medicine of USC: Radiation Safety
Committee
LAC+USC Medical Center: Radiation Safety Committee
LAC+USC Medical Center: Senior Consultant, OB-Diabetic

Clinic and OB-Medical Problems Clinic
K. Allen Milani, MD
Agnesian HealthCare: System Wide Quality Control

Committee
Vivian Y. Mo, MD
Keck School of Medicine of USC: Electronic Health Record
USC Care: Integrated Ambulatory Quality Committee
Keck School of Medicine of USC: Chair, Musculoskeletal

System Committee
Department of Medicine: Medicine Council/Quality

Assessment and Value Improvement Program; and
Residency Review Committee
Department of Medicine: Interviewer, Internal Medicine

Residency Program
USC Diabetes and Obesity Research Institute: Chair,
Maternal-Child Section
Keck School of Medicine: HEAL (Humanities, Ethics, Art

and the Law) Curriculum Committee
Keck School of Medicine of USC: Nephrology Applicant

Selection Committee; and Nephrology Fellowship
Interviewer and Ranking Committee
Anne L. Peters, MD
University of Colorado: Scientific Advisory Board, Center

for Womens Health Research

Investigations Committee; and Leadership Council
126
Department of Medicine: Educational Steering Committee

Keck Medical Center of USC: Electronic Medical Record
Task Force
LAC+USC Medical Center: Clinical Competency

Committee; Combined Internal Medicine and Pediatrics
Graduate Medical Education Committee; Chair,
Education Steering Committee; Health Information
Committee; Internal Medicine Inpatient Clinical
Council; Medical Executive Committee, Attending Staff
Association; and Co-Chair, Residency Performance
Review Committee
Fred R. Sattler, MD

Keck School of Medicine of USC: Graduate Student PhD
Committee
LAC+USC Medical Center: Antimicrobial Subcommittee
Leslie A. Saxon, MD

Committee
Keck School of Medicine of USC: Physician Technology
Advisory Group
University of Colorado: Scientific Council, Center for
Womens Health Research
USC: Clinical Research Faculty Advisory Committee;
mHealth Collaboratory Steering Committee; and
University Committee on Appointments, Promotions and
Tenure, Clinical Sciences Panel
USC Office of the Provost: Non-Tenure-Track Promotions
Committee

Hoag Hospital: Infectious Disease Committee; and Sedation

Committee
and MD/PhD Committee

Institute: Advisory Committee, Center for Human Studies
Aaron D. Storms, MD
Keck School of Medicine of USC: Critical Care Committee;

and Risk Management & Patient Safety Committee
LAC+USC Medical Center: STEMI Receiving Center
Committee
LAC+USC Medical Center: Cancer Committee; Ethics

Resource Committee; and Organ and Tissue Donation
Committee
Andrew A. Stolz, MD
Department of Medicine: Practice Operations Committee

Keck School of Medicine of USC: Bariatric Surgery Steering
Committee, Cardiovascular; Evaluation and Treatment
Center Steering Committee; and Integrated Credentialing
Committee
Department of Medicine: Chair, Appointments and

Promotions Committee
Division of Gastrointestinal and Liver Diseases: Executive
Committee; and Co-Chair, Fellowship Applicant Review
Committee
Keck School of Medicine of USC: Faculty Appointments,
Promotions and Tenure Committee
USC Research Center for Liver Diseases: Executive
Committee; and Screening Committee, Pilot and
Feasibility Letters of Intent
Institute: Reviewer
Peter A. Singer, MD
Anil Tulpule, MD
Sylvia J. Shaw, MD
Rancho Los Amigos National Rehabilitation Center: Medical

Education Committee; and Secondary Case Reviewer,
Utilization Committee
Keck School of Medicine of USC: Compliance Committee;

and Practice Operations & Development Committee
Keck Hospital of USC: Subcommittee on Infection

Prevention
LAC+USC Medical Center: Clinical Council Committee,
Department of Medicine; Institutional Review Board;
Peer Review Committee; and Quality Assessment and
Value Improvement Committee
Brad Spellberg, MD
Keck School of Medicine of USC: Interviewer, Medical

School Admission
Edy E. Soffer, MD
Keck School of Medicine of USC: Anesthesiology

Department Chair Search Committee; Emergency
Medicine Department Chair Search Committee; and
Psychiatry Department Chair Search Committee
LAC+USC Medical Center: Graduate Medical Education
Committee; Infection Control Committee; Medical
Executive Committee; Pharmacy and Therapeutics
Committee; Quality Improvement Committee; and Senior
Executive Committee
Darcy V. Spicer, MD
Keck School of Medicine of USC: Scientific Conduct

Committee
USC Norris Cancer Hospital: Pharmacy and Therapeutics
Committee; Professional Staff Review Committee; and
Quality Assurance Committee
USC: Institutional Review Board, Research Review
Subcommittee

Committee
Keck School of Medicine of USC: Ad-hoc Committees for
Evaluation of Faculty Promotion; Admissions Committee;
Huntington Memorial Hospital: Gastroenterology Section

Keck Medical Center of USC: Chair, Endoscopy Committee;
Chair, Hospital Laser Safety Committee; and Value
Analysis Steering Committee
USC/Norris Comprehensive Cancer Center: Gastrointestinal
Cancers Program
Subcommittee; Medical Records Committee; and

Performance Improvement Committee
Keck Medical Center of USC: EMR Compliance Committee;
and Associate Medical Director, Information Services
(Inpatient Core)
Darren W. Wong, MD
Keck Medical Center of USC: Antimicrobial Stewardship

Committee
LAC+USC Medical Center: Antibiotic Subcommittee;
Antimicrobial Stewardship Committee; and Infection
Control Subcommittee
Vickie Wu, MD
Keck Hospital of USC: Infection Control Committee; and

Pressure Ulcer Committee
Andrew J. Yoon, MD
Keck Hospital of USC: Heart Transplant Selection

Committee
Keck School of Medicine of USC: Evaluation and
Recruitment Subcommittee
Andrew S. Young, DO
LAC+USC Medical Center: Discharge Planning Process

Workgroup; Chair, Dual Diagnosis Meeting; Health
Information Committee; Chair, Hospital Medicine
Meeting; Internal Medicine Clinical Council; NurseProvider Council; Operational Efficiency Committee;
ORCHID Implementation Project Workgroup; ORCHID
Policy and Procedure Lead; ORCHID Subject Matter
Expert, Patient Portal Group, Provider Workflow Group;
Patient Flow Committee; Resident QI/Patient Safety
Committee; and Utilization Review Committee
Keck Hospital of USC: Endoscopy Committee
Beiyun Zhou, PhD
Keck School of Medicine of USC: Admissions Evaluation

and Recruitment Subcommittee; and Preceptor,
Introduction to Clinical Medicine, Health, Technology
and Engineering Group
Hoag Memorial Presbyterian Hospital: Oncology

Department Committee
Mabel Vasquez, MD
Keck School of Medicine: Operations Committee

LAC+USC Medical Center: Ethics Resource Committee
Michael D. Wang, MD
Keck Hospital of USC: Physician Champion, Catheter

Associated UTI Prevention Committee; Chair, EHR
Department of Medicine: Research Advisory Committee,

Division of Pulmonary, Critical Care and Sleep Medicine
Keck School of Medicine of USC: Admissions Committee;

Competency-Based Implementation Committee;
Competency Committee for Community and SystemsBased Practice; Curriculum Revision Task Force
Committee; Curriculum Revision Task Force Working
Group for ICM/PPM/Intersessions; Chair, Curriculum
Revision Task Force Working Group for SSP Cases;
Student Affairs Committee; Medical Education
Committee; Year I/II Curriculum Committee; and Year I/
II Student Performance Committee
LAC+USC Medical Center: Medical Executive Committee;
and Trauma Survivor Reunion Planning Committee
Editorial Boards & Editorships

Mojtaba Akhtari, MD
Blood & Lymph
Case Reports in Practice
Chemotherapy
QA Hematology
WedMed Central
Outcomes, Inc., Editor
Zea Borok, MD
American Journal of Physiology: Lung

Cellular and Molecular Physiology
American Journal of Respiratory Cell and
Molecular Biology, Associate Editor
Stefan Bughi, MD
Natural Standard
Portugese Journal of Gastroenterology
Video Journal & Encyclopedia of GI

Endoscopy
Journal of General Internal Medicine

Journal of Hospitalist Medicine
Endocrinology, Diabetes and Metabolism

Case Reports, Senior Editorial Board
Member
Faculty of 1000- Diabetes and
Endocrinology
Pituitary
American Journal of Cancer Research,

Senior Editor
Blood and Lymphatic Cancer: Targets and
Therapy
Cancer Biology and Therapy
Experimental Biology and Medicine
Hematology and Leukemia, Senior Editor

Hematology and Transfusion International,
Associate Editor
International Archive of Bioscience
International Journal of Blood Research and
Disorders, Editor-in-Chief
International Journal of Microbiology
Journal of Blood Disorders and Therapy
Journal of Cancer Therapeutics and
Research
Journal of Case Reports and Studies
Journal of Gene Therapy
Journal of Hematology, Blood Transfusion
and Disorders
Journal of Hematology and Thrombosis
Journal of Medical Disorders
Oncology Discovery
The Open Leukemia Journal
Research Journal of Infectious Diseases
Sci Forschen Genetics and Gene Therapy
Virology: Research and Treatment
Virology Discovery, Editor-in-Chief
127
Cardiovascular Revascularization Medicine

Journal of Interventional Cardiology
Vascular Disease Management

Clinical and Translational Science
Experimental Lung Research
Tanya B. Dorff, MD
Clinical Genitourinary Cancer, Associate

Editor
Therapeutic Advances in Medical Oncology,
Associate Editor
Uri Elkayam, MD
American Journal of Cardiology

Cardiology
Cardiology in Review
Journal of the American College of
Cardiology: Heart Failure

Cancer Epidemiology, Biomarkers and

Prevention
Cancer Prevention Research
Journal of the National Cancer Institute
American Journal of Physiology: Renal

Physiology
BioMed Research International
Frontiers in Renal and Epithelial Physiology,
Associate Editor
Journal of the American Society of
Nephrology
Association for the Advancement of Medical

Instrumentation
Urban Health
Howard N. Hodis, MD
Menopause
Menopause Management
Journal of Clinical Immunology, Associate

Editor
Journal of Immunology, Associate Editor
Henry W. Huang, MD
Cardiovascular Pharmacology: Open Access

Journal, Editor
Immunology and Immunogenetics Insights
Cheng Ji, PhD
World Journal of Gastroenterology
Cage S. Johnson, MD
Blood Reviews
International Journal of Biomedical Science
American Journal of Physiology

Gastroenterologie Clinique et Biologique
Hepatology
Molecular Hepatology
Pharmacology
Therapeutic Advances in Drug Safety

World Journal of Gastroenterology
Magnesium Bulletin
Nephron
Renal Physiology
Seminars in Nephrology
Kwang-Jin Kim, PhD
Frontiers in Membrane Physiology and

Biophysics
Jorge J. Nieva, MD
Convergent Science Physical Oncology,

Founding Editor
American Journal of Cardiology

Basic Research in Cardiology
Circulation, Guest Editor
International Journal of Impotence Research
Journal of Cardiovascular Pharmacology
and Therapeutics
Life Sciences
Regenerative Medicine
Arthritis Self- Management

Journal of Rheumatology
The Rheumatologist
Yearbook of Medicine, Editor
American Journal of Physiology: Renal

Physiology
Frontiers in Renal and Epithelial Physiology,
Associate Editor
Clinical Cancer Advances, Gastrointestinal

Cancers Section, Editorial Advisor
Clinical Cancer Research
Colorectal Cancer: Index and Reviews,
Editor
European Society for Medical Oncology
Future Medicine, Colorectal Cancer
Gastrointestinal Cancers Symposium Daily
News
International Journal of Cancer, Oncology
Reports
Oncology REALTIME
Onkologie: International Journal for Cancer
Research and Treatment
The Pharmacogenomics Journal, Editor
Sanofi Lilly Oncology
Targeted Oncology
Vasu Punj, PhD
BMC Bioinformatics, Associate Editor

Current Trends in Biotechnology and
Chemical Research
Journal of Hematology and Transfusion
Renli Qiao, MD, PhD
Chinese Journal of Tuberculosis and

Respiratory Medicine
Clinical Respiratory Medicine, Associate
Editor
American Journal of Clinical Oncology

Annals of Oncology
Cancer.net
Clinical Genitourinary Cancer
Therapeutic Advances in Medicine
Therapeutic Advances in Hematology
World Journal of Gastroenterology,

Associate Editor

Current Problems in Cardiology, Editor
Dialogues in Cardiovascular Medicine
Egyptian Heart Journal
Journal of Cardiovascular Magnetic
Resonance
Journal of Clinical and Basic Cardiology
Journal of Clinical and Experimental
Cardiology
Parag Mallick, PhD

BMC Systems Biology
Shaul G. Massry, MD
American Journal of Kidney Diseases

Contributions to Nephrology
Journal of Heart Valve Disease

Journal of Saudi Heart Association
Cancer Information Database on Breast

Cancer, American Cancer Society, Editor
Frontiers in Gastroenterology
Journal of Medical Virology
Leslie A. Saxon, MD
Cardiology News
Journal of Cardiovascular Electrophysiology
Now-Up-To-Date
Cardiology Clinics, Associate Editor

Current Medical Research and Opinion
Heart, Deputy Editor
Journal of Cardiovascular Pharmacology
and Therapeutics
Miroslaw Smogorzewski, MD, PhD
American Journal of Nephrology, Associate

Editor
Mineral and Electrolyte Metabolism,
Associate Editor
Brad Spellberg, MD
Journal of Infectious Diseases
Autoimmunity, Associate Editor

Journal of Immunology, Section Editor
Clinical Gastroenterology and Hepatology
Michael D. Wang, MD
Hospital Medicine Review

Cure Magazine
Beiyun Zhou, PhD
Pulmonary Research and Respiratory

Medicine- Open Journal
International Lectures
Anne L. Peters, MD
Euglycemic DKA Associated with SGLT-2 Inhibitors in T1D. EASD Annual Meeting,
Stockholm, Sweden, 9/18/2015.
Howard N. Hodis, MD
Late vs. Early Estradiol Hypothesis of Postmenopausal Hormone Replacement Therapy. XI

Congreso Colombiano de Menopausia,Cartagena, Colombia, 3/19-21, 2015.
Postmenopausal Hormone Replacement Therapy for the Primary Prevention of
Coronary Heart Disease: Have we Come Full Circle? XI Congreso Colombiano de
Menopausia,Cartagena, Colombia, 3/19-21, 2015.
Risks and Benefits of Hormone Replacement Therapy: Facts and Perceptions. XI Congreso
Colombiano de Menopausia,Cartagena, Colombia, 3/19-21, 2015.

Prospective Controlled Trial of Narrow Band Imaging for Detection of Gastric Cancer
Precursors. United European Gastroenterology Meeting, Barcelona, Spain, 10/26/2015.
Aortic Stenosis: An Update. In Las Leyendas de la Cardiologia, Congreso Anual de

Cardiologia Internacional 2015, Guadalajara, MX, 2/19/2015.
Hibernating Myocardium. In Las Leyendas de la Cardiologia, Congreso Anual de Cardiologia
Internacional 2015, Guadalajara, MX, 2/19/2015.
Choice of Prosthetic Heart Valves in Adults. In New horizons in Cardiovascular Interventions,
Congreso Anual de Cardiologia Internacional 2015, Guadalajara, MX, 2/20/2015.
Leslie A. Saxon, MD
The Future of Medicine: Informatics, Imaging and Computing. 2015 USC Global Conference,
Grand Hyatt, Shanghai, China, 10/31/2015.

Helen L. Baron, MD
Emerging Basil Insulins: Changing the Clinical Landscape. National Endocrinology Congress
of Peru, Lima, Peru, 10/15/2015.
Invited Keynote Talk. Japan Digestive Disease Week, Tokyo, Japan, 10/2015.
Retinoid Regulation of Hepatic Antiviral Innate Immunity. Biomedical Research Centre

Seminar Series, University of British Columbia, Vancouver, BC, Canada, 4/2015.
RNA Patters Sensed a Non-Self. Acuitas Therapeutics Science Day 2015, Vancouver, BC,
Canada, 4/2015.
Anisa Shaker, MD
The Esophagiome: What is the Impact of Provocative Testing on Esophageal Sensory

Pathways? Monaco 13th World Conference OESO, Grimaldi Forum, Monaco, 9/1/2015.
The Esophagiome: Can Modulation of the Parasympathetic Nervous System be used to Treat
Esophageal Hypersensitivity? Monaco 13th World Conference OESO, Grimaldi Forum,
Monaco, 9/1/2015.
The Esophagiome: What is the Role of Stromal Cells as Immunomodulators? Monaco 13th
World Conference OESO, Grimaldi Forum, Monaco, 9/2/2015.
128

Edy E. Soffer, MD
Personalising Treatment in mCRC. Merck Serono, Great Britain, London, 1/28-2/1/2015.

Advances in Management of mCRC: Role of Cetuximab as 1st Line Targeted Therapy in
mCRC. Saudi mCRC International Tour, Merck Serono, Riyadh and Jeddah, Saudi Arabia,
2/15-19/2015.
Molecular Biology and Impact on Individual Outcome. The Metastatic Colorectal Cancer:
Patient First. Accademia, Nazionale di Medicina, (ACC M MED), Milan, Italy, 3/67/2015.
Next Generation Personalized Medicine in US: 4th Meeting on External Quality Assessment
in Molecular Pathology. The Italian Association of Medical Oncology (AIOM), Naples,
Italy, 4/9-11/2015.
Diagnostik Und Therafie Von Kolon Krabs. Roche Pharma AG, Basel, Switzerland,
5/5-10/2015.
Stivarg New Strategies in mCRC Treatment (Regorafenib Efficacy and Safety): Interactive
Session Regorafenib Patients Profile and Real Cases. Bayer Middle East FZE KSA,
Jeddah, Saudi Arabia, 5/13-16/2015.
Personalised Therapy in mCRC Prolonging OS: Implementing the Evidence, Personlising
Therapy in mCRC. Merck Serono, Dublin, Ireland, 6/23-27/2015.
Revealing the True Benefit of Personalized Medicine; mCRC Myth-Busters: Separating
Fact from Fiction, Satellite Symposium Held in Conjunction with the ESMO 17th World
Congress on Gastrointestinal Cancer. Merck Serono, Barcelona, Spain, 7/3/2015.
Where Will We Go From Here? Better Selection, Improved Therapies? Proceedings of ESMO
17th World Congress on GI Cancer, Barcelona, Spain, 7/3/2015.
Biomarker and its Impact to Clinical Therapy in mCRC. Erbitux 10 Years Anniversary
Summit, Zhejiang, China,7/15-18/2015.
What Has Been Presented at ECC 2015 that Can Be Considered Practice Changing for
Patients with mCRC? Global Erbitux Advisory Board. Merck Serono during the 18th
ECCO 40th ESMO European Cancer Congress in Vienna, Austria, 9/24-29/2015.
The Future of Cooperative Groups in the US. 50 Years Anniversary SAKK, DGHO
Symposium. Schweizeriche Arbeitsgemeinschaft fu Klinische krebsforschung, Berne,
Switzerland, 10/12/2015.
Does Changing Bolus Consistency Provide Added Information on Esophageal Symptoms and
Contractile Pattern? OESO, 13th World Conference the Esophagiome, Monaco, 9/2015.
How Helpful is Esophageal Acid Perfusion as a Provocative Test? OESO, 13th World
Conference the Esophagiome, Monaco, 9/2015.

Internal Medicine
Aaron D. Storms, MD
Un Viaje Inesperado: Trayectoria de la Medicina Clnica a la Salud Pblica Global.

Universidad Panamericana Medical School, XVIII Annual Research Symposium, Mexico
City, Mexico, 4/24/2015.
Hematology
Current and Emerging Therapies for Immune Thrombocytopenia (ITP): Role of TPO
Agonists. CEMA Conference, Cancun, Mexico, 3/7/2015.
A Functional Genomic Screen to identify Peptide Modulators of NFkB links Inflammation to

Carcinogenesis. University of Toronto, Canada, 1/16/2015.
Ilene C. Weitz, MD
New Concepts in Thrombotic Microangiopathies. QE II Health Science Center, Division of

Hematology and Hematopathology, Halifax, Nova Scotia, 3/6/2015.
Integration of Genetic Testing and Counseling into the Oncologic Care of Underserved Breast
and Ovarian and Cancer Patients: The LAC+USC Experience. Italy-USC Meeting Instituto
Tumori Hereditary Breast and Ovarian Cancers: Networking to Address Biological and
Therapeutic Challenges, Bari, Italy, 2015.
AMPK-dependent Regulation of ENaC. Invited Symposium Presenter, 8th International

Symposium Aldosterone, MR, and Salt Whats new?, Zermatt, Switzerland, 10/2015.
Mitra K. Nadim, MD
Persistant Acute Kidney Injury and Renal Recovery. 16th International Acute Dialysis Quality
Initiative Meeting (ADQI), 11/2015.
Oncology
Tanya B. Dorff, MD
Radium223: Optimizing its use for the Future and Moving Sipuleucel-T Forward. Summit on
GU Malignancies, Banff, Canada, 10/2015.
Individualizing the Treatment of Early Stage Breast Cancer: Understanding the Patients
Tumor Biology. Cancer de Mama 2015 Avancos e Perspectivas, Hospital Sirio-Libanes.,
Sao Paulo, Brazil, 6/26/2015.
Tailored Medicine for Breast Cancer: Its a New Day. Cancer de Mama 2015 Avancos e
Perspectivas, Hospital Sirio-Libanes, Sao Paulo, Brazil, 6/26/2015.
Improving Outcomes in HER2neu Early and Advanced Breast Cancer. IMPANGO Making
Africa Paramount in Global Oncology, Naivasha, Kenya, 9/12/2015.
HCC Scientific Advisory Committee: International Liver Cancer Associate (ILCA) 9th
Annual Conference, Paris, France, 9/4-7/2015.
Current and Emerging Immuno-Oncology Clinical Research in HCC. Bristol-Myers Squibb
Symposium: Emerging Research in Immuno-Onolcogy: Hepatocellular Carcinoma during
the International Liver Cancer Associate (ILCA) 9th Annual Conference, Paris, France,
9/6/2015.
Renli Qiao, MD, PhD
Mechanical Ventilation. Anzhen Respiratory and Critical Care Forum, Beijing, China,
4/11/2015.
Pulmonary Embolism in 2015. Anzhen Respiratory and Critical Care Forum, Beijing, China,
4/11/2015.
Why China Needs PCCM Subspecialty Training. Northwest Jiaotong University Medical
College, XiAn, China, 4/14/2015.
The Science Behind PCCM Fellowship Training. Second General Assembly, Chest and CTS
Joint Steering Committee on PCCM Fellowship, Prime Hotel, Beijing, China, 4/1718/2015.
Pulmonary Hypertension in COPD. Anzhen PCCM Symposium, Anzhen, China, 4/25/2015.
The Evolving Concept of Cor Pulmonale. Best of Chest Joint Symposium ACCP-CTS,
Beijing, China, 7/16/2015.
A Days Life of a PCCM fellow. Invited Speech, The 16th Annual Congress, Chinese
Thoracic Society, Guiyang, Guizhou, 9/4/2015.
Quantification of Critical Medicine. 16th Annual Conference, Chinese Thoracic Society,
Guiyang, Guizhou, 9/4/2015.
TILs and Tumors: Using Genetics to Decipher Colorectal Cancer. CHS National Israeli
Cancer Control Center, Haifa, Israel, 7/22/2015.
Global Epidemiology of Colorectal Cancer: Strategies to Improve Prevention and Cures.
Navigating Cancer Care by Early Detection and Prevention 3rd International Oncology
Conference, Sheikh Nahayan Mabarak Al-Nahayan, Abu Dhabi, United Arab Emirates,
9/10/2015.
CALGB: First-Line anti-EGFR or Anti-VEGF Agents in Combination with Chemotherapy

for Patients with RAS Wild-Type mCRC. Scientific lecture, Implementing the Evidence:
Invited Lectures
Philip M. Chang, MD
Same-Day Discharge for Devices: How Does It Work? Allied Professionals Forum, Heart
Rhythm Society 36th Scientific Sessions, Boston, MA, 5/15/2015.
Michael W. Fong, MD
Updates in Heart Failure with Preserved Ejection Fraction. White Memorial Medicine Lecture
Series. White Memorial Hospital, Los Angeles CA, 2/5/2015.
Destination Mechanical Circulatory Support. Keck School of Medicine, Division of

Nephrology Grand Rounds, Los Angeles, CA, 2015.
Heart Failure Clinics: The Evidence, the Need and the Redesign, Trends in Cardiovascular
Medicine for the Primary Physician. Renown Institute for Heart and Vascular Health, Reno
NV, 2015.
Heart Failure: Guideline Directed Therapy. Department of Medicine Grand Rounds, Fountain
Valley Regional Hospital, Fountain Valley, CA, 2015.
Heart Failure: New Developments. Division of Cardiology Grand Rounds, Hollywood
Presbyterian Medical Center, Los Angeles, CA, 2015.
Heart Failure: State of the State. Department of Medicine Grand Rounds, Annenberg Center
for Health Sciences, Eisenhower Medical Center, Palm Springs, CA, 2015.
Mechanical Circulatory Support: Who, When, How, The State of Heart Failure: A Look
at Current Issues and the Future of Care. Los Angeles Heart Failure Symposium, Los
Angeles, CA, 2015.
Too Many Biomarkers to Count: Sorting Out Which May Be Best for Heart Failure, Trends
129

in Cardiovascular Medicine for the Primary Physician. Renown Institute for Heart and
Vascular Health, Reno NV, 2015.
Triggers of Cardiovascular Events. Huntington Memorial Hospital, Pasadena, CA, 3/6/2015.

Coming to Grips with Stable Ischemic Heart Disease: Adopting New Guidelines, Absorbing
New Insights. Medical Grand Rounds, Good Samaritan Hospital, Los Angeles, CA,
3/25/2015.
Stable Ischemic Heart Disease: General Medicine Practices for Healthcare Providers.
California Northstate University, Elk Grove, CA, 4/22/2015.
Coming to Grips with Stable Ischemic Heart Disease: Adopting New Guidelines, Absorbing
New Insights. Valley Hospital Medical Center, Las Vegas, NV, 4/22/2015.
Testosterone Therapy and the Heart. American Society of Hypertension. Thirtieth Annual
Scientific Meeting, NY, NY, 5/16/2015.
Translational Efforts within Cardiovascular Research. Translational Medicine Symposium:
Engineering the Future of Medicine, UC San Diego School of Medicine, San Diego, CA,
5/21/2015.
Best Practices in SIHD Management: Advancing a Partnership Between Patients, Physicians,
and the Heart Care Team. Cardiology Napa Valley, 2015 Symposium, Piedmont Heart
Institute and Mount Sinai, Napa, CA, 6/3/2015.
Triggers of Cardiovascular Events. Harbor UCLA Cardiology Grand Rounds, Torrance, CA,
6/23/2015.
Cell Therapy for Myocardial Infarction. Huntington Medical Research Institutes/Huntington
Memorial Hospital, Pasadena, CA, 6/30/2015.
Research Process. Huntington Medical Research Institute, Pasadena, CA, 7/9/2015.
Epidemiology, Pathophysiology and Therapeutic Targets in SIHD. California Northstate
University, Elk Grove, CA, 7/16/2015.
Use of Neonatal Cardiomyocyte Transplants into the Aorta and Vena Cava as Biologic
Pumps. TERMIS World Congress, Boston, MA, 9/10/2015.
Biologic LV Assist Devices. Keck School of Medicine at USC; LAC/USC Cardiology
Lecture; Los Angeles, CA, 9/23/2015.
Primer on Cardiac Phsyiology. Caltech Med E101, Caltech, Pasadena, CA, 10/1/2015.
Novel Approaches to Myocardial Salvage. TCT 2015, San Francisco, CA, 10/11/2015.
Interventional Heart Failure: State of the art. TCT 2015, San Francisco, CA, 10/12/2015.
Introduction to ECG and arrhythmias. Caltech Med E101, Caltech, Pasadena, CA,
10/13/2015.
Electrocardiogram and Telemetry Clinical Pearls. American College of Physicians, Internal

Medicine Meeting Pre-Course, Boston, MA, 4/29/15.
Ray V. Matthews, MD
Update in TAVR Transcatheter Aortic Valve Replacement. Citrus Valley Medical Center,
Covina, CA, 4/2015.
Update on Diagnosis and Therapy. 19th Annual Heart Failure Conference 2015, Los Angeles,
CA, 4/2015.
Science of Hemodynamic Support: A Review of Hemodynamic Support Principles and
Cardiac Support Strategies. ABIOMED, Tustin, CA, 11/2015.
Vivian Y. Mo, MD
Echocardiography Evaluation of the Aortic Valve. Aortic Valve Workshop for Cardiothoracic
Surgeons, Los Angeles, CA, 10/2015.
Hibernating Myocardium: An Update. Milwaukee Heart Institute, University of Wisconsin

Milwaukee Campus, Milwaukee, WI, 5/12/2015.
Lipid Management: Recent Recommendations. St Lukes Medical Center, University of
Wisconsin Milwaukee Campus, Milwaukee, WI, 5/13/2015.
How to Keep Your Heart Healthy. Mountview Senior Retirement Community, Montrose, CA,
2/17/2015.
Love Your Heart. Soroptimist International of Glendale, Oakmont Country Club,
Glendale,CA, 2/19/2015.
Heart Disease in Women. Medicine Grand Rounds, Henry Mayo Newhall Memorial Hospital,
Valencia, CA, 2/25/2015.
Cardiovascular Disease in Women: Understanding the Risk Factor. Health Talk, Verdugo Hills
Hospital, Glendale CA, 3/27/2015.
How Practicing Physicians Manage Their Practices. Keck School of Medicine-Deans Panel,
Los Angeles, CA, 3/31/2015.
Knowing Your Numbers: Heart Disease in Women. American Heart Association CEO
Breakfast, Los Angeles Chapter, Los Angeles, CA, 6/10/2015.
Anatomy of the Heart. Camp Cardiac for High School Students, Los Angeles, CA, 7/13/2015.
The Beating Heart. La Canada Elementary School, La Canada, CA, 2015.
Andrew J. Yoon, MD
Basics of the Stress Test and Myocardial Perfusion Imaging. Pediatric Cardiology Fellows
Conference, Childrens Hospital Los Angeles, Los Angeles, CA, 3/2015.
Magnetic Resonance Imaging When and How to Use it for Diagnosis and Assessment of
Prognosis in Patients with Heart Failure. 19th Annual Heart Failure Symposium 2015,
Update on Diagnosis and Therapy, Los Angeles, CA, 4/2015.

Helen L. Baron, MD
Evaluating GLP1 Receptor Agonist Therapy. PRIMED, Anaheim Convention Center,

Anaheim, CA, 4/10/2015.
Diabetes & Insulin Therapy. Dr. Min Cha Medical Group, Los Angeles, CA, 4/28/2015.
Introducing Toujeo (Insulin Glargine Injection) U300. AACE Sanofi Product Theater, Omni
Nashville Hotel, Nashville, TN, 5/15/2015.
Diabetes & Insulin Therapy. MidValley Family Clinic, Albany, OR, 6/30/2015.
Diabetes & Insulin Therapy. Watts Health Center, Los Angeles, CA, 7/8/2015.
Diabetes & Insulin Therapy. South Central Family Health Clinic, Los Angeles, CA, 7/9/2015.
Diabetes & Insulin Therapy. Medical Park Family Care Clinic, Anchorage, AK, 7/30/2015.
Diabetes & Insulin Therapy. Capstone Family Medicine Clinic, Wasilla, AK, 7/31/2015.
Diabetes & Insulin Therapy. Sanford Southpointe Clinic, Fargo, ND, 9/17/2015.
Diabetes & Insulin Therapy. Sanford Wahpeton Clinic, Fargo, ND, 9/17/2015.
Diabetes & Insulin Therapy. Peace Health Endocrinology, Eugene, OR, 10/28/2015.
Diabetes & Insulin Therapy. Sellwood Medical Clinic, Portland, OR, 10/28/2015.
Diabetes & Insulin Therapy. MultiCare Endocrinology, Tacoma, WA, 10/29/15.
Diabetes & Insulin Therapy. Advanced Diabetes & Endocrine Care, Federal Way, WA,
10/29/2015.
Diabetes & Insulin Therapy. MultiCare Internal Medicine, Puyallup, WA, 10/30/2015.
Initiation of Prandial Insulin in Type 2 Diabetes. South Bay Family Health Clinic, Gardena,
CA, 11/13/2015.
The Search for a Minimally Invasive Alternative to Gastric Bypass Surgery. USC Grand
Rounds, Los Angeles, CA, 1/18/2015.
Gestational Diabetes and Beta Cells: Syposium Lecture. American Diabetes Annual Meeting,
Boston MA, 6/5/2015.
Stefan Bughi, MD
Sports Science: Performance Analytics. MIT Sloan Sports Analytics Conference, Cambridge,
MA, 2/27/2015.
Be the Hero of Your Own Health Story. 7th Annual USC Womens Conference, Los Angeles,
CA, 3/5/2015.
Biometrics & Identity: Beyond Wearable. 2015 South by Southwest Confernce, Austin TX,
3/15/2015.
Hot Topics in Tech, Innovation, Culture & Venture Capital. 13th Annual San Diego Venture
Summit, San Diego, CA, 9/25/2015.
Hypoglycemia. Core Lecture to Western University Medical Students, Ranchos Los Amigos
National Rehabilitation Center, Downey, CA, 1/2/2015.
Using Music to Teach Writing Admission orders: Core lecture Co-Presented with Dr Sylvia
Shaw. Rancho Los Amigos National Rehabilitation Center, Downey, CA, 1/28/2015.
Pre-Diabetes : Medical Grand Rounds, Citrus Valley Medical Center, Covina CA, 9/15/2015.
Insulin Resistance, Pre-Diabetes Hypoglycemia: What the Connection? Diabetes Symposium,
Antelope Valley Medical Center, Lancaster, CA, 10/10/2015.
Daily Mindfulness: The Secret of Happiness. Rancho 6th Annual Women Health Conference,
Downey, CA, 10/16/2015.
Physician Wellness: How to Prevent Burnout. Medical Grand Rounds Pacifica Hospital of the
Valley, Sun Valley, CA, 10/29/2015.
Leslie A. Saxon, MD
CardioMEMs HF System: A Novel Approach to Monitoring Heart Failure Patients. Internal

Medicine Grand Grounds, Hemet Valley Medical Center, Hemet, CA, 2/2015.
Reducing Heart Failure Hospital Readmissions with Pressure Guided Therapy: A
New Approach to Improve Patient Outcome. 2015 Congress on Reducing Hospital
Readmissions, Las Vegas, NV, 4/2015.
Management of Acute Coronary Syndromes. Meet the Professor Series, American College of
Physicians (ACP) Annual Meeting, Boston, MA, 5/2015.
Percutaneous Approaches for Mitral Valve Therapies. Keck Medical Center 2nd Annual
Complex Care Symposium, Pasadena, CA, 5/2015.
How to Integrate Innovative Practices to Improve Efficiencies in EP Care. Who to

Defibrillation Test: Whats the Data? Heart Rhythm Society 2014, 35th Annual Scientific
Sessions, Boston, MA, 5/15/2015.
Diagnosis and Management of Anterior Pituitary Failure. USC Chordoma Patient Day, Los
Angeles, CA, 3/14/2015.
Comorbidities of Acromegaly: Focus on Vertebral Fractures. USC Bone Club, Pasadena, CA,
4/8/2015.
Diagnosis and Management of Acromegaly: 10th Annual Contemporary Issues in Pituitary
Disease, Cleveland Clinic, Cleveland, OH, 4/24/2015.
Perioperative and Long-Term Management of Patients with Pituitary Disease. Annual
Southern California Pituitary Symposium at USC, Los Angeles, CA, 5/9/2015.
Step Wise Approach to The Diagnosis of Cushings Disease. Annual Southern California
Pituitary Symposium at USC, Los Angeles, CA, 5/9/2015.
Subclinical Cushings Syndrome: Endocrinology Grand Rounds. Cedars-Sinai Medical
Center Los Angeles, CA, 5/12/2015.
Subclinical Cushings Syndrome: A Critical Analysis. American Association of Clinical
Endocrinologists - National Annual Meeting, Nashville, TN, 5/17/2015.
Hypopituitarism after Traumatic Brain Injury: Diagnosis and Management of Pituitary
130

Deficiencies. American Association of Clinical Endocrinologists - California Annual
Meeting, Newport Beach, CA, 9/13/2015.
Endoscopy, Torrance, CA, 9/25/2015.

Management of Acute Pancreatitis. New Paradigm in the Management of Pancreatitis
Symposium, Hoag Presybterian Hospital, Irvine, CA, 10/7/2015.
Insulin Sensitivity and -cell Function are Reduced in Children Exposed to Gestational
Diabetes in utero. American Diabetes Association Scientific Sessions, Boston, MA,
6/2015.
Lily Dara, MD
Anne L. Peters, MD
Southern California Society of Gastroenterology Post Digestive Disease Week Continuing

Medical Education Symposium, Dana Point, CA, 6/2015.
Reducing CVD Risk in the Management of T2DM. Right Care Initiative University of Best
Practices, Los Angeles, CA, 1/30/2015.
Novel Therapy Highlights. Endocrine Society Annual Meeting, San Diego, CA, 3/4/2015.
Community-Based Diabetes Management. Endocrine Society Annual Meeting. San Diego,
CA, 3/5/2015.
Applying the Evidence for GLP-1 Receptor Agonists. Endocrine Society Annual Meeting.
San Diego, CA, 3/6/2015.
Principles of Diabetes Prevention. USC School of Gerontology Annual Retreat, Rancho, CA,
3/21/2015.
Treatment of T2DM Using GLP1-RAs. Primed Meeting, Anaheim, CA, 4/9/2015.
Transitioning Care. Scripps Annual Diabetes Symposium, San Diego, CA, 4/16/2015.
Updates on Diabetes Management. Scripps Annual Diabetes Symposium, San Diego, CA,
4/17/2015.
Use of GLP-1 RAs. AADE Annual Meeting, Orlando, FL, 4/18/2015.
A Diabetologists Perspective on T1D Treatment. Helmsley T1D Exchange Meeting, Boston,
MA, 4/30/2015.
Update on CVD Risks and Benefits of T2D Medications. Torrance Memorial Annual CVD
Symposium, Torrance, CA, 5/8/2015.
A Clinicians Perspective on T1D Care. Cavendish Global Conference, San Diego, CA,
5/13/2015.
Interactive Diabetes Case Presentation and Program Chair. AACE Annual Meeting, Nashville,
TN, 5/14/2015.
Transitioning Care, Technology and SGLT-2 Inhibitors. Visiting Professor, University of
Chicago, Chicago, IL, 5/18/2015.
Transitioning Care and Euglycemic DKA with SGLT-2 Inhibitors. Visiting Professor,
University of Florida, Gainesville, FL, 5/27/2015.
HCP Perspective on the Artificial Pancreas. ADA National Meetings, Boston, MA, 6/5/2015.
CVD in Women: Role of Glycemia. ADA National Meetings, Boston, MA, 6/6/2015.
Rationale Behind Use of Basal Insulin in T2D. ADA National Meetings, Boston, MA,
6/7/2015.
Combined Targeted Approaches for the Treatment of Type 2 Diabetes: The Role of the
Kidney. Nevada Association of Family Practitioners. Las Vegas, NV, 8/1/2015.
Update on the Management of T2DM. American Association of Family Practitioners, Annual
Meeting, Denver, CO, 9/30/2015.
Paving the Way to Patient Acceptance, Adherence and Satisfaction: The Role of NextGeneration Insulin Therapies. Annual Cardiometabolic Health Conference, Boston, MA,
10/23/2015.
The Evolution of Insulin Therapy: New Developments in Treatment, Technology, and
Methods of Administration. Annual Cardiometabolic Health Conference, Boston, MA,
10/24/2015.
Update on the Use of Technology in the Treatment of Type 2 Diabetes. Annual
Cardiometabolic Health Conference, Boston, MA, 10/24/2015.
Published Cases of SGLT2 and DKA. AACE Conference on DKA and SGLT-2 Inhibitors,
Dallas, TX, 10/25/2015.
New Medications in the Management of Diabetes in Adults. Optum Medical Directors
Conference, Las Vegas, NV, 11/5/2015.
Non-Insulin Approaches to the Management of Type 2 Diabetes. PRIMED Conference, Los
Angeles, CA, 11/10/2015.
Lecture to Trainees: What Thyroid Tests Should I Order? 15th International Thyroid
Congress, Orlando, FL, 10/18/2015.
Meet the Professor Session: Technical and Clinical Implications in Thyroglobulin Assays.
15th International Thyroid Congress, Orlando, FL, 10/21/2015.
Neurocognitive Decline and Dyslipidemia of Obesity. American Academy of Neurology,

Minneapolis, MN, 4/2015.

Fluid and Nutritional Management of Acute Pancreatitis. 22nd International Symposium on

Pancreatic and Biliary Endoscopy, Los Angeles, CA, 1/29/2015.
How to Navigate Chronic Pancreatic Disorders. 22nd International Symposium on Pancreatic
and Biliary Endoscopy, Los Angeles, CA, 1/29/2015.
Stone Extraction: Instruments and Techniques. 22nd International Symposium on Pancreatic
and Biliary Endoscopy, Los Angeles, CA, 1/31/2015.
Pancreas Cysts 2015. Kaiser Los Angeles Grand Rounds, Los Angeles, CA, 4/23/2015.
ASGE Annual Endoscopic Video Forum. American Gastroenterology Association Annual
Meeting, Washington, DC, 5/19/2015.
Premalignant Lesions of the Pancreas: Role of EUS in Diagnosis and Treatment. USC
Symposium Premalignant Lesions of the Gastrointestinal Tract, Liver, and Pancreas:
Standard of Care in 2015, Pasadena, CA, 7/18/2015.
Methods to Prevent Post-ERCP Pancreatitis. Harbor UCLA Symposium on Interventional
Liver Sinusoidal Endothelial Cell Progenitor Cells and Liver Regeneration. Columbia
University Medical Center, New York, NY, 6/1/2015.
Liver Sinusoidal Endothelial Cells and Liver Regeneration, Pediatric Acute Liver Failure of
Undetermined Cause: A Clinical Research Workshop. NIH-National Institute of Diabetes
and Digestive and Kidney Diseases, Bethesda MD, 10/16/2015.
Liver Sinusoidal Endothelial Cells and Fibrosis, Special Interest Group Program: Antifibrotic
Strategies at the Brink of Translation. American Association for the Study of Liver
Disease, San Francisco, CA, 11/13/2015.
Caroline Hwang, MD
The Impact of Diet on the Pathogenesis and Management of IBD. Oregon Health Sciences
University, Gastroenterology Grand Rounds, Portland OR, 2/2015.
Controversies in Inflammatory Bowel Disease. Southern California Society of
Gastroenterology Post-Digestive Disease Week Symposium, Laguna Niguel CA, 6/2015.
Gregory E. Idos, MD
Premalignant Lesions of the Gastrointestinal Tract, Liver and Pancreas: Standards of Care.
Colorectal Cancer Screening and Surveillance, USC Continuing Medical Education,
Pasadena, CA, 7/18/2015.
Cheng Ji, PhD
Golgi Stress Response is Associated with Anti-HIV Drug-Induced ER Stress and Liver Cell
Injury. American Association for the Study of Liver Diseases 2015, San Francisco, CA,
11/14-18/2015.
Research Seminar, FIU Feinberg School of Medicine, Miami, FL, 2/2015.

Visiting Professor, University of Kansas, Kansas City, MO, 9/2015.
Anisha Shaker, MD
Esophageal Dysphagia: Manifestations and Diagnosis. Medical Speech Pathology Forum,

Keck School of Medicine of USC Premalignant Lesions of the Gastrointestinal Tract,
Liver and Pancreas: Standards of Care in 2015: Advances in the Endoscopic Diagnosis,
Treatment and Surveillance of Barretts Esophagus, Keck School of Medicine of USC,
Edy E. Soffer, MD
Endoscopic Treatment Modalities for Gastroparesis. American Society for Metabolic and
Bariatric Surgery (ASMBS) Obesity Week-End, ASMBS Annual Clinical Symposium,
Las Vegas, NV, 6/2015.
How to Program a Gastric Stimulator. American Society for Metabolic and Bariatric Surgery
(ASMBS) Obesity Week-End, ASMBS Annual Clinical Symposium, Las Vegas, NV,
6/2015.
Pathophysiology of Gastroparesis: American Society for Metabolic and Bariatric Surgery
(ASMBS) Obesity Week-End. ASMBS Annual Clinical Symposium, Las Vegas, NV,
6/2015.
Andrew A. Stolz, MD
Anabolic Steroid-Associated Liver Injury, Liver Injury from Herbal and Dietary Supplements.
NIH-American Association for the Study of Liver Diseases Workshop, Bethesda, MD,
5/4-5/5/2015.
Overview of Current Status of Human, Animal and in Vitro Hepatic Tests Systems,
Hepatotoxicity SIG American Association for the Study of Liver Diseases Meeting, San
Francisco, CA, 11/13/2015.
Biliary Strictures: US, CT, MRCP, EUS, ERCP Whats Appropriate for Diagnosis
and Planning? The Basics of ERCP: Introduction to Endoscopic Ultrasound. 22nd
International Symposium on Pancreatic and Biliary Endoscopy, Cedars Sinai Medical
Center, Los Angeles, CA, 2015.
Colorectal Cancer Screening: Current Evidence-Based Guidelines. Medical Grand Rounds,
Verdugo Hills Hospital, Glendale, CA, 2015.
Controversies in Advanced Endoscopy: Endoscopic Ultrasonography. Annual Post-Digestive
Disease Week Symposium, Southern California Society of Gastroenterology, Laguna
Niguel, CA, 2015.
Premalignant Lesions of the Gastrointestinal Tract, Liver and Pancreas: Standards of Care
2015. The Keck School of Medicine of USC, Pasadena, CA, 2015.

Internal Medicine
Ron Ben-Ari, MD
The Pressure is Still On: Update in Hypertension 2015. USC Contemporary Topics in Internal
131

Medicine, Pasadena, CA, 11/2015.
Michael Hochman, MD
New Models in Primary Care. 2015 Society for Healthcare Strategy and Market
Development, Executive Dialogue, Amelia Island, FL, 3/3-4 2015.
Adult Malnutrition: Physician Awareness and Treatment. Medical Grand Rounds, Glendale
Adventist Medical Center, Glendale, CA, 2015.
Advances in Anti-Obesity Therapeutics. Medical & Surgical Grand Rounds, St. Vincent
Medical Center, Los Angeles, CA, 2015.
Aging Gracefully: Nutrition Support for the Geriatric Patients. 43rd Annual USC Internal
Medicine Conference, Los Angeles, CA, 2015.
Critical Care Nutrition: Promoting GI Tolerance Through Interal Nutrition. Critical Care
Noon Conference, University of Washington Harborview Medical Center, Seattle, WA,
2015.
Medical Nutrition Support for Chronic Kidney Disease. 43rd Annual USC Internal Medicine
Conference, Los Angeles, CA, 2015.
Medical and Surgical Treatment of Adult Obesity. Medical Grand Rounds, Providence Holy
Cross Medical Center, Mission Hills, CA, 2015.
Novel Advances in Obesity Therapeutics. Resident Lecture Series, Keck Hospital of USC,
Los Angeles, CA, 2015.
Nutrition Support for Critical Care. Medical Grand Rounds, Torrance Memorial Medical
Center, Torrance CA, 2015.
Obesity and the Physicians Role and Responsibility. Medical Grand Rounds, St. Frances
Medical Center, Lynwood, CA, 2015.
Physician Awareness and Diagnosis of Malnutrition. 43rd Annual USC Internal Medicine
Conference, Los Angeles, CA, 2015.
Dohwa Kim, MD
Palliative Care CME Conference. Good Samaritan Medical Center, Los Angeles, CA,
4/22/2015.
Edward Lee, MD
Addressing the Quality Gap in Cardiovasular Care in the Developing World. Western
Regional Meeting, American Federation for Medical Research, Carmel, CA, 1/30/2015.
Venous Thromboembolism. 1st Annual USC Contemporary Topics in Internal Medicine,
Pasadena, CA, 11/7/2015.
Eye Conditions for the Generalist. 1st Annual USC Contemporary Topics in Internal
Medicine, Pasadena, CA, 11/2015.
The Upshot to Upkeep, Hot Topics in Primary Care. Jonathan Club Womens Lecture Series,
Los Angeles, CA, 10/2015.
Sunita Puri, MD
Holding Difficult Conversations with Families Who Want Everything Done: Strategies for
Advanced Communication. Los Angeles Internal Medicine Residency Noon Conference
Lecture, Kaiser Permanente, Los Angeles, CA, 1/10/2015.
The Heart of the Matter: Goals of Therapy Conversations for Patients with Heart Failure. Los
Angeles Department of Cardiology Noon Conference, Kaiser Permanente, Los Angeles,
CA, 2/25/2015.
Hospice and Palliative Medicine: An Introduction for Medical Residents. Los Angeles
Internal Medicine Residency Noon Conference Lecture, Kaiser Permanente, Los Angeles,
CA, 3/20/2015.
The Ethics of Cardiac Device Deactivation: Approaching Decision-Making with Patients and
Families. Los Angeles Department of Cardiology Noon Conference, Kaiser Permanente,
Palliative Medicine and End of Life Care for the Surgical Patient: CME Presentation. West
Los Angeles Department of Surgery, Kaiser Permanente, Los Angeles, CA, 4/28/2015.
Liver Issues for Psychiatrists. Department of Psychiatry, University of Southern California,

Carin van Zyl, MD
Consultant Etiquette in Palliative Care. Lecture to VA Palliative Care fellows, VA of West Los
Angeles, Los Angeles, CA, 9/2015.
Michael D. Wang, MD
43rd Annual USC Diagnostics & Therapeutic Skills in Internal Medicine Course. Geriatrics
Lecturer, Kona, Hawaii, 3/2015.
1st Annual USC Contemporary Topics in Internal Medicine Symposium, Pasadena, CA,
11/2015.
Hematology
Role of KSHV-Encoded Viral FLICE Inhibitory Protein (vFLIP) K13 in Cell Signaling: Basic
Mechanisms and Therapeutic Implications. Cedars Sinai Medical Center Cancer Institute
Hematology/Oncology Grand Rounds, Los Angeles, CA, 1/13/2015.
Role of KSHV-Encoded Viral FLICE Inhibitory Protein (vFLIP) K13 in Cell Signaling: Basic
Mechanisms and Therapeutic Implications. Nohl Division of Hematology and Center for
the Study of Blood Diseases Grand Rounds, Los Angeles, CA, 1/16/2015.
Targeted Drug Development for KSHV-Associated Malignancies. California Cancer
Consortium Conference, Pasadena, CA, 8/9/2015.
ASH Highlights for 2014. Immune Thrombocytopenia. American Society of Hematology,

Austin, TX, 1/16/2015; San Diego, CA, 1/23/2015; Orlando, FL, 1/30/2015.
Pathophysiology and Management of Cancer-related VTE. Seattle Blood Club. Seattle, WA,
3/5/2015.
Pathophysiology of Cancer-Related VTE: The View from the Khorana Score. University of
Washington Hematology Grand Rounds, Seattle, WA, 3/6/2015.
Functional Genomic Approaches to Identify Modulators of NFkB. Mayo Clinic, Rochester,

MN, 8/20/2015.
57th American Society of Hematology Annual Meeting and Exposition Education Session:
Incidental Pulmonary Embolism, Orlando, FL, 12/2015.
Ilene C. Weitz, MD
Reversal Strategies of Old and New Oral Anticoagulants. Henry Mayo Hospital, Valencia,
CA, 2/5/2015.
Infectious Diseases
Emily Blodget, MD
Health Care Associated Pneumonia. Northridge Hospital, Northridge, CA, 10/2015.
Brad Spellberg, MD
Documentation Improvement. Department of Obstetrics and Gynecology Ground Rounds,

Keck School of Medicine of USC, Los Angeles, CA, 3/2015.
The Future of Antibiotics and Resistance. USC School of Public Health, Los Angeles, CA,
3/2015.
The Future of Antibiotics and Resistance. 2015 Keystone Symposium on Gram Negative
Resistance, Lake Tahoe, CA, 3/2015.
The Future of Antibiotics and Resistance. 2015 X-Prize Visioneering Symposium, Palos
Verdes, CA, 5/2015.
Monoclonal Antibodies and Vaccines Targeting Resistant Gram Negative Bacteria. American
Thoracic Society Annual Meeting, Denver, CO, 5/2015.
Resistant Organisms in the ICU: Fighting with Intelligent Weapons. 22nd Annual USC
National Trauma, Emergency Surgery, and Surgery Critical Care Symposium, Los
Angeles, CA, 5/2015.
Update on Documentation Improvement Efforts. Department of Neurosurgery Grand Rounds,
Keck School of Medicine of USC, Los Angeles, CA, 5/2015.
A Clinicians View of Phage Therapy for Infections: Real or Hype? NIH/NIAID
Bacteriophage Therapy: An Alternative Strategy to Combat Drug Resistance, Rockville,
MD, 7/2015.
The Future of Antibiotics and Resistance. PTC Therapeutics, Plainsfield, NJ, 8/2015.
Clinical Documentation Challenges and Solutions. LA County Department of Health Services
Clinical Operations Meeting, Los Angeles, CA, 9/2015.
Quality Improvement and Patient Safety Overview. Department of Psychiatry Grand Rounds,
LAC+USC Medical Center, Los Angeles, CA, 9/2015.
Antibiotic Resistance and Stewardship: Where Are We and Where Must We Go. US News
and World Report Annual Meeting on the Hospital of Tomorrow, Washington, DC,
10/2015.
The Future of Antibiotics and Resistance. 1st Annual Contemporary Topics in Internal
Medicine, Keck School of Medicine of USC, Pasadena, CA, 11/2015.
Darren W. Wong, MD
Clostridium Difficile Recurrence in High Risk Populations. University of Texas

Southwestern Medical Center, Dallas, TX, 2/28/2015.
Secondary Prophylaxis for Clostridium Difficile. Grand Rounds Montefiore Medical Center,
Bronx, NY, 6/2015.

Arshia Ghaffari, DO
Urgent-Start PD: Approaches and Challenges. Annual Dialysis Conference, New Orleans,
LA, 1/31/2015.
Renal Replacement Therapy in Decompensated Cirrhosis. Annual Dialysis Confreence, New
Orleans, LA, 2/2/2015.
Urgent-Start Peritoneal Dialysis. National Kidney Foundation CNNT Spring Clinical
Meetings, Dallas, TX, 3/28/2015.
Urgent-Start PD Update. UC Irvine Nephrology Grand Rounds, Long Beach Veterans
Administration Campus, Long Beach, CA, 3/30/2015.
Role of Metabolic Changes in Kidney Disease. Medical Grand Rounds, Department of

Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2/2015.
AMPK Regulation of Kidney Tubular Transport. Experimental Biology Annual Meeting,
Boston, MA, 3/2015.
132

Role of Metabolic Changes in Acute and Chronic Kidney Disease. Grand Rounds, HarborUCLA Medical Center, Division of Nephrology and Hypertension, Torrance, CA, 12/2015.
Mitra K. Nadim, MD
Evolving Technology to Treat the Patient with Resistant Hypertension. 19th Annual Max R.
Gaspar Symposium: Contemporary Management of Challenging Vascular Conditions,
Millennium Biltmore Hotel Los Angeles, CA, 9/17/2015.
Regulation of Proton Secretion in Kidney Intercalated Cells. Department of Physiology, The

Johns Hopkins University, Baltimore, MD, 10/7/2015.
New Developments in Urothelial Cancer Therapeutics. 11th Annual California Cancer

Consortium Conference, Pasadena, CA, 8/7/2015.
Oncology
Tanya B. Dorff, MD
Fasting and Oxidative Stress Resistance: What Have We Learned so Far? USC Norris Cancer
Center Grand Rounds, University of Southern California, Los Angeles, CA, 4/2015.
Radium223: Defining Timing, Patients, and Duration with Limited Data. American Society of
Clinical Oncology Annual Meeting, Chicago, IL, 6/2015.
Next-Generation Angiogenesis Inhibitors and Renal Cell Cancer Agents in Development.
California Cancer Consortium Meeting, Pasadena, CA, 8/2015.
Advanced Prostate Cancer Management. Society of Utah Medical Oncologists,
Salt Lake City, UT, 9/2015.
Prostate Cancer. Comprehensive Oncology Board Review Course, Seattle, WA, 9/2015.
Zea Borok, MD
Robert L. Johnson Lectureship, University of Texas Southwestern, Dallas, TX, 3/13/2015.

William N. Rom Symposium, New York University, New York, NY, 4/9/2015.
Ching-Fei Chang, MD
Electromagnetic Navigational Bronchoscopy in the Workup of Lung Cancer. Lung Cancer

in 2015: A Multidisciplinary Update Regional CME Conference, Westin Hotel, Pasadena,
CA, 4/18/2015.
Basics of Ultrasound Physics and Knobology. Southern California Regional PCCM
Fellowship Bedside Ultrasonography Course, LAC+USC Medical Center, Los Angeles,
CA, 11/13/15.
Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced
Hepatocellular Carcinoma: Oral Presentation in Clinical Science Symposium. ASCO
Annual Meeting, Chicago, IL, 2015.
Hepatocellular and Hepatobiliary Cancers: 11th Annual California Cancer Consortium
Conference. CME, The Medical Educator Consortium, Pasadena, CA, 8/7-9/2015.
Annual Meeting and SU2C-AACR Progress Review Team Visit: VARI-SU2C Epigenetic
Dream Team, Grand Rapids, MI, 8/24-28/2015.
ALK, HSP 90 and Combos: AT 13387. International Association for the Study of Lung
Cancer, 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA,
2/19/2015.
Antibody/Antibody Congugates: AGS 003. International Association for the Study of Lung
Cancer, 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA,
2/19/2015.
FGFR +/- VEGFR, PDGFR/Angiogenesis; EPH. International Association for the Study of
Lung Cancer, 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica,
CA, 2/21/2015.
Targeting EphB4 in Metastatic Head & Neck Squamous Cell Carcinoma. SoCal Head & Neck
Consortium, City of Hope, Duarte, CA, 3/7/2015.
Personalized Therapy for Lung Cancer. Lung Cancer in 2015: A Multidisciplinary Update.
USC Multidisciplinary Lung Cancer Program, Pasadena, CA, 4/18/2015.
Lung Cancer Diagnosis and Treatment: An integrated care model in the era of targeted
therapy. 2015 Pulmonary and Critical Care Medicine Regional Symposium, Southern
California Permanente Medical Group, Anaheim, CA, 4/25/2015.
Novel Targeted Pathways in Non-Squamous NSCLC: EGFR, ALK, ROS-1, and more. 10th
Annual New Orleans Summer Cancer Meeting, New Orleans, LA, 7/18/2015.
Amir Goldkorn, MD
AXIN2 Predicts Prostate Cancer Recurrence and Promotes an Invasive, Cancer Stem-Like
Phenotype. WAFMR Outstanding Investigator Plenary Session Presentation, Carmel, CA,
1/2015.
Cancer Stem Cells: Defining, Tracking, and Targeting an Elusive Phenotype. UCSD Sanford
Consortium Research Seminar, San Diego, CA, 2015.
Circulating Tumor Cells in Urologic Malignancies: Leveraging Novel Technologies to
Elucidate Disease Biology and Improve Clinical Outcomes. UCLA Urology Grand
Rounds, Los Angeles, CA, 2015.
Insomnia: Implications and Treatment. CME Invited Lecture, Citrus Valley Medical Center,
Covina CA, 4/7/2015.
Diagnosis/Management of Pulmonary Arterial Hypertension. CME Invited Lecture, Citrus
Valley Medical Center Conference Center, Covina, CA, 4/21/2015.
Chronic Thromboembolic Pulmonary Hypertension: What you Need to Know? CME Invited
Lecture, Providence Tarzana Medical Center, Tarzana, CA, 4/27/2015.
Update: Non-infectious interstitial lung disease. CME Invited Lecture, Citrus Valley Medical
Center Conference Center, Covina, CA, 6/9/2015.
Prevention of PE/DVT. CME Invited Lecture, Providence Tarzana Medical Center, Tarzana
CA, 7/13/2015.
Interstitial Lung Disease. CME Invited Lecture, West Hills Medical Center, West Hills, CA,
8/7/2015.
Interstitial Lung Disease. CME Invited Lecture, Northridge Hospital Education Auditorium,
Northridge, CA, 8/18/2015.
Bassam Yaghmour, MD
Lung Ultrasound in Respiratory Failure. University of Tennessee Health Science Center,

Division of Pulmonary, Critical Care and Sleep Medicine, Memphis, TN, 2015.
Beiyun Zhou, PhD
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis. Vermont Lung
Center, University of Vermont, Burlington, VT, 4/8/2015.
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis. The Ohio State
University, Columbus, OH, 5/6/2015.
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis: Integrative
Respiratory Physiology and Pathophysiology Program, University of Wisconsin, Madison,
WI, 5/29/2015.
Effects of Endoplasmic Reticulum Stress on Epithelial Injury and Fibrosis. Center for
Comparative Respiratory Biology and Medicine, University of California, Davis, CA,
6/5/2015.
Rheumatology
Evaluation of Patients with Inflammatory Arthritis. Keck Medicine of USC Orthopedic

Residency Program Lecture Series, Los Angeles, CA, 1/2015.
Medical Management of Inflammatory Arthritis. Keck Medicine of USC Orthopedic
Residency Program Lecture Series, Los Angeles, CA, 1/2015.
James S. Hu, MD
Sarcoma: The Medical Oncologists Viewpoint. Asia Pacific Network Dinner, Los Angeles,
CA, 2/28/2015.
Systemic Treatment of Chordoma: A Medical Oncologists View. Chordoma Foundation
Symposium, University of Southern California, Los Angeles, CA, 3/14/2015.
Sarcoma: Latest and Greatest. California Consortium Conference, Pasadena, CA, 8/9/2015.
Breast Cancer The Road Forward. A SABCS and ASCO update. Kaiser Permanente
Inaugural Multi-Disciplinary Oncology Symposium, Long Beach, CA, 6/13/2015.
First, a Lump in a Breast: Personalized Medicine for Breast Cancer. The 24th Annual Cancer
Surveillance Program Educational Symposium, Los Angeles, CA, 8/7/2015.
Endocrine Therapy for DCIS. 17th Annual Lynn Sage Breast Cancer Symposium, Chicago,
IL, 11/1/2015.
Current and Future Treatment of HER2-Positive Breast Cancer: Expert Advice for Clinicians.
University of Texas Health Science Center at San Antonio; CTRC Institute for Drug
Development Oncology Conference, San Antonio, TX, 11/18/2015.
Osteoporosis Treatment. 1st Annual USC Contemporary Topics in Internal Medicine,

San Antonio Breast Cancer Symposium Update. 2nd Annual USC Multidisciplinary Breast
Cancer Symposium, Los Angeles, CA, 1/17/2015.
HER-2 Directed Therapy in Breast Cancer. Scripps 35th Annual Conference: Clinical
Hematology and Oncology, San Diego, CA, 2/17/2015.
Optimal Management of the Pre-Menopausal Patient with Estrogen Receptor-Positive Breast
Cancer. Scripps 35th Annual Conference: Clinical Hematology and Oncology, San
Diego, CA, 2/17/2015.
Optimal Multidisciplinary Treatment of Breast Cancer. USC Keck School of Medicine Deans
Clinical Lecture Series, Los Angeles, CA, 3/4/2015.
One Physicians Journey in Balancing Work with Cancer Patients. 15th Annual USC
Psychosocial Seminar, Los Angeles, CA, 3/12/2015.
Adjuvant Therapy of Breast Cancer. 21st Annual NOCR Meeting, Las Vegas, NV, 3/13/2015.
Targeting the BAFF/APRIL axis in SLE: Can We Do Better? Rheumatology Research

Seminar Series, University of California, Los Angeles, Los Angeles, CA, 10/21/2015.
133
Peer-Reviewed Publications
Fong MW, Shavelle D, Weaver FA, Nadim MK: Renal Denervation in Heart Failure.
Current Hypertension Reports 17(4), 2015.
Chang PM, Patel AR, Aziz P, Shah MJ: Fasciculoventricular Accessory Pathways Following
Repair of Ventricular Septal Defects. HeartRhythm Case Reports 1:331-336, 2015.
Garg PK: Preoperative Cardiovascular Evaluation in Patients Undergoing Vascular Surgery.

Cardiol Clin 33(1):139-50, 2015.
Chang PM, Powell B, Jones PW, Carter N, Hayes D, Saxon LA: Implantable CardioverterDefibrillator Programming Characteristics, Shocked Rhythms, and Survival Among Patients
Under Thirty Years of Age. Heart Rhythm, submitted, 2015.
Garg PK, McClelland RL, Jenny NS, Criqui MH, Greenland P, Rosenson RS, Siscovick DS,
Jorgensen N, Cushman M: Lipoprotein-Associated Phospholipase A2 and Risk of Incident
Cardiovascular Disease in a Multi-Ethnic Cohort: The Multi-Ethnic Study of Atherosclerosis.
Atherosclerosis 241(1): 176-82, 2015.
Vaikunth SS, Uzunyan MY, Shinbane JS, Baker CJ, Starnes VA, Chang PM: Interrupted
Aortic Arch from the Neonate to the Adult: A Comparison and Contrast. World Journal for
Pediatric and Congenital Heart Surgery, submitted, 2015.
Fung E, Fong MW, Correa AJ, Yoon AJ, Grazette LP: Fulminant Eosinophilic Myocarditis
Following ICD Implantation in a Patient with Undisclosed Nickel Allergy. Int J Cardiol
[Epub ahead of print], 2015.
McComb M, Chao JY, Ng T: Direct Vasodilators and Sympatholytics Agents: A Review.

Journal of Cardiovascular Pharmacology and Therapeutics, in press, 2015.
Alexy T, Pais E, Wenby RB, Mack WJ, Hodis HN, Kono N, Wang J, Baskurt OK, Fisher TC,
Meiselman HJ: Abnormal Blood Rheology and Chronic Low Grade Inflammation: Possible
Risk Factors for Accelerated Atherosclerosis and Coronary Artery Disease in Lewis Negative
Subjects. Atherosclerosis 239:248251, 2015.
Azarbal A, Clavijo L, Gaglia MA: Antiplatelet Therapy for Peripheral Arterial Disease
and Critical Limb Ischemia: Guidelines Abound, but Where are the Data? J Cardiovasc
Pharmacol Ther 20(2):144-56, 2015.
Clavijo LC, Maya J, Carlson G, Angiolillo DJ, Teng R, Caplan R, Price MJ: Platelet
Inhibition with Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary
Artery Disease with or without Diabetes Mellitus. Cardiovasc Revasc Med 16(8):450-4, 2015.
Elsayed S, Clavijo LC: Critical Limb Ischemia. Cardiology Clinics 33(1): 37-47, 2015.
Hanna DB, Post WS, Deal JA, Hodis HN, Jacobson LP, Mack WJ, Anastos K, Gange
SJ, Landay AL, Lazar JM, Palella FJ, Tien PC, Witt MD, Xue X, Young MA, Kaplan
RC, Kingsley LA: HIV Infection Is Associated with Progression of Subclinical Carotid
Atherosclerosis. Clin Infect Dis 61(4):640-50, 2015.
Price MJ, Clavijo L, Angiolillo DJ, Carlson G, Caplan R, Teng R, Maya J: A Randomised
Trial of the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor Compared
with Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease. J Thromb
Thrombolysis 39(1):8-14, 2015.
Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, Budoff MJ,
Henderson VW, for the Early versus Late Intervention Trial with Estradiol Research Group:
Methods and Baseline Cardiovascular Data from the Early versus Late Intervention Trial with
Estradiol Testing the Menopausal Hormone Timing Hypothesis. Menopause 22:391401,
2015.
Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, Agler D, Lytle
BW, Lever HM, Desai MY: Left Ventricular Outflow Tract Obstruction in Hypertrophic
Cardiomyopathy Patients without Severe Septal Hypertrophy: Implications of Mitral Valve
and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and
Echocardiography. Circ Cardiovasc Imaging 8(7):e003132, 2015.
Jung M, Parrinello CM, Xue X, Mack WJ, Anastos K, Lazar JM, Selzer RH, Shircore
AM, Plankey M, Tien P, Cohen M, Gange SJ, Hodis HN, Kaplan RC: Echolucency of
the Carotid Artery Intima-Media Complex and Intima-Media Thickness have Different
Cardiovascular Risk Factor Relationships: the Womens Interagency HIV Study. J Am Heart
Assoc4(2):e001405, 2015.
Carlson SK, Chang PM, Doshi RN: Prolapse of Pacemaker Leads Resulting in Complete
IVC Obstruction in an Adult Congenital Patient. The Journal of Innovations in Cardiac
Rhythm Management 6:2117-2120, 2015.
Karim R, Stanczyk FZ, Brinton RD, Rettberg J, Hodis HN, Mack WJ: Association of
Endogenous Sex Hormones with Adipokines and Ghrelin in Postmenopausal Women. J Clin
Endocrinol Metab 100:50815, 2015.
Carlson SK, Doshi RN: Device Therapy for Acute Systolic Heart Failure and Atrial
Fibrillation. Card Electrophysiology Clin 7(3): 469-477, 2015.
Miller VM, Jenkins GD, Biernacka JM, Heit JA, Huggins GS, Hodis HN, Budoff MJ,
Lobo RA, Taylor HS, Manson JE, Black DM, Naftolin F, Harman SM, de Andrade M:
Pharmacogenomics of Estrogens on Changes in Carotid Artery Intima-Medial Thickness and
Coronary Arterial Calcification: Kronos Early Estrogen Prevention Study. Physiol Genomics
Doshi R: Atrial Fibrillation Detected via Remote Monitoring: Big Data Solutions for
Big Problems--or Just More Questions? The Journal of Innovations in Cardiac Rhythm
Management 6:18811883, 2015.
Doshi RN: My Best Case, My Worst Case. The Journal of Innovations in Cardiac Rhythm
Management, in press, 2015.
Doshi RN: Interview with Rahul N. Doshi, MD, FACC, FHRS on Leadless Multi-Sensor
Wireless Monitoring. The Journal of Innovations in Cardiac Rhythm Management (6): 20572058, in press, 2015.
Fung E, Jarvelin M-R, Doshi RN, Shinbane JS, Carlson SK, Grazette LP, Chang PM,
Sangha RS, Huikuri HV, Peters NS: Electrocardiographic Patch Devices and Contemporary
Wireless Cardiac Monitoring. Frontiers in Physiology 6:149, 2015.
Huntsinger M, Rabara R, Peralta I, Doshi RN: Current Technology to Maximize Cardiac
Resynchronization Therapy Benefit for Patients with Symptomatic Heart Failure. AACN
Advanced Critical Care 26:329-40, 2015.
Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch J, Tomassoni GF, Friedman PA, Estes
III M, Ip J, Niazi I, Plunkitt K, Banker R, Porterfield J, Ip JE, Dukkipati SR: Percutaneous
Implantation of an Entirely Intracardiac Leadless Pacemaker. The New England Journal of
Medicine 373(12):1125-35, 2015.
McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis
JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J 3rd, Wu WC,
Lin Y, Halder I, Pisarcik J, Cooper LT, Fett JD; IPAC Investigators: Clinical Outcomes for
Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of
Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66(8):905-14, 2015.
Miller VM, Lahr BD, Bailey KR, Hodis HN, Mulvagh SL, Jayachandran M: Specific
Cell-Derived Microvesicles: Linking Endothelial Function to Carotid Artery Intima-Media
Thickness in Low Cardiovascular Risk Menopausal Women. Atherosclerosis 246:21-28,
2015.
Stein JH, Ribaudo HJ, Hodis HN, Brown TT, Tran TT, Yan M, Lauer-Brodell E, McComsey
GA, Kelesidis T Dub MP, Murphy RL, Currier JS: A Prospective, Randomized Clinical
Trial of Antiretroviral Therapies on Carotid Wall Thickness: AIDS Clinical Trial Group study
A5260s. AIDS 29:1775-83, 2015.
Dai W, Herring MJ, Hale SL, Kloner RA: Rapid Surface Cooling by Thermo Suit System
Dramatically Reduces Scar Size, Prevents Post-Infarction Adverse Left Ventricular
Remodeling, and Improves Cardiac Function in Rats. Journal of the American Heart
Association 4(7), 2015.
Dow JS, Bhandari A, Hale SL, Kloner RA: Does Gender Influence the Incidence or Serverity
of Reperfusion-Induced Cardiac Arrhythmias? Springer Plus 4:96, 2015.
Hale SL, Kloner RA: Dabigatran Treatment: Effects on Infarct Size and the No-Reflow
Phenomenon in a Model of Acute Myocardial Ischemia/Reperfusion. Journal of Thrombosis
and Thombolysis 39(1): 50-54, 2015.
Kloner RA: New Observations Regarding Post-Ischemia/Reperfusion Myocardial Swelling.
Journal of the American College of Cardiology 65(4):324-326, 2015.
Kloner RA: Testosterone and Cardiovascular Health: Safety of Treatment of Hypogonadism.
Sexual Medicine Reviews 3: 56-62, 2015.
Ng TM, Goland S, Elkayam U: Relaxin for the Treatment of Acute Decompensated Heart
Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence. Cardiol Rev [Epub
ahead of print], 2015.
Kloner RA, Dai W, Shi J, Hale SL, Ceste M: Rebuilding the Infarcted Heart with NonCellular Material. Regenerative Medicine, in press, 2015.
Chaudhry MA, Correa A, Lee C, Yoon A, Grazette L, Saremi F, Fong MW: Modern Day
Management of Giant Cell Myocarditis. Int J Cardiol 178:82-84, 2015.
Kloner RA, Shi J, Dai W: New Therapies for Reducing Post-Myocardial Left Ventricular
Remodeling. Ann Transl Med 3(2):20, 2015.
Kraus AS, Pasha EP, Mackin DR, Alkatan M, Kloner RA, Tanaka H: Bilateral Upper Limb
134

Remote Ischemic Preconditioning Improves Anaerobic Power. The Open Sports Medicine
Journal 9:1-6, 2015.
Patients: Big Data Saving Lives? J Am Coll Cardiol 65(24):2611-3, 2015.

Haberman Z, Jahn R, Bose R, Tun H, Shinbane J, Doshi R, Chang P, Saxon L: Wireless
Smartphone ECG Enables Large Scale Screening in Diverse Populations. J Cardiovasc
Electrophysiol 26(5):520-6, 2015.
Oskui PM, Kloner RA, Burstein S, Zhiroff K, Kartub BR, Economides C, Brook J, Mayeda
GS: The Safety and Efficacy of Peripheral Vascular Procedures Performed in the Outpatient
Setting. Journal of Invasive Cardiology 27(5): 243-249, 2015.
Hsu JC, Saxon LA, Jones PW, Wehrenberg S, Marcus GM: Utilization Trends and Clinical
Outcomes in Patients Implanted with a Single- vs a Dual-Coil Implantable CardioverterDefibrillator Lead: Insights from the ALTITUDE Study. Heart Rhythm 12(8):1770-5, 2015.
Schwartz BG, Qualls C, Kloner RA, Laskey WK: Relation of Total and Cardiovascular
Death Rates to Climate System, Temperature, Barometric Pressure and Respiratory Infection.
Am J Cardiology 116 (8):1290-1297, 2015.
Maurer MS, Adamson PB, Costanzo MR, Eigler N, Gilbert J, Gold MR, Klapholz M, Saxon
LA, Singh JP, Troughton R, Abraham W: Rationale and Design of the Left Atrial Pressure
Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail 21(6):479488, 2015.
Shi J, Dai W, Hale SL, Brown DA, Wang M, Han X, Kloner RA: Bendavia Restores
Mitochondrial Energy Metabolism Gene Expression and Suppresses Cardiac Fibrosis in the
Border of the Infarcted Heart. Life Sciences, in press, 2015.
Stankowski RV, Kloner RA, Rezkalla SH: Cardiovascular Consequences of Cocaine Use.
Trends in Cardiovascular Medicine 25 (6): 517-526, 2015.
Mooney DM, Fung E, Doshi RN, Shavelle DM: Evolution from Electrophysiologic to
Hemodynamic Monitoring: the Story of Left Atrial and Pulmonary Artery Pressure Monitors.
Frontiers in Physiology 6:271, 2015.
Ebrille E, Konecny T, Konecny D, Spacek R, Jones P, Ambroz P, Powel BD, Hayes

DL, Friedman PA, Asirvatham SJ: Implantable Cardioverter Defibrillator Therapies and
Geomagnetic Activity. Mayo Clin Proc 90(2):202-8, 2015.
Nairooz R, Ayoub K, Shavelle D: Duration of Triple Therapy: a Clinical Question Yet to Be

Answered. J Am Coll Cardiol 66(20):2266, 2015.
Konecny T, Friedman PA, Sanon S, Rihal CS, Mulpuru SK: Percutaneous Trans-Apical
Access with Closure for Ventricular Tachycardia Ablation. Circ Arrhythm Electrophysiol
8(2):508-11, 2015.
Nichol G, Strickland W, Shavelle D, Maehara A, Ben-Yehuda O, Genereux P, Dressler O,

Parvataneni R, Nichols M, McPherson J, Barbeau G, Laddu A, Elrod JA, Tully GW, Ivanhoe
R, Stone GW: VELOCITY Investigators: Prospective, Multicenter, Randomized, Controlled
Pilot Trial of Peritoneal Hypothermia in Patients with ST-Segment- Elevation Myocardial
Infarction. Circ Cardiovasc Interv 8(3):e001965, 2015.
Konecny T, Geske JB, Ludka O, Orban M, Brady PA, Abudiab MM, Albuquerque FN,
Placek A, Kara T, Sahakyan KR, Gersh BJ, Tajik AJ, Allison TG, Ommen SR, Somers VK:
Decreased Exercise Capacity and Sleep-Disordered Breathing in Patients with Hypertrophic
Cardiomyopathy. Chest 147(6):1574-81, 2015.
Stolker JM, Lim MJ, Shavelle DM, Morris DL, Angiolillo DJ, Guzman LA, Kennedy KF,
Weber E, Zareh M, Neumayr RH, Zenni MM: Pooled Comparison of Regadenoson versus
Adenosine for Measuring Fractional Flow Reserve and Coronary Flow in the Catheterization
Laboratory. Cardiovasc Revasc Med 16(5):266-71, 2015.
Konecny T, Ludka O, Orban M, Abudiab MM, Brady PA, Konecny V, Kara T, Soucek M,
Dhoble A, Macedo P, Allison TG, Tajik AJ, Ommen SR, Somers VK: Decreased Exercise
Capacity and Sleep Disordered Breathing in Patients with Hypertrophic Cardiomyopathy.
Chest, [Epub ahead of print], 2015.
Sung G, Bosson N, Kaji AH, Eckstein M, Shavelle D, French WJ, Thomas JL, Koenig W,
Niemann JT: Therapeutic Hypothermia after Resuscitation From a Non-Shockable Rhythm
Improves Outcomes in a Regionalized System of Cardiac Arrest Care. Neurocrit Care [Epub
Konecny T, Noseworthy PA, Kapa S, Cooper LT, Mulpuru SK, Sandhu GS, Asirvatham S:
Endomyocardial Biopsy-Integrating Electrode at the Bioptome Tip. Ther Adv Cardiovasc Dis
9(3):66-9, 2015.
Youssef G, Guo M, McClelland RL, Shavelle DM, Nasir K, Rivera J, Carr JJ, Wong
ND, Budoff MJ: Risk Factors for the Development and Progression of Thoracic Aorta
Calcification: The Multi-Ethnic Study of Atherosclerosis. Acad Radiol 22(12):1536-45, 2015.
Konecny T, Saxon LA: Integration of Smartphone Based Monitoring-No Modality is an

Island, Entire of Itself. Journal of Cardiovascular Electrophysiology [Epub ahead of print],
2015.
Qamruddin S, Huang HW, Mehra A, Bonyadlou S, Yoon AJ: ST Segment Elevation ECG
Changes During Pharmacologic Stress with Regadenoson. Clinical Nuclear Medicine,
submitted, 2015.
Podrouzkova H, Bedanova H, Tretina M, Korinek J, Stepanova R, Hruskova J, Nemec P,

Konecny T, Orban M: Decrease in Longitudinal Strain in Heart Transplant Recipients is
Associated with Rejection. Biomed Pap Med 159(4):601-6, 2015.
Yoon AJ, Sohn J, Grazette L, Fong MW, Bowdish M: Pan-Cardiac Cycle Fixed Mitral
Valve Opening in an LVAD Patient Presenting with Hemorrhagic Shock. Echocardiography,
submitted, 2015.
Ruzek L, Konecny T, Soucek F, Konecny D, Mach L, Ommen SR, Kopecky SL, Nishimura
RA: Phosphodiesterase 5 Inhibitor Use in Men with Hypertrophic Cardiomyopathy. Am J
Cardiol 116(4):618-21, 2015.
Cohen MG, Matthews R, Maini B, Dixon S, Vetrovec G, Wohns D, Palacios I, Popma J,

Ohman EM, Schreiber T, ONeill WW: Percutaneous Left Ventricular Assist Device for HighRisk Percutaneous Coronary Interventions: Real-World versus Clinical Trial Experience. Am
Heart J 170(5):872-9, 2015.
Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH,
Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE,
Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L, Dual Antiplatelet Therapy (DAPT) Study
Investigators (including Matthews R): Antiplatelet Therapy Duration Following Bare Metal
or Drug-Eluting Coronary Stents: The Dual Antiplatelet Therapy Randomized Clinical Trial.
JAMA 313(11):1113-21, 2015.
Kron IL, Hung J, Overbey JR, Bouchard D, Gelijns AC, Moskowitz AJ, Voisine P, OGara
PT, Argenziano M, Michler RE, Gillinov M, Puskas JD, Gammie JS, Mack MJ, Smith PK,
Sai-Sudhakar C, Gardner TJ, Ailawadi G, Zeng X, OSullivan K, Parides MK, Swayze R,
Thourani V, Rose EA, Perrault LP, Acker MA, CTSN Investigators (including Matthews
R): Predicting Recurrent Mitral Regurgitation after Mitral Valve Repair for Severe Ischemic
Mitral Regurgitation. J Thorac Cardiovasc Surg 149(3):752-61, 2015.
Mehra A, Mohan B: Value of FFR in Clinical Practice. Indian Heart J 67(1):77-80, 2015.
Shantouf RS, Mehra A: Coronary Fractional Flow Reserve. AJR Am J Roentgenol
204(3):W261-5, 2015.
Akar JG, Bao H, Jones P, Wang Y, Varosy P, Masoudi FA, Stein K, Saxon LA, Norman ST,
Curtis JP: Use of Remote Monitoring is Associated with Lower Risk of Adverse Outcomes
Among Patients with Implanted Cardiac Defibrillators. Circulation: Arrhythmia and
Electrophysiology 8(5):1173-80, 2015.
Cesario D, Powell B, Roosevelt G, Day J, Hayes D, Jones P, Wold N, Saxon L: The Role
of Atrial Fibrillation in CRT-D Patients: The ALTITUDE Study Group. The Journal in
Innovations in Cardiac Rhythm Management 6;1873-80, 2015.
Freeman JV, Saxon L: Remote Monitoring and Outcomes in Pacemaker and Defibrillator
Karamanos E, Dulchavsky S,Beale E, Inaba K, Demetriades D: Diabetes Mellitus in Patients

Presenting with Adhesive Small Bowel Obstruction: Delaying Surgical Intervention Results
in Worse Outcomes.World J Surg [Epub ahead of print], 2015.
Sivrikoz E, Karamanos E, Beale E, Teixeira P, Inaba K, Demetriades D: The Effect
of Diabetes on Outcomes following Emergency Appendectomy in Patients without
Comorbidities: a Propensity Score-Matched Analysis of National Surgical Quality
Improvement Program Database. Am J Surg 209(1):206-11, 2015.
Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, Hopkins
PN, Brown N, Raby BA, Lasky-Su J, Adler GK, Cui J, Guo X, Taylor KD, Chen YD, Xiang
A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Pojoga LH: a Prevalent Caveolin-1
Gene Variant is Associated with the Metabolic Syndrome in Caucasians and Hispanics.
Metabolism 64(12):1674-81, 2015.
Black MH, Wu J, Takayanagi M, Taylor KD, Haritunians T, Trigo E, Lawrence JM, Watanabe
RM, Buchanan TA, Xiang AH: Variation in PPARG is Associated with Longitudinal Change
in Insulin Resistance in Mexican Americans at Risk for Type 2 Diabetes. J Clin Endocrinol
Metab 100(3):1187-95, 2015.
Chen Z, Salam MT, Karim R, Toledo-Corral CM, Watanabe RM, Xiang AH, Buchanan TA,
Habre R, Bastain TM, Lurmann F, Taher M, Wilson JP, Trigo E, Gilliland FD: Living Near
a Freeway is Associated with Lower Bone Mineral Density among Mexican Americans.
Osteoporos Int [Epub ahead of print], 2015.
Oh YT, Tran D, Buchanan TA, Selsted ME, Youn JH: The Theta-Defensin RTD-1 Improves
Insulin Action and Normalizes Plasma Glucose and FFA Levels in Diet-Induced Obese Rats.
Am J Physiol Endocrinol Metab 309(2):E154-60, 2015.
Palmer ND, Goodarzi MO, Langefeld CD, Wang N, Guo X, Taylor KD, Fingerlin TE, Norris
JM, Buchanan TA, Xiang AH, Haritunians T, Ziegler JT, Williams AH, Stefansovski D, Cui
J, Mackay AW, Henkin LF, Bergman RN, Gao X, Gauderman J, Varma R, Hanis CL, Cox NJ,
Highland HM, Below JE, Williams AL, Burtt NP, Aguilar-Salinas CA, Huerta-Chagoya A,
135

Gonzalez-Villalpando C, Orozco L, Haiman CA, Tsai MY, Johnson WC, Yao J, RasmussenTorvik L, Pankow J, Snively B, Jackson RD, Liu S, Nadler JL, Kandeel F, Chen YI, Bowden
DW, Rich SS, Raffel LJ, Rotter JI, Watanabe RM, Wagenknecht LE: Genetic Variants
Associated with Quantitative Glucose Homeostasis Traits Translate to Type 2 Diabetes
in Mexican Americans: The GUARDIAN (Genetics Underlying Diabetes in Hispanics)
Consortium. Diabetes 64(5):1853-66, 2015.
Tripathy D, Cobb JE, Gall W, Adam KP, George T, Schwenke DC, Banerji MA, Bray GA,
Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB,
Reaven PD, Musi N, Ferrannini E, DeFronzo RA: A Novel Insulin Resistance Index to
Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study. J Clin
Endo Metab 100(5):1855-62, 2015.
Xiang AH, Black MH, Li BH, Martinez MP, Sacks DA, Lawrence JM, Buchanan TA,
Jacobsen SJ: Racial and Ethnic Disparities in Extremes of Fetal Growth after Gestational
Diabetes Mellitus. Diabetologia 58(2):272-81, 2015.
Bughi S,Fanchiang S, Joyo B, Nazarian A, Kekehashi B, et al: Hypoglycemia Reported in
Patient Safety Network (PSN). Int J Pharma Sci Res 2:109, 2015.
Bonert V, Bose N, Carmichael JD: Cyclic Cushings Disease with Misleading Inferior
Petrosal Sinus Sampling Results During a Trough Phase. Neurosurgical FOCUS 38(2):E7,
2015.
Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN,
Melmed S: a Structural and Functional Acromegaly Classification. J Clin Endocrinol Metab
100(1):122-31, 2015.
Jeswani, S, Nuo M, Wu A, Bonert V, Carmichael JD, Black KL, et al: Comparative
Analysis of Outcomes following Craniotomy and Expanded Endoscopic Endonasal
Transsphenoidal Resection of Craniopharyngioma and Related Tumors: a Single-Institution
Study. Journal of Neurosurgery 11:1-12, 2015.
Newman CB, Carmichael JD, Kleinberg DL: Effects of Low Dose versus High Dose Human
Growth Hormone on Body Composition and Lipids in Adults with GH Deficiency: a MetaAnalysis of Placebo-Controlled Randomized Trials. Pituitary 18(3):297-305, 2015.
Schievink WI, Nuno M, Rozen TD, Maya MM, Mamelak AN, Carmichael J, Bonert VS:
Hyperprolactinemia Due to Spontaneous Intracranial Hypotension. J Neurosurg 122(5):10205, 2015.
Seltzer J, Ashton CE, Scotton TC, Pangal D, Carmichael JD, Zada G: Gene and Protein
Expression in Pituitary Corticotroph Adenomas: a Systematic Review of the Literature.
Neurosurgical FOCUS 38(2):E17, 2015.
Seltzer J, Lucas J, Commins D, Lerner O, Lerner A, Carmichael JD, Zada, G: Ectopic
ACTH-Secreting Pituitary Adenoma of the Sphenoid Sinus: Case Report of Endoscopic
Endonasal Resection and Systematic Review of the Literature. Neurosurgical FOCUS
38(2):E10, 2015.
Seltzer J, Scotton TC, Kang K, Zada G, Carmichael JD: Gene Expression in Prolactinomas:
a Systematic Review. Pituitary [Epub ahead of print], 2015.
Wilson D, Jin D L, Wen T, Carmichael JD, Cen S. Mack WJ, Zada G: Demographic Factors,
Outcomes, and Patient Access to Transsphenoidal Surgery for Cushings Disease: Analysis of
the Nationwide Inpatient Sample from 2002 to 2010. Neurosurgical FOCUS 38(2):E2, 2015.
Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, Lopresti JS: Clinical
Features and Hospital Outcomes in Thyroid Storm: A Retrospective Cohort Study. J Clin
Endocrinol Metab100(2):451-9, 2015.
Aghajanian P, Spencer CA, Wilson ML, Lee RH, Goodwin TM, Mestman JH: Evaluation of
Risk-Factor-Based Screening for Thyroid Peroxidase Antibody Positivity in Pregnancy. Clin
Endocrinol, in press, 2015.
Luo S, Monterosso JR, Sarpelleh K, Page KA: Differential Effects of Fructose versus
Glucose on Brain Reward and Appetitve Responses to Food Cues and Decisions for Food
Rewards. Proc Natl Acad Sci 112(20):6509-14, 2015.
Xiang AH, Wang X, Martinez M, Walthall JC, Curry ES, Page KA, Buchanan TA,
Coleman, K, Getahun, D: Association of Maternal Diabetes with Autism in Offspring. JAMA
313(14):1425-34, 2015.
Belalcazar LM, Lang W, Haffner SM, Schwenke DC, Kriska A, Balasubramanyam A,
Hoogeveen RC, Pi-Sunyer FX, Tracy RP, Ballantyne CM, Look AHEAD Research Group
(including Peters AL): Improving Adiponectin Levels in Individuals with Diabetes and
Obesity: Insights from Look AHEAD. Diabetes Care 38(8):1544-50, 2015.
Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D,
Diamant M: Is Insulin the Most Effective Injectable Antihyperglycaemic Therapy? Diabetes,
Obesity and Metabolism 17:145-151, 2015.
Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS,
Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW,
Greenbaum CJ: Prevalence of Detectable C-Peptide According to Age at Diagnosis and
Duration of Type 1 Diabetes. Diabetes Care 38(3):476-81, 2015.
DuBose SN, Hermann JM, Tamborlane WV, Beck RW, Dost A, DiMeglio LA, Schwab KO,
Holl RW, Hofer SE, Maahs DM, Type I Diabetes Exchange Clinic Network and Diabetes
Prospective Follow-up Registry (including Peters AL): Obesity in Youth with Type I
Diabetes in Germany, Austria, and the United States. J Pediatr 167(3)627-32, 2015.
Eby EL, Curtis BH, Gelwicks SC, Hood RC, Idris I, Peters AL, Bergenstal RM, Jackson
JA: Initiation of Human Regular U-500 Insulin Use is Associated with Improved Glycemic
Control: a Real-World US Cohort Study. BMJ Open Diabetes Res Care 3(1):e000074, 2015.
Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson
KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL,
Osei K, Rehman SU, Cushman WC, Look AHEAD Research Group (including Peters AL),
ACCORD Study Group: Systolic Blood Pressure Control Among Individuals with Type 2
Diabetes: a Comparative Effectiveness Analysis of Three Interventions. Am J Hypertens
28(8):995-1009, 2015.
Fisher L, Polonsky WH, Hessler DM, Masharani U, Blumer I, Peters AL, Strycker LA,
Bowyer V: Understanding the Sources of Diabetes Distress in Adults with Type 1 diabetes.
J Diabetes Complications 29(4):572-7, 2015.
Fox LA, Mubasher M, Wolfsdorf JI, Buckingham BA, Peters AL, Tamborlane WV, Schatz
DA, Maahs DM, Miller KM, Beck RW, T1D Exchange Clinic Network: Characteristics of
Youth with Type 1 Diabetes with and without a Parent with Type 1 Diabetes in the T1D
Exchange Clinic Registry. J Diabetes [Epub ahead of print], 2015.
Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL: Insulin Pump
Risks and Benefits: a Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting,
and Research Needs: a Joint Statement of the European Association for the Study of Diabetes
and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care
38(4):716-22, 2015.
Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL: Insulin Pump
Risks and Benefits: a Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting
and Research Needs. a Joint Statement of the European Association for the Study of Diabetes
and the American Diabetes Association Diabetes Technology Working Group. Diabetologia
58(5):862-70, 2015.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL,
Tsapas A, Wender R, Matthews DR: Management of Hyperglycemia in Type 2 Diabetes,
2015: a Patient-Centered Approach. Update to a Position Statement of the ADA and the
EASD. Diabetes Care 38:140-149, 2015.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL,
Tsapas A, Wender R, Matthews DR: Management of Hyperglycaemia in Type 2 Diabetes,
2015: a Patient-Centered Approach. Update to a Position Statement of the American
Diabetes Association and the European Association for the Study of Diabetes. Diabetologia
58(3):429-42, 2015.
Lu Y, Pyatak EA, Peters AL, Wood JR, Kipke M, Cohen M, Sequeira PA: Patient
Perspectives on Peer Mentoring: Type 1 Diabetes Management in Adolescents and Young
Adults. The Diabetes Educator 41:59-68, 2015.
Marquez R, Anderson A, Wing RR, West DS, Newton RL, Meacham M, Hazuda HP, Peters
A, Montez MG, Broyles ST, Walker M, Evans-Hudsnall G, The Look AHEAD Research
Group: The Relationship of Social Support with Treatment Adherence and Weight Loss in
Latinos with Type 2 Diabetes. Obesity, submitted, 2015.
Padilla M, Peters AL: Diabetes and Cardiovascular Disease Risk Factors as Influenced by
Race and Ethnic Background. Curr Cardiovasc Risk Reports, submitted, 2015.
Peters AL, Buschur E, Buse JB, Cohan P, Dimer J, Hirsch I: Euglycemic Diabetic
Ketoacidosis: a Potential Complication of Sodium Glucose Cotransporter 2 Inhibition.
Diabetes Care 38:1687-93, 2015.
Peters AL, Pollom RD, Zielonka JS, Carey MA, Edelman SV: Biosimilars and New Insulin
Versions. Endocr Pract 21(12):1387-94, 2015.
Pownall HJ, Bray GA, Wagenknecht LE, Walkup MP, Heshka S, Hubbard VS, Hill J, Kahn
SE, Nathan DM, Schwartz AV, Johnson KC; Look AHEAD Research Group (including
Peters AL): Changes in Body Composition over 8 Years in a Randomized Trial of a Lifestyle
Intervention: the Look AHEAD Study. Obesity (Silver Spring) 23(3):565-72, 2015.
Raynor HA, Anderson AM, Miller GD, Reeves R, Delahanty LM, Vitolins MZ, Harper P,
Mobley C, Konersman K, Mayer-Davis E; Look AHEAD Research Group (including Peters
AL): Partial Meal Replacement Plan and Quality of the Diet at 1 Year: Action for Health in
Diabetes (Look AHEAD) Trial. J Acad Nutr Diet 115:731-42, 2015.
Romley JA, Gong C, Jena AB, Goldman DP, Williams B, Peters A: Association Between Use
of Warfarin with Common Sufonylureas and Serious Hypoglycemic Events: Retrospective
Cohort Analysis. BMJ 351:h6223, 2015.
Sepah SC, Jiang L, Peters AL: Long-Term Efficacy of an Online Diabetes Prevention
Program: 2-Year Study Outcomes. J Med Internet Res 17(4), 2015.
Sequeira PA, Pyatak EA, Weigensberg MJ, Vigen CP, Wood JR, Ruelas V, Montoya L,
Cohen M, Speer H, Clark S, Peters AL: Lets Empower and Prepare (LEAP): Evaluation
of a Structured Transition Program for Young Adults With Type 1 Diabetes. Diabetes Care
136

38:1412-9, 2015.
Pancreatic Hyperlipasemia. Pancreas, in press, 2015.
Stevens GD, Shi L, Vane C, Nie X, Peters AL: Primary Care Medical Home Experience and
Health-Related Quality of Life Among Adult Medicaid Patients with Type 2 Diabetes. J Gen
Intern Med 30(2):161-8, 2015.
Jani N, Buxbaum J: Autoimmune Pancreatitis and Cholangitis. World J Gastroenterol

6(4):199-206, 2015.
Unick JL, Neiberg RH, Hogan PE, Cheskin LJ, Dutton GR, Jeffery R, Nelson JA, Pi-Sunyer
X, West DS, Wing RR, Look AHEAD Research Group (including Peters A): Weight Change
in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. Obesity
(Silver Spring) 23(7):1353-6.
Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi
MN, Perrin AJ, Miller KM, Beck RW, Lilijenquiest DR, Aleppo G, Buse JB, Kruger D,
Bhargava A, Goland RS, Edelen RC, Pratley RE, Peters AL, Rodriguez H, Ahmann AJ, Lock
JP, Garg SK, Rickels MR, Hirsch IB, T1D Exchange Severe Hypoglycemia in Older Adults
with Type I Diabetes Study Groups: Risk Factors Associated with Severe Hypoglycemia in
Older Adults with Type I Diabetes. Diabetes Care [Epub ahead of print], 2015.
Weissberg-Benchell J, Hood K, Laffel L, Heinemann L, Ball D, Kowalski A, Peters A,
Damiano E, Schiller M, Davis A, Beck S, Barnard K: Toward Development of Psychosocial
Measures for Automated Insulin Delivery. J Diabetes Sci Technol [Epub ahead of print],
2015.
Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV,
Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH; T1D Exchange Clinic
Network (including Peters AL): Racial-Ethnic Disparities in Management and Outcomes
among Children with Type 1 Diabetes. Pediatrics 135(3):424-34, 2015.
Angell T, Lechner M, Ngyuen C, Nicoloff J, LoPresti J: Clinical Features and Hospital
Outcomes in Thyroid Storm: A Retrospective Cohort Study. JCEM 100: 451-59, 2015.
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC,
Johnston P, Kober LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield
JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA, ELIXA Investigators (including Shaw
SJ): Rationale, Design and Baseline Characteristics in Evaluation of Lixisenatide in Acute
Coronary Syndrome, a Long-Term Cardiovascular End Point Trial of Lixisenatide versus
Placebo. Am Heart J 169(5):631-638.e7.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC, Ping L,
Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD,
Tardif JC, ELIXA Investigators (including Shaw SJ): Lixisenatide in Patients with Type 2
Diabetes and Acute Coronary Syndrome. N Engl J Med 373(23):2247-57, 2015.
Netzel BC, Grebe SK, Carranza Leon BG, Castro MR, Clark PM, Hoofnagle AN, Spencer
CA, Turcu AF, Algeciras-Schimnich A: Thyroglobulin (Tg) Testing Revisited: Tg Assays,
TgAb Assays and Correlation of Results with Clinical Outcomes JCEM 100:E1074, 2015.
Stagnaro-Green A, Dogo-Isonaige E, Pearce E, Spencer C, Gaba N: Marginal Iodine
Status and High Rate of Subclinical Hypothyroidism in Washington DC Women Planning
Conception. Thyroid 25:1151-4, 2015.
Kimzey MJ, Kinsky O, Yassine HN, Tsaprailis G, Stump CS, Monks TJ, Lau SS: 2015 Site
Specific Modification of the Human Plasma Proteome by Methylglyoxal. Toxicology and
Applied Pharmacology 289(2):155-62, 2015.
Yassine HN, Trenchevska O, He H, Borges C, Nedelkov D, Mack W, Kono N, Koska J,
Reaven PD, Nelson RW: Serum Amyloid A Truncations in Type 2 Diabetes Mellitus. PLOS
ONE 10(1):e0115320, 2015.
Yassine HN, Trenchevska O, Ramrakhiani A, Parekh A, Koska J, Walker RW, Billheimer
D, Reaven PD, Yen FT, Nelson RW, Goran MI, Nedelkov D: The Association of Human
Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. PLoS One
10(12):e0144138.

Beshoy Y, Nneji J, Buxbaum J: A Case of the Hiccups in the Setting of Colonic Ulcers.
Gastroenterology 148(1):e8-9, 2015.
Beshoy Y, Nneji J, Buxbaum J: Clinical Challenges and Images in GI: a Case of Diarrhea,
Singultus, and Unexplained Fever. Gastroenterology 148(1): e8-9, 2015.
Buxbaum J, Nguyen N, Kulkarni S, Palmer S, Rao A, Selby R: Multidisciplinary Treatment
of Cystic Fibrosis Related Recurrent Pyogenic Cholangitis (CF-RPC). Dig Dis Sci
60(6):1801-4, 2015.
Buxbaum J, Roth, N, Motamedi N, Salem M, Leonor P, Gibbs D, Vargo J: Monitored
Anesthesia Care Favors Success of Advanced Endoscopic Procedures. Gastrointest Endosc,
submitted, 2015.
Da B, Kulkarni S, Selby R, Buxbaum J: Diagnostic and Therapeutic Utility of Device
Assisted Enteroscopy and Cholangiography for Afferent Loop Syndrome. Surgical Endosc,
submitted, 2015.
Da B, Shulman I, Lane C, Buxbaum J: Origin, Presentation, and Clinical Course of Non-
Kelly T, Buxbaum J: Gastrointestinal Manifestations of Cystic Fibrosis. Dig Dis Sci 60

(7):1903-13, 2015.
Kulkarni S, Bogart A, Buxbaum J, Matsuoka L, Selby R, Parekh D: Surgical Transgastric
Debridement of Walled off Pancreatic Necrosis: an Option for Patients with Necrotizing
Pancreatitis. Surg Endosc 29(3):575-82, 2015.
Rochefort H, Matsuoka L, Chouliaras K, Mwengela D, Buxbaum J, Alexopoulos S: Multiple
ERCP and Large Common Bile Duct Diameter Predict Complex Surgery for Management of
Bile Duct Stones. American Surgeon, in press, 2015
Saberi B, Da B, Sheibani S, Chen B, Park S, Lee K, Buxbaum J: Outcomes of Upper
Gastroinestinal Bleeding Due to Cameron Lesions. Dis of Esophagus, submitted, 2015.
Yan A, Shindel A, Buxbaum J: Massive Obscure Bleeding from a Jejunal Diverticulum.
Gastrointest Endosc 81(5):1289-90, 2015.
Dara L, Johnson H, Win S, Gaarde W, Han D, Kaplowitz N: Receptor Interacting Protein
Kinase-1 Mediates Murine Acetaminophen Toxicity Independent of the Necrosome and not
through Necroptosis. Hepatology 62(6):1847-57, 2015.
Dara L, Liu ZX, Kaplowitz N: Mechanisms of Adaptation and Progression in Idiosyncratic
Drug Induced Liver Injury, Clinical Implications. Liver Int [Epub ahead of print], 2015.
DeLeve LD: Liver Sinusoidal Endothelial Cells in Hepatic Fibrosis. Hepatology 61:1740-6,
2015.
Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan Q-Q, Yu AS, Mohammed W,
Velasco A, LeDuc V-H, Nguyen N, Han S-B, Chang M, Bae H-S, Cho Y-W, Tong MJ, Cooper
SL: Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients
Treated with Entecavir or Tenofovir. Digestive Disease and Science 60(11):3465-72, 2015.
Tien C, Xu JJ, Chan LS, Chang M, Lim C, Lee S, Huh B, Shinada S, Bae H-S, Fong TL:
Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients is
Associated with Abnormal Renal Phosphate Handling. Digestive Diseases and Science
60:566-72, 2015.
Yeh KE, Marcus PS, Fong TL: Paraneoplastic Cholestasis Associated with Ovarian
Dysgerminoma. Obstetrics and Gynecology 126:431-4, 2015.
Zhu J, Khemichian S, Nghiem D, Zhang SR, Limurti J, Saito T, Redeker AG, Fong TL:
Comparison of Demographic and Clinical Characteristics of Hispanic and Asian Chronic
Hepatitis B Patients in Southern California. American Journal of Gastroenterology,
submitted, 2015.
Christian KE, Barth RN, Hanish SI, LaMattina JC, Han H, Hutson WR, Mindikoglu AL,
Potosky DR: Predicting Recidivism in Patients Undergoing Early Liver Transplantation for
Alcoholic Liver Disease: A Retrospective Cohort Study. Liver Transplantation, submitted,
2015.
Tang DM, Koh C, Twaddell WS, von Rosenvinge EC, Han H: Acute Hepatoceullular DrugInduced Liver Injury From Bupropion and Doxycycline. ACG Case Rep J 3(1):66-8, 2015.
Hou L, Laine L, Motamedi N, Sahakian A, Buxbaum J: Optimal Timing of Endoscopic
Retrograde Cholangiopancreatography (ERCP) in Ascending Cholangitis. Endoscopy,
submitted, 2015.
Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, Hsu L, Huang SC,
Fischer CP, Harju JF, Idos GE, Lejbkowicz F, Manion FJ, McDonnell K, McNeil CE, Melas
M, Rennert HS, Shi W, Thomas DC, Van Den Berg DJ, Hutter CM, Aragaki AK, Butterbach
K, Caan BJ, Carlson CS, Chanock SJ, Curtis KR, Fuchs CS, Gala M, Giocannucci EL,
Gogarten SM, Hayes RB, Henderson B, Hunter DJ, Jackson RD, Kolonel LN, Kooperberg
C, Kury S, LaCroix A, Laurie CC, Laurie CA, Lemire M, Levine D, Ma J, Makar KW, Qu C,
Taverna D, Ulrich CM, Wu K, Kono S, West DW, Berndt SI, Bezieau S, Brenner H, Campbell
PT, Chan AT, Chang-Claude J, Coetzee GA, Conti DV, Duggan D, Figueiredo JC, Fortini
BK, Gallinger SJ, Gauderman WJ, Giles G, Green R, Haile R, Harrison TA, Hoffmeister
M, Hopper JL, Hudson TJ, Jacobs E, Iwasaki M, Jee SH, Jenkins M, Jia WH, Joshi A, Li
L, Lindor NM, Matsuo K, Moreno V, Mukherjee B, Newcomb PA, Potter JD, Raskin L,
Rennert G, Rosse S, Severi G, Schoen RE, Seminara D, Shu XO, Slattery ML, Tsugane S,
White E, Xiang YB, Zanke BW, Zheng W, Le Marchand L, Casey G, Gruber SB, Peters
U: Corrigendum: Genome-Wide Association Study of Colorectal Cancer Identifies Six New
Susceptibility Loci. Nat Commun 6:8739, 2015.
Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, Hsu L, Huang SC,
Fischer CP, Harju JF, Idos GE, Lejbkowicz F, Manion FJ, McDonnell K, McNeil CE, Melas
M, Rennert HS, Shi W, Thomas DC, Van Den Berg DJ, Hutter CM, Aragaki AK, Butterbach
K, Caan BJ, Carlson CS, Chanock SJ, Curtis KR, Fuchs CS, Gala M, Giocannucci EL,
Gogarten SM, Hayes RB, Henderson B, Hunter DJ, Jackson RD, Kolonel LN, Kooperberg
C, Kury S, LaCroix A, Laurie CC, Laurie CA, Lemire M, Levine D, Ma J, Makar KW, Qu C,
Taverna D, Ulrich CM, Wu K, Kono S, West DW, Berndt SI, Bezieau S, Brenner H, Campbell
PT, Chan AT, Chang-Claude J, Coetzee GA, Conti DV, Duggan D, Figueiredo JC, Fortini
137

Sheibani S, Russell C, Kane S, Dubinsky M, Church J, Mahadevan U: The Effect of
Maternal Peripartum Anti-TNF Use on Infant Immune Response Digestive Diseases and
Sciences, submitted, 2015.
BK, Gallinger SJ, Gauderman WJ, Giles G, Green R, Haile R, Harrison TA, Hoffmeister
M, Hopper JL, Hudson TJ, Jacobs E, Iwasaki M, Jee SH, Jenkins M, Jia WH, Joshi A, Li L,
Lindor NM, Matsuo K, Moreno V, Mukherjee B, Newcomb PA, Potter JD, Raskin L, Rennert
G, Rosse S, Severi G, Schoen RE, Seminara D, Shu XO, Slattery ML, Tsugane S, White E,
Xiang YB, Zanke BW, Zheng W, Le Marchand L, Casey G, Gruber SB, Peters U: GenomeWide Association Study of Colorectal Cancer Identifies Six New Susceptibility Loci. Nat
Commun 6:7138, 2015.
Rodriguez L, Rodriguez1 P, Gmez B, Ayala JC, Oksenberg D, Perez-Castilla A, Netto MG,

Soffer E, Boscardin J, Crowell MD: Two-Year Results of Intermittent Electrical Stimulation
for the Lower Esophageal Sphincter Treatment of Gastroesophageal Reflux Disease. Surgery
157(3):556-67, 2015.
Hu J, Han H, Lau MY, Lee H, MacVeigh-Aloni M, Ji C: Effects of Combined Alcohol and

Anti-HIV Drugs on Cellular Stress Responses in Primary Hepatocytes and Hepatic Stellate
and Kupffer Cells. Alcohol Clin Exp Res 39(1):11-20, 2015.
Rodrguez L, Rodriguez P, Gmez B, Netto MG, Boscardin J, Crowell MD, Soffer E:

Electrical Stimulation Therapy of the Lower Esophageal Sphincter is Successful in Treating
GERD Long-term 3 Year Results. Surgical Endoscopy, in press, 2015.
Ji C: Advances and New Concepts in Alcohol-Induced Organelle Stress, Unfolded Protein

Responses and Organ Damage. Biomolecules 5(2):1099-121, 2015.
Soffer E, Rodrguez L, Rodriguez P, Gmez B, Netto MG, Crowell MD: Electrical

Stimulation Therapy of the Lower Esophageal Sphincter is Successful in Treating GERD
in Proton Pump Inhibitors (PPI) Incomplete Responders. World Journal of Gastrointestinal
Pharmacology and Therapeutics, submitted, 2015.
Zhang L, Zhang H, Lv M, Jia J, Fan Y, Tian X, Li X, Li B, Ji J, Wang L, Zhao Z, Han D,

Ji C: Increased Expression of 78 kD Glucose-Regulated Protein Promotes Cardiomyocyte
Apoptosis in a Rat Model of Liver Cirrhosis. Int J Clin Exp Pathol 8(8):9256-63, 2015.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins
PB, Navarro V, Barnhart H, Gu J, Serrano J: United States Drug Induced Liver Injury
Network. Features and Outcomes of 899 Patients with Drug-Induced Liver Injury: The DILIN
Prospective Study. Gastroenterology 148:1340-52, 2015.
Baulies A, Ribias V, Nunez S, Torres S, Alarcon-Vila C, Martinez L, Suda J, Ybanez M,

Kaplowitz N, Garcia-Ruiz C, Fernandez-Checa J: Lysosomal Cholesterol Accumulation
Sensitizes to Acetaminophen Hepatotoxicity by Impairing Mitophagy. Sci Rep 5:18017, 2015.
Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz
A, Phillips T, Serrano J, Watkins PB: Persistent Liver Biochemistry Abnormalities are More
Common in Older Patients and those with Cholestatic Drug Induced Liver Injury. Am J
Gastroenterol 110:1450-9, 2015.
Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N, Fernandez-Checa JC: Acid

Sphingomyelinase-Ceramide System in Steatohepatitis: a Novel Target Regulating Multiple
Pathways. J Hepatol 62(1):219-33, 2015.
Han D, Johnson H, Martin G, Sancheti H, Silkwood K, Decker W, Nguyen K, Cadenas E,
Kaplowitz N: Mitochondrial Remodeling in the Liver following Chronic Alcohol Feeding to
Rats, submitted, 2015.
Foureau DM, Walling TL, Maddukuri V, Anderson W, Culbreath K, Kleiner DE, Ahrens WA,
Jacobs C, Watkins PB, Fontana RJ, Chalasani N, Talwalkar J, Lee WM, Stolz A, Serrano J,
Bonkovsky HL: Comparative Analysis of Portal Hepatic Infiltrating Leucocytes in Acute
Drug-Induced Liver Injury, Idiopathic Autoimmune and Viral Hepatitis. Clin Exp Immunol
180:40-51, 2015.
Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, Kaplowitz N, Lucena M, Andrade R:

Definition, Incidence and Risks Factors for Chronicity following Acute Drug-Induced Liver
Injury, submitted, 2015.
Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, Reddy KR,
Stolz AA, Hoofnagle JH, Rockey DC: Reliability of Causality Assessment for Drug, Herbal
and Dietary Supplement Hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN).
Liver Int 35:1623-32, 2015.
Powles T, Bracrada S, Chen M, Norry E, Compton N, Hase M, Hutson T, Harta P, Carpenter

C, Pandite L, Kaplowitz N: Characterization of Liver Chemistry Abnormalities Associated
with Pazopanib Monotherapy: a Systemic Review and Meta-Analysis of Clinical Trials in
Advanced Cancer Patients. European J Cancer 51(10):1293-302, 2015.
Watkins P, Lewis J, Kaplowitz N, Alpers D et al: Clinical Pattern of Tolvaptan-Associated
Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of
Clinical Trials Database. Drug Safety 38(11):1103-13, 2015.
Hayashi PH, Fontana RJ, Chalasani NP, Stolz AA, Talwalkar JA, Navarro VJ, Lee WM,
Davern TJ, Kleiner DE, Gu J, Hoofnagle JH: US Drug-Induced Liver Injury Network
Investigators. Under-Reporting and Poor Adherence to Monitoring Guidelines for Severe
Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol 13:1676-82, 2015.
Xu C, Johnson T, Wang X, Carpenter C, Kaplowitz N, Pandite L: HLA-B*5701 Confers

Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clinical Cancer
Res, in press, 2015.
Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, Gu J,
Hoofnagle JH, Chalasani N: Clinical and Histologic Features of Azithromycin-Induced Liver
Injury. Clin Gastroenterol Hepatol 13:369-376, 2015.
Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J, Fong TL: Nucleoside-Nucleotide
Analog Combination Therapy is Effective in Preventing Recurrent Hepatitis B after Liver
Transplantation. Dig Dis Sci 60:2807-12, 2015.
Schmeltzer PA, Kosinski AS, Kleiner DE, Hoffnagle JH, Stolz A, Fontana RJ, Russo
MW, Drug-Induced Liver Injury Network (DILIN): Liver Injury from Nonsteroidal AntiInflammatory Drugs in the United States. Liver Int [Epub ahead of print], 2015.
Khemichian S, Lee B, Kahn J, Noureddin M, Kim B, Harper T, Esmailian Y, Fong

TL: Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection after Liver
Transplantation. Transplantation Direct 1:1-5, 2015.
Ng T, Rochefort H, Czaplicki C, Teixeira P, Zheng L, Matsuoka L, Van Dam J, Alexopoulos

S: Massive Pancreatic Pseudocyst with Portal Vein Fistula: Case Report and Proposed
Treatment Algorithm. Pancreatology 15(1):88-93, 2015.
Kim B, Tan A, Limketkai BN, Pinney SP, Schiano TD: Comparison of Outcome in Patients
with versus without Ascites Referred for Either Cardiac Transplantation or Ventricular Assist
Device Placement. Am J Cardiol 116:1596-00, 2015.
Radosevich AJ, Mutyal NN, Eshein A, Nguyen T-Q, Gould B, Rogers JD, Goldberg MJ,
Bianchi LK, Yen EF, Konda V, Rex DK, Van Dam J, Backman V, Roy HK: Rectal Optical
Markers for in vivo risk Stratification of Premalignant Colorectal Lesions. Clin Cancer Res
1-9, 2015.
Muniraj T, Sahakian A, Ciarleglio MM, Deng YH, Aslanian HR: Cold Snare Polypectomy
for Large Sessile Colonic Polyps: a Single Center Experience. Gastroenterol Res Pract
2015:175959, 2015.
Win S, Than T, Le B, Garcia-Ruiz C, Fernandez-Checa J, Kaplowitz N: Sab (SH3BP5)

Dependence of JNK-Mediated Inhibition of Mitochondrial Respiration in Palmitic Acid
Induced Hepatocyte Lipotoxicity. J Hepatol 62: 1367-1374, 2015.
Sahakian AB, Laine L, Jamidar PA, Siddiqui UD, Duffy A, Ciarleglio MM, Deng Y, Nagar
A, Asianian HR: Can a Computerized Simulator Assess Skill Level and Improvement in
Performance of ERCP? Dig Dis Sci [Epub ahead of print], 2015.
Cho NE, Bang BR, Gurung P, Li M, Clemens DL, Underhill TM, James LP, Chase JR, Saito T:
Retinoid Regulation of Antiviral Innate Immunity in Hepatocytes. Hepatology, in press, 2015.
Minassian A, Zhang J, Zhao J, He S, Zandi E, Saito T, Liang C, Feng P: An Internally
Translated Variant of MAVS Exposes its Amino-Terminal TRAF-Binding Motifs to
Deregulate Interferon Induction. PLOS Pathogen 11(7):e1005060, 2015.
Gargus M, Niu C, Binkley J, Rubin DC, Shaker A: Human Esophageal Myofibroblasts
Secrete Pro-Inflammatory Cytokines in Response to Acid and Toll-Like Receptor-4 Ligands
Am J Physiol Gastrointest Liver Physiol, 308(11):G904-23, 2015.
Win S, Than T, Min R, Kaplowitz N: Activated JNK Promotes Mitochondrial Dysfunction

and Liver Injury by Sab (SH3BP5) Dependent Inactivation of Intramitochondrial Src,
submitted, 2015.
Yuan L, Bambha K: Bile Acid Receptors and Nonalcoholic Fatty Liver Disease. The World
Journal of Hepatology 7(28):2811-8, 2015.

Internal Medicine
Addala A, Middleton B, Ho CH: A 14-Year-Old Boy with a Painful Abdominal Mass.
Gastroenterology 148(3):e3-4, 2015.
Gargus M, Niu C, Shaker A: Isolation of Myofibroblast from Mouse and Human Esophagus.
J Vis Exp (95):52215, 2015.
Basravi S, Shastry P, Ho CH, Zia S, Chan R: Delayed Scalp Bleeding in a 2-Year-Old Boy.
Pediatric Annals, in press, 2015.
Sheibani S, Khemichian S, Hou LA, Kim JJ, Yan A, Buxbaum JL, Dara L, Laine L:
Randomized Trial of 1-Week vs. 2-Week Intervals for Endoscopic Ligation in the Treatment
of Patients with Esophageal Variceal Bleeding. Digestive Disease Week, submitted, 2015.
Chan R, Shah AK, Lewis K, Johnson JL, Sequeira P, Ho CH: Hyperglycemic Hyperosmolar
State During Induction Chemotherapy for Acute Lymphoblastic Leukemia. Pediatric
Emergency Care, in press, 2015.
138

Doshi V, Ho CH, Chan RY: A Perplexing Target Sign. J Pediatr [Epub ahead of print],
2015.
Hematology
Edberg D, Lal R, Ho CH: Stump Appendicitis. Consultant for Pediatricians, submitted, 2015.
Bowen JM, Perry AM, Quist E, Akhtari M: Extramedullary Hematopoiesis in a Sentinel

Lymph Node as an Early Sign of Chronic Myelomonocytic Leukemia. Case Rep Pathol
[Epub], 2015.
Ho CH: a Clumsy Teenager. Consultant 360, submitted, 2015.

Ho CH, Chan RY, Salazar AM, Lewis KE, Johnson JL: T-Cell Lymphoblastic Lymphoma in a
Boy with a Mediastinal Mass. Consultant for Pediatricians 14(3):137-8, 2015.
Ho CH, Samko T, Escobedo E, Im D, Lewis K: Rapid Gingival Enlargement. Consultant 360,
in press, 2015.
Ho CH, Sinatra FR, Pietzak M: a 9-Year-Old Girl with Postprandial Vomiting and Poor
Weight Gain. Gastroenterology 148(5):904-5, 2015.
Ho CH, Uzunyan MY: Myocarditis in Drug Rash with Eosinophilia and Systemic Symptoms.
Cardiol Young 25(6):1210-3, 2015.
Ho CH, Zargarpour J, Evans M: Raised in Darkness: a 7-month old with Nystagmus from
Severe Visual Deprivation. Pediatric Emergency Care, in press, 2015.
Im DD, Ho CH, Chan RY: Hypersegmented Neutrophils in an Adolescent Male with
Heatstroke. Journal of Pediatric Hematology/Oncology 37(6):488-8, 2015.
Kim J, Ho CH, Lewis KE, Warner WL, Chan R: Delayed-Onset Thrombocytopenia in a
Pediatric Burn Patient. Burns, submitted, 2015.
Laster M, Im D, Anh A, Ho CH: a 12-Year-Old Boy with Hypertension, Hematuria and
Proteinuria. Hospital Pediatrics 5(6):348-51, 2015.
OBrien B, Middleton B, Cua E, Williams-Resnick A, Ho CH: 7-Week Old with Jaundice.
Pediatric Annals, submitted, 2015.
Samko T, Ho CH, Ford H: Upside-Down. Journal of Pediatrics, in press, 2015.
Santohigashi K, Lewis K, Ho CH: Its Not Appendicitis! Clinical Gastroenterology and
Hepatology, in press, 2015.
Yanger S, Tanaka K, Ho CH, Zia S: Abdominal Pain in an Adolescent Female. Bilateral
Parovarian Cysts with Left Ovarian Torsion and Right Cyst Hemorrhage. Annals of
Emergency Medicine 66(2):216-7, 2015.
Hochman M: Improvement Happens: Team-Based Primary Care: An Interview with Stuart
Pollack. J Gen Intern Med 30(4):521-8, 2015.
Hochman M, Cohen PA: Reconsidering Guidelines on the Use of Pneumococcal Vaccines in
Adults 65 Years or Older. JAMA Internal Med 175(12):1895-6, 2015.
Boone E, Lewis L, Karp M: Discontent and Confusion: Primary Care Providers Opinions
and Understanding of Current Cervical Cancer Screening Recommendations. J Womens
Health (Larchmont) [Epub ahead of print], 2015.
Russo C, Jin Z, Sera F, Lee ES, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR:
Left Ventricular Systolic Dysfunction by Longitudinal Strain is an Independent Predictor of
Incident Atrial Fibrillation: a Community-Based Cohort Study. Circ Cardiovascular Imaging
8(8);e003520, 2015.
Sera F, Jin Z, Russo C, Lee ES, Schwartz J, Rundek T, Elkind M, Homma S, Sacco R,
Di Tullio MR: Ambulatory Blood Pressure Control and Subclinical Left Ventricular
Dysfunction in Treated Hypertensive Subjects. Journal of American College of Cardiology
22;66(12):1408-9, 2015.
Sera F, Jin Z, Russo C, Lee ES, Schwartz JE, Rundek T, Elkind MS, Homma S, Sacco RL,
Di Tullio MR: Relationship of Office and Ambulatory Blood Pressure with Left Ventricular
Global Longitudinal Strain. Am J Hypertension, submitted, 2015.
Awdishu L, Coates CR, Lyddane A, Tran K, Daniels CE, Lee J, Il-Kareh R: The Impact of
Real-Time Alerting on Appropriate Prescribing in Kidney Disease: a Cluster Randomized
Controlled Trial. J Am Med Inform Assoc [Epub ahead of print], 2015.
Storms AD, Kusriastuti R, Misriyah S, Praptiningsih CY, Amalya M, Lafond KE, Samaan
G, Triada R, Iuliano AD, Ester M, Sidjabat R, Chittenden K, Vogel R, Widdowson MA,
Mahoney F, Uyeki TM: The East Jakarta Project: Surveillance for Highly Pathogenic Avian
Influenza A(H5N1) and Seasonal Influenza Viruses in Patients Seeking Care for Respiratory
Disease, Jakarta, Indonesia, October 2011-September 2012. Epidemiol Infect 1-11 [Epub
Borneman T, Sun V, Williams AC, Fujinami R, Del Ferraro C, Burhenn PS, Irish T, Zachariah
F, van Zyl C, Buga S: Support for Patients and Family Caregivers in Lung Cancer:
Educational Components of an Interdisciplinary Palliative Care Intervention. J Hosp Palliat
Nurs 17(4):309-318, 2015.
Pon D, Hwang J, Lo T, van Zyl C: Decreased Responsiveness to Oxycodone: a Case of
Pharmacokinetic Drug Interaction? J Opioid Management, in press, 2015.
Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M: An

Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians. Korean J
Fam Med 36(5):197-202, 2015.
Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, Pullarkat V:
Toxicity Profile of Repeated Doses of PEG-Asparaginase Incorporated into a Pediatric-Type
Regimen for Adult Acute Lymphoblastic Leukemia. Eur J Haematol [Epub ahead of print],
2015.
Gopalakrishnan R, Matta H, Tolani B, Triche T, Chaudhary PM: Immunomodulatory Drugs
Target IKZF1-IRF4-MYC Axis in Primary Effusion Lymphoma in a Cereblon-Dependent
Manner and Display Synergistic Cytotoxicity with BRD4 Inhibitors. Oncogene, submitted,
2015.
Zhu H, Lou S, Zhou S, Sun W, Li L, Warburton D, He Q, Jing, Y, Chaudhary PM, Wu
L: Decrease in Phosphorylation of RARS77 Overcomes Retinoid-Resistance to Induce
Transcription Response Inhibiting AML Cell Growth. Submitted, 2015.
Feinstein DI: Disseminated Intravascular Coagulation in Patiens with Solid Tumors
Oncology 29:2, 96-102, 2015.
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar
H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM,
Salgia R, Kimple RJ, Wheeler DL: AXL is a Logical Molecular Target in Head and Neck
Squamous Cell Carcinoma. Clin Cancer Res 21(11):2601-12, 2015.
Ferguson BD, Tan YH, Kanteti RS, Liu R, Gayed MJ, Vokes EE, Ferguson MK, Iafrate AJ,
Gill PS, Salgia R: Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway
Analysis in Lung Cancer. Sci Rep 5:10641, 2015.
Liang M, Adisetiyo H, Liu X, Liu R, Gill P, Roy-Burman P, Jones JO, Mulholland DJ:
Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate
Cancer Model. PLoS One 10(7):e0131232, 2015.
Lin YG, Shen J, Yoo E, Liu R, Yen HY, Mehta A, Rajaei A, Yang W, Mhawech-Fauceglia P,
DeMayo FJ, Lydon J, Gill P, Lee AS: Targeting the Glucose-Regulated Protein-78 Abrogates
Pten-Null Driven AKT Activation and Endometrioid Tumorigenesis. Oncogene 19, 2015.
Noy A, Lee JY, Cesarman E, Ambinder R, Baiocchi R, Reid E, Ratner L, Wagner-Johnston
N, Kaplan L, AIDS Malignancy Consortium, Sparano J, Dezube B, Kasamon Y, Henry D,
Wachsman W, Mitsuyasu R, Gill P, Aboulafia D, Craig M: AMC 048: Modified CODOX-M/
IVAC-Rituximab is Safe and Effective for HIV-Associated Burkitt Lymphoma. Blood
126(2):160-6, 2015.
Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult
C, Gandara DR, Liu E, de Vere White RW: Development and Characterization of Bladder
Cancer Patient-Derived Xenografts for Molecularly Guided Target Therapy. PLoS One
10(8):e0134346, 2015.
Wang H, Li D, Liu S, Liu R, Yuan H, Krasnoperov V, Shan H, Conti PS, Gill PS, Li Z: SmallAnimal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal
Antibody MAb 159. J Nucl Med 56(6):908-13, 2015.
Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim
MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu
A, Ling M, Fackler MJ, Merino V, Zhang, Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC,
Sukumar S, Gill PS, Pandey A: Global Phosphotyrosine Survey in Triple-Negative Breast
Cancer Reveals Activation of Multiple Tyrosine Kinase Signaling Pathways. Oncotarget
6(30):29143-60, 2015.
Zhou B, Wang H, Liu R, Wang M, Deng H, Giglio BC, Gill PS, Shan H, Li Z: PET Imaging
of DII4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled
Monoclonal Antibody 61B. Mol Pharm 12(10):3527-34, 2015.
Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly
K, Chanan-Khan A, Ailawadhi S: Persistent Disparities among Patients with T-Cell NonHodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: a SEER
Database Review. Clin Lymphoma Myeloma Leuk 15(10):578-85, 2015.
Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST:
Junctional Adhesion Molecule-A is Overexpressed in Advanced Multiple Myeloma and
Determines Response to Oncolytic Reovirus. Oncotarget 6(38):41275-89.
Shah JJ, Jakubowiak AJ, OConnor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D,
Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ,
Lonial S: Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor
Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or
Lymphoma. Clin Cancer Res [Epub ahead of print], 2015.
139

Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y,
Carraway HE, Nazha A, Advani AS, Maciejewski JP, Sekeres MA, Carew JS: Comprehensive
Quantitative Proteomic Profiling of the Pharmacodynamic Changes Induced by MLN4924 in
Acute Myeloid Leukemia Cells Establishes Rationale for its Combination with Azacitidine.
Leukemia [Epub ahead of print], 2015.
Barsam SJ, Pinheiro M, Ghanima W, Solomon J, Thompson MV, Liebman HA, Bussel JB:
Inflammation is the Major Cause of Impaired Health-Related Quality of Life in Patients with
Immune Thrombocytopenia. British Journal of Haematology, submitted, 2015.
Di Nisio M, Lee A, Carrier M, Liebman HA, Khorana AA: Diagnosis and Treatment of
Incidental Venous Thromboembolism in Cancer Patients. Guidance from the SSC of the
ISTH. Journal of Haemostasis and Thrombosis [Epub ahead of print], 2015.
Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke
JM, Flowers CR, Francis CW, Gates LE, Kakkar A, Key NS, Levine MN, Liebman HA,
Tempero MA, Wong SL, Somerfield M, Falanga A: Venous Thromboembolism Prophylaxis
and Treatment in Patients with Cancer: American Society of Clinical Oncology Clinical
Practice Guideline Update 2014. Journal of Clinical Oncology 33(6):654-6, 2015.
Thachil J, Falanga A, Levi M, Liebman H, Di Nisio M: Management of Cancer-Associated
Disseminated Intravascular Coagulation: Guidance from the SCC of the ISTH. Journal of
Thrombosis Haemostasis [Epub ahead of print], 2015.
Lim Y, Gondek L, Li L, Wang Q, Ma H, Chang E, Huso DL, Foerster S, Marchionni L,
McGovern K, Watkins DN, Peacock CD, Levis M, Smith BD, Merchant AA, Small D,
Matsui W: Integration of Hedgehog and Mutant FLT3 Signaling in Myeloid Leukemia. Sci
Transl Med 7(291):291ra96.
Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, OConnell C, Yee K, Tibes R, Griffiths
EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN,
Azab M, Kantarijan H: Safety and Tolerability of Guadecitabine (SGI-110) in Patients with
Myelodysplastic Syndrome and Acute Myeloid Leukaemia: a Multicentre, Randomised,
Dose-Escalation Phase 1 Study. Lancet Oncol 16(9):1099-110, 2015.
OConnell C: How I Treat Pulmonary Embolism. Blood 125(12):1877-82, 2015.
OConnell C: Incidentally Found Pulmonary Embolism: Whats the Clinician to do?
Hematology Am Soc (1):197-201.
OConnell CL, Hanna DL, Ali D, Groshen S, Tsao-Wei D, Piatek CI, Dilday E, Tagawa
S, Akhtar NH, Rochanda L, Quinn DI, Liebman HA: D-Dimer Levels Predict the Presence
and Proximity of Incidental Pulmonary Emboli in Cancer Patients: Implications for Clinical
Practice and Outcomes. Journal of Clinical Oncology, submitted, 2015.
van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, Jimenez D,
Portillo AK, OConnell C, Liebman HA, Shteinberg M, Adir Y, Tiseo M, Bersanelli
M, Abdel-Razeq HN, Mansour AH, Donnelly OG, Radhakrisna G, Ramasamy S, Bozas
G, Maraveyas A, Shinagare AB, Hatabu H, Nishino M, Huisman MV, Klok FA: Risk
of Recurrent Venous Thromboembolism and Major Haemorrhage in Cancer-Associated
Incidental Pulmonary Embolism amongst Treated and Untreated Patients: a Pooled Analysis
of 926 Patients. J Thromb Haemost [Epub ahead of print], 2015.
Piatek CI, Akhtari M: Management of Thrombocytopenia in Cancer. Oncology (Williston
Park) 29(4):297-8, 2015.
Piatek C, El-Hemaidi I, Feinstein DI, Liebman HA, Akhtari A: Management of ImmuneMediated Cytopenias in Pregnancy. Autoimmunity Reviews 14(9):806-11, 2015.
Piatek C, Lee G, Garcia AA, et al: Phase I Clinical Trial of Vinorelbine and Temsirolimus in
Advanced Solid Tumors. Cancer Chemo Pharmacol, submitted, 2015.
Andersen CL, Nielsen HM, Kristensen LS, Sgaard A, Vikes J, Jnson L, Nielsen FC,
Hasselbalch H, Bjerrum OW, Punj V, Grnbk K: Whole-Exome Sequencing and GenomeWide Methylation Analyses Identify Novel Disease Associated Mutations and Methylation
Patterns in Idiopathic Hypereosinophilic Syndrome. Oncotarget 6(38):40588-97, 2015.
Chen CL, Kumar DB, Punj V, Xu J, Sher L, Tahara SM, Hess S, Machida K: NANOG
Metabolically Reprograms Tumor-Initiating Stem-Like Cells: Tumorigenic Changes in
Oxidative Phosphorylation and Fatty Acid Metabolism. Cell metabolism [Epub ahead of
print], 2015.
Gupta I, Sehgal R, Kanwar RK, Punj V, Kanwar JR: Nanocapsules Loaded with IronSaturated Bovine Lactoferrin have Antimicrobial Therapeutic Potential and Maintain
Calcium, Zinc and Iron Metabolism. Nanomedicine 10(8): 1289-314, 2015.
HaDuong JH, Blavier L, Baniwal SK, Frenkel B, Malvar J, Punj V, Sposto R, DeClerck
YA: Interaction Between Bone Marrow Stromal Cells and Neuroblastoma Cells Leads to a
VEGFA-Mediated Osteoblastogenesis. Int J Cancer 137(4):797-809, 2015.
Kim JM, Kim K, Punj V, Liang G, Ulmer TS, Lu W, An W: Linker Sistone H1.2 Establishes
Chromatin Compaction and Gene Silencing Through Recognition of H3K27me3. Science
Report 5:16714, 2015.
Kim JM, Kim K, Schmidt T, Punj V, Tucker H, Rice JC, Ulmer TS, An W: Cooperation
Between SMYD3 and PC4 Drives a Distinct Transcriptional Program in Cancer Cells.
Nucleic Acids Res 43(18):8868-83, 2015.

Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq
CM, Crothers JR, Esserman LJ, Tripathy D, van t Veer L, Park JW: Expression Profiling of
Circulating Tumor Cells in Metastatic Breast Cancer. Breast Cancer Res Treat 149(1):121-31,
2015.
Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom
E, Austria T, Widschwendter M, Maxson R, Dubeau L: Brca1 Mutations Enhance Mouse
Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS One 21;
10(10):e0139013, 2015.
Ring A, Mineyev N, Zhu W, Park E, Lomas C, Punj V, Yu M, Barrak D, Forte V, Porras T,
Tripathy D, Lang JE: EpCAM Based Capture Detects and Recovers Circulating Tumor Cells
from all Subtypes of Breast Cancer Except Claudin-Low. Oncotarget [Epub ahead of print],
2015.
Ryland KE, Hawkins AG, Weisenberger DJ, Punj V, Borinstein SC, Laird PW, Martens JR,
Lawlor ER: Promoter Methylation Analysis Reveals that KCNA5 Ion Channel Silencing
Supports Ewing Sarcoma Cell Proliferation. Molecular Cancer Res [Epub ahead of print],
2015.
Siddique HR, Feldman DE, Chen CL, Punj V, Tokumitsu H, Machida K: NUMB
Phosphorylation Destabilizes p53 and Promotes Self-Renewal of Tumor-Initiating Cells by a
NANOG-Dependent Mechanism in Liver Cancer. Hepatology 62(5):1466-79, 2015.
Xu J, Chi F, Guo T, Punj V, Lee WNP, French SW, Tsukamoto H: NOTCH Reprograms
Mitochondrial Metabolism for Macrophage Pro-Inflammatory Activation. J Clin Invest
125(4):1579-90, 2015.
Wong, TN*, Ramsingh G*, Young AL*, et al: The Role of Early TP53 Mutations in the
Evolution of Therapy-Related AML. Nature 518(7540):552-5, 2015.
Boonyasampant M, Weitz IC, Kay B, Garratty G, Boonchalermvichian C, Liebman HA,
Shulman IA: Life-Threatening Delayed Hyper-Haemolytic Transfusion Reaction in a Patient
with Sickle Cell Disease: Effective Treatment with Eculizumab followed by Rituximab.
Transfusion 55(10):2398-403, 2015.
Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, Weitz IC, Armstrong
E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier
H, Peffault de Latour R: Eculizumab in Pregnant Patients with Paroxysmal Nocturnal
Hemoglobinuria. N Engl J Med 373(11):1032-9.
Infectious Diseases
Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dub MP,
Murphy R, Stein JH, McComsey GA: Changes in Bone Mineral Density after Antiretroviral
Initiation with Tenofovir Disoproxil Fumarate-Emtricitabine plus Atazanavir-Ritonavir,
Darunavir-Ritonavir, or Raltegravir. J Infect Dis 212:1241-1249, 2015.
Dub MP, Komarow L, Fichtenbaum CJ, Cadden JJ, Overton ET, Hodis HN, Currier JS,
Stein JH: Extended Release Niacin vs. Fenofibrate in HIV-Infected Participants with Low
HDL Cholesterol: Effects on Endothelial Function, Lipoproteins and Inflammation. Clin
Infect Dis 61:840-9, 2015.
Gianella A, Massanella M, Richman D, Little S, Spina C, Vargas M, Lada N, Daar E, Dub
MP, Haubrich R, Morris S, Smith D: Genital Cytomegalovirus Replication Predicts Syphilis
Acquisition among HIV-1 Infected Men who Have Sex with Men. PLoS One 10(6):e0130410,
2015.
Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dub MP, Murphy R,
Yang OO, Currier JS, McComsey GA: Changes in Inflammation and Immune Activation
with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin
Infect Dis 61(4):651-60, 2015.
Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS
Clinical Trials Group Study A5224s Team (including Dub MP): Reductions in Plasma
Cystatin C after Initiation of Antiretroviral Therapy are Associated with Reductions in
Inflammation: ACTG A5224s. J Acquir Immune Defic Syndr 69(2):168-77, 2015.
Massanella M, Gianella A, Schrier R, Dan J, Perez-Santiago J, Richman D, Little S, Benson
CA,Daar ES, Dub MP, Haubrich RH, Smith DM, Morris SR: Methamphetamine Use in
HIV-Infected Individuals Affects T-Cell Function and Viral Outcome During Suppressive
Antiretroviral Therapy. Scientific Reports 5:13179, 2015.
Milam J, Morris S, Jain S, Sun X, Dub MP, Daar ES, Jimenez G, Haubrich R; CCTG 592
Team: Randomized Controlled Trial of an Internet Application to Reduce HIV Transmission
Behavior among HIV Infected Men who Have Sex with Men. AIDS Behav [Epub ahead of
print], 2015.
Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn
SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever
A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team
(including Dub MP): Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir
or Atazanavir versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257.
140

Clin Infect Dis 60(12):1842-51, 2015.
Scarier than We Thought. J Infect Dis 212(12):1853-5, 2015.
Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins
B, Robertson K, Landay A, Ofotokun I, Brown T; AIDS Clinical Trials Group A5303 Study
Team (including Dub MP): Less Bone Loss with Maraviroc- versus Tenofovir-Containing
Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis
61(7):1179-88, 2015.
Wong D, R Grossberg: Tenofovir Alafenamide: An Effective Option for HIV Treatment with
Reduced Risk. Future Virology, submitted, 2015.
Vanpouille C, Introini A, Morris SR, Margolis L, Daar ES, Dub MP, Little SJ, Smith
D, Lisco A, Gianella S: Distinct Cytokine/Chemokine Network in Semen and Blood
Characterize Different Stages of HIV Infection. AIDS, in press, 2015.

Woodell TB, Hughes-Austin JM, Tran TV, Malhotra A, Abdelamlek JA, Rifkin DE:
Associations Between Cystatin C-Based eGFR Ambulatory Blood Pressure Parameters, and
In-Clinic versus Ambulatory Blood Pressure Agreement in Older Community-Living Adults.
Blood Press Monit [Epub ahead of print], 2015.
Berbari EF, Souha SK, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, Hendershot
EF, Holtom PD, Huddleston III PM, Petermann GW, Osmon DR: 2015 Infectious Diseases
Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of
Native Vertebral Osteomyelitis in Adults. Clin Inf Dis 61:26-46, 2015.
Campese V: Statins and the Kidney: Friend or Foe? Lancet Diab Endo (2) S2213-8587, 2015.
Venkatasubramanian S, Dhiman R, Paidipally P, Cheekatla SS, Tripathi D, Welch E,

Tyinnereim, Jones BE, Theodorescu D, Barnes PF, Ramakrishna V: A Rho GDP Dissociation
Inhibitor Produced by Apoptotic T-Cells Inhibits Growth of Mycobacterium tuberculosis.
PLoS Pathog 11(2):e1004617, 2015.
Maringer KV, Li H, King JD, Rush E, Xiong S, Hallows KR: Metabolic Status Modulates
the Binding and Interregulation of AMPK and CFTR. PLoS ONE, submitted, 2015.
Villarino ME, Scott N, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R,
Moro R, Shang N, Sterling TR, the International Maternal Pediatric and Adolescents AIDS
Clinical Trials Group (IMPAACT), and the Tuberculosis Trials Consortium (TBTC): New
Treatment for Preventing Tuberculosis in Children: a 3 Month (12 Dose) Regimen of
Rifapentine and Isoniazid. JAMA Pediatrics 169(3):247-55, 2015.
Alderete TL, Sattler FR, Richey JM, Allayee H, Mittelman SD, Sheng X, Tucci J,
Glyllenhammer LE, Grant EG, Goran M: Salsalate Treatment Improves Glycemia but Does
not Alter Adipose Tissue Inflammation in Non-Diabetic Obese Hispanic Young Adults.
Obesity 23(3):543-51, 2015.
Alderete TL, Sattler FR, Sheng X, Tucci J, Mittelman SD, Grant EG, Goran MI: a Novel
Biopsy Method to Increase Yield of Subcutaneous Abdominal Adipose Tissue. Internatl J
Obesity 39(1):183-6, 2015.
Dieli-Conwright CM, Kiwata JL, Tuzon C, Spektor TM, Sattler FR, Rice JC, Schroeder ET:
Acute Response of PGC-1 and IGF-1 Isoforms to Maximal Eccentric Exercise in Skeletal
Muscle of Postmenopausal Women. J Strength Cond Res [Epub ahead of print], 2015.
Sattler F, He J, Letendre S, Wilson C, Sanders C, Heaton R, Ellis R, Franklin D,
Aldrovandi G, Marra CM, Clifford D, Morgello S, Grant I, McCutchan JA: Abdominal
Obesity Contributes to Neurocognitive Impairment in HIV Infected Patients with Increased
Inflammation and Immune Activation. JAIDS 68(3):281-8, 2015.
Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker DV,
Detry MA, Le T, Berry SM: A Meta-Analysis Platform Methodology for Determining the
Comparative Effectiveness of Antihepatitis C Virus Regimens. J Comp Eff Res 4:101-14,
2015.
Bruhn KW, Dekitani K, Nielsen T, Pantapalangkoor P, Spellberg B: Ly6G-Mediated
Depletion of Neutrophils is Dependent on Macrophages. Res Immunol [Epub ahead of print],
2015.
Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, Wright MS, Bonomo
RA, Adams MD, Chen W, Spellberg B: Host Fate is Rapidly Determined by Innate
Effector-Microbial Interactions During Acinetobacter Baumannii Bacteremia. J Infect Dis
211(8):1296-305, 2015.
Bruhn KW, Spellberg B: Transferrin-Mediated Iron Sequestration as a Novel Therapy for
Bacterial and Fungal Infections. Curr Opin Microbiol 27:57-61, 2015.
Fleischman RJ, Kaji AH, Diaz VM, McKenzie K, Soltero P, Van Natta TL, Spellberg B:
a Simple Intervention to Improve Hospital Flow from Emergency Department to Inpatient
Units. JAMA Internal Med 175:289-90, 2015.
Nielsen TB, Bruhn KW, Pantapalangkoor P, Junus JL, Spellberg B: Cryopreservation of
Virulent Acinetobacter Baumannii to Reduce Variability of in vivo Studies. BMC Micro
Method 15:252, 2015.
Russo TA, Spellberg B, Johnson JR: Important Complexities of the Antivirulence Target
Paradigm: a Novel Ostensibly Resistance-Avoiding Approach for Treating Infections. J Infect
Dis [Epub ahead of print], 2015.
Spellberg B, Bartlett JG, Wunderink R, Gilbert DN: Novel Approaches are Needed to
Develop Tomorrows Antibacterial Therapies. Am J Resp Crit Care Medicine 191:135-40,
2015.
Spellberg B, Bonomo R: Combination Therapy for Extreme Drug Resistant (XDR)
Acinetobacter Baumannii: Ready for Prime-Time? Crit Care Med 43:1332-4, 2015.
Spellberg B, Brass EP: Non-Inferiority Does Not Mean Non-Inferior. Clin Infect Dis [Epub
Spellberg B, Doi Y: The Rise of Fluoroquinolone-Resistant E. Coli in the Community:
Campese V, Lakdawala R: The Challenges of Blood Pressure Control in Dialysis Patients.

Recent Pat Cardiovasc Drug Discov [Epub ahead of print], 2015.
Jiang C, Veon W, Li H, Hallows KR, Roy P: Epithelial Morphological Reversion Drives

Profilin-1-Induced Elevation of p27kip1 in Mesenchymal Triple-Negative Human Breast
Cancer Cells Through AMPK Activation. Cell Cycle 14: 2914-2923, 2015.
Li H, Satriano J, Thomas JL, Miyamoto S, Sharma K, Pastor-Soler NM, Hallows KR, Singh
P: Interactions Between HIF-1 and AMPK in the Regulation of Cellular Hypoxia Adaptation
in Chronic Kidney Disease. Am J Physiol Renal Physiol 309: F414-F428, 2015.
Massry SG, Iseki K, Niwa T: Uremia Research and Toxicity. J Ren Nutr 25(2):144, 2015.
Al-bataineh MM, Alzamora R, Marciszyn AL, Li H, Gong F, Hallows KR, Pastor-Soler
NM: Aurora Kinase A Activates the Vacuolar H+-ATPase (V-ATPase) in Kidney Cancer Cells.
PLoS ONE, submitted, 2015.
Pastor-Soler NM, Sutton TA, Mang HE, Kinlough CL, Gendler SJ, Madsen CS, Bastacky S,
Ho J, Al-bataineh MM, Hallows KR, Singh S, Monga SP, Kobayashi H, Haase VH, Hughey
RP: Muc1 is Protective During Kidney Ischemia-Reperfusion Injury. Am J Physiol Renal
Physiol 308: F1452-F1462, 2015.
Roy A, Al-bataineh MM, Pastor-Soler NM: Collecting Duct Intercalated Cell Function and
Regulation. Clin J Am Sco Nephrol 10(2):305-24, 2015.
Roy A, Al-Qusairi L, Donnelly BF, Ronzaud C, Marciszyn AL, Gong F, Chang YP,
Butterworth, MB, Pastor-Soler NM, Hallows KR, Staub O, Subramanya AR: Alternatively
Spliced Proline-Rich Cassettes Link WNK1 to Aldosterone Action. J Clin Invest 125: 34333348, 2015.
Al-Khafaji A, Nadim MK, Kellum JA: Hepatorenal Disorders. Chest 148(2):550-8, 2015.
Di Norcia J, Meouchy J, Genyk Y, Nadim MK: Intraoperative Hemodialysis During Liver
Transplantation. International Anesthesiology Clinics, submitted, 2015.
Durand F, Gines P, Olson J, Nadim MK: Pathogenesis of Hepatorenal Syndrome. Am J
Kidney Disease, submitted, 2015.
Durand F, Karvellas C, Nadim MK: Acute Kidney Injury in Patients with End-Stage Liver
Disease. Critical Care Clinics of North America 31(4):737-50, 2015.
Durand F, Nadim MK: Management of Acute on Chronic Liver Failure. Seminars in Liver
Disease, submitted, 2015.
Ghofrani H, Weaver FA, Nadim MK: Resistant Hypertension: Medical Management and
Alternative Therapies. Cardiology Clinics 33(1):75-87, 2015.
Karvellas CJ, Durand F, Nadim MK: Acute Kidney Injury in Cirrhosis. Crit Care Clin
31(4):737-50, 2015.
Nadim MK, Durand F, Jalan R, Kellum JA, Levitsky J, Davenport A, Karvellas C, OLeary
J, Angeli P, Bajaj R, Caldwell S, Francoz C, Fernandez J, Garcia-Tsao G, Gines P, Ison M,
Kramer D, Mehta R, Moreau R, Mulligan D, Olson J, Pomfret E, Senzolo M, Subramanian
R, Vincent JL, Genyk YS: Management of the Critically Ill Patient with Cirrhosis: a
Multidisciplinary Persepective. J of Hepatology, in press, 2015.
Olson J, Hashemi N, Nadim MK: Acute Kidney Injury following Liver Transplantation.
World J of Gastroenterology, submitted, 2015.
Parke CY, Bunnapradist S: Renal Dysfunction in Cirrhosis. Clinical Liver Disease, in press,
2015.
Matsuoka L, Alicuben E, Woo K, Cao S, Groshen S, Qazi Y, Smogorzewski M, Selby R,
Alexopoulos S: Kidney Transplantation in the Hispanic Population. Clin Transplant 3: 10-11
Shah N, Meouchy J, Qazi Y: Bortezomib in Kidney Transplantation. Curr Opin Organ
Transplant 20(6):652-6, 2015.
141
Oncology
Gallbladder Carcinoma. J Clin Oncol 33(24):2617-22, 2015.
Dzau VJ, Ginsburg GS, Van Nuys K, Agus D, Goldman D: Aligning Incentives to Fulfil the
Promise of Personalized Medicine. Lancet 385(9982):2118-9, 2015.
Govindarajan R, Adusumilli J, Baxter DL,El-Khoueiry AB, Harik SI: Reversible Posterior

Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibtor BAY 43-9006. J Clin
Oncol 24(28):e48, 2015.
Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE: Intolerance
of Uncertainty, Cognitive Complaints, and Cancer-Related Distress in Prostate Cancer
Survivors. Psychooncology 24(2):228-35, 2015.
Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey
SR, Chen HX, Erlichman C: a Phase II Trial of Bevacizumab plus Temsirolimus in Patients
with Advanced Hepatocellular Carcinoma. Invest New Drugs 33(1):241-6, 2015.
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas
G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee S-Y, Webb IJ,
Tejura B, Borgstein N, Dreicer R: Phase III, Randomized, Double-Blind, Multicenter Trial
Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients
with Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After
Docetaxel-Based Therapy: ELM-PC 5. Journal of Clinical Oncology 33(7):723-31, 2015.
Kuang Y, El-Khoueiry AB, Taverna P, Ljungman M, Neamati N: Guadecitabine (SGI-110)

Priming Sensitizes Hepatocellular Carcinoma Cells to Oxaliplatin. Mol Oncol 9(9):1799-814,
2015.
Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB,
Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH: a Phase I, Pharmacokinetic,
and Pharmacodynamic Evaluation of the DNA Methyltransferase Inhibitor 5-Fluoro-2Deoxycytidine, Administered with Tetrahydrouridine. Cancer Chemother Pharmacol
75(3):537-46, 2015.
Hsu CY, Ballard S, Batlle D, Bonventre JV, Bttinger EP, Feldman HI, Klein JB, Coresh
J, Eckfeldt JH, Inker LA, Kimmel PL, Kusek JW, Liu KD, Mauer M, Mifflin TE, Molitch
ME, Nelsestuen GL, Rebholz CM, Rovin BH, Sabbisetti VS, Van Eyk JE, Vasan RS, Waikar
SS, Whitehead KM, Nelson RG, CKD Biomarkers Consortium (including Agus D): CrossDisciplinary Biomarkers Research: Lessons Learned by the CKD Biomarkers Consortium.
Clin J Am Soc Nephrol 10(5):894-902, 2015.
Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna
EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS
Jr.: Phase I Trial of Sorafenib following Liver Transplantation in Patients with High-Risk
Hepatocellular Carcinoma. Liver Cancer 4(2):115-25, 2015.
Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran
S, Kong N, Suri A, Bargfrede M, Liu G: Phase 1/2 Study of Orteronel (TAK-700), an i\
Investigational 17,20-Lyase Inhibitor, with Docetaxel-Prednisone in Metastatic CastrationResistant Prostate Cancer. Invest New Drugs 33(2):397-408, 2015.
Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney
R, Levin WJ, El-Khoueiry AB: a Phase I Study of PF-04449913, an Oral Hedgehog
Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 21(5):1044-51, 2015.
Barzi A, Klein EA, Dorff TB, Quinn DL, Sadeghi S: Prostatectomy at High Volume Centers
Improves Outcomes and Lowers the Costs of Care for Prostate Cancer. Prostate Cancer, in
press, 2015.
Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M,
Mishra K, Upalawanna A, Wang Y, Kristeleit R: Second-Line Dovitinib (TKI258) in Patients
with FGFR2-Mutated or FGFR2-Non-Mutated Advanced or Metastatic Endometrial Cancer:
a Non-Randomized, Open-Label, Two-Group, Two-Stage, Phase 2 Study. Lancet Oncol
16(6):686-94, 2015.
Barzi A, Lenz HJ: Cost-Effectiveness of Genomic Testing for Colorectal Cancer: Are We
There Yet? Oncology (Williston Park), 29(3):183-4, 2015.
Barzi A, Sadeghi S, Kattan MW, Meropol NJ: Comparative Effectiveness of Screening
Strategies for Lynch Syndrome. J Natl Cancer Inst 107(4), 2015.
Grubman J, Barzi A: Lost in Translation: The Patient-Physician Relationship in the Molecular
Era. J Palliat Med 18(11):987-8, 2015.
Grubman J, Barzi A: We Dont Know What We Dont Know About Adolescent and Young
Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. J Adolesc
Young Adult Oncol 4(3):105-7, 2015.
Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland
W, Burich RA, Snyder-Solis L, Mack P, Lara PN Jr: Pharmacodynamic Separation of
Gemcitabine and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer: Therapeutic
and Biomarker Results. Int J Clin Oncol 20(3):518-24, 2015.
Chimge NO, Little GH, Baniwal SK, Adesitiyo H, Xie Y, Zhang T, OLaughlin A, Liu ZY,
Ulrich P, Martin A, Mhawech-Fauceglia P, Ellis MJ, Tripathy D, Groshen S, Liang C, Li
Z, Schones D, Frenkel B: RUNX1 Prevents Estrogen-Mediated AXIN1 Suppression and
B-Catenin Activation in ER-Positive Breast Cancer. Nature Communications, in press, 2015.
Martin A, Xiong J, Koromila T, Ji JS, Chang S, Song YS, Miller JL, Han CY, Kostenuik
P, Krum SA, Chimge NO, Gabet Y, Frenkel B: Estrogens Antagonize RUNX2-Mediated
Osteoblast-Driven Osteoclastogenesis Through Regulating RANKL Membrane Association.
Bone 75:96-104, 2015.
Agarwal SK, Daniels AM, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV, Daniels
JR: Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and
Supplementary Testosterone. BioMed Res Int, in press, 2015.
Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, Dubeau L, Yap LP,
Park R, Vinciguerra M, DiBiase S, Mirzaei H, Mirisola MG, Childress P, Ji L, Groshen S,
Penna F, Odetti P, Perin L, Conti PS, Ikeno Y, Kennedy BK, Cohen P, Morgan TE, Dorff
TB, Long VD: a Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration,
Enhanced Cognitive Performance, and Healthspan. Cell Metab 22:86-99, 2015.
Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB:
Patient Experience in the Treatment of Metastatic Castration-Resistant Prostate Cancer: State
of the Science. Prost Cancer Prost Dis, in press, 2015.
Adjei AA, Richards D, El-Khoueiry AB, Braiteh F, Becerra C, Stephenson J, Hezel AF,
Sherman M, Garbo LE, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S,
Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ: a Phase I Study of the
Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib
plus Sorafenib in Patients with Advanced Cancer. Clin Cancer Res [Epub ahead of print],
2015.
Ben-Josef E, Guthrie KA, El-Khoueiry A, Corless CL, Zalupski MM, Lowy AM, Thomas
Jr CR, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD: SWOG
S0809: a Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine followed
by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and
Bertelsen C, Ji L, Garcia AA, et al: Efficacy of Low-Dose Capecitabine in Metastatic Breast

Cancer. The Oncologist, submitted, 2015.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ,
Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM,
Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD,
Hortobagyi GN, Albain KS; POEMS/S0230 Investigators: Goserelin for Ovarian Protection
During Breast-Cancer Adjuvant Chemotherapy. N Engl J Med 372(10):923-32, 2015.
Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia
AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I: Phase I/II Study of Pilaralisib
(SAR245408) in combination with Trastuzumab or Trastuzumab plus Paclitaxel in
Trastuzumab-Refractory HER2-Positive Metastatic Breast Cancer. Breast Cancer Res Treat
149(1):151-61, 2015.
Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A,
Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J,
Hawthorne T, Yellin MJ, Davis TA, Vahdat LT: EMERGE: a Randomized Phase II Study of
the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMBExpressing Breast Cancer. J Clin Oncol 33(14):1609-19, 2015.
Lara PN Jr, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T,
Koczywas M, Reckamp KL, Gandara DR: Phase II Study of the AKT Inhibitor MK-2206 plus
Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer who Previously Progressed
on Erlotinib. Clin Cancer Res 21(19):4321-6, 2015.
Lara PN Jr, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara
DR: Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated
Extensive Stage Small-Cell Lung Cancer: Results from the Southwest Oncology Group
(SWOG) Database. Clin Lung Cancer [Epub ahead of print], 2015.
Lara PN Jr, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC,
Gandara DR: Relevance of Platinum-Sensitivity Status in Relapsed/Refractory ExtensiveStage Small-Cell Lung Cancer in the Modern Era: a Patient-Level Analysis of Southwest
Oncology Group Trials. J Thorac Oncol 10(1):110-5, 2015.
Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA,
Gitlitz B: I1171 Missense Mutation (particularly I1171N) is a Common Resistance Mutation
in ALK-Positive NSCLC Patients who have Progressive Disease while on Alectinib and is
Sensitive to Ceritinib. Lung Cancer 88(2):231-4, 2015.
Challagundla KB, Wise PM, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Vannini
I, Fanini F, Amadori D, Calin GA, Shimada H, Asgharzadeh S, Goldkorn A, Fabbri M:
Exosome-Mediated Transfer of miR-155 in the Tumor Microenvironment Regulates
Resistance to Chemotherapy. J Natl Cancer Inst 107(7), 2015.
Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal
N, Carducci MA, Monk JP III, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M,
Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI: Circulating Tumor Cell Telomerase
Activity as a Prognostic Marker for Overall Survival in SWOG 0421: a Phase III Metastatic
Castration Resistant Prostate Cancer Trial. Int J Cancer 136(8):1856-62, 2015.
142

Liu Y, Xu T, Xu Y, Park J, Chang H-C, Xu Lei, Kang D, Zhang X, Goldkorn A, Tai Y-C:
Magnesium Etching Properties and Magnesium-Embedded Live Cell Filter for CTC Isolation.
J Micromech Microeng, in press, 2015.
Gross ME: Blood-Based Gene Expression Profiling in Castrate-Resistant Prostate Cancer.
BMC Med 13:219, 2015.
Ukimura O, Gross ME, de Castro Abreu AL, Azhar RA, Matsugasumi T, Ushijima S,
Kanazawa M, Aron M, Gill IS: a Novel Technique Using Three-Dimensionally Documented
Biopsy Mapping allows Precise Re-Visiting of Prostate Cancer Foci with Serial Surveillance
of Cell Cycle Progression Gene Panel. Prostate 75(8):863-71, 2015.
Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S,
Matsugasumi T, Gross M, Dasgupta P, Gill IS: Trans-Rectal Ultrasound Visibility of Prostate
Lesions Identified by Magnetic Resonance Imaging Increases Accuracy of Image-Fusion
Targeted Biopsies. World J Urol 33(11):1669-76, 2015.
Eroglu Z, Hu JS: a Randomized Phase II Trial of Selumetinib vs Selumetinib plus

Temsirolimus for Soft Tissue Sarcomas. Br J Cancer 112(10):1644-51, 2015.
Gulati M, Hu JS: Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy
in Soft Tissue Sarcomas. J Ultrasound Med 34(8):1489-99, 2015.
Gibbs DC, Orlow I, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H,
Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla
E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE, GEM
Study Group: Inherited Genetic Variants Associated with Occurrence of Multiple Primary
Melanoma. Cancer Epidemiol Biomarkers Prev 24:992-997, 2015.
Olimpiadi Y, Song S, Hu JS, Matcuk GR, Chopra S, Eisenberg BL, Sener SF, Tseng WW:
Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep
17(8):39, 2015.
Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, Chan AT, Chang-Claude J,
Du M, Gong J, Harrison TA, Hayes RB, Hoffmeister M, Hutter CM, Lin Y, Nishihara R,
Ogino S, Prentice RL, Schumacher FR, Seminara D, Slattery ML, Thomas DC, Thornquist
M, Newcomb PA, Potter JD, Zheng Y, White E, Peters U: Colorectal Transdisciplinary
(CORECT) Study; Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO).
a Model to Determine Colorectal Cancer Risk Using Common Genetic Susceptibility Loci.
Gastroenterology 148:1330-1339.e14, 2015.
Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ,
Hezel AF, Vaccaro GM, Blanke CD: Phase 2 study of MK-2206, an Allosteric Inhibitor of
AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer:
a SWOG Cooperative Group Trial (S1005). Cancer [Epub ahead of print], 2015.
Bianconi D, Schuler A, Pausz C, Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer
W, Zielinski CC, Pabinger I, Ay C, Prager GW: Integrin Beta-3 Genetic Variants and Risk of
Venous Thromboembolism in Colorectal Cancer Patients. Throm Res 136(5):865-9, 2015.
Hung RJ, Ulrich CM, Goode EL, Brhane Y, Muir K, Chan AT, Marchand LL, Schildkraut J,
Witte JS, Eeles R, Boffetta P, Spitz MR, Poirier JG, Rider DN, Fridley BL, Chen Z, Haiman
C, Schumacher F, Easton DF, Landi MT, Brennan P, Houlston R, Christiani DC, Field JK,
Bickebller H, Risch A, Kote-Jarai Z, Wiklund F, Grnberg H, Chanock S, Berndt SI, Kraft
P, Lindstrm S, Al Olama AA, Song H, Phelan C, Wentzensen N, Peters U, Slattery ML,
GECCO, Sellers TA, FOCI, Casey G, Gruber SB, CORECT, Hunter DJ, DRIVE, Amos CI,
Henderson B, GAME-ON Network: Cross Cancer Genomic Investigation of Inflammation
Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.
J Natl Cancer Inst 107(11), 2015.
Bohanes P, Rankin C, Blanke CD, Winder T, Ulrich CM, Smalley SR, Rich TA, Martenson
JA, Benson AB 3rd, Mayer RJ, Cripps CM, Danenberg KD, Makar KW, Zhang W, Benedetti
JK, Lenz HJ: Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms
with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin
Cancer Res 21(7):1583-90, 2015.
Lemire M, Qu C, Loo LW, Zaidi SH, Wang H, Berndt SI, Bzieau S, Brenner H, Campbell
PT, Chan AT, Chang-Claude J, Du M, Edlund CK, Gallinger S, Haile RW, Harrison TA,
Hoffmeister M, Hopper JL, Hou L, Hsu L, Jacobs EJ, Jenkins MA, Jeon J, Kry S, Li L,
Lindor NM, Newcomb PA, Potter JD, Rennert G, Rudolph A, Schoen RE, Schumacher FR,
Seminara D, Severi G, Slattery ML, White E, Woods MO, Cotterchio M, Le Marchand L,
Casey G, Gruber SB, Peters U, Hudson TJ: a Genome-Wide Association Study for Colorectal
Cancer Identifies a Risk Locus in 14q23.1. Hum Genet 134:1249-1262, 2015.
Stenzel SL, Ahn J, Boonstra PS, Gruber SB, Mukherjee B: The Impact of Exposure-Biased
Sampling Designs on Detection of Gene-Environment Interactions in Case-Control Studies
with Potential Exposure Misclassification. Eur J Epidemiol 30:413-423, 2015.
Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, Lu KH, Roach
N, Limburg PJ: Hereditary Colorectal Cancer Syndromes: American Society of Clinical
Oncology Clinical Practice Guideline Endorsement of the Familial Risk-Colorectal Cancer:
European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol
33(2):209-17, 2015.
Zhang C, Doherty JA, Burgess S, Hung RJ, Lindstrm S, Kraft P, Gong J, Amos CI, Sellers
TA, Monteiro AN, Chenevix-Trench G, Bickebller H, Risch A, Brennan P, Mckay JD,
Houlston RS, Landi MT, Timofeeva MN, Wang Y, Heinrich J, Kote-Jarai Z, Eeles RA, Muir
K, Wiklund F, Grnberg H, Berndt SI, Chanock SJ, Schumacher F, Haiman CA, Henderson
BE, Amin Al Olama A, Andrulis IL, Hopper JL, Chang-Claude J, John EM, Malone KE,
Gammon MD, Ursin G, Whittemore AS, Hunter DJ, Gruber SB, Knight JA, Hou L, Le
Marchand L, Newcomb PA, Hudson TJ, Chan AT, Li L, Woods MO, Ahsan H, Pierce BL;
GECCO and GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, TRICL: Genetic
Determinants of Telomere Length and Risk of Common Cancers: a Mendelian Randomization
Study. Hum Mol Genet 24(18):5356-66, 2015.
Hanna DL, Yang D, Loupakis F, Cremolini C, Antoniotti C, Schirripa M, Salvatore L, Moran
M, Zeger G, Astrow SH, Falcone A, Lenz HJ: Predictive and Prognostic Angiogenesis
Biomarkers in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy
with Bevacizumab: Results from the Phase III TRIBE Study. Clinical Cancer Research,
submitted, 2015.
van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA,
Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR,
Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ: Salvage Ablative Therapy in
Prostate Cancer: International Multidisciplinary Consensus on Trial Design. Urol Oncol
33(11):495.e1-7, 2015.
Li L, Hamel N, Baker K, McGuffin MJ, Couillard M, Gologan A, Marcus VA, Chodirker B,

Chudley A, Stefanovici C, Durandy A, Hegele RA, Feng BJ, Goldgar DE, Zhu J, De Rosa M,
Gruber SB, Wimmer K, Young B, Chong G, Tischkowitz MD, Foulkes WD: a Homozygous
PMS2 Founder Mutation with an Attenuated Constitutional Mismatch Repair Deficiency
Phenotype. J Med Genet 52:348-352, 2015.
among patients with higher-risk primary melanoma. JAMA Oncol 1:359-368, 2015.
Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Kinkhardt U, Beier F,

Duecker K, VanKrieken JH, Tejpar S: FOLFOX4 plus Cetuximab Treatment and RAS
Mutations in Colorectal Cancer. Eur J Cancer 51(10):1243-52, 2015.
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace
J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu
P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL:
Randomized Phase Ib/II Study of Gemcitabine plus Placebo or Vismodegib, a Hedgehog
Pathway Inhibitor, in Patients with Metastatic Pancreatic Cancer. J Clin Oncol 33(36):428492, 2015.
Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D,
Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen
JS, Hogdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B,
Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevauz
H, Tejpar S: FCGR Polymorphisms and Cetuximab Efficacy in Chemorefractory Metastatic
Colorectal Cancer: an International Consortium Study. Gut 64(6):921-8, 2015.
Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler
HL, Lenz HJ, Chen H, Erlichman C: Multicenter Phase II Trial of Temsirolimus and
Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol 33(14):1551-6, 2015.
Hochster HC, Uboha N, Messersmith W, Gold PJ, ONeil BH, cohen D, Denlinger C,
Cohen S, Leichman CG, Leichman L, Lenz HJ: Erratum to: Phase II Study of Selumetinib
(AZD6244, ARRY-142866) plus Irinotecan as Second-Line Therapy in Pateints with K-RAS
Mutated Colorectal Cancer. Cancer Chemother Pharmacol 75(1):17-23, 2015.
Taylor NJ, Busam KJ, From L, Groben PA, Anton-Culver H, Cust AE, Begg CB, Dwyer T,
Gallagher RP, Gruber SB, Orlow I, Rosso S, Thomas NE, Zanetti R, Rebbeck TR, Berwick
M, Kanetsky PA: Inherited Variation at MC1R and Histological Characteristics of Primary
Melanoma. PLoS One 10:e0119920, 2015.
Lee NS, Evgrafov OV, Souaiaia T, Bonyad A, Herstein J, Lee JY, Kim J, Ning Y, Sixto M,
Weitz AC, Lenz HJ, Wang K, Knowles JA, Press MF, Salvaterra PM, Shung KK, Chow RH:
Non-Coding RNAs Derived from an Alternatively Spliced REST Transcript (REST-003)
Regulate Breast Cancer Invasiveness. Sci Rep 5:11207, 2015.
Taylor NJ, Reiner AS, Begg CB, Cust AE, Busam KJ, Anton-Culver H, Dwyer T, From L,
Gallagher RP, Gruber SB, Rosso S, White KA, Zanetti R, Orlow I, Thomas NE, Rebbeck
TR, Berwick M, Kanetsky PA, GEM Study Group: Inherited Variation at MC1R and ASIP
and Association with Melanoma-Specific Survival. Int J Cancer 136:2659-2667, 2015.
Lenz HJ, Stintzing S, Loupakis F: TAS-102, a Novel Antitumor Agent: a Review of the
Mechanism of Action. Cancer Treat Rev 41(9):777-83, 2015.
Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK,
Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L,
Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso
S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group:
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival
Loupakis F, Yand D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer
C, Scherer SJ, Muller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ: Primary Tumor Location
as a Prognostic Factor in Metastatic Colorectal Cancer. J Natl Cancer Inst 107(3), 2015.
Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Yang D, Ueno M, Mizunuma N, Zhang W,
Ning Y, Parekh A, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Okazaki S, Berger MD,
El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. CXCR4 Polymorphism
143

Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe
M, Koizumi W, Lenz HJ: Association of Variants in Genes Encoding for MacrophageRelated Functions with Clinical Outcome in Patients with Locoregional Gastric Cancer. Ann
Oncol 26(2):332-9, 2015.
Predicts Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with

First-Line Bevacizumab-Based Chemotherapy. The Pharmacogenomics Journal, submitted,
2015.
Matsusaka S, Lenz HJ: Pharmacogenomics of Fluorouracil-Based Chemotherapy Toxicity.
Expert Opin Drug Metab Toxicol 11(5):811-21, 2015.
Szkandera J, Herzog S, Pichler M, Stiegelbauer V, Stotz M, Schaberi-Moser R, Samonigg

H, Asslaber M, Lax S, Leitner G, Renner W, Lenz HJ, Berghold A, Gerger A: LGR5
rs17109924 is Predictive Genetic Biomarker for Time to Recurrence in Patients with Colon
Cancer Treated with 5-Fluorouracil-Based Adjuvant Chemotherapy. Pharmacogenomics J
15(5):391-6, 2015.
Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning
Y, Parekh A, Okazaki A, Berger MD, Mendez A, Ichikawa W, Mizunuma N, Lenz HJ:
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer
Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Molecular Cancer
Therapeutics, submitted, 2015.
Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O,

Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent
D, Teufel M, Jeffers M, Grothey A, Van Cutsem E: Analysis of Circulating DNA and Protein
Biomarkers to Predict the Clinical Activity of Regorafenib and Assess Prognosis in Patients
with Metastatic Colorectal Cancer: a Retrospective, Exploratory Analysis of the CORRECT
Trial. Lancet Oncol 16(8):937-48, 2015.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N,

Yamazaki N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E,
Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti
F, Mizuquchi H, Makris L, Ito M, Ohtsu A: Randomized Trial of TAS-102 for Refractory
Metastatic Colorectal Cancer. N Engl J Med 372(20):1909-19, 2015.
Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Teipar S, Melezinek I, Beier F, Stroh
C, Rougier P, Van Krieken JH, Ciardiello F: Fluorouracil, Leucovorin, and Irinotecan plus
Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin Oncol 33(7):692-700,
2015.
Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG,
Berger NA, Markowitz SD, Lenz HJ, Nadeau JH, Pizarro TT, Heaney JD: IL-33 Activates
Tumor Stroma to Promote Intestinal Polyposis. Proc Natl Acad Sci USA 112(19):E2487-96,
2015.
Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley
W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV: Circulation Cytokines and
Monocyte Subpopulations as Biomarkers of Outcome and Biological Activity in SunitinibTreated Patients with Advanced Neuroendocrine Tumours. Br J Cancer 112(7):1199-205,
2015.
Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa

Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ: Cyokeratin-20 and
Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal
Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther
14(10):2401-8, 2015.
Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S, Sunakawa Y,
Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ: Genetic Variants within Obesity-Related
Genes are Associated with Tumor Recurrence in Patients with Stages II/III Colon Cancer.
Pharmacogenet Genomics 25(1):30-7, 2015.
Sebio A, Lenz HJ: Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor. Clin
Cancer Res 21(22):5002-7, 2015.
Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Sunakawa Y, Yamauchi S,
Fujimoto Y, Ueno M, Lenz HJ: Germline Polymorphisms in Genes Involved in the Hippo
Pathway as Recurrence Biomarkers in Stages II/III Colon Cancer. Pharmacogenomics J
Ghaffarizadeh A, Friedman SH, Macklin P: BioFVM: an Efficient, Parallelized Diffusive

Transport Solver for 3-D Biological Simulations. Bioinformatics [Epub ahead of print], 2015.
Bemis KD, Harry A, Eberlin LS, Ferreira C, van de Ven SM, Mallick P, Stolowitz M, Vitek
O: Cardinal: an R Package for Statistical Analysis of Mass Spectrometry-Based Imaging
Experiments. Bioinformatics 31(14):2418-20, 2015.
Frieboes HB, Curtis LT, Wu M, Kani K, Mallick P: Simulation of the Protein-Shedding
Kinetics of a Fully Vascularized Tumor. Cancer Inform 14:163-75, 2015.
Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM: a Fully
Human scFv Phage Display Library for Rapid Antibody Fragment Reformatting. Protein Eng
Des Sel 28(10):307-16, 2015.
Stintzing S, Stremitzer S, Sebio A, Lenz HJ: Predictive and Prognostic Markers in the
Treatment of Metastatic Colorectal Cancer (mCRC): Personalized Medicine at Work.
Hematol Oncol Clin North Am 29(1):43-60, 2015.
Schubert OT, Gillet LC, Collins BC, Navarro P, Rosenberger G, Wolski WE, Lam H, Amodei
D, Mallick P, MacLean B, Aebersold R: Building High-Quality Assay Libraries for Targeted
Analysis of SWATH MS Data. Nat Protoc 10(3):426-41, 2015.
Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A,

Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi
S, Loupakis F, Cremolini C, Falcome A, Lenz HJ: Polymorphisms in Genes Involved in
EGFR Turnover are Predictive for Cetuximab Efficacy in Colorectal Cancer. Mol Cancer
Ther 14(10):2374-81, 2015.
Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, Gibson EM, Mount
CW, Polepalli J, Mitra SS, Woo PJ, Malenka RC, Vogel H, Bredel M, Mallick P, Monje
M: Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion. Cell
161(4):803-16, 2015.
Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y,
Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD,
El-Khoueiry R, Birner P, Preusser A, Lenz HJ: Genetic Variants Associated with Colorectal
Brain Metastases Susceptibility and Survival. Pharmacogenomics J [Epub ahead of print],
2015.
Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S,
Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ: Variations in Genes
Involved in Immune Response Checkpoints and Association with Outcomes in Patients with
Resected Colorectal Liver Metastases. Pharmacogenomics J [Epub ahead of print], 2015.
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S,
Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ: Genetic Variations
in Angiopoietin and Pericyte Pathways and Clinical Outcome in Patients with Resected
Colorectal Liver Metastases. Cancer 121(11):1898-905, 2015.
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S,
Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz
HJ: Variations in Genes Involved in Dormancy Associated with Outcome in Patients with
Resected Colorectal Liver Metastases. Ann Oncol 26(8):1728-1733, 2015.
Sunakawa Y, Lenz HJ: Molecular Classification of Gastric Adenocarcinoma: Translating
New Insights from the Cancer Genome Atlas Research Network. Curr Treat Options Oncol
16(4):17, 2015.
Davis EJ, Griffith KA, Kim EJ, Ruch JM, McDonnell KJ, Zalupski MM: a Phase II Study of
Biweekly Cisplatin, Fixed-Dose Rate Gemcitabine and Infusional 5-Fluorouracil in Patients
with Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol [Epub ahead of print], 2015.
McDonnell KJ, Gallanis GT, Heller KA, Melas M, Idos GE, Culver JO, Martin SE, Peng
DH, Gruber SB: a Novel BAP1 Mutation is Associated with Melanocytic Neoplasms and
Thyroid Cancer. Cancer Genet [Epub ahead of print], 2015.
Frieboes HB, Smith BR, Wang Z, Kotsuma M, Ito K, Day R, Loewenberg M, Cahill B,
Flinders C, Mumenthaler SM, Mallick P, Gambhir SS, Cristini V: Predictive Modeling of
Drug Response in Non-Hodgkins Lymphoma. PLOS ONE 10(6):e0129433, 2015.
Garvey CM, Spiller E, Lindsay D, Chiang C, Choi NC, Agus DB, Mallick P, Foo J,
Mumenthaler SM: a High-Content Image-Based Method for Quantitatively Studying Cell
Population Dynamics Nature Methods, submitted, 2015.
Mumenthaler SM*, Foo J*, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor FM,
Mallick P: The Impact of Microenvironmental Heterogeneity on the Evolution of Drug
Resistance in Cancer Cells. Cancer Informatics 14(4):19-31, 2015.
Yang-Kolodji G, Mumenthaler SM, Mehta A, Ji L, Tripathy D: Phosphorylated Ribosomal
S6 (p-rpS6) as a Post-Treatment Indicator of HER2 Signaling Targeted Drug Resistance.
Biomarkers 20(5):313-22, 2015.
Burke J, Nieva J, Borad MJ, Breitbach CJ: Oncolytic Viruses: Perspectives on Clinical
Development. Curr Opin Virol 13:55-60, 2015.
Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W,

Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver
S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ: Variations in Genes Regulating TumorAssociated Macrophages (TAMs) to Predict Outcomes of Bevacizumab-Based Treatment in
Patients with Metastatic Colorectal Cancer: Results from TRIBE and FIRE3 trials. Ann Oncol
Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyahnon T, Leon ME, Neil Hayes D, Haigentz
M Jr, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH: a Randomized
Phase II Efficacy and Correlative Studies of Cetuximab with or without Sorafenib in
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.Oral Oncol
51(4):376-82, 2015.
Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S,
In GK, Nieva J: Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics
144

for Non-Small Cell Lung Cancer. Transl Cancer Res 4(4):340-355, 2015.
JH, Jung JU, Akbari O: Lack of Autophagy Induces Steroid-Resistant Airway Inflammation.
J Allergy Clin Immunol [Epub ahead of print], 2015.
Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee
GA, Gross ME, Fini ME: Expression and Functional Role of Orphan Receptor GPR158 in
Prostate Cancer Growth and Progression. PLoS One 10(2):e0117758, 2015.
Soong M, Masket K, Pallickal L, Baydur A: Relationship of Change in 6-Minute Walking

Test to Baseline Hyperinflation in Patients with Chronic Obstructive Pulmonary Disease
(COPD) Undergoing Pulmonary Rehabilitation. Jacobs J Pulmonol 1(1):003, 2015.
Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI,
Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J,
Stephens AW, Worden F, Hammer GD: Linsitinib (OSI-906) versus Placebo for Patients with
Locally Advanced or Metastatic Adrenocortical Carcinoma: a Double-Blind, Randomized,
Phase 3 Study. Lancet Oncol 16(4):426-35, 2015.
Li C, Bellusci S, Borok Z, Minoo P: Non-Canonical WNT Signalling in the Lung. J Biochem

158(5):355-65, 2015.
Li C, Li M, Li S, Xing Y, Yang CY, Li A, Borok Z, De Langhe S, Minoo P: Progenitors of
Secondary Crest Myofibroblasts are Developmentally Committed in Early Lung Mesoderm.
Stem Cells 33: 999-1012, 2015.
Jadvar H, Challa S, Quinn DI, Conti PS: One-Year Postapproval Clinical Experience with
Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Cancer Biother Radiopharm 30(5):195-9, 2015.
Marconett C, Zhou B, Wang HJ, Pouldar TM, Liu Y, Rieger ME, Tran E, Flodby P,
Siegmund KD, Crandall ED, Laird-Offringa IA, Borok Z: Genome-Wide Transcriptional
Profiling in Human and Rat Identifies New Cell-Specific Genes to Study Alveolar Epithelial
Biology. PLoS Genetics, submitted, 2015.
Jadvar H, Groshen SG, Quinn DI: Association of Overall Survival with Glycolytic Activity
of Castrate-Resistant Prostate Cancer Metastases. Radiology 274(2):624-5, 2015.
Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis
MD, Colevas AD, Doroshow J, Newman EM: Pharmacodynamics (PD) and pharmacokinetics
(PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with
advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol
76(5):897-907, 2015.
Quinn DI, Lara PN Jr.: Renal-Cell Cancer- Targeting an Immune Checkpoint or Multiple
Kinases. N Engl J Med 373(19):1872-4, 2015.
Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts
WG, Kim S, Motzer RJ: Hypertension Among Patients with Renal Cell Carcinoma Receiving
Axitnib or Sorafenib: Analysis from the Randomized Phase III AXIS Trial. Target Oncol
10(1):45-53, 2015.
Flodby P, Liebler JM, Krishnaveni MS, Banfalvi A, Li M, Zhou B, Crandall ED, Minoo
P, Borok Z: Region-Specific Role for Pten in Maintenance of Epithelial Integrity following
Acute Lung Injury. AJP Lung, submitted, 2015.
Tang V, Pato M, Sobell J, Hammond TC, Valdez MA, Lane C: Substance Use Associated
with Short Sleep Duration in Patients with Schizophrenia or Schizoaffective Disorder.
Psychiatry, in press, 2015.
Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern
MC, Hamilton AS, Aron M, Gill IS: Radical Prostatectomy or External Beam Radiation
Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEERMedicare Analysis. J Urol 194(2):378-85, 2015.
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB,
Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen
CM, Thompson IM Jr: SWOG S0925: a Randomized Phase II Study of Androgen Deprivation
Combined with Cixutumumab versus Androgen Deprivation Alone in Patients with New
Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33(14):1601-8, 2015.
Patsch K, Chiu C, Agus DB, Mallick P, Mumenthaler SM, Ruderman D: High Throughput
Single Cell Dynamic Phenotyping Nature Methods, submitted, 2015.
Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK,
Russell CA, et al: Double-Blind Phase III Randomized Trial of the Antiprogestin Agent
Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol
33:4093-4098, 2015.

Balekian AA, Fisher JM, Gould MK: Brain Imaging for Staging of Patients with Clinical
Stage IA Non-Small Cell Lung Cancer in the National Lung Screening Trial: Adherence with
Recommendations From the Choosing Wisely Campaign. Chest [Epub ahead of print], 2015.
Suzuki Y, Maazi H, Sankaranarayanan I, Lam J, Khoo B, Soroosh P, Barbers RG, James Ou
Sevransky JE, Checkley W, Herrera P, Pickering BW, Barr J, Brown SM, Chang SY,
Dabbagh O, Chong D, Fremont RD, Girard TD, Hoag J, Johnson SB, OBrien J, Liebler J,
Park PK, Pastores SM, Patil NT, Pietropaoli AP, Putman M, Rice T, Rotello L, Siner J, Sajid
S, Murphy DJ, Martin GS, USCIITG-CIOS Investigators: Protocols and Hospital Mortality
in Critically Ill Patients: The United States Critical Illness and Injury Trials Group Critical
Illness Outcomes Study. Crit Care Med 43:2076-2084, 2015.
Rheumatology
Wu AH, Spicer D, Garcia A, Tseng CC, Hovanessian-Larsen L, Sheth P, Martin SE,

Hawes D, Russell C, MacDonald H, Tripathy D, Su LM, Ursin G, Pike MC: Double Blind
Randomized 12 Month Osy Intervention Had no Effects on Breast MRI Fibroglandular Tissue
Density or Mammographic Density. Cancer Prev Res (Phila) 8(10):942-51, 2015.
Xiong S, Wang Q, Liu SV, Montgomery RB, Stanczyk FZ, Vallone JG, Merin NM, Pinski
J: Effects of Luteinizing Hormone Receptor Signaling in Prostate Cancer Cells. Prostate
75(2):141-50, 2015.
Liebler JM, Marconett CN, Juul N, Wang H, Liu Y, Flodby P, Laird-Offringa IA, Minoo P,
Zhou B: Combinations of Differentiation Markers Distinguish Subpopulations of Alveolar
Epithelial Cells in Adult Lung. Am J Physiol Lung Cell Mol Physiol [Epub ahead of print],
2015.
Truong LN, OConnell R, Oren A: A 49-Year-Old Man with Fever, Erythema Nodosum,
and Ankle Swelling. Final Diagnosis: Extrapulmonary Tuberculosis with Hepatic and Bone
Marrow Involvement. Ann Am Thorac Soc 12(10):1575-7, 2015.
Wecsler JS, Tereffe W, Pedersen RC, Sieffert MR, Mack WJ, Cui H, Russell CA, Woods RR,
Viscusi RK, Sener SF, Lang JE: Lymph Node Status in Inflammatory Breast Cancer. Breast
Cancer Res Treat 151(1):113-20, 2015.
Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA,
George DJ, Vogelzang NJ: Prognostic Factors for Survival following Initiation of SecondLine Treatment with Everolimus for Metastatic Renal Cell Carcinoma: Evidence from a
Nationwide Sample of Clinical Practice in the United States. Expert Opin Pharmacother
16(6):805-19, 2015.
Catalan MA, Kondo Y, Pena-Munzenmayer G, Jaramillo Y, Liu F, Crandall ED, Borok Z,

Flodby P, Shull GE, Melvin JE: a Novel Fluid Secretion Pathway Unmasked by AcinarSpecific Tmem16A Gene Ablation in the Adult Mouse Salivary Gland. Proc Natl Acad Sci,
112(7):2263-2268, 2015.
Flodby P, Kim YH, Beard LL, Gao D, Ji Y, Kage H, Liebler JM, Minoo P, Kim KJ,
Borok Z, Crandall ED: Knockout Mice Reveal a Major Role for Alveolar Epithelial Type I
Cells in Alveolar Fluid Clearance. Am J Respir Cell Mol Biol, submitted, 2015.
Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K: Immunotherapy for CastrationResistant Prostate Cancer: Progress and New Paradigms. Urol Oncol 33(5):245-60, 2015.
Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand
HE, Wong MK, McKee GM, Salazar AM, Kast WM: Human Papillomavirus-Exposed
Langerhans Cells are Activated by Stabilized Poly-I:C. Papillomavirus Res 1:12-21, 2015.
Rieger ME, Zhou B, Solomon N, Li C, Nguyen C, Phan JH, Minoo P, Crandall ED,
Brody SL, Kahn M, Borok Z: p300/-Catenin Interactions Regulate Adult Progenitor Cell
Differentiation Downstream of Wnt5a/Protein Kinase C(PKC). J Cell Biol, submitted, 2015.
Kreitenberg AJ, Ortiz EC, Arkfeld DG: Priapism after Tumor Necrosis Factor Alpha
Inhibitor Use. Clin Rheumatol 34(4):801-2, 2015.
Metyas SK, Solyman JS, Arkfeld DG: Inflammatory Firomyalgia: Is it Real? Curr
Rheumatol Rev [Epub ahead of print], 2015.
Escalante P, Kooda KJ, Khan R, Aye SS, Christianakis S, Arkfeld DG, Ehresmann GR,
Kort JJ, Jones BE: Diagnosis of Latent Tuberculosis Infection with T-SPOT() TB in a
Predominantly Immigrant Population with Rheumatologic Disorders. Lung 193(1):3-11,
2015.
McHugh MD, Park J, Uhrich R, Gao W, Horwitz DA, Fahmy TM: Paracrine Co-Delivery
of TGF- and IL-2 using CD4-Targeted Nanoparticles for Induction and Maintenance of
Regulatory T cells. Biomaterials 59:172-81, 2015.
Alarcn-Riquelme ME, Ziegler JT, Molineros J, Howard TD, Moreno-Estrada A, SnchezRodrguez E, Ainsworth HC, Ortiz-Tello P, Comeau ME, Rasmussen A, Kelly JA, Adler
A, Acevedo-Vzquez E, Cucho JM, la Torre IG, Cardiel MH, Miranda P, Catoggio L,
Maradiaga-Cecea M, Nath SK, Salinas CA, Orozco L, Tusi-Luna T, Zidovetzki R,
Pons-Estel BA, Langefeld CD, Jacob CO: GWAS in an Amerindian Ancestry Population
Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European
Admisture. Arthritis Rheumatol [Epub ahead of print], 2015.
Armstrong DL, Eisenstein M, Zidovetzki R, Jacob CO: 207 Structural Basis of the Effect
of Systemic Lupus Erythematosus (SLE)-Associated Mutations on the Activity of NADPH
Oxidase. J Biomol Struct Dyn 33(1):139-40, 2015.
145

Armstrong DL, Eisenstein M, Zidovetzki R, Jacob CO: Systemic Lupus ErythematosusAssociated Neutrophil Cytosolic Factor 2 Mutation Affects the Structure of NADPH Oxidase
Complex. J Biol Chem 290(20):12595-602, 2015.
IgG1 Protects against Renal Disease in a Mouse Model of Cryoglobulinaemia. Nature

517(7535):501-4, 2015.
Vaughn SE, Foley C, Lu X, Patel ZH, Zoller EE, Magnusen AF, Williams AH, Ziegler JT,
Comeau ME, Marion MC, Glenn SB, Adler A, Shen N, Nath S, Stevens AM, Freedman BI,
Tsao BP, Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcn GS, Reveille JD, Anaya
JM, James JA, Moser KL, Criswell LA, Vil LM, Alarcn-Riquelme ME, Petri M, Scofield
RH, Kimberly RP, Ramsey-Goldman R, Binjoo Y, Choi J, Bae SC, Boackle SA, Vyse TJ,
Guthridge JM, Namjou B, Gaffney PM, Langefeld CD, Kaufman KM, Kelly JA, Harley
IT, Harley JB, Kottyan LC: Lupus Risk Variants in the PXK Locus Alter B-Cell Receptor
Internalization. Front Genet 5:450, 2015.
Jacob CO, Yu N, Sindhava V, Cancro MP, Pawar RD, Putterman C, Stohl W: Differential
Development of Systemic Lupus Erythematosus in NZM 2328 Mice Dificient in Discrete
Pairs of BAFF Receptors. Arthritis Rheumatol 67(9):2523-35, 2015.
Kottyan LC, Zoller EE, Bene J, Lu X, Kelly JA, Rupert AM, Lessard CJ, Vaughn SE,
Marion M, Weirauch MT, Namjou B, Adler A, Rasmussen A, Glenn S, Montgomery CG,
Hirschfield GM, Xie G, Coltescu C, Amos C, Li H, Ice JA, Nath SK, Mariette X, Bowman
S, Segal BM, Merrill JT, James JA, Guthridge JM, Scofield RH, Alarcon-Riquelme M, Bae
SC, Boackle SA, Criswell LA, Gilkeson G, Kamen DL, Jacob CO, Kimberly R, Brown E,
Edberg J, Martin J, Siminovitch K, Moser Sivils KL, Gaffney PM, Langefeld CD, Harley JB,
Kaufman KM: The IRF5-TNPO3 Association with Systemic Lupus Erythematosus has Two
Components that other Autoimmune Disorders Variably Share. Hum Mol Genet 24(2):582-96,
2015.
Kubagawa H, Carroll MC, Jacob CO, Lang KS, Lee KH, Mak T, McAndrews M, Morse HC
3rd, Nolan GP, Ohno H, Richter GH, Seal R, Wang JY, Wiestner A, Coligan JE: Nomenclature
of Toso, Fas Apoptosis Inhibitory Molecule 3, and IgM FcR. J Immunol 194(9):4055-7, 2015.
Lessard CJ, Sajuthi S, Zhao J, Kim K, Ice JA, Li H, Ainsworth H, Rasmussen A, Kelly JA,
Marion M, Bang SY, Bin Joo Y, Choi J, Lee HS, Kang YM, Suh CH, Chung WT, Lee SK,
Choe JY, Shim SC, Oh JH, Kim YJ, Han BG, Shen N, Howe HS, Wakeland EK, Li QZ, Song
YW, Gaffney PM, Alarcn-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Vyse TJ,
Harley JB, Sivils KL, Bae SC, Langefeld CD, Tsao BP: Identification of a Systemic Lupus
Erythematosus Risk Locus Spanning ATG16L2, FCHSD2, and P2RY2 in Koreans. Arthritis
Rheumatol [Epub ahead of print], 2015.
Zhao J, Wu H, Langefeld CD, Kaufman KM, Kelly JA, Bae SC; Alarcn-Riquelme ME for
the BIOLUPUS and GENLES networks, Alarcn GS, Anaya JM, Criswell LA, Freedman
BI, Kamen DL, Gilkeson GS, Jacob CO, James JA, Merrill JT, Gaffney PM, Sivils KM,
Niewold TB, Petri MA, Song ST, Jeong HJ, Ramsey-Goldman R, Reveille JD, Scofield RH,
Stevens AM, Boackle SA, Vil LM, Chang DM, Song YW, Vyse TJ, Harley JB, Brown EE,
Edberg JC, Kimberly RP, Hahn BH, Grossman JM, Tsao BP, La Cava A: Genetic Associations
of Leptin-Related Polymorphisms with Systemic Lupus Erythematosus. Clin Immunol
161(2):157-62, 2015.
Torralba KD, Villasenor-Ovies P, Evelyn CM, Koolaee RM, Kalish RA: Teaching of Clinical
Anatomy in Rheumatology: a Review of Methodologies. Clinical Rheumatology 34(7):115763, 2015.
Johnson JA, Yu SS, Elist M, Arkfeld D, Panush RS: Rheumatologic Manisfestations of the
MonoMAC Syndrome: a Systematic Review. Clin Rheumatol 34(9):1643-5, 2015.
Kaptein AA, Smyth JM, Panush RS: Wolf-Living with SLE in a Novel. Clin Rheumatol
34(5):887-90, 2015.
Lu X, Zoller EE, Weirauch MT, Wu Z, Namjou B, Williams AH, Ziegler JT, Comeau ME,
Marion MC, Glenn SB, Adler A, Shen N, Nath SK, Stevens AM, Freedman BI, Tsao BP,
Jacob CO, Kamen DL, Brown EE, Gilkeson GS, Alarcn GS, Reveille JD, Anaya JM,
James JA, Sivils KL, Criswell LA, Vil LM, Alarcn-Riquelme ME, Petri M, Scofield RH,
Kimberly RP, Ramsey-Goldman R, Joo YB, Choi J, Bae SC, Boackle SA, Graham DC,
Vyse TJ, Guthridge JM, Gaffney PM, Langefeld CD, Kelly JA, Greis KD, Kaufman KM,
Harley JB, Kottyan LC: Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1
Expression. Am J Hum Genet 96(5):731-9, 2015.
Leatherwood C, Panush RS: Did King Herod, in the Opera, Salome, Suffer from Chronic
Lead Intoxication? JAMA, submitted, 2015.
Savvas S, Panush RS: Should all Rhematologists Study Musculoskeletal Anatomy? Clin
Rheumatol 34(7):1153-6, 2015.
Kumar V, Dasoveanu DC, Chyou S, Tzeng TC, Rozo C, Liang Y, Stohl W, Fu YX, Ruddle
NH, Lu TT: a Dendritic-Cell Stromal Axis Maintains Immune Responses in Lymph Nodes.
Immunity 42(4):719-30, 2015.
Strait RT, Posgai MT, Mahler A, Barasa N, Jacob CO, Khl J, Ehlers M, Stringer K,
Shanmukhappa SK, Witte D, Hossain MM, Khodoun M, Herr AB, Finkelman FD: Erratum:
IgG1 Protects against Renal Disease in a Mouse Model of Cryoglobulinaemia. Nature
526(7575):728, 2015.
Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke
B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J,
Belouski SS, Tsuji W, Zack DJ: Treatment of Systemic Lupus Erythematosus Patients with
the BAFF Antagonist Peptibody Blisibimod (AMG 623/A-623): Results from Randomized,
Double-Blind Phase 1a and Phase 1b Trials. Arthritis Res Ther 17:215, 2015.
Strait RT, Posgai MT, Mahler A, Barasa N, Jacob CO, Khl J, Ehlers M, Stringer K,
Shanmukhappa SK, Witte D, Hossain MM, Khodoun M, Herr AB, Finkelman FD:
Books, Chapters & Other Publications

Rezkalla SH, Kloner RA: Drug-Related Diseases of the Coronary Artery. In: Pan Vascular
Medicino, (2nd edition; Dr. Peter Lazer [editor]). Springer Publications, Berlin, Heidelberg,
pp1917-1938, 2015.
Clavijo LC: Vascular Disease. Cardiology Clinics 33, 2015.

Goland S, Elkayam U: Of mice and (wo)men: The Need to Confirm Results of Animal
Experimentations with Solid Clinical Data. Trends Cardiovasc Med 25(6):505-7, 2015.
Ranjan R, Lawrence T: Cardiac Tamponade following Mitral Valve Replacement for

Active Infective Endocarditis with Ring Abscess. Case Rep Cardiol: http://dx.doi.
org/10.1155/2015/790213, 2015.
Kuo A, Fong MW: The Role of Statin in Heart Failure. In: Lipid Management from Basics to
Clinic. (Yassine H [editor]). Springer, London, pp177-188, 2015.
Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, Pencina KM, Vita J,
Dzekov C, Mazer NA, Coviello AD, Knapp PE, Hally K, Pinjic E, Yan M, Storer TW, Bhasin S:
Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in
Older Men with Low or Low-Normal Testosterone Levels: a Randomized Clinical Trial: JAMA
314(6):570-81, 2015.
Hodis HN, Mack WJ: Hormone Therapy and Risk of All-Cause Mortality in Women Treated
with Statins. Menopause 22:363364, 2015.
Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA,
Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM,
Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S: Effects of Hormone Therapy on
Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized,
Controlled KEEPS-Cognitive and Affective Study. PLoS Med 12(6):e1001833, 2015.
Bughi S, Shaw S: Chapter 90: Diabetes and Infections. In: Clinical Infectious Disease. (2nd
edition; David Schlossberg [editor]). Cambridge University Press. New York, NY, pp 585-590,
2015.
Carmichael JD, Zada G, Selman WR: Making the Diagnosis of Cyclic Cushings Syndrome:
a Position Statement from the Topic Editors. Neurosurgical FOCUS 38(2), E8, 2015.
Zada G, Carmichael JD, Selman WR: Introduction: Cushings Disease: a Century of
Evolving Diagnostics and Therapeutics for an Often Elusive Entity. Neurosurgical FOCUS
38(2), E1, 2015.
Adam TA, Tsao, S, Page, KA, Hu H, Hasson, RE, Goran, MI: Insulin Sensitivity and Brain
Reward Activation in Overweight Hispanic Girls: a Pilot Study. Pediatr Obes 10(1):30-6,
2015.
Lake JE, Seang S, Kelesidis T, Liao DH, Hodis HN, Stein JH, Currier JS: Telmisartan to
Reduce Cardiovascular Risk in Older HIV-Infected Adults: a Pilot Study. HIV Clin Trials
16(5):197-206, 2015.
Pyatak EA, Sequeira,PA, Carandang KM, Wood JR, Peters AL, Montoya L, Yang Lu: Peer
Mentoring Program Development for Adolescents and Young Adults with Type 1 Diabetes:
Focus Groups Findings, submitted, 2015.
Kloner RA, Hale SL: Reperfusion Injury. Invited Chapter in: Preparation for Myocardial
Infarction: A Companion to Brownwalds Heart Disease. In preparation, 2015.
Lipid Management: From Basics to Clinic (Yassine H [editor]). Springer, New York, NY,
2015.
Kloner RA: Troponin: Its Role in Detecting Acute Myocardial Infarction. In: ADVANCE for
Administrators of the Laboratory. 24(10): pp16-19, 2015.
146
Dub MP: Dyslipidemia in HIV. In: Lipid Management: From Basics to Clinic. (1st edition;
Yassine HN [editor]). Springer Science and Business New York, NY, in press, 2015.
Buxbaum J: Preps and Sedation. In: ASGE Gastrointestinal Endoscopy Self Assessment
Program ASGE, Oak Brook, IL, 2015.
Baker BJ, Holtom PD: Additional Benefits of GeneXpert MTB/RIF Assay for the Evaluation
of Pulmonary Tuberculosis among Inpatients. Clin Infect Dis 60(8):1287-8, 2015.
Buxbaum J, Eloubeidi M: Role of EUS Sampling in Solid Pancreas Lesions. Endoscopic

Ultrasonography, in press, 2015.
Croker C, Soriano J, Civen R, Larsen RA, Schwartz B; Centers for Disease Control and
Prevention (CDC): Notes from The Field: Identification of a Taenia Tapeworm Carrier- Los
Angeles County, 2014. MMWR Morb Mortal Wkly Rep 64(3):74, 2015.
Buxbaum J, Lus S: Cystic Diseases of the Liver and Biliary Tract. In: Yamadas Atlas of
Gastroenterology (5th edition) Wiley and Blackwell, Hoboken, NJ, 2015.
Buxbaum J, Lu S: Cystic Diseases of the Liver and Biliary Tract. In: Yamadas Textbook of
Gastroenterology (6th edition) Wiley and Blackwell, Hoboken, NJ, 2015.
Campese VM: Neurogenic Factors in Hypertension Associated with Chronic Kidney Disease.
In: Chronic Kidney Disease and Hypertension (Weir MR, Lerma EV [editors]). Springer, New
York, NY, Chapter 4, pp37-45, 2015.
Dara L, Johnson H, Kaplowitz N: The Central Role of Mitochondria in Drug Induced Liver
Toxicity. In: Role of Mitochondria in Liver Diseases. (Kaplowitz N, Han, D [editors]), CRC
Press Taylor and Francis Publishing, New York, NY, in press, 2015.
Staruschenko A, Ilatovskaya D, Hallows KR: Fundamentals of Epithelial Na+ Absorption. In:

Ion Channels and Transporters ofEpithelia in Health and Disease (Hamilton KL, Devor DC,
Harvey BJ [editors]). Springer, New York, NY, in press, 2015.
Dara L, Liu ZX, Kaplowitz N: Mechanisms of Adaptation and Progression in Idiosyncratic

Drug-Induced Liver Injury. Liver International, in press, 2015.
Oncology
Seijo S, DeLeve LD: Budd-Chiari Syndrome and Sinusoidal Obstruction Syndrome. In:
Zakim and Boyers Hepatology (7th edition) Elsevier, in press, 2015.
Dorff TB, Gross ME: Radium 223: How Can we Optimize this New Tool for Metastatic
Castration-Resistant Prostate Cancer? Am Soc Clin Oncol Educ Book e270-3, 2015.
Seijo S, DeLeve LD: Chapter 111: Vascular Diseases of the Liver. In: Yamadas Textbook of
Gastroenterology (6th edition; Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F,
Wang TC [editors]). Wiley-Blackwell Publishing, Oxford, in press, 2015.
Dorff TD, Hu JS, Quinn DI: Relapsed and Refractory Germ Cell Tumors: Finessing the
Rough End of a Beautiful Story. Urol Oncol 33(8):341-2, 2015.
Seijo S, DeLeve LD: Vascular Diseases of the Liver. In: Atlas of Gastroenterology (5th
edition; Podolsky DK, Camilleri M, Fitz JG, Kalloo AN, Shanahan F, Wang TC [editors]).
Wiley-Blackwell Publishing, Oxford, in press, 2015.
Dorff TB, Mack P: Chapter 14: The Role of mTOR Inhibitors and PI3K Pathway Blockade
in Kidney Cancer. In: Kidney Cancer: Principles and Practice (Lara P [editor]). Springer, New
York, NY, in press, 2015.
Hwang C, Hong K: Other Micronutrient Deficiencies in IBD. In: Nutritional Management

of Inflammatory Bowel Disease: A Comprehensive Guide (Ananthakrishnan AN [editor]).
Springer, New York, NY, in press, 2015.
Dorff TB, Pal SK: Hitting Prostate Cancer Where it Hurts: Maximizing Control of Osseous
Metastases. Oncology 29:424, 426, 2015.
In G, Dorff TB: Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors:
Current Concepts and Controversies. Urologic Clinics of North America 42:347-58, 2015.
Kaplowitz N, Win S, Than T, Liu ZX, Dara L: Targeting Signal Transduction Pathways
with Regulate Necrosis in Acetaminophen Hepatotoxicity. J Hepatology 63:5-7, 2015.
Forte V, Garcia AA: Clinical Activity of Metronomic Chemotherapy in Gynecological

Tumors. In: Metronomic Chemotherapy: Pharmacology and Clinical Applications (Bocci G,
Francia G [editors]). Springer, New York, NY, in press, 2015.
Roth N, Kanel G, Kaplowitz N: Alcoholic Foamy Degeneration and Alcoholic Fatty Liver
with Jaundice: Often Overlooked Causes of Jaundice and Hepatic Decompensation that Can
Mimic Alcoholic Hepatitis. Clinical Liver Disease, in press, 2015.
Cremolini C, Loupakis F, Lenz HJ: Response. J Natl Cancer Inst 107(10), 2015.
Uetrecht J, Kaplowitz N: Inhibition of Immune Tolerance Unmasks Drug-Induced Allergic

Hepatitis. Hepatology 62(2):346-8, 2015.
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F,

Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M,
Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houd N, Jacqmin D, Kaplan R, Malavaud
B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn
D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P,
Escudier B, Filleron T; DATECAN Renal Cancer Group: Guidelines for the Definition of
Time-to-Event End Points in Renal Cell Cancer Clinical Trials: Results of the DATECAN
Project. Ann Oncol 26(12):2392-8, 2015.
Bonthala N, Khemichian S: The Approach to Abnormal Liver Tests. In: Tarascon

Gastroenterology Pocketbook. (Esrailian E [editor]), Jones and Bartlet Learning, Burlington,
MA, pp191-196, 2015.
Bonthala N, Khemichian S: Primary Sclerosing Cholangitis. In: Tarascon Gastroenterology
Pocketbook. (Esrailian E [editor]), Jones and Bartlet Learning, Burlington, MA, pp225-227,
2015.
Noureddin M, Alexanian D, Kaplowitz N: Non-Alcoholic Fatty Liver Disease: The Lipid
Disease of the Liver and the Effect of Statins. In: Lipid Management, Spinger, New York, NY,
in press, 2015.
Win S, Than T, Kaplowitz N. The Role of JNK in Lipotoxicity in the Liver. In:
Mitochondria in Liver Disease (Han D, Kaplowitz N [editors]). CRC Press Taylor and Francis
Publishing, New York, NY, in press, 2015.

Internal Medicine

Kakal K, Kumar S, Baydur A: Phenotypic Variance in COPD: Recent Developments in
Clinical, Radiographic and Molecular Aspects, and Relevance to Management Strategies.
Jacobs J Pulmonol 2(1):012, 2015.
Fazlollahi F, Kim YH, Sipos A, Borok Z, Kim KJ, Crandall ED: Interactions with Alveolar
Epithelium. In: Nanoparticles in the Lung: Environmental Exposure and Drug Delivery
(Tsuda A, Gehr P [editors]). CRC Press, Boca Raton, FL, pp107-131, 2015.
Liu S, Qiao R: Hypoxic Pulmonary Hypertension. In: Pulmonary Arterial Hypertension
(Wang C [editor]), in press, 2015.
Swiger K, Thomas JR, Hochman ME, Hochman SD: 50 Studies Every Internist Should
Know (www.50studies.com). Oxford University Press, Oxford UK, 2015.
Rheumatology
Rossetti G, Sapru S, Hsieh E, Ben-Ari R, Panush RS: The New Program Director: Directing
Change During Transition. In: The Toolkit Series: A Textbook for Internal Medicine Programs
(12th edition; Williams F, Costa ST [editors]). Alliance for Academic Internal Medicine,
Alexandria VA, in press, 2015.
Panush RS: Patient Information: Complementary Therapies for Rheumatoid Arthritis

(Beyond the Basics). UpToDate, submitted, 2015.
Hematology
Quismorio Jr FP, Johnson D: Rheumatoid Arthirits. In: Primary Care, A Collaborative

Practice (4th edition; Buttaro T, Trubulski JA, Bailey PP, Sandberg-Cook [editors]). Harcourt,
Philadelphia, PA, in press, 2015.
Liebman HA, Tulpule A: Hematologic Manifestations of HIV Disease. In: Hematology:

Basic Principles and Practice (7th edition; Hoffman R, Benz EJ, Shattil SJ, Weitz J, Cohen HJ,
Silbertein L, McGlave P [editors]). McGraw-Hill, Inc., New York, NY, in press, 2015.
Quismorio Jr FP, Johnson D: Systemic Lupus Erythematosus. In: Primary Care, A

Collaborative Practice (4th edition; Buttaro T, Trubulski JA, Bailey PP, Sandberg-Cook
(editors). Harcourt, Philadelphia, PA, in press, 2015.
Infectious Diseases
Stohl W: Editorial: The BAFFling Immunology of Systemic Lupus Erythematosus: Beyond

B Cells. Arthritis Rheumatol 67(3):612-5, 2015.
Supriya B, Blodget E: Ochoroconis in a Lung Transplant Patient: Case Report and Review of
the Literature. Transplant Infectious Diseases, submitted, 2015.
147
Federal Grants
Principal Investigator / Co-Investigator
Agency
Title of Account or Grant
Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
319,995
47,087
367,081
8/21/12
5/31/15
CARDIOVASCULAR MEDICINE
Hodis, Howard
Nat'l Heart, Lung, Blood

Institute
Vitamin D Intervention and Atherosclerosis Progression
Hodis, Howard
Albert Einstein College of

Medicine (NHLBI)
Role of Innate Immunity in HIV Related Vascular Disease:

Biomarkers and Mechanisms
6,008
3,905
9,913
6/4/15
5/31/16
Hodis, Howard
Social & Scientific Systems

(NHLBI)
Cardiovascular, Anthropometric and Skeletal Effects of

Anti-HIV Therapy
18,900
18,900
5/1/09
5/31/15
Shavelle, David
Brigham & Women's Hospital

(NIH)
Cardiovascular Inflammation Reduction Trial (CIRT)
13,084
4,527
17,611
6/1/14
4/30/17
TOTAL CARDIOVASCULAR MEDICINE
357,986
55,519
413,505
274,558
52,617
327,175
7/21/14
6/30/16
5,494,789
2,768,621
8,263,410
7/1/10
3/31/15
ENDOCRINOLOGY AND DIABETES

Buchanan, Thomas
Kaiser Permanente (NIH)
The Role of Adipokines in Glucose Regulation and Metabolic

Decline
Buchanan, Thomas
Nat'l Center for Research

Resources
Los Angeles Basin Clinical and Translational Science

Institute
Buchanan, Thomas/Beale, Elizabeth
Nat'l Inst of Diabetes &

Digestive & Kidney Dis
Beta Cell Restoration through Fat Mitigation
551,692
152,104
703,796
9/23/11
6/30/16
Page, Kathleen

Mechanisms Underlying Increased Risk for Obesity and

Diabetes
138,391
11,146
149,537
8/2/11
4/30/16
Page, Kathleen

Neural Mechanisms for Obesity Risk in Children Exposed to

Diabetes in Utero
45,574
29,556
75,130
7/1/14
6/30/16
Peters, Anne

Vitamin D and Type 2 Diabetes (D2d)
50,624
50,624
6/1/13
5/31/18
Peters, Anne/Beale, Elizabeth

Clinical Center for Look AHEAD: Health in Diabetes
422,759
96,192
518,951
9/30/99
7/31/15
Yassine, Hussein

Institute
Effect of Saturated Fat Ingestion on the HDL Proteome
127,131
10,170
137,301
12/1/12
4/30/17
TOTAL ENDOCRINOLOGY AND DIABETES
7,105,519
3,120,407
10,225,925
GASTROINTESTINAL AND LIVER DISEASES

DeLeve, Laurie

Liver Sinusoidal Endothelial Cell Progenitor Cells
174,517
114,095
288,612
4/1/13
3/31/18
DeLeve, Laurie

Liver Sinusoidal Endothelial Cells and Fibrosis
215,028
139,190
354,218
8/1/14
7/31/18
Hwang, Caroline
University of North Carolina

(NIH)
Methotrexate Response in Treatment of UC - MERIT UC
5,887
3,789
9,676
7/1/14
9/30/15
Ji, Cheng
Nat'l Institute of Alcohol Abuse

& Alcoholism
Nanocapsules that Decompose Alocohol as Antidotes for

Alcohol Intoxication
34,074
22,119
56,193
5/15/15
4/30/17
Kaplowitz, Neil/Deleve, Laurie/Liu,

Zhang-Xu/Ookhtens, Murad

USC Research Center for Liver Diseases
290,753
158,511
449,264
3/1/97
2/28/15
Kaplowitz, Neil/Ji, Cheng

& Alcoholism
Homocysteine, ER Stress and Alcoholic Liver Injury
49,950
30,969
80,919
7/1/03
3/31/15
Kaplowitz, Neil/Win, Sanada/Than, Tin

Aung

Cellular Mechanisms of Hepatotoxicity
282,591
179,298
461,889
4/1/04
2/28/20
Liu, Zhang-Xu/Kaplowitz, Neil

& Alcoholism
Immunity in Alcoholic Hepatitis
167,761
104,666
272,427
7/1/13
8/31/18
Saito, Takeshi

& Alcoholism
Retinoid Regulation of Hepatic Innate Immunity
113,652
73,516
187,168
8/20/14
7/31/16
Saito, Takeshi

Innate Defense Program against HCV
70,424
45,679
116,103
4/1/15
3/31/20
Shaker, Anisa
Nat'l Cancer Institute
Epimorphin Deletion Alters Stem Cell Niche Myofibroblast
167,929
13,434
181,363
7/1/11
1/31/17
Shaker, Anisa
Epithelial-Stromal Cross-Talk in Esophageal Inflammation

and Carcinogenesis
4,644
3,019
7,663
8/1/15
7/31/17
Shao, Ling

The Ubiquitin Editing Enzyme A20 Preserves Intestinal

Epithelial Cell Homeostasis
156,444
12,516
168,959
9/3/14
7/31/19
Stolz Andrew/Kaplowitz Neil
Southern California Institute

for Research and Education
(NIAAA)
Safety and Efficacy of Mycophenolate Mofetil and Rilonacept

(Anti-Interleukin-1) in Patients with Alcohol
143,163
92,774
235,937
9/1/14
8/31/16
Stolz, Andrew/Kaplowitz, Neil/Liu,

Zhang-Xu
Duke University (NIDDK)
USC-UCLA Drug-Induced Liver Injury (DILI) Clinical

Center
207,458
95,695
303,153
9/30/08
6/30/18
Tsukamoto, Hidekazu/Kaplowitz, Neil/

Saito, Takeshi/Ji, Cheng

& Alcoholism
Southern California Research Center for ALPD and Cirrhosis
991,098
451,577
1,442,675
1/1/99
12/31/18
TOTAL GASTROINTESTINAL AND LIVER DISEASES
3,075,374
1,540,844
4,616,218
HEMATOLOGY
Chaudhary, Preet/Matta, Hittu
Nat'l Institute of Dental and

Craniofacial Res
Cell Penetrating Helical Peptide Inhibitors of vFLIP K13
135,387
62,268
197,655
6/1/10
3/31/15
Liebman, Howard
Cornell University (NIH)
Determining Optimum Medical Therapy for ITP
16,380
12,359
28,739
2/15/13
1/31/16
148

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
Role of Hedgehog/Gli in Normal Hematopoiesis and

Leukemia
149,841
11,171
161,012
9/18/12
8/31/17
TOTAL HEMATOLOGY
301,608
85,798
387,406
Principal Investigator / Co-Investigator
Agency
Merchant, Akil
INFECTIOUS DISEASES
Dube, Michael
University of California San

Diego (CHRP)
Active Linkage Engagement and Retention to Reduce HIV

(ALERT)
444,535
117,677
562,213
4/1/12
3/31/16
Sattler, Fred/Dube, Michael
UC San Diego (NIAID)
University of Southern California Clinical Research Site
498,399
298,591
796,990
12/1/13
11/30/15
Spellberg, Brad
Duke University (FDA)
Increasing the Quality and Efficiency of Clinical Trials
16,541
10,724
27,265
9/1/14
8/31/19
Spellberg, Brad
Nat'l Institute of Allergy &

Infectious Dis
Monoclonal Antibody Passive Vaccination
166,353
97,816
264,169
7/1/14
3/31/16
Spellberg, Brad

Infectious Dis
Antibody Targeting of KPC and NDM1
71,649
46,214
117,863
7/1/14
3/31/16
Spellberg, Brad
University of Chicago (NIAID)
A New Approach to Staphylococcus Aureus
157,699
25,413
183,112
7/1/14
7/31/16
Spellberg, Brad

Infectious Dis
Acinetobacter Virulence and Host Immuno
126,533
78,492
205,024
10/1/14
7/31/16
Spellberg, Brad
Duke University (NIAID)
Antibacterial Resistance Leadership Group
10/1/14
7/31/16
TOTAL INFECTIOUS DISEASES
23,788
15,396
39,184
1,505,497
690,323
2,195,821
NEPHROLOGY AND HYPERTENSION

Hallows, Kenneth/Li, Hui
Army Medical Research

Acquisition Activity
Cellular Energy Pathways as Novel Targets for the Therapy of

Autosomal Dominant Polycystic Kidney Disease
42,791
27,742
70,533
9/1/15
8/31/18
Hallows, Kenneth/Li, Hui
University of Maryland
(NIDDK)
Effects of Metformin on the AMPK Pathway and

Metabolomic Biomarkers in ADPKD Kidney Epithelial Cells
13,977
13,977
7/1/15
6/30/16
Hallows, Kenneth/Pastor-Soler, Nuria

Mechanisms and Relevance of Sodium Transport Regulation

by AMPK
84,622
55,004
139,626
8/1/15
7/30/16
TOTAL NEPHROLOGY AND HYPERTENSION
141,390
82,746
224,135
ONCOLOGY
Agus, David/Macklin, Paul/Ruderman,
Daniel/Mumenthaler, Shannon/Lenz,
Heinz-Josef
(PQB6) An Integrative Computational and Bioengineered

Tissue Model of Metastasis
586,917
154,381
741,299
9/5/13
7/31/17
Goldkorn, Amir/Pinski, Jacek/Xiong,

Shigang/Quinn, David
Biomarkers of Hormone Therapy Response in Multicenter

Prostate Cancer Trial
412,112
266,741
678,853
9/10/14
8/31/19
Gruber, Stephen/Lenz, Heinz-Josef/

El-Khoueiry, Anthony/Iqbal, Syma/Garcia,
Agustin
USC/Norris Comprehensive Cancer Center (CORE) Support
4,097,604
2,438,932
6,536,537
12/1/96
11/30/15
Lenz Heinz-Josef/Quinn, David
University of California Davis

(NCI)
Early Therapeutics Development with Phase II Emphasis
60,926
15,841
76,766
9/23/11
9/22/16
Lenz, Heinz-Josef
Mayo Clinic (NCCIH)
Assessing Patient Experience in Cancer Care: An

Observational Communication Study
55,210
35,886
91,096
7/1/15
6/30/16
Lenz, Heinz-Josef/El-Khoueiry, Anthony
Efficacy of Novel Wnt Modulator in Colon Cancer
241,360
156,273
397,632
4/1/13
3/31/18
Lenz, Heinz-Josef/Garcia, Agustin
Mayo Clinic (NCCIH)
Decision Making About CAM Across the Cancer Continuum
88,411
57,025
145,436
7/1/12
6/30/16
Lenz, Heinz-Josef/Quinn, David/ElKhoueiry, Anthony
NCI NCTN-Network Lead Academic Participating Site: USC
125,909
81,211
207,120
4/17/14
2/28/19
Lenz, Heinz-Josef/Quinn, David/ElKhoueiry, Anthony/Iqbal, Syma/Gitlitz,

Barbara
Beckman Research Institute
Phase 1 Molecular and Clinical Pharmacodynamic Trials
60,719
15,787
76,505
3/1/09
2/28/15
5,796,231
3,269,179
9,065,411
TOTAL ONCOLOGY
PULMONARY, CRITICAL CARE AND SLEEP MEDICINE

Borok, Zea
Proteogenomics Research
Institute (NIH)
Novel Targeted Therapies for Pulmonary Fibrosis
69,794
45,337
115,131
3/3/15
2/9/16
Borok, Zea/Flodby, Ulf

Institute
Mechanisms of Beta-Catenin Signaling in Alveolar Epithelial

Cell Differentation
342,026
220,943
562,969
7/1/13
6/30/17
Crandall, Edward/Chaudhary, Preet/Zhou,

Xianghong

Institute
MAPGen Knowledge Base (MAPGenKB) and Coordination

Center
675,164
272,334
947,498
8/25/11
6/30/16
Laird-Offringa, Ite/Borok, Zea/Zhou,

Beiyun

Institute
Epigenomic Profiling of Human Lung Alveolar
145,756
94,455
240,211
9/23/11
6/30/16
Zhou, Beiyun/Borok, Zea

Institute
Epithelial Abnormalities in IPF: Role of ER Stress and

GRP78/BiP
264,822
159,081
423,903
8/1/13
6/30/18
1,497,562
792,151
2,289,713
Regulation of Humoral Immunity by NKT Cells
15,805
10,222
26,027
8/4/14
7/31/15
TOTAL RHEUMATOLOGY
15,805
10,222
26,027
21,782,721
10,166,787
31,949,509
TOTAL PULMONARY, CRITICAL CARE AND SLEEP

MEDICINE
RHEUMATOLOGY
Stohl, William
University of Oklahoma
(NIAID)
TOTAL ALL DIVISIONS
149
Other Grants
Principal Investigator/ Co-Investigator
Agency
Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
CARDIOVASCULAR MEDICINE
Chang, Philip
Quadripolar Pacing Post Approval Study
St. Jude Medical
1,758
264
2,021
7/1/12
Present
Chang, Philip
Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients

"MultiSENSE" Study
Boston Scientific
7,661
1,915
9,577
3/25/11
Present
Chang, Philip
Eisenmenger Quality Enhancement Research Initiative (QuERI)
Canadian Heart
Research Centre
640
160
800
6/19/13
Present
Chang, Philip
Adult Congenital Heart Disease - Quality Enhancement Research

Initiative (QuERI)
MD Primer
640
160
800
4/9/13
Present
Chang, Philip
Quadripolar Pacing Post-Approval Study
St. Jude Medical
9,446
2,362
11,808
12/4/12
Present
Chang, Philip
S-ICD System Post Approval Study
Boston Scientific
17,364
4,341
21,706
11/20/13
Present
Chang, Philip
ImageReady MR Conditional Pacing System SAMURAI Clinical

Study
Boston Scientific
4,722
1,181
5,903
11/11/13
Present
Clavijo, Leonardo
Global Observational Study
Montreal Heart
Institute
3,547
1,241
4,788
10/24/13
Present
Clavijo, Leonardo
USC Cardiology Interventional Fellowship Program
St. Jude Medical
27,116
2,712
29,827
11/21/14
Present
Clavijo, Leonardo
Interventional Cardiology and Vascular Fellowship
Abbott Fund
6,108
611
6,719
7/1/14
Present
Clavijo, Leonardo
Interventional/Cardiology Fellowship
Medtronic Inc.
23,905
23,905
7/1/14
Present
Clavijo, Leonardo
Prevalence of High on-Treatment (Aspirin and Clopidogrel) Platelet

Reactivity in Patients with Critical Limb Ischemia
Astra Zeneca
10,300
2,575
12,875
6/13/13
Present
Clavijo, Leonardo
Switch to Ticagrelor in Critical Limb Ischemia Anti-Platelet Study "STT-CLIPS"
Astra Zeneca
36,757
9,189
45,946
11/25/13
Present
Doshi, Rahul
Crt Implant Strategy Using the Longest Electrical Delay for Non-Left
Bundle Branch Block Patients (Enhance Crt)
St. Jude Medical
3,244
811
4,055
4/9/14
Present
Doshi, Rahul
The Leadless II - Nanostim's Safety and Effectiveness Trial for a

Leadless Cardiac Pacemaker System
St. Jude Medical
35,767
8,942
44,709
2/14/14
Present
Doshi, Rahul
Evaluation of ACUITY X4 Quadripolar Coronary Venous Leads and

RELIANCE 4-FRONT Defibrillation Leads
Cardiac Pacemakers
15,126
3,781
18,907
9/10/14
Present
Fong, Michael
Digital Detection and Monitoring of Polypharmacy Use in Stable

Heart Failure Patients with Ingestible and Wearable Sensor
Technology
Proteus Digital
Health
6,052
1,513
7,565
12/1/14
Present
Garg, Parveen
Assessment of Rivaroxaban vs. Placebo in Reducing Post-Discharge

Venous Thrombo-Embolism Risk
PAREXEL
International
8,095
2,024
10,119
5/1/15
Present
Grazette, Luanda
LCZ696 vs. Enalapril on Morbidity and Mortality
Novartis
2,602
651
3,253
8/10/12
Present
Grazette, Luanda
Serelaxin when Added to Standard Therapy in Acute Heart Failure

Patients
Novartis
65,177
16,294
81,471
7/1/13
Present
Lawrence, Tracy
Laptop HF IDE Study Core Lab Contract
St. Jude Medical
44,659
7,268
51,926
9/24/10
Present
Lawrence, Tracy
Closure of Atrial Defects with the AMPLATZER Septal Occluder

(ASO) Post Market Surveillance
St. Jude Medical
112,466
39,363
151,829
2/25/15
Present
Matthews, Ray
Hemodynamically Guided Home Self-Therapy in Severe Heart Failure

Patients: (HOMEOSTASIS II)
St. Jude Medical
1,667
417
2,084
5/9/08
Present
Matthews, Ray
Stenting and Angioplasty with Protection in Patients at High Risk for

Endarterectomy
Quintiles
6,320
1,580
7,900
2/21/08
Present
Matthews, Ray
Left Atrial Pressure Monitoring to Optimize Health Failure Therapy

Study (LAPTOP HF)
St. Jude Medical
24,456
6,114
30,570
12/6/10
Present
Matthews, Ray
ANALYZE Study - ST Monitoring to Detect ACS Events in ICD

Patients
St. Jude Medical
1,591
398
1,989
11/28/12
Present
Matthews, Ray
Carotid Artery Stenting Outcomes in the Standard Risk Population for

Carotid Endarterectomy
Abbott Vascular
Solutions
1,400
350
1,750
3/22/13
Present
Matthews, Ray
Transluminal Aortic Balloon Valvuloplasty Registry (TAB-R)
Libra Medical
8,242
2,061
10,303
9/12/14
Present
Matthews, Ray
Closure of Atrial Septal Defects with the AMPLATZER Septal

Occluder
St. Jude Medical
3,000
750
3,750
10/15/15
Present
Mehra, Anilkumar
Randomized Evaluation of Recurrent Stroke Compaparing Pfo

Closure to Established Current Standard of Care Treatment
St. Jude Medical
5,720
1,430
7,150
10/11/06
Present
Mehra, Anilkumar
Patent Foramen Ovale Closure with the Amplatzer PFO Occluder I
St. Jude Medical
800
200
1,000
7/25/07
Present
Shavelle, David
USpella Registry
ABIOMED
21,935
5,484
27,419
6/30/10
Present
Shavelle, David
Evaluation of XIENCE PRIME or XIENCE V vs. Coronary Artery

Bypass Surgery for Effectiveness of Left Main Revascularization
Abbott Vascular
Solutions
6,562
1,641
8,203
10/20/12
Present
Shavelle, David
Intra-Coronary Infusion of AMR-001, a Bone Marrow Derived

Autologous CD34+ Selected Cell Product for Myocardial Infarction
Cardiovascular
Clinical Science
Foundation
7,287
1,822
9,109
12/18/12
Present
Shavelle, David
Hospital Wearable Defibrillator Inpatient Study
ZOLL
56,437
14,109
70,547
8/15/14
Present
Shavelle, David
Mechanical Left Ventricular Unloading with Counterpulsation to

Reduce Infarct Size Pre-PCI
Maquet
Cardiovascular
1,280
320
1,600
9/26/14
Present
Shavelle, David
CardioMEMS HF System Post Approval Study
St. Jude Medical
36,306
9,077
45,383
12/23/14
Present
Yoon, Andrew
Remede System for Central Sleep Apnea
Respicardia
58,121
14,530
72,651
9/18/13
Present
684,278
167,638
851,916
TOTAL CARDIOVASCULAR MEDICINE
150

Agency
Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
12,406
3,102
15,508
10/9/14
Present
ENDOCRINOLOGY AND DIABETES

Carmichael, John
Treating Patients with SOM230 (Pasireotide) LAE who Have Need to

Receive Medical Therapy
United BioSource
Carmichael, John
Safety And Efficacy of Lci699
Novartis
11,760
2,940
14,700
8/27/14
Present
Carmichael, John
Efficacy and Safety of Once Weekly Dosing of NNC0195-0092
Novo Nordisk
18,854
4,713
23,567
2/11/15
Present
Page, Kathleen
Effects of Sugar Ingestion on Brain Reward and Energy Signaling
Doris Duke
Charitable
Foundation
74,231
5,938
80,170
7/1/12
Present
Page, Kathleen
Neural Mechanisms in Maternal-Fetal Programming for Obesity and

Diabetes
American Diabetes
Association
231,698
56,845
288,542
1/1/14
Present
Page, Kathleen
Effects of Dietary Fructose Intake on Brain Appetite and Reward

Pathways
American Heart
Association
99,267
9,726
108,993
1/1/14
Present
Page, Kathleen
Mark Bieber Award
American Heart
Association
4,768
4,768
1/1/14
Present
Peters, Anne
Efficacy and Safety of Canagliflozin as add-on Therapy to Insulin
PAREXEL
International
73,660
18,415
92,075
10/13/14
Present
Yassine, Hussein
Determinants of HDL Efflux in Diabetes
American Heart
Association
30,787
3,079
33,865
7/1/15
Present
Yassine, Hussein
Does Apo E e4 Genotype Reduce the Delivery of Essential Omega-3

Fatty Acids to the Brain?
Alzheimer's
Association
7,852
785
8,637
10/1/15
Present
Yassine, Hussein
Proteomic Investigator of Inflammatory HDL
American Heart
Association
11,441
1,144
12,585
7/1/12
Present
576,724
106,687
683,411
450
450
8/1/15
Present
450
450
TOTAL ENDOCRINOLOGY AND DIABETES
GERIATRIC, HOSPITAL, PALLIATIVE AND GENERAL INTERNAL MEDICINE

Hsieh, Eric
Association of
American Medical
Colleges
Effects of Physician Stima on Medical Decisions
TOTAL GERIATRIC, HOSPITAL, PALLIATIVE AND GENERAL INTERNAL MEDICINE
GASTROINTESTINAL AND LIVER DISEASES

Buxbaum, James
Prospective Randomized Trial of EUS-Guided Celial Block for

Chronic Pancreatitis
Sidney Stern
Memorial Trust
7,936
1,984
9,920
7/1/14
Present
Hwang, Caroline
Enhanced Treatment Algorithm for the Management of Crohn's

Disease- Study 2 (REACT2)
Robarts Clinical
Trials
30,700
7,675
38,375
6/18/14
Present
Hwang, Caroline
Placental Transfer of Certolizumab Pegol in Pregnant Women

Receiving Treatment with Cimzia
Pharmaceutical
Product
Development
2,787
697
3,484
6/13/14
Present
Hwang, Caroline
Concentration of Certolizumab Pegol in the Breast Milk of Mothers

Receiving Treatment with Cimzia
Pharmaceutical
Product
Development
2,253
563
2,816
6/24/14
Present
Idos, Gregory
USC Norris Comprehensive Cancer Center and Stanford Cancer

Institute Cancer Genetics Hereditary Cancer Panel Testing
Myriad
131,452
32,863
164,315
5/6/14
Present
Khemichian, Saro
Beckman Coulter DxN HCV Viral Load Assay as an Aid in the

Management of HCV-Infected Individuals Undergoing Antiviral
Therapy
SC Liver Research
Consortium
5,640
1,410
7,051
7/17/12
Present
Khemichian, Saro
MK-5172 with/without MK-8742 and/or Ribavirin (RBV) in

Treatment-Naive Subjects with Chronic Hepatitis C
Merck Sharp &

Dohme
5,603
1,401
7,004
1/28/14
Present
Khemichian, Saro
Daclatasvir (BMS-790052) with Sofosbuvir for the Treatment of

Post-Liver Transplant Subjects with Chronic Hepatitis C
University of
Florida
11,274
2,818
14,092
8/21/14
Present
Khemichian, Saro
MK-5172 and MK-8742 in Subjects with Chronic HCV GT1, GT4

and GT6 Infection
Clinical Financial
Services
24,275
6,069
30,344
1/8/15
Present
Khemichian, Saro
Subjects with Chronic Hepatitis C who Have Been Previously Treated

with MK-5172
Clinical Financial
Services
10,348
2,587
12,935
12/17/14
Present
Khemichian, Saro
OCR-002 (Ornithine Phenylacetate) in Hospitalized Patients with

Cirrhosis and Associated Hyperammonemia
Ocera Therapeutics
1,680
420
2,100
11/25/13
Present
Khemichian, Saro
Rifaximim Soluble Solid Dispersion (SSD) Tablets
Salix
3,717
929
4,647
11/4/13
Present
Kim, Brian
An Observational Study to Assess Documentation of Hepatic

Encephalopathy in Clinical Practice
inVentive Health
4,516
1,129
5,645
3/16/15
Present
Noureddin, Mazen
GR-MD-02 in Subjects with Non-Alcoholic Steatohepatitis (NASH)
CTI Clinical Trial

Services
63,237
15,809
79,046
2/20/14
Present
Shaker, Anisa
General Mills Bell Institute of Health and Nutrition Research
American
Gastroenterological
Association
69,235
69,235
7/1/12
Present
Van Dam, Jacques
Photodynamic Therapy Using Porfimer Sodium for Injection as

Treatment
Quintiles
13,733
3,433
17,166
1/23/15
Present
388,385
79,788
468,173
TOTAL GASTROINTESTINAL AND LIVER DISEASES
HEMATOLOGY
Gill, Parkash
Targeting Tumor Cell Surface GRP78 with an Antibody Drug

Conjugate for Cancer Therapy
Pfizer
86,927
39,117
126,044
3/1/15
Present
Kelly, Kevin
BT062 with Lenalidomide and Dexamethasone in Subjects with

Relapsed or Refractory Multiple Myeloma
Aptiv Solutions
256,943
64,236
321,179
9/30/13
Present
Kelly, Kevin
Ro5503781 Administered Orally
INC Research
120,756
30,189
150,946
8/15/14
Present
151

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
INC Research
20,556
5,139
25,695
1/27/15
Present
Bosutinib (Bosulif) in Patients with Philadelphia Chromosome

Positive Chronic Myeloid Leukemia
ICON Clinical
Research
19,156
4,789
23,945
4/3/15
Present
Kelly, Kevin
Orally Administered CUDC-907, a PI3K and HDAC Inhibitor
Curis
45,170
11,293
56,463
3/13/15
Present
Kelly, Kevin
REOLYSIN with Bortezomib and Dexamethasone in Patients with

Relapsed/Refractory Multiple Myeloma
Oncolytics Biotech
1,200
300
1,500
5/22/15
Present
Liebman, Howard
Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult

Patients with Chronic Immune Thrombocytopenic Purpura
Immunomedics
640
160
800
12/21/07
Present
Liebman, Howard
AMG531, a Thrombopoietin Receptor Agonist, Administered Once

Weekly to Thrombocytopenic Hepatitis C Infected Patients
Amgen
1,280
320
1,600
6/30/09
Present
Liebman, Howard
Fostamatinib Disodium in the Treatment of Persistent/Chronic

Immune Thrombocytopenic Purpura
CFS Clinical
20,041
5,010
25,051
9/5/14
Present
Liebman, Howard
Extension Study of Fostamantinib Disodium in the Treatment of

Persistent/Chronic Immune Thromboctopenic Purpura
CFS Clinical
18,361
4,590
22,951
2/11/15
Present
Liebman, Howard
Bi 655064 Administered Weekly
Boehringer
Ingelheim
16,924
4,231
21,155
5/13/15
Present
Merchant, Akil
Preclinical Evaluation of SMO Inhibitors in Myelofibrosis
Pfizer
18,274
11,695
29,970
10/28/13
Present
Merchant, Akil
BB-10901 (IMGN901, huN901-DM1) with Lenalidomide and

Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/
Refractory Multiple Myeloma
ImmunoGen
4,640
1,160
5,800
5/12/10
Present
Merchant, Akil
Treatment-Free Remission after Achieving Sustained MR4.5 on

Nilotinib
Novartis
37,522
9,381
46,903
10/18/12
Present
Merchant, Akil
Substitution of Marqibo for Standard Vincristine Sulfate Injection
Talon Therapeutics
640
160
800
5/6/14
Present
Merchant, Akil
PF-04449913, an Oral Hedgehog Inhibitor, with Intensive

Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute
Myeloma
ICON Clinical
Research
1,680
420
2,100
8/8/13
Present
Merchant, Akil
Inotuzumab Ozogamicin vs. Defined Investigator's Choice in Adult

Patients with Relapsed or Refractory CD22-Positive Acute
Lymphoblastic Leulemia
ICON Clinical
Research
41,536
10,384
51,920
9/25/13
Present
Merchant, Akil
Pracinostat with Azacitidine in Elderly Patients with Newly Diagnosed

SynteractedHCR
108
27
135
7/25/14
Present
Merchant, Akil
Addition of Pracinostat to a Hypomethylating Agent in Patients with

Myelodysplastic Syndrome
SCRI Development
Innovations
16,600
4,150
20,750
5/1/14
Present
Mohrbacher, Ann
RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large

B-Cell Lymphoma
Novartis
1,600
400
2,000
1/8/10
Present
Mohrbacher, Ann
Lenalidomide and Low-Dose Dexamethasone with Dalteparin in

Previously Untreated Multiple Myeloma
Celgene
3,680
920
4,600
12/7/11
Present
Mohrbacher, Ann
Bortezomib/Dexamethasone with or without Elotuzumab in Subjects

with Relapsed/Refractory Multiple Myeloma
PAREXEL
International
11,081
2,770
13,851
10/15/12
Present
Mohrbacher, Ann
Treatment of Newly Diagnosed Adult Acute Lymphoblastic Leukemia

with Intensified Post-Remission Therapy
Sigma-Tau
Pharmaceuticals
7,776
1,944
9,720
11/15/04
Present
Mohrbacher, Ann
Pomalidomide, Bortezomib and Low-Dose Dexamethasone vs. Bortezomib and Low-Dose Dexamethasone
Celgene
24,960
6,240
31,200
5/23/14
Present
O'Connell, Casey
JAK Inhibitor INCB018424 Tablets Administered Orally
PPD Development
1,440
360
1,800
11/17/09
Present
O'Connell, Casey
The PNH (Paroxysmal Nocturnal Hemoglobinuria) Registry
ICON Clinical
Research
15,346
3,837
19,183
8/25/09
Present
O'Connell, Casey
Elacytarabine vs. Investigator's Choice in Patients with Late Stage

INC Research
432
108
540
11/8/10
Present
O'Connell, Casey
Two Subcutaneous Regimens of SGI 110, a DNA Hypomethylating

Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic
Syndromes
Astex
246,501
61,625
308,126
12/17/10
Present
O'Connell, Casey
Dasatinib vs. Imatinib in Patients with Chronic Phase Chronic

Myeloid Leukemia who Have Not Achieved an Optimal Response to
3 Months of Therapy
ICON Clinical
Research
4,788
1,197
5,985
5/13/13
Present
O'Connell, Casey
Managing Patients with Chronic Myeloid Leukemia in Chronic Phase:

The 5-Year Prospective Cohort Study (SIMPLICITY)
ICON Clincial
Research
3,840
960
4,800
5/12/11
Present
O'Connell, Casey
Astx727, a Combination of Oral Cytidine Deaminaase Inhibitor (Cdai)

E7727 with Oral Decitabine
INC Research
20,013
5,003
25,016
3/26/15
Present
O'Connell, Casey
Oral Pacritinib vs. Best Available Therapy in Patients with

Thromboctopeniz and Primary Myelofibrosis, Post-Polycythemia Vera
Myelofibrosis
Ockham
Development
Group
19,032
4,758
23,790
1/13/15
Present
O'Connell, Casey
Sgi-110 vs. Treatment Choice in Adults with Previously Untreated

Pharmaceutical
Research
Associates
35,549
8,887
44,436
4/22/15
Present
Ramsingh, Giridharan
Hematopoietic Stem and Progenitor Cell Senescence and Therapy

Related Acute Myeloid Leukemia
Tower Cancer
Research
Foundation
36,152
36,152
7/1/14
Present
Ramsingh, Giridharan
Characterizing Hematopoietic Senescence with Aging in Humans
Leukemia and
Lymphoma Society
161,635
17,941
179,576
1/1/15
Present
Tulpule, Anil
Bendamustine Hydrochloride and Rituximab (BR) vs. Rituximab,

Cyclophosphamide, Vincristine and Prednisone
PPD Development
3,148
787
3,935
1/6/10
Present
Tulpule, Anil
Bendamustine Hydrochloride with Rituximab in the Treatment of

Patients with Relapsed/Refractory Mantle Cell Lymphoma
Teva
1,301
325
1,626
3/29/10
Present
Agency
Kelly, Kevin
Oprozomib and Dexamethasone in Patients with Replapsed and/or

Refractory Multiple Myeloma
Kelly, Kevin
152

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
MedNet Solutions
1,360
340
1,700
9/24/10
Present
RCHOP with or without VELCADE in Previously Untreated

Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma
Quintiles
22,098
5,524
27,622
12/30/10
Present
Tulpule, Anil
A+AVD vs. ABVD as Frontline Therapy in Patients with Advanced

Classical Hodgkin's Lymphoma
ICON Clincial
Research
98,008
24,502
122,510
10/23/13
Present
Weitz, Ilene
Anti-Von Willebrand Factor Nanobody Administered as Adjunctive

Treatment
Pharmaceutical
Research
Associates
2,519
630
3,149
10/1/12
Present
Weitz, Ilene
SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease

Patients
Quintiles
27,460
6,865
34,325
8/29/14
Present
Weitz, Ilene
APL-2 as an add-on to Standard of Care
Appellis
Pharmaceuticals
20,601
5,150
25,751
6/17/15
Present
1,499,275
367,825
1,867,100
Agency
Tulpule, Anil
Multinational Registry of Patients with Newly Disgnosed Peripheral

T-Cell Lymphoma
Tulpule, Anil
TOTAL HEMATOLOGY
INFECTIOUS DISEASES
Dube, Michael
EGRIFTA (Tesamorelin for Injection)
inVentive Health
3,991
998
4,989
3/6/13
Present
Dube, Michael
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide vs.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir
PPD Development
6,525
1,631
8,156
7/23/13
Present
Dube, Michael
GSK 201147: Fixed-Dose Combination of Abacavir/Dolutegravir/

Lamivudine vs. Current Antiretroviral Therapy
Pharmaceutical
Product
Development
55,511
13,878
69,389
5/9/14
Present
Jones, Brenda
Evaluation of the 4th Generation QuantiFERON-TB Gold Test for the

Detection of Tuberculosis Infection
Qiagen
49,256
12,314
61,570
1/29/14
Present
Sattler, Fred
Effects of Sitagliptin on Arterial Vasoreactivity and Proatherogenic
L.K. Whittier
Foundation
50
50
9/14/15
Present
Spellberg, Brad
Humanized Monoclonal Antibodies to Treat Acinetobacter Infections
BioAIM
134,563
22,808
157,371
7/1/14
Present
249,896
51,629
301,525
9,575
2,394
11,969
12/18/13
Present
223,183
55,796
278,978
10/1/13
Present
232,758
58,189
290,947
TOTAL INFECTIOUS DISEASES
NEPHROLOGY AND HYPERTENSION

Qazi, Yasir
Benefits and Risks in Maintenance Renal Transplant Recipients

following Conversion to Nulojix (Belatacept)-Based
Immunosuppression
ICON Clinical
Research
Qazi, Yasir
Concentration-Controlled Everolimus with Reduced Calcineurin

Inhibitor vs. Mycophenolate with Standard Calcineurin Inhibitor
Novartis
TOTAL NEPHROLOGY AND HYPERTENSION
ONCOLOGY
Agus, David
TAK-700 in Advanced Prostate Cancer
Millennium
16,386
4,097
20,483
7/1/09
Present
Agus, David
TAK-700 with Docetaxel and Prednisone in Men with Metastatic

Castration-Resistant Prostate Cancer
PPD Development
3,144
786
3,930
6/28/10
Present
Agus, David/Macklin, Paul/

Mumenthaler, Shannon
Application of Breast Cancer Data Element Standardization in

Predictive Multi-Scale Cancer Models
The Breast Cancer

Foundation
79,937
16,004
95,941
9/9/14
Present
Agus, David/Macklin, Paul/

Mumenthaler, Shannon
Multiscale Dynamical Computational Platform for Clinical Breast

Cancer Predictions
Breast Cancer
Research
Foundation
41,151
148
41,299
10/1/13
Present
Agus, David/Macklin, Paul/Ruderman,

Daniel
Developing a Quantitative Pathologic Image Analysis Platform
Breast Cancer
Research
Foundation
23,897
4,779
28,676
10/1/15
Present
Agus, David/Ruderman, Daniel
Evaluation of Clinical Data Availability for Hypothesis Generation

and Prospective T1D Trial Design
Helmsley
Charitable Trust
154,369
15,437
169,806
2/20/15
Present
Barzi, Afsaneh
Neoadjuvant Bevacizumab with FOLFOX in Patients with Curable

Rectal Cancer
Genentech
16,988
4,247
21,235
7/1/13
Present
Barzi, Afsaneh
Overall Survival Using MABp1 as a Monotherapy in Metastatic

Colorectal Cancer Patients with Cachexia
Xbiotech
8,326
2,082
10,408
8/22/13
Present
Barzi, Afsaneh
Gemcitabine with TH-302 vs. Gemcitabine
EMD Serono
7,922
1,980
9,902
11/6/13
Present
Dorff, Tanya
Ipilimumab vs. Placebo Following Radiotherapy in Subjects with

Castration Resistant Prostate Cancer Who Have Received Prior
Treatment
Bristol Myers
Squibb
1,791
448
2,239
5/13/10
Present
Dorff, Tanya
Oral MDV3100 in Chemotherapy Naive Patients with Progressive

Metastatic Prostate Cancer
Mediviation
20,973
5,243
26,216
1/10/11
Present
Dorff, Tanya
Dasatinib plus Abiraterone Compared to Abiraterone Alone for

Metastatic, Castration-Resistant Prostate Cancer Prior to
Chemotherapy
Bristol Myers
Squibb
48,696
12,174
60,870
8/23/12
Present
Dorff, Tanya
Cabozantinib (XL184) vs. Prednisone in Metastatic CastrationResistant Prostate Cancer Patients who Have Received Prior
Docetaxel
Exelixis
8,121
2,030
10,151
5/28/13
Present
Dorff, Tanya
SPARTAN: ARN-509 in Men with Metastatic Castration-Resistant

Prostate Cancer
Aragon
Pharmaceuticals
13,215
3,304
16,519
1/12/15
Present
El-Khoueiry, Anthony
SEPHB4-HAS
L.K. Whittier
Foundation
45,112
45,112
4/1/15
Present
VARI-SU2C
Van Andel
Research Institute
13,960
1,396
15,356
9/24/14
Present
Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma after

Surgical Resection or Local Ablation
Bayer Healthcare
22,466
5,617
28,083
12/18/08
Present
153

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
Medical Univ Of
South Carolina
8,876
2,219
11,095
9/25/09
Present
GDC-0623 Administered Daily in Patients with Locally Advanced or

Metastatic Solid Tumors
Genentech
24,727
6,182
30,909
5/5/10
Present
PRI-724 in Patients with Advanced Solid Tumors
Prism Biolab
11,731
2,933
14,664
2/14/11
Present
BMS-906024 in Subjects with Advanced Solid Tumors
Bristol Myers
Squibb
51,989
12,997
64,986
3/24/11
Present
Everolimus (RAD001) plus Best Supportive Care vs. Placebo plus

Best Supportive Care in the Treatment of Patients with Advanced
NET of GI
Novartis
1,440
360
1,800
6/24/12
Present
Effect of Hepatic Impairement on the Pharmacokinetics and Safety of

Crizotinib in Advanced Cancer Patients
Pfizer
130,263
32,566
162,829
6/18/12
Present
Oral PI3K/mTOR Inhibitor P7170 in Patients with Advanced

Refractory Solid Tumors
Piramal Life
Science
33,418
8,354
41,772
12/17/12
Present
BMS-906024 with Several Chemotherapy Regimens in Subjects with

Advanced or Metastatic Tumors
Bristol Myers
Squibb
163,216
40,804
204,020
11/12/12
Present
Extension Study of NKTR-102 in Subjects Previously Enrolled in

NKTR-102 Studies
Nektar
1,859
465
2,324
10/19/12
Present
Safety, Immunoregulatory Activity, Pharmacokinetics, and

Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1)
Antibody
Bristol Myers
Squibb
214,363
53,591
267,954
3/18/13
Present
Treatment of Advanced Hepatocelluular Carcinoma (HCC) Subjects

who Failed Prior Treatment with Sorafenib
Astex
33,940
8,485
42,425
4/29/13
Present
Oral IGF-1R Inhibitor PL225B in Subjects with Advanced Refractory

Solid Tumors
Piramal Life
Science
30,481
7,620
38,101
5/2/13
Present
NKTR-102 for Injection (Etirinotecan Pegol) in Patients with

Advanced or Metastatic Solid Tumors
Nektar
21,764
5,441
27,205
5/1/13
Present
Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for

Injection in Patients with Advanced Solid Tumors
Jina
6,004
1,501
7,505
11/7/13
Present
OMP-54F28 with Sorafenib in Patients with Hepatocellular Cancer
Oncomed
45,721
11,430
57,151
4/2/14
Present
Cabozantinib (XL184) vs. Placebo in Subjects with Hepatocellular

Carcinoma Who Have Received Prior Sorafenib
Exelixis
38,831
9,708
48,539
5/6/14
Present
Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib

in Subjects with Advanced Solid Tumors
Daiichi
130,379
32,595
162,974
6/27/14
Present
Nab Paclitaxel plus Gemcitabine vs. Gemcitabine Alone as Adjuvant

Therapy in Subjects with Surgically Resected Pancreatic
Adenocarcinoma
Celgene
14,095
3,524
17,619
12/11/14
Present
BMS-986115 in Subjects with Advanced Solid Tumors
Bristol Myers
Squibb
93,347
23,337
116,684
7/31/14
Present
PF-06664178 in Patients with Locally Advanced or Metastatic Solid

Tumors
Pfizer
154,187
38,547
192,734
8/12/14
Present
Oral BGJ398 in Adult Patients with Advanced or Metastatic

Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR
Genetic Alterations
Novartis
28,694
7,174
35,868
4/15/14
Present
Anti-Tumor Activity of Ascending Doses of AZD6738
Astra Zeneca
34,107
8,527
42,633
1/9/15
Present
Anti-Tumor Activity of Ascending Doses of AZD5363 Under

Adaptable Dosing Schedules
Astra Zeneca
37,104
9,276
46,380
12/30/14
Present
PF-04518600 in Patients with Locally Advanced or Metastatic

Hepatocellular Carcinoma (HCC), Melanoma, or Clear Cell Renal
Cell Carcinoma (RCC)
Pfizer
17,064
4,266
21,330
5/1/15
Present
DKN-01 with Gemcitabine and Cisplatin in Patients with Advanced

Carcinoma Primary to the Intra- or Extra-Hepatic Biliary System
Healthcare
Pharmaceuticals
21,525
5,381
26,907
6/15/15
Present
Abraxane Administered on a Weekly and Three Weekly Schedule with

Vandetanib (Iruszact)
Abraxis
Biosciences
33,923
8,481
42,404
4/4/08
Present
Garcia, Agustin
Neratinib in Metastatic HER2 Non-Amplified
Puma Biotech
7,557
4,793
12,350
6/18/14
Present
Garcia, Agustin
Ramucirumab (IMC-1121B) or IMC-18F1 with Capecitabine or

Capecitabine Monotherapy
Imclone Systems
9,786
2,447
12,233
2/11/11
Present
Garcia, Agustin
Oral TKI258 as Second-Line Therapy in Patients with Either FGFR2

Mutated or Wild-Type Advanced and/or Metastatic Endometrial
Cancer
Novartis
869
217
1,086
4/10/12
Present
Garcia, Agustin
Eribulin in Advanced or Recurrent Cervical Cancer
Eisai
43,959
10,990
54,949
8/9/12
Present
Garcia, Agustin
MM-111 with Multiple Treatment Regimens in Patients with

Advanced HER2 Positive Solid Tumors
Merrimack
85,571
21,393
106,963
5/29/12
Present
Garcia, Agustin
NKTR-102 vs. Treatment of Physician's Choice
Nektar
5,828
1,457
7,285
6/28/12
Present
Garcia, Agustin
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive

Breast Cancer with Low to Intermediate HER2 Expression with
NeuVax Treatment
Galena Biopharma
17,651
4,413
22,063
9/12/12
Present
Garcia, Agustin
MM-121 with Paclitaxel vs. Paclitaxel Alone in Patients with Platinum

Resistant/ Refractory Advanced Ovarian Cancers
Merrimack
8,960
2,240
11,199
10/10/12
Present
Garcia, Agustin
IDO Inhibitor INCB024360 vs. Tamoxifen for Subjects with

Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary
Peritoneal Carcinoma
Incyte
2,960
740
3,700
11/5/12
Present
Agency
Bevacizumab (Avastin) and Erlotinib (Tarceva) vs. Sorafenib in the

First-Line Treatment of Patients with Advanced
Hepatocellularcarcinoma
154

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
Sanofi-Aventis
15,806
3,952
19,758
11/9/12
Present
Treatment Patterns and Outcomes in Patients with HER2 Positive

(HER2+) Metastatic Breast Cancer
Genentech
10,052
2,513
12,566
5/1/13
Present
Garcia, Agustin
BKM120 with Fulvestrant, in Postmenopausal Women with Hormone

Receptor-Positive HER2-Negative Locally Advanced or Metastatic
Breast Cancer
Novartis
9,892
2,473
12,365
6/1/13
Present
Garcia, Agustin
Fulvestrand (Faslodex) with or without PD-0332992 (Palbociclip)

Goserelin in Women with Hormone Receptor-Positive,
HER2-Negative Breast Cancer
Pfizer
21,793
5,448
27,242
3/31/14
Present
Garcia, Agustin
Combination of Yondelis and Doxil/Caelyx vs. Doxil/Caelyx

Monotherapy for the Treatment of Advanced-Relapsed Epithelial
Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research
9,080
2,270
11,350
2/14/14
Present
Garcia, Agustin
CDX-011(CR011-vcMMAE) in Patients with Metastatic GPNMB

Over-Expressing, Triple-Negative Breast Cancer
Celldex
Therapeutics
6,558
1,639
8,197
2/10/14
Present
Garcia, Agustin
Niraparib vs. Physician's Choice in Previously-Treated, HER2

Negative, Germline BRCA Mutation-Positive Breast Cancer Patients
Tesaro
6,200
1,550
7,751
6/17/14
Present
Garcia, Agustin
Veliparib plus Carboplatin vs. the Addition of Carboplatin
Abbvie
23,107
5,777
28,884
9/25/14
Present
Garcia, Agustin
ANG1005 in HER2+ Breast Cancer Patients with Progressive/

Recurrent Brain Metastases
Angiochem
30,269
7,567
37,836
9/18/14
Present
Garcia, Agustin
AEZS-108 with Doxorubicin as Second Line Therapy for Locally

Advanced, Recurrent or Metastatic Endometrial Cancer
Aeterna Zentaris
21,580
5,395
26,975
3/18/14
Present
Garcia, Agustin
Ruxolitinib/Placebo with Capecitabine in Subjects with Advanced or

Metastatic HER2-Negative Breast Cancer
Incyte
24,298
6,075
30,373
5/6/14
Present
Garcia, Agustin
Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast

Cancer
Clovis
13,688
3,422
17,110
5/5/14
Present
Gitlitz, Barbara
Genomics of Young Lung Cancer (ALCMI-005)
Addario Lung
Cancer Medical
Institute
3,563
344
3,906
8/6/14
Present
Gitlitz, Barbara
STA-9090 with Docetaxel vs. Docetaxel Alone in Subjects with Stage

IIIB or IV Non-Small Cell Lung Cancer
Synta
7,820
1,955
9,775
10/16/12
Present
Gitlitz, Barbara
Palifosfamide-Tris, a Novel DNA Crosslonker, with Carboplatin and

Etoposide Chemotherapy vs. Carboplatin
Ziopharm
2,206
551
2,757
8/30/12
Present
Gitlitz, Barbara
BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced

Non-Small Cell Lung Cancer and BRAF Mutations
GlaxoSmithKline
3,040
760
3,800
4/29/13
Present
Gitlitz, Barbara
HSP90 Inhibitor AT13387 Alone with Crizotinib in the Treatment of

Non-Small Cell Lung Cancer (NSCLC)
Astex
96,660
24,165
120,825
5/2/13
Present
Gitlitz, Barbara
Chemotherapy plus Cetuximab with VTX-2337 in Patients with

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and
Neck
Ventirx
57,529
14,382
71,911
2/4/14
Present
Gitlitz, Barbara
Oral CO-1686 in Patients with Previously Treated Mutant EGFR N

on-Small Lung Cancer (NSCLC)
Clovis
50,365
12,591
62,957
9/5/14
Present
Gitlitz, Barbara
Alisertib (MLN8237) with Paclitaxel vs. Placebo with Paclitaxel as

Second Line Therapy
Millennium
14,773
3,693
18,466
3/17/15
Present
Gitlitz, Barbara
Oral RXDX-101 in Adult Patients with Locally Advanced or

Metastatic Cancer Positive for TrKA, TrkB, TrkC, ROS1 or ALK
Ignyta
8,200
2,050
10,250
5/8/15
Present
Gitlitz, Barbara
Oral Ceritinib Treatment for Patients with ALK-Positive Non-Small

Cell Lung Cancer (NSCLC)
Novartis
11,216
2,804
14,020
12/18/14
Present
Gitlitz, Barbara
Tarceva (Erlotinib) Following Complete Tumor Resection with or

without Adjuvant Chemotherapy
Osi
2,243
561
2,804
3/29/07
Present
Gitlitz, Barbara
Cancer Vaccine Stimuvax in Non-Small Cell Lung Cancer Subjects
Merck KGaA
4,760
1,190
5,950
6/12/07
Present
Goldkorn, Amir
Global CTCs Biomarker Projects
Prostate Cancer
Foundation
51,157
45,753
96,910
1/1/13
Present
Goldkorn, Amir/Gill, Parkash/

Targeting the Ephrin Pathway: A Phase I Therapeutic Trial
V Foundation for
Cancer Research
59,144
6,004
65,148
10/1/10
Present
Gross, Mitchell
Patients with Metastatic Castration Resistant Prostate Cancer

Currently on Therapy with Enzalutamide or Abiraterone
Janssen Research
28,647
7,162
35,809
7/21/14
Present
Hu, James
SARC028: Anti-PD1 Antibody Pembrolizumab (MK-3
Sarcoma Alliance
For Research
4,900
4,900
5/13/15
Present
Hu, James
Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma
Eisai
30,051
7,513
37,564
9/22/11
Present
Hu, James
Yondelis (Trabectedin) or Dacarbazine for the Treatment of Advanced

Liposarcoma or Leiomyosarcoma
Janssen Research
4,957
1,239
6,196
5/24/13
Present
Hu, James
TH-302 with Doxorubicin vs. Doxorubicin Alone in Subjects with

Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Threshold
24,496
6,124
30,620
12/21/12
Present
Hu, James
Orally Administered PLX3397 in Subjects with Pigmented

Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Daiichi
16,524
4,131
20,655
8/31/15
Present
Lenz, Heinz-Josef
Cabazitaxel in Refracto
Weill Cornell
Medical College
11,192
3,287
14,479
1/29/14
Present
Lenz, Heinz-Josef
Pre-Clinical in vivo Pharmacology and Transnational Research
Merck KGaA
58,205
25,089
83,294
2/9/15
Present
Lenz, Heinz-Josef
GI Cancer Explant Model Collaboration with BMS
Bristol Myers
Squibb
28,188
11,235
39,423
12/18/13
Present
Lenz, Heinz-Josef
HyperAcute-Pancreatic Cancer Vaccine in Subjects with Surgically

Resected Pancreatic Cancer
Newlink Genetics
1,440
360
1,800
1/5/09
Present
Agency
Garcia, Agustin
Subjects who Completed a Phase 1/Phase 2 Parental Study to

Continue Receiving Treatment w/SAR245408 or SAR24509
Garcia, Agustin
155

Agency
Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
Lenz, Heinz-Josef
LBH589 and Infusional 5-FU/LV in Patients with Metastatic

Colorectal Cancer who Failed 5-FU Based Chemotherapy
Novartis
16,011
4,003
20,014
10/7/10
Present
Lenz, Heinz-Josef
NKTR-102 (PEG-Irinotecan) vs. Irinotecan in Patients with

Second-Line, Irinotecan-Naive, KRAS-Mutant, Colorectal Cancer
Nektar
25,657
6,414
32,072
7/27/09
Present
Lenz, Heinz-Josef
Chemotherapy and Chemoradiotherapy with or without HyperAcute

Pancreatic Cancer Vaccine in Subjects with Surgically Resected
Pancreatic Cancer
Newlink Genetics
2,791
698
3,488
7/16/10
Present
Lenz, Heinz-Josef
Bevacizumab/Mfolfox9 vs. Bevacizumab/Folfiri with Biomarker

Stratification in Patients with Previously Untreated Metastatic
Colorectal Cancer
Genentech
211,193
52,798
263,992
10/19/11
Present
Lenz, Heinz-Josef
Regorafenib in Patients with Metastatic Colorectal Cancer (CRC) who

Have Progressed after Standard Therapy
Bayer Healthcare
2,456
614
3,070
6/13/12
Present
Lenz, Heinz-Josef
Folfiri+Mehd7945e vs. Folfiri+Cetuximab in Second Line in Patients

with KRAS Wild-Type Metastatic Colorectal Cancer
Genentech
4,807
1,202
6,009
10/23/12
Present
Lenz, Heinz-Josef
LGX818 and Cetuximab or LGX818, BYL719 and Cetuximab in

Patients with BRAF Mutant Metastatic Colorectal Cancer
Novartis
28,004
7,001
35,005
6/11/13
Present
Lenz, Heinz-Josef
Escalation Trial to Determine the Safety, Tolerance and Preliminary

Antineoplastic Activity of Gemcitabine
Prism Pharma
22,079
5,520
27,599
9/4/13
Present
Lenz, Heinz-Josef
STEAM (Sequencing Triplet with Avastin and Maintenance):

Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) vs.
Folfox/Bevacizumab In First-Line Metastatic Colorectal Cancer
Genentech
170,233
42,558
212,791
8/28/13
Present
Lenz, Heinz-Josef
Vantictumab (OMP-18R5) with NAB-Paclitaxel and Gemcitabine in

Patients with Previously Intreated Stage IV Pancreatic Cancer
Oncomed
3,505
876
4,381
4/1/14
Present
Lenz, Heinz-Josef
PF-05212384 plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI)

vs. Bevacizumab plus Folfiri in Metastatic Colorectal Cancer
Pfizer
18,141
4,535
22,676
10/23/14
Present
Lenz, Heinz-Josef
TAS-114 with Capecitabine in Patients with Advanced Solid Tumors
Taiho
38,782
9,695
48,477
3/4/14
Present
Lenz, Heinz-Josef
Safety, Tolerability, Pharmacokinetics, Biological and Clinical

Activity of MSB0010718C
EMD Serono
9,409
2,352
11,761
4/23/14
Present
Lenz, Heinz-Josef
Regorafenib (BAY 73-4506) with Cetiximab in Subjects with Locally

Advanced or Metastatic Solid Tumors
Bayer Healthcare
58,790
14,698
73,488
4/28/14
Present
Lenz, Heinz-Josef
BBI608 Administered with Paclitaxel in Adult Patients with Advanced

Malignancies
Boston Biomedical
36,732
9,183
45,915
8/11/14
Present
Lenz, Heinz-Josef
OMP-54F28 with Nab-Paclitaxel and Gemcitabine in Patients with

Previously Untreated Stage IV Pancreatic Cancer
Oncomed
17,628
4,407
22,035
4/1/14
Present
Lenz, Heinz-Josef
Adjuvant Regorafenib vs. Placebo for Patients with Stage IV

Colorectal Cancer After Curative Treatment of Liver Metastases
Bayer Healthcare
16,221
4,055
20,276
11/26/14
Present
Lenz, Heinz-Josef
Nivolumab and Nivolumab plus Ipilimumab in Recurrent and

Metastatic Microsatellite High Colon Cancer
Bristol Myers
Squibb
47,629
11,907
59,537
8/13/14
Present
Lenz, Heinz-Josef
2 Sym004 Doses vs. Investigator's Choice (Best Supportive Care,

Capecitabine, 5-FU) in Subjects with Metastatic Colorectal Cancer
EMD Serono
18,933
4,733
23,666
9/16/14
Present
Lenz, Heinz-Josef
TH-302 with Gemcitabine and Nab-Oaclitaxel in Previously Untreated

Subjects with Metastatic or Locally Advanced Unresectable Pancreatic
Cancer
EMD Serono
17,049
4,262
21,311
10/27/14
Present
Lenz, Heinz-Josef
Ruxolitinib or Placebo with Regorafenib in Subjects with Relapsed or

Refractory Metastatic Colorectal Cancer
Incyte
81,258
20,315
101,573
11/21/14
Present
Lenz, Heinz-Josef
Nintedanib plus Best Supportive Care (BSC) vs. Placebo plus BSC in
Patients with Colorectal Cancer Refractory to Standard Therapies
Boehringer
Ingelheim
28,073
7,018
35,091
4/9/15
Present
Lenz, Heinz-Josef
TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to

or Failing Standard Chemotherapy(s)
Taiho
13,600
3,400
17,000
4/24/15
Present
Nieva, Jorge
MEDI4736 Monotherapy in Patients with Recurrent or Metastatic

Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Astra Zeneca
12,568
3,142
15,710
2/5/15
Present
Nieva, Jorge
Tiger 1: Co-1686 or Erlotinib as First-Line Treatment of Patients with

EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Clovis
14,336
3,584
17,920
2/23/15
Present
Nieva, Jorge
Alectinib for Patients with ALK-Rearranged Non-Small Cell Lung

Cancer After Disease Progression on or Intolerance to Prior Alk
Tyrosine
Genentech
12,200
3,050
15,250
7/27/15
Present
Pinski, Jacek
Cabazitaxel plus Prednisone with Depot Octreotide in the Treatment

of Metastatic Castration-Resistant Prostate Cancer Previously Treated
with Docetaxel
Sanofi-Aventis
26,119
6,530
32,649
5/31/12
Present
Quinn, David
Abiraterone with or without ABT-888 for Patients with Metastatic

Castration-Resistant Prostate Cancer
University of
Michigan (SU2C)
6,403
640
7,043
8/1/12
Present
Quinn, David
Axitinib for Metastatic Renal Cell Cancer: Axis Trial
Pfizer
2,240
560
2,800
6/28/09
Present
Quinn, David
Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally

Advanced Renal Cell Carcinoma
GlaxoSmithKline
1,040
260
1,300
8/15/11
Present
Quinn, David
Docetaxel with Ramucirumab or IMC-18F1 or without Investigational

Therapy
Imclone Systems
22,121
5,530
27,652
8/29/11
Present
Quinn, David
Registry of Sipuleucel-T Therapy in Men with Advanced Prostate

Cancer
Dendreon
88
22
110
11/23/11
Present
Quinn, David
DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+

Urothelial Carcinoma
Dendreon
1,728
432
2,160
12/17/11
Present
Quinn, David
Gemcitabine and Cisplatin with OGX-427 or Placebo in Patients with

Advanced Transitional Cell Carcinoma
Oncogenex
Technologies
6,304
1,576
7,880
2/17/12
Present
Quinn, David
Extension Protocol for Subjects who were Previously Enrolled in

other ARQ 197 Protocols
Arqule
18,772
4,693
23,465
11/18/11
Present
156

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
Aveo
2,204
551
2,755
1/30/13
Present
BMS-936558 vs. Everolimus in Advanced or Metastatic Clear-Cell

Renal Cell Carcinoma
Bristol Myers
Squibb
22,573
5,643
28,216
3/17/13
Present
Quinn, David
Rollover Protocol to Allow Continued Access to Tivozanib for

Subjects Enrolled in other Tivozanib Protocols
Aveo
2,675
669
3,344
7/18/13
Present
Quinn, David
Docetaxel Alone to Docetaxel with Ogx-427 in Patients with Relapsed

or Refractory Metastatic Urothelial Carcinoma
Hoosier Oncology
Group
15,221
3,805
19,026
12/12/13
Present
Quinn, David
Sipuleucel-T with Concurrent vs. Sequential Administration of

Enzalutamide for Metastatic Castrate Resistant Prostate Cancer
Dendreon
4,812
1,203
6,015
2/19/14
Present
Quinn, David
Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent

Renal Cell Carcinoma
SFJ
11,138
2,784
13,922
8/6/14
Present
Quinn, David
Neratinib in Patients with Solid Tumors with Somatic Human

Epidermal Growth Factory Receptor (EGFR, HER2, HER3)
Mutations of EGFR Gene Amplification
Puma
Biotechnology
23,900
5,975
29,875
11/25/13
Present
Quinn, David
Radium-223 Dichloride with Abiraterone Acetate or Enzalutamide in

Subjects with Castration-Resistant Prostate Cancer
Bayer Healthcare
41,246
10,312
51,558
10/8/14
Present
Quinn, David
Mpdl3280a in Patients with Locally Advanced or Metastatic

Urothelial Bladder Cancer
Genentech
50,918
12,730
63,648
8/18/14
Present
Quinn, David
BAY 73-4506
Bayer Healthcare
44,834
11,209
56,043
10/27/14
Present
Quinn, David
Oral Bgj398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with

Advanced Solid Malignancies
Novartis
52,824
13,206
66,030
7/1/14
Present
Quinn, David
Lee011 in Patients with Relapsed, Refractory, Incurable Teratoma with

Recent Progression
Novartis
14,560
3,640
18,200
6/24/14
Present
Quinn, David
Nivolumab with Ipilimumab vs. Sunitinib Monotherapy in Subjects

with Previously Untreated Advanced or Metastatic Renal Cell
Carcinoma
Bristol Myers
Squibb
26,206
6,552
32,758
3/10/15
Present
Quinn, David
Pembrolizumab (MF-3475) vs. Paclitaxel or Vinflunine in Subjects

with Recurrent or Progressive Metastatic Urothelial Cancer
Merck
51,976
12,994
64,970
2/3/15
Present
Quinn, David
Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable

or Metastatic Urothelial Cancer
Merck Sharp &

Dohme
13,736
3,434
17,170
7/21/15
Present
Quinn, David
Galeterone vs. Enzalutamide in Men Expressing Androgen Splice

Variant-7 mRNA(AR-V7) Metastatic (M1) Castrate Resistant Prostate
Cancer
Tokai
Pharmaceuticals
16,524
4,131
20,655
10/5/15
Present
Ricker, Charite
Predicting BRCA1 Mutation Status from Tumor Pathology
University of Calif.
Berkeley (CBCRP)
25,065
9,107
34,172
8/1/12
Present
Ricker, Charite/Spicer, Darcy
Promoting Participation in Cancer Risk Counseling
Bernadette
Pabillare
16,134
3,227
19,361
7/1/10
Present
Russell, Christy
Doxorubicin & Cyclophosphamide Followed by Docetaxel with

Doxorubicin & Cyclophoshamide Followed by Docetaxel &
Trastuzumab
Avantis
4,180
1,045
5,225
12/20/05
Present
Russell, Christy
Docetaxel with Doxorubicin and Cyclophosphamide vs. Doxorubicin

and Cyclophosphamide followed by Docetaxel
Breast Cancer
International
3,040
760
3,800
5/23/03
Present
Siegel/Hu, James
AYA Research and Data Coordinator for Clinical Trials
St. Baldrick's
Foundation
30,312
30,312
11/26/14
Present
Tripathy, Debasish
Temsirolimus plus Neratinib for Subjects with Metastatic

HER2-Amplified or Triple-Negative Breast Cancer
Puma
Biotechnology
1,152
288
1,440
3/11/13
Present
Wong, Michael
Proleukin Observational Registry to Evaluate the Treatment Patterns

and Clinical Response in Malignancy
Prometheus
4,159
1,040
5,198
6/1/12
Present
Wong, Michael
Talimogene Laherparapvec and Ipilimumab vs. Ipilimumab Alone in

Subjects
Amgen
22,239
5,560
27,799
9/29/14
Present
Wong, Michael
LGX818 plus MEK162 and LGX818 Monotherapy with Vemurafenib

In Patients with Unresectable or Metastatic Braf V600 Mutant
Melanoma
Novartis
12,701
3,175
15,876
6/19/13
Present
4,393,474
1,080,551
5,474,024
Agency
Quinn, David
Tivozanib vs. Sunitinib in the Treatment of Subjects with Locally

Advanced and/or Metastatic Renal Cell Carcinoma
Quinn, David
TOTAL ONCOLOGY
PULMONARY, CRITICAL CARE AND SLEEP MEDICINE

Balekian, Alex
Early Diagnosis of Pulmonary Nodules Using a Plasma Proteomic

Classifier
Integrated
Diagnostics
10,281
2,570
12,852
7/15/13
Present
Balekian, Alex
Patient and Oncologist Decision Making Related to Maintenance

Treatment for Advanced NSCLC
ICON Clincial
Research
2,500
625
3,125
8/14/15
Present
Barbers, Richard
Multi-Center Mult-International Retrospective Review of Safety
University Health
Network
7,858
4,179
12,036
4/10/13
Present
Barbers, Richard
Effects of Lebrikizumab on Airway Eosinophilic Inflammation in

Patients with Uncontrolled Asthma
Quintiles
37,138
9,285
46,423
2/23/15
Present
Ganesh, Sivagini
Pulmonary Arterial Hypertension (PAH) Quality Enhancement
MD Primer
2,492
623
3,115
8/5/11
Present
Ganesh, Sivagini
Registry of Sarcoidosis Associated Pulmonary Hypertension

(RESAPH)
University Internal
Medicine
Associates
1,460
365
1,825
5/14/12
Present
Ganesh, Sivagini
Macitentan in Patients with Pulmonary Arterial Hypertension to

Psychometrically Validate the PAH-SYMPACT Instrument
United BioSource
5,776
1,444
7,220
10/16/13
Present
Ganesh, Sivagini
US-based, Observational, Drug Registry of Opsumit (Macitentan)

New Users in Clinical Practice
Pharmaceutical
Research
Associates
9,200
2,300
11,500
7/7/14
Present
157

Direct Cost
Indirect Cost
Total Cost
Beginning
Date
End
Date
Cystic Fibrosis
Foundation
13,547
13,547
7/1/08
Present
2015 Therapeutic Development Network Spring Meeting
Cystic Fibrosis
Foundation
998
170
1,168
2/1/15
Present
Rao, Adupa
CFF Therapeutics Development Center 2015
Cystic Fibrosis
Foundation
40,114
3,209
43,323
1/1/15
Present
Rao, Adupa
Study to Monitor the Susceptibility to Aztreonam of Pseudomonas

Aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the
United States
Gilead Sciences
2,483
621
3,104
12/6/11
Present
Rao, Adupa
Lumacaftor with Ivacaftor in Subjects Aged 12 Years and Older
Quintiles
2,520
630
3,150
9/6/13
Present
Rao, Adupa
Prevalence of Antibodies to Selected Porcine Viruses in Patients

with Cystic Fibrosis who are Receiving Porcine-Derived Pancreatic
Enzyme Replacement Therapy
Mapi USA
1,240
310
1,550
2/26/14
Present
Rao, Adupa
Lumacaftor with Ivacaftor in Subjects Aged 12 Years and Older with

Cystic Fibrosis
Quintiles
53,377
13,344
66,721
2/25/14
Present
Rao, Adupa
Tobramycin Inhalation Powder (TIP) Administered Once Daily

Continuously vs. TIP Administered Bid in 28 Day on/28 Day off
Premier Research
Group
14,360
3,590
17,950
8/31/14
Present
Rao, Adupa
Pulmaquin in the Management of Chronic Lung Infections with

Pseudomonas Aeruginosa
SynteractedHCR
16,503
4,126
20,629
11/20/14
Present
Rao, Adupa
Liposomal Amikacin for Inhalation (LAI) in Adult Patients with

Nontuberculous Mycobacterial (NTM) Lung Infections
SynteractedHCR
15,980
3,995
19,975
7/7/15
Present
237,828
51,386
289,213
Agency
Rao, Adupa
CFF Care Center Grant 2015-2016
Rao, Adupa
TOTAL PULMONARY, CRITICAL CARE AND SLEEP MEDICINE
RHEUMATOLOGY
Jacob, Chaim
Towards Understanding the Role of NCF2 in SLE
Alliance for Lupus

Research
202,163
16,173
218,336
4/1/14
Present
Jacob, Chaim
Target DNA Capture and Parallel Sequencing
Alliance for Lupus

Research
217
217
2/1/10
Present
Stohl, William
Belimumab (HGS1006, LymphoStat-B ), a Fully Human Monoclonal

Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus
who Completed the Phase 3 Protocol
INC Research
640
160
800
5/29/09
Present
Stohl, William
CP-690,550, a Moderately Selective Janus-Kinase-3 Inhibitor, for

Treatment of Rheumatoid Arthritis
ICON Clincial
Research
8,023
2,006
10,028
5/10/10
Present
Stohl, William
Belimumab (HGS1006) Administered Subcutaneously to Subjects

with Systemic Lupus Erythematosus
Quintiles
37,987
9,497
47,484
6/14/12
Present
Stohl, William
Adverse Events of Special Interest in Adults with Active,

Autoantibody- Positive Systemic Lupus Erythematosus Receiving
Belimumab
Quintiles
84,601
21,150
105,751
5/29/14
Present
Stohl, William
Belimumab plus Standard of Care vs. Placebo plus Standard of Care

in Adult Subjects with Active Lupus
Quintiles
2,240
560
2,800
4/3/13
Present
Stohl, William
Adverse Events of Interest and Effectiveness in Adults with Active,

Autoantibody-Positive Systemic Lupus Erythematosus
Quintiles
8,945
2,236
11,181
10/13/14
Present
Stohl, William
5MG of Tofacitinib with and without Methotrexate vs. Adalimumab

with Methotrexate in Subjects with Moderately to Severely Active
ICON Clincial
Research
12,084
3,021
15,105
5/12/15
Present
Stohl, William
Lymphostat-B Antibody (Monoclonal Anti-Blys Antibody) in Subjects

with Systemic Lupus Erythematosus who Completed the Phase 2
Protocol
GlaxoSmithKline
26,133
6,533
32,666
10/27/05
Present
Stohl, William/Jacob, Chaim
Therapeutic Targeting of FcgRIIb on B Cells on SLE
Alliance for Lupus

Research
96,463
7,717
104,180
2/1/15
Present
Stohl, William/Jacob, Chaim/Zheng,

Song Guo
Roles of Individual Elements of the Baff Axis in Murine
Alliance for Lupus

Research
112,630
9,010
121,641
2/1/13
Present
Stohl, William/Zheng, Song Guo
Role of the Baff Axis
Nat'l Multiple
Sclerosis Society
115,464
11,167
126,630
7/1/12
Present
707,589
89,230
796,819
8,970,655
2,052,922
11,023,578
TOTAL RHEUMATOLOGY
TOTAL ALL DIVISIONS
158
Designed and compiled by John Ryan Daniel, Special Projects Coordinator

Edited by Eva Blaauw, Executive Administrator
159

Ar 2015

Uploaded by

Copyright:

Ar 2015

Uploaded by

Document Information

Original Title

Copyright

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Ar 2015

Uploaded by

Copyright:

Department of Medicine 2015

2015 By The Numbers...

Endocrinology and Diabetes

Gehr Family Center for Implementation Science

The Hastings Center for Pulmonary Research

Service on University, School, Hospital and

Editorial Boards and Editorships

Keck School of Medicine of USC

2015 By The Numbers...

Department of Medicine 2015

Comments from the Chair

Keck School of Medicine of USC

Kenneth R. Hallows, MD, PhD

Vice Chair, Educational Affairs

Chief, Division of Infectious Diseases

Vice Chair, Clinical Affairs

Chief, Division of Nephrology and

Senior Associate Chair, Scientific Affairs

Chief, Division of Oncology

Laurie D. DeLeve, MD, PhD

Senior Associate Chair, Scientific Affairs

Chief, Division of Pulmonary, Critical Care

John L. Brodhead, Jr., MD

Chief of Medicine, Keck Hospital of USC

William Stohl, MD, PhD

Chief, Division of Rheumatology

Chief, Division of Cardiovascular Medicine

Vice Chair, Finance and Administration

Chief, Division of Endocrinology and

Chief, Division of Gastrointestinal and

Director, Administrative Operations

Chief, Division of Geriatric, Hospital,

Preet M. Chaudhary, MD, PhD

Research and Financial Reporting

Chief, Division of Hematology

Department of Medicine 2015

Gehr Family Center for

Gehr Center Triple Aim Principles

Per Capita Cost

Keck School of Medicine of USC

The Hastings Center for

between researchers and clinicians must be present.

Department of Medicine 2015

The new multi-photon confocal microscope, capable

Keck School of Medicine of USC

Department of Medicine 2015

Basic/Translational Science (Prinicipal Investigator)

Large Scale Clinical Trials (Principal Investigator)

Atherosclerosis Research Unit (Hodis)

Interdisciplinary Research Programs

Large-Scale Clinical Trial Centers

Keck School of Medicine of USC

Department of Medicine 2015

LAC+USC Medical Center

Keck School of Medicine of USC

Adult Primary Care Service Enhancements

Implementation of a New Electronic Medical Record: ORCHID

Adult Ambulatory Subspecialty Medicine Enhancements

Department of Medicine 2015

New Admitting Protocol

Keck School of Medicine of USC

Department of Medicine 2015

Vice Chair, Educational